WO2024022433A1 - Prmt5抑制剂 - Google Patents
Prmt5抑制剂 Download PDFInfo
- Publication number
- WO2024022433A1 WO2024022433A1 PCT/CN2023/109524 CN2023109524W WO2024022433A1 WO 2024022433 A1 WO2024022433 A1 WO 2024022433A1 CN 2023109524 W CN2023109524 W CN 2023109524W WO 2024022433 A1 WO2024022433 A1 WO 2024022433A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- haloalkyl
- halogen
- cycloalkyl
- atom
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 59
- 101100434927 Caenorhabditis elegans prmt-5 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 217
- 150000003839 salts Chemical class 0.000 claims abstract description 108
- 239000000651 prodrug Substances 0.000 claims abstract description 96
- 229940002612 prodrug Drugs 0.000 claims abstract description 96
- 230000000155 isotopic effect Effects 0.000 claims abstract description 84
- 239000012453 solvate Substances 0.000 claims abstract description 77
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 42
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 claims abstract description 39
- 150000004677 hydrates Chemical class 0.000 claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 26
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 claims abstract 7
- 125000000217 alkyl group Chemical group 0.000 claims description 541
- 229910052739 hydrogen Inorganic materials 0.000 claims description 474
- 229910052805 deuterium Inorganic materials 0.000 claims description 457
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 454
- 229910052736 halogen Inorganic materials 0.000 claims description 279
- 150000002367 halogens Chemical class 0.000 claims description 279
- 125000000623 heterocyclic group Chemical group 0.000 claims description 255
- 125000003118 aryl group Chemical group 0.000 claims description 185
- 125000004432 carbon atom Chemical group C* 0.000 claims description 170
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 125
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 106
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 106
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 105
- 229910052799 carbon Inorganic materials 0.000 claims description 94
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 87
- 229910052760 oxygen Inorganic materials 0.000 claims description 84
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 72
- 239000000126 substance Substances 0.000 claims description 64
- 125000001424 substituent group Chemical group 0.000 claims description 55
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 54
- 125000004429 atom Chemical group 0.000 claims description 52
- 125000005842 heteroatom Chemical group 0.000 claims description 50
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 47
- -1 BTK inhibitors Substances 0.000 claims description 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 42
- 229910052717 sulfur Inorganic materials 0.000 claims description 35
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 34
- 208000009956 adenocarcinoma Diseases 0.000 claims description 32
- 125000002947 alkylene group Chemical group 0.000 claims description 32
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims description 28
- 206010025323 Lymphomas Diseases 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 27
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
- 201000009030 Carcinoma Diseases 0.000 claims description 24
- 206010039491 Sarcoma Diseases 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 22
- 238000006467 substitution reaction Methods 0.000 claims description 22
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 21
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims description 21
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 21
- 125000006713 (C5-C10) cycloalkyl group Chemical group 0.000 claims description 20
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 18
- 201000011066 hemangioma Diseases 0.000 claims description 18
- 206010024612 Lipoma Diseases 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 206010043276 Teratoma Diseases 0.000 claims description 15
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 14
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 13
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 13
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 12
- 102100034187 S-methyl-5'-thioadenosine phosphorylase Human genes 0.000 claims description 12
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 12
- 206010016629 fibroma Diseases 0.000 claims description 12
- 230000001404 mediated effect Effects 0.000 claims description 12
- 206010018338 Glioma Diseases 0.000 claims description 11
- 101710136206 S-methyl-5'-thioadenosine phosphorylase Proteins 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 10
- 230000001684 chronic effect Effects 0.000 claims description 9
- 208000005017 glioblastoma Diseases 0.000 claims description 9
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 9
- 201000003076 Angiosarcoma Diseases 0.000 claims description 8
- 206010003571 Astrocytoma Diseases 0.000 claims description 8
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 8
- 206010014733 Endometrial cancer Diseases 0.000 claims description 8
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 8
- 208000002927 Hamartoma Diseases 0.000 claims description 8
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 8
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 8
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 8
- 208000034578 Multiple myelomas Diseases 0.000 claims description 8
- 201000004404 Neurofibroma Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 201000010881 cervical cancer Diseases 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 201000010260 leiomyoma Diseases 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- 206010027191 meningioma Diseases 0.000 claims description 8
- 206010005003 Bladder cancer Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 206010007275 Carcinoid tumour Diseases 0.000 claims description 7
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 7
- 206010027406 Mesothelioma Diseases 0.000 claims description 7
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 7
- 208000008383 Wilms tumor Diseases 0.000 claims description 7
- 210000000988 bone and bone Anatomy 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 208000002458 carcinoid tumor Diseases 0.000 claims description 7
- 125000004980 cyclopropylene group Chemical group 0.000 claims description 7
- 125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 claims description 7
- 201000010536 head and neck cancer Diseases 0.000 claims description 7
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 201000000849 skin cancer Diseases 0.000 claims description 7
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 7
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 claims description 6
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 6
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims description 6
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims description 6
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 claims description 6
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 6
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 5
- 210000002418 meninge Anatomy 0.000 claims description 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 5
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 4
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010006417 Bronchial carcinoma Diseases 0.000 claims description 4
- 208000009458 Carcinoma in Situ Diseases 0.000 claims description 4
- 206010008263 Cervical dysplasia Diseases 0.000 claims description 4
- 201000005262 Chondroma Diseases 0.000 claims description 4
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 4
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 4
- 206010048832 Colon adenoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010010356 Congenital anomaly Diseases 0.000 claims description 4
- 208000007033 Dysgerminoma Diseases 0.000 claims description 4
- 201000009051 Embryonal Carcinoma Diseases 0.000 claims description 4
- 206010014967 Ependymoma Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 4
- 208000005917 Exostoses Diseases 0.000 claims description 4
- 208000007659 Fibroadenoma Diseases 0.000 claims description 4
- 206010053717 Fibrous histiocytoma Diseases 0.000 claims description 4
- 206010018404 Glucagonoma Diseases 0.000 claims description 4
- 206010018691 Granuloma Diseases 0.000 claims description 4
- 206010019629 Hepatic adenoma Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 208000002260 Keloid Diseases 0.000 claims description 4
- 206010023330 Keloid scar Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 4
- 208000002404 Liver Cell Adenoma Diseases 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 208000000172 Medulloblastoma Diseases 0.000 claims description 4
- 206010027145 Melanocytic naevus Diseases 0.000 claims description 4
- 102000016397 Methyltransferase Human genes 0.000 claims description 4
- 108060004795 Methyltransferase Proteins 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 4
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 208000007256 Nevus Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 4
- 208000000035 Osteochondroma Diseases 0.000 claims description 4
- 208000027067 Paget disease of bone Diseases 0.000 claims description 4
- 208000007641 Pinealoma Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 201000000582 Retinoblastoma Diseases 0.000 claims description 4
- 208000005678 Rhabdomyoma Diseases 0.000 claims description 4
- 201000010208 Seminoma Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 206010048215 Xanthomatosis Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 208000001119 benign fibrous histiocytoma Diseases 0.000 claims description 4
- 210000003445 biliary tract Anatomy 0.000 claims description 4
- 208000016738 bone Paget disease Diseases 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims description 4
- 201000002143 bronchus adenoma Diseases 0.000 claims description 4
- 210000003679 cervix uteri Anatomy 0.000 claims description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000009060 clear cell adenocarcinoma Diseases 0.000 claims description 4
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 claims description 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 210000003238 esophagus Anatomy 0.000 claims description 4
- 201000003444 follicular lymphoma Diseases 0.000 claims description 4
- 201000010175 gallbladder cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
- 208000006359 hepatoblastoma Diseases 0.000 claims description 4
- 201000002735 hepatocellular adenoma Diseases 0.000 claims description 4
- 201000004933 in situ carcinoma Diseases 0.000 claims description 4
- 206010022498 insulinoma Diseases 0.000 claims description 4
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 210000001117 keloid Anatomy 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 208000022013 kidney Wilms tumor Diseases 0.000 claims description 4
- 210000002429 large intestine Anatomy 0.000 claims description 4
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 4
- 206010024627 liposarcoma Diseases 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 4
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 4
- 201000004593 malignant giant cell tumor Diseases 0.000 claims description 4
- 201000000289 malignant teratoma Diseases 0.000 claims description 4
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 claims description 4
- 208000025113 myeloid leukemia Diseases 0.000 claims description 4
- 208000009091 myxoma Diseases 0.000 claims description 4
- 201000008026 nephroblastoma Diseases 0.000 claims description 4
- 210000000653 nervous system Anatomy 0.000 claims description 4
- 208000007538 neurilemmoma Diseases 0.000 claims description 4
- 208000029974 neurofibrosarcoma Diseases 0.000 claims description 4
- 208000003388 osteoid osteoma Diseases 0.000 claims description 4
- 208000008798 osteoma Diseases 0.000 claims description 4
- 210000001672 ovary Anatomy 0.000 claims description 4
- 210000000496 pancreas Anatomy 0.000 claims description 4
- 208000021255 pancreatic insulinoma Diseases 0.000 claims description 4
- 230000001855 preneoplastic effect Effects 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 4
- 208000004548 serous cystadenocarcinoma Diseases 0.000 claims description 4
- 210000003625 skull Anatomy 0.000 claims description 4
- 210000000813 small intestine Anatomy 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 210000001550 testis Anatomy 0.000 claims description 4
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 4
- 208000022271 tubular adenoma Diseases 0.000 claims description 4
- 210000004291 uterus Anatomy 0.000 claims description 4
- 210000001215 vagina Anatomy 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 4
- 208000009540 villous adenoma Diseases 0.000 claims description 4
- 210000003905 vulva Anatomy 0.000 claims description 4
- 239000012664 BCL-2-inhibitor Substances 0.000 claims description 3
- 229940124291 BTK inhibitor Drugs 0.000 claims description 3
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 claims description 3
- 229940123711 Bcl2 inhibitor Drugs 0.000 claims description 3
- 206010004593 Bile duct cancer Diseases 0.000 claims description 3
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 claims description 3
- 206010058314 Dysplasia Diseases 0.000 claims description 3
- 239000012824 ERK inhibitor Substances 0.000 claims description 3
- 208000007569 Giant Cell Tumors Diseases 0.000 claims description 3
- 208000005234 Granulosa Cell Tumor Diseases 0.000 claims description 3
- 101000896224 Homo sapiens Baculoviral IAP repeat-containing protein 3 Proteins 0.000 claims description 3
- 101001028782 Homo sapiens Histone-lysine N-methyltransferase EZH1 Proteins 0.000 claims description 3
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims description 3
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 claims description 3
- 101001052490 Homo sapiens Mitogen-activated protein kinase 3 Proteins 0.000 claims description 3
- 101000947881 Homo sapiens S-adenosylmethionine synthase isoform type-2 Proteins 0.000 claims description 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 3
- 208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 claims description 3
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims description 3
- 229940124785 KRAS inhibitor Drugs 0.000 claims description 3
- 229940122339 MALT1 inhibitor Drugs 0.000 claims description 3
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims description 3
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 claims description 3
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 claims description 3
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 3
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 3
- 239000012661 PARP inhibitor Substances 0.000 claims description 3
- 239000012828 PI3K inhibitor Substances 0.000 claims description 3
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 3
- 101710084434 Protein arginine N-methyltransferase 1 Proteins 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 102100035947 S-adenosylmethionine synthase isoform type-2 Human genes 0.000 claims description 3
- 229940044665 STING agonist Drugs 0.000 claims description 3
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 claims description 3
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims description 3
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims description 3
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims description 3
- 102100025093 Zinc fingers and homeoboxes protein 2 Human genes 0.000 claims description 3
- 208000002718 adenomatoid tumor Diseases 0.000 claims description 3
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 3
- 201000009480 botryoid rhabdomyosarcoma Diseases 0.000 claims description 3
- 229940044683 chemotherapy drug Drugs 0.000 claims description 3
- 201000005217 chondroblastoma Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229940121647 egfr inhibitor Drugs 0.000 claims description 3
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims description 3
- 201000000052 gastrinoma Diseases 0.000 claims description 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 210000003101 oviduct Anatomy 0.000 claims description 3
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims description 3
- 239000003197 protein kinase B inhibitor Substances 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 210000002536 stromal cell Anatomy 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 201000009657 thyroid sarcoma Diseases 0.000 claims description 3
- 210000003708 urethra Anatomy 0.000 claims description 3
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 claims description 2
- 208000034715 Enchondroma Diseases 0.000 claims description 2
- 108091008794 FGF receptors Proteins 0.000 claims description 2
- 108700022176 SOS1 Proteins 0.000 claims description 2
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 claims description 2
- 101150100839 Sos1 gene Proteins 0.000 claims description 2
- 239000003708 ampul Substances 0.000 claims description 2
- 229940125904 compound 1 Drugs 0.000 claims description 2
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 claims description 2
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 241000189617 Chorda Species 0.000 claims 1
- 102000057028 SOS1 Human genes 0.000 claims 1
- 208000000728 Thymus Neoplasms Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 201000007487 gallbladder carcinoma Diseases 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 78
- 235000002639 sodium chloride Nutrition 0.000 description 75
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 64
- 239000000243 solution Substances 0.000 description 62
- 230000015572 biosynthetic process Effects 0.000 description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 238000003786 synthesis reaction Methods 0.000 description 36
- 125000001072 heteroaryl group Chemical group 0.000 description 35
- 101000924530 Homo sapiens Protein arginine N-methyltransferase 5 Proteins 0.000 description 32
- 239000000203 mixture Substances 0.000 description 32
- 239000007787 solid Substances 0.000 description 32
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 31
- 230000002829 reductive effect Effects 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 239000002904 solvent Substances 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
- 239000002585 base Substances 0.000 description 23
- 239000000706 filtrate Substances 0.000 description 23
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 21
- 239000012074 organic phase Substances 0.000 description 21
- 239000000543 intermediate Substances 0.000 description 20
- 125000003342 alkenyl group Chemical group 0.000 description 19
- 125000000304 alkynyl group Chemical group 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 235000008504 concentrate Nutrition 0.000 description 18
- 239000012141 concentrate Substances 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 239000002253 acid Substances 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 125000001188 haloalkyl group Chemical group 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000000460 chlorine Substances 0.000 description 10
- 239000003208 petroleum Substances 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 239000003480 eluent Substances 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 125000006574 non-aromatic ring group Chemical group 0.000 description 9
- 238000010898 silica gel chromatography Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 208000032612 Glial tumor Diseases 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 229920000858 Cyclodextrin Polymers 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 5
- 229960001570 ademetionine Drugs 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 4
- 206010001233 Adenoma benign Diseases 0.000 description 4
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 4
- 239000005977 Ethylene Substances 0.000 description 4
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- 125000004450 alkenylene group Chemical group 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 229910052796 boron Inorganic materials 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- JJDDVGAESNBKMY-UHFFFAOYSA-N 5-(trifluoromethyl)pyridine-2-carbaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)N=C1 JJDDVGAESNBKMY-UHFFFAOYSA-N 0.000 description 3
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 201000009047 Chordoma Diseases 0.000 description 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 3
- 208000021309 Germ cell tumor Diseases 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229940125897 PRMT5 inhibitor Drugs 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 150000001335 aliphatic alkanes Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- 201000003149 breast fibroadenoma Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 208000024724 pineal body neoplasm Diseases 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 206010039667 schwannoma Diseases 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 208000008732 thymoma Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 2
- KBLGGRWUEVCNPY-UHFFFAOYSA-N 5-bromo-3-methylpyridin-2-amine Chemical compound CC1=CC(Br)=CN=C1N KBLGGRWUEVCNPY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 101150065749 Churc1 gene Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102100030528 Methylosome protein 50 Human genes 0.000 description 2
- 101710168413 Methylosome protein 50 Proteins 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102100038239 Protein Churchill Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 206010048214 Xanthoma Diseases 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000004419 alkynylene group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 208000011825 carcinoma of the ampulla of vater Diseases 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 125000006410 propenylene group Chemical group 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- PAQZWJGSJMLPMG-UHFFFAOYSA-N propylphosphonic anhydride Substances CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006586 (C3-C10) cycloalkylene group Chemical group 0.000 description 1
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- KIPSRYDSZQRPEA-UHFFFAOYSA-N 2,2,2-trifluoroethanamine Chemical compound NCC(F)(F)F KIPSRYDSZQRPEA-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- TWJGQZBSEMDPQP-UHFFFAOYSA-N 2-chloro-n-[4-[5-(3,4-dichlorophenyl)-3-(2-methoxyethoxy)-1,2,4-triazol-1-yl]phenyl]acetamide Chemical compound C=1C=C(NC(=O)CCl)C=CC=1N1N=C(OCCOC)N=C1C1=CC=C(Cl)C(Cl)=C1 TWJGQZBSEMDPQP-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- JLPYUDJJBGYXEZ-UHFFFAOYSA-N 3-methyl-5-nitropyridin-2-amine Chemical compound CC1=CC([N+]([O-])=O)=CN=C1N JLPYUDJJBGYXEZ-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- SRQYLNYQAPCPIR-UHFFFAOYSA-N 4-[4-(5,5-dimethyl-4H-thiazol-2-yl)-1-piperazinyl]-6-propylthieno[2,3-d]pyrimidine Chemical compound N1=CN=C2SC(CCC)=CC2=C1N(CC1)CCN1C1=NCC(C)(C)S1 SRQYLNYQAPCPIR-UHFFFAOYSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- 108010034457 5'-methylthioadenosine phosphorylase Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 229940126638 Akt inhibitor Drugs 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 1
- 206010062805 Dysplastic naevus Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- 229940119544 Menin-MLL inhibitor Drugs 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108700021610 Mitochondrial Precursor Protein Import Complex Proteins Proteins 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229940126271 SOS1 inhibitor Drugs 0.000 description 1
- 101000985737 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Protein arginine N-methyltransferase HSL7 Proteins 0.000 description 1
- 101000651946 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein arginine N-methyltransferase skb1 Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 102100032929 Son of sevenless homolog 1 Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- FUASJQSBFUVWJQ-UHFFFAOYSA-N [N].NC(N)=N Chemical group [N].NC(N)=N FUASJQSBFUVWJQ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000002355 alkine group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940024548 aluminum oxide Drugs 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 201000007434 ampulla of Vater carcinoma Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 201000011143 bone giant cell tumor Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960004979 fampridine Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 150000004687 hexahydrates Chemical class 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007916 intrasternal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000005990 isobenzothienyl group Chemical group 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 229940125399 kras g12c inhibitor Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 150000004704 methoxides Chemical class 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 208000004649 neutrophil actin dysfunction Diseases 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000005693 optoelectronics Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Substances ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 238000009512 pharmaceutical packaging Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- FCJSHPDYVMKCHI-UHFFFAOYSA-N phenyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OC1=CC=CC=C1 FCJSHPDYVMKCHI-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000005494 pyridonyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- BHRZNVHARXXAHW-UHFFFAOYSA-N sec-butylamine Chemical compound CCC(C)N BHRZNVHARXXAHW-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 125000005156 substituted alkylene group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 125000004964 sulfoalkyl group Chemical group 0.000 description 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005458 thianyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000005881 triazolinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910009112 xH2O Inorganic materials 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention requires the Chinese application CN202210898107.7 submitted on July 28, 2022, the Chinese application CN202211541013.0 submitted on December 2, 2022, the Chinese application CN202310484698.8 submitted on April 28, 2023, and the submission of The priority right of CN202310897087.6 was filed in China on July 20, 2023, and they are incorporated into this article as a reference in their entirety.
- the present invention relates to a new class of PRMT5 inhibitors, or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvates thereof.
- the present invention also relates to methods for preparing the compounds, pharmaceutical compositions containing the compounds, and the effects of the compounds in preventing and treating PRMT5-mediated diseases such as cancer.
- Protein arginine methyltransferase 5 belongs to type II PRMT. It is a type of S-adenosylmethionine (SAM)-dependent methyltransferase and is mainly responsible for converting the methyl group of SAM. Symmetrically transferred to the guanidine nitrogen atom at the end of an arginine residue in histones or other proteins.
- SAM S-adenosylmethionine
- PRMT5 forms a complex with MEP50 (methylosome protein 50) to recognize the substrate and localize it. At the same time, the complex morphology is also required for PRMT5 to catalyze the methyl transfer activity of histone 2A and histone 4.
- PRMT5 is a general transcriptional repressor that can regulate the process of gene transcription and protein modification. At the same time, PRMT5 plays an important role in the proliferation, differentiation, and apoptosis of tumor cells and is a highly potential tumor treatment target. However, PRMT5 is also an essential gene for normal cells. PRMT5 knockout and siRNA knockdown studies have shown that inhibiting the activity of PRMT5 in normal tissues may cause many toxic side effects such as thrombocytopenia, infertility, skeletal muscle loss, and cardiac hypertrophy.
- MTAP methylthioadenosine phosphorylase
- PRMT5 inhibitors under investigation include SAM competitive inhibitors, substrate competitive inhibitors, SAM and substrate dual competitive inhibitors, and MTA synergistic inhibitors.
- Non-MTA synergistic PRMT5 inhibitors indiscriminately inhibit the activity of PRMT5, and dose-limiting toxic side effects such as thrombocytopenia, anemia, and neutropenia have been found.
- MTA synergistic inhibitors target the PRMT5/MTA complex and are expected to inhibit MTAP-deficient tumor cells while eliminating the impact on MTAP WT cells, which can improve the treatment window.
- the present invention uses the PRMT5/MTA complex as a target and develops a new class of small molecule inhibitors that can be used to treat various cancers.
- the compound of the present invention targets the PRMT5/MTA complex, is an MTA synergistic PRMT5 inhibitor, has excellent PRMT5/MTA inhibitory activity, and has obvious selectivity for the PRMT5/SAM complex.
- the compounds of the present invention have good ADMET (absorption-distribution-metabolism-excretion-toxicity) properties.
- the invention provides a compound of formula (X), or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof Object:
- Ring A is C 6-10 aryl or 5-10 membered heteroaryl
- L 1 is NH or CHR x ;
- L 2 is CR x R y ;
- L 3 is -C(O)-, -S(O)- or -S(O) 2 -;
- R x and R y are independently H, D, C 1-6 alkyl or C 1-6 haloalkyl
- L 1 is CHR x and L 2 is CR x R y , the two R x groups can be combined to form a chemical bond or a C 1-4 alkylene group;
- n 0, 1, 2, 3 or 4;
- R 4 is selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl
- X 1 is a C atom or N atom, which is optionally substituted by R 2b ;
- X 2 is a C atom or N atom, which is optionally substituted by R 2c ;
- X 3 is a C atom or N atom, which is optionally substituted by R 2d ;
- R 2a is selected from H, D, CN, OR a , NR b R c , C(O)OR a or C(O)NR b R c ;
- R 2b is selected from H, D, halogen, C(O)OR a , C(O)NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl or 3- 10-membered heterocyclyl;
- R 2c is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R 2d is selected from H, D, halogen, CN, NO 2 , OR a , NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 5-10 cycloalkyl, 5-10 membered hetero Ring group, C 6-10 aryl group or 5-10 membered heteroaryl group;
- R 3 is selected from -C 1-6 alkylene -OR a , -C 1-6 alkylene -NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl , C 2-6 alkynyl, -LC 3-10 cycloalkyl, -L-3-10 membered heterocyclyl, -LC 6-10 aryl or -L-5-10 membered heteroaryl, which is optional Replaced by 1, 2 or 3 R 3s1 and 1 R 3s2 ;
- L is a chemical bond, C 1-6 alkylene, C 2-6 alkenylene or C 2-6 alkynylene, which is optionally substituted by 1, 2 or 3 R;
- R 3s1 is selected from H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 3-10 yuan Heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl;
- R 3s2 is selected from H, D, -L-OR a , -L-NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 5-10 membered heterocycle Base, C 6-10 Aryl or 5-10 membered heteroaryl, which is optionally substituted by 1, 2 or 3 R 3s ;
- R and R 3s are independently selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 3-10 membered heterocyclyl, C 6-10 Aryl or 5-10 membered heteroaryl; or R b , R c and the atoms they are connected together form a 5-10 membered heterocyclic group;
- the invention provides a compound of formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvent thereof Compound:
- Ring A is C 6-10 aryl or 5-10 membered heteroaryl
- L 1 is NH or CHR x ;
- L 2 is CR x R y ;
- L 3 is -C(O)-, -S(O)- or -S(O) 2 -;
- R x and R y are independently H, D, C 1-6 alkyl or C 1-6 haloalkyl
- L 1 is CHR x and L 2 is CR x R y , the two R x groups can be combined to form a chemical bond or a C 1-4 alkylene group;
- R 1 is selected from H, D, halogen, CN, NO 2 , -L-OR a , -L-SR a , -L-NR b R c , SF 5 , C(O)R a , C(O)OR a , C(O)NR b R c , OC(O)R a , NR b C(O)R c , S(O)R a , S(O) 2 R a , S(O)OR a , S (O) 2 OR a , S(O)NR b R c , S(O) 2 NR b R c , P(O)(R a ) 2 , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, -LC 3-7 cycloalkyl, -L-3-7-membered heterocyclyl, -LC 6-10 aryl or
- n 0, 1, 2, 3 or 4;
- X 1 is a C atom or N atom, which is optionally substituted by R 2b ;
- X 2 is a C atom or N atom, which is optionally substituted by R 2c ;
- X 3 is a C atom or N atom, which is optionally substituted by R 2d ;
- R 2a is selected from H, D, CN, OR a , NR b R c , C(O)OR a or C(O)NR b R c ;
- R 2b is selected from H, D, halogen, C(O)OR a , C(O)NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl or 3- 10-membered heterocyclyl;
- R 2c is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R 2d is selected from H, D, halogen, CN, NO 2 , OR a , NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 5-10 cycloalkyl, 5-10 membered hetero Ring group, C 6-10 aryl group or 5-10 membered heteroaryl group;
- R 3 is selected from -C 1-6 alkylene -OR a , -C 1-6 alkylene -NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl , C 2-6 alkynyl, -LC 3-10 cycloalkyl, -L-3-10 membered heterocyclyl, -LC 6-10 aryl or -L-5-10 membered heteroaryl, which is optional By 1, 2 or 3 R 3s1 and 1 R 3s2 replace;
- L is a chemical bond, C 1-6 alkylene, C 2-6 alkenylene or C 2-6 alkynylene, which is optionally substituted by 1, 2 or 3 R;
- R 3s1 is selected from H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 3-10 yuan Heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl;
- R 3s2 is selected from H, D, -L-OR a , -L-NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 5-10 membered heterocycle base, C 6-10 aryl or 5-10 membered heteroaryl, which is optionally substituted by 1, 2 or 3 R 3s ;
- R and R 3s are independently selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl; or R b , R c and the atoms to which they are connected together form a 5-10 membered heterocyclyl group ;
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the invention, and optionally a pharmaceutically acceptable excipient, such as a carrier, adjuvant or vehicle.
- the invention provides a pharmaceutical composition containing a compound of the invention and a pharmaceutically acceptable excipient, which also contains other therapeutic agents, such as selected from the following target drugs/cell activity modulators, including CDK4/ 6 inhibitors, MAT2A inhibitors, MAPK1/MAPK3 inhibitors, Type I PRMT inhibitors, EGFR inhibitors, SHP2 inhibitors, pan-KRAS inhibitors, KRASG12C inhibitors, RAF inhibitors, MEK inhibitors, ERK inhibitors, Bcl -2 inhibitors, SOS1 inhibitors, PARP inhibitors, MALT1 inhibitors, MALT2 inhibitors, BTK inhibitors, PI3K inhibitors, AKT inhibitors, FGFR inhibitors, DNA methyltransferase (DNMT) inhibitors, EZH1/ 2 inhibitors, EZH2 inhibitors, Menin-MLL inhibitors, IDH1 inhibitors, IDH2 inhibitors, IDH1/2 inhibitors, chemotherapy drugs, radiotherapy, STING agonists or immune checkpoint inhibitors/modul
- the invention provides the use of a compound of the invention for the preparation of a medicament for the treatment and/or prevention of PRMT5-mediated diseases.
- the invention provides a method of treating and/or preventing a PRMT5-mediated disease in a subject, comprising administering to said subject a compound of the invention or a pharmaceutical composition of the invention.
- the invention provides a compound of the invention or a pharmaceutical composition of the invention for use in the treatment and/or prevention of PRMT5-mediated diseases.
- the present invention is used to treat and/or prevent cancer.
- the present invention is used for the treatment and/or prevention of the following cancers: Heart: sarcomas (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyomas, fibromas, lipomas and teratomas.
- bronchial carcinoma squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma
- alveolar (bronchiolar) carcinoma bronchial adenoma, sarcoma, lymphoma, enchondromatous hamartoma, mesothelial carcinoma Tumors
- gastrointestinal tract esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastric Secretinoma, carcinoid tumor, hemangioma), small intestine (adenocarcinoma, lymphoma, carcinoid tumor), Kaposi's sarcoma, leiomyoma, hemangioma
- the PRMT5-mediated disease of the invention is selected from the following cancers: malignant peripheral nerve sheath tumors, mesothelioma, glioblastoma multiforme, pancreatic cancer, cholangiocarcinoma, prostate cancer, Breast cancer, brain cancer, skin cancer, cervical cancer, bladder cancer, astrocytoma, colorectal cancer, endometrial cancer, esophageal cancer, gastric cancer, thymoma, head and neck cancer, hepatocellular carcinoma, laryngeal cancer, lung squamous cell carcinoma , lung adenocarcinoma, oral cancer, ovarian cancer, kidney cancer and thyroid cancer, and sarcoma.
- cancers malignant peripheral nerve sheath tumors, mesothelioma, glioblastoma multiforme, pancreatic cancer, cholangiocarcinoma, prostate cancer, Breast cancer, brain cancer, skin cancer, cervical cancer, bladder cancer, astrocytoma, colore
- the PRMT5-mediated disease of the invention is selected from MTAP-related cancers, such as hepatocellular carcinoma, breast cancer, skin cancer, bladder cancer, liver cancer, pancreatic cancer or head and neck cancer.
- MTAP-related cancers such as hepatocellular carcinoma, breast cancer, skin cancer, bladder cancer, liver cancer, pancreatic cancer or head and neck cancer.
- C 1-6 alkyl includes C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 1-6 , C 1-5 , C 1-4 , C 1-3 , C 1 -2 , C 2-6 , C 2-5 , C 2-4 , C 2-3 , C 3-6 , C 3-5, C 3-4 , C 4-6 , C 4-5 and C 5 -6 alkyl.
- C 1-6 alkyl refers to a straight or branched chain saturated hydrocarbon group having 1 to 6 carbon atoms. In some embodiments, C 1-4 alkyl and C 1-2 alkyl are preferred. Examples of C 1-6 alkyl groups include: methyl (C 1 ), ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-butyl (C 4 ), tert-butyl base (C 4 ), sec-butyl (C 4 ), isobutyl (C 4 ), n-pentyl (C 5 ), 3-pentyl (C 5 ), pentyl (C 5 ), neopentyl ( C 5 ), 3-methyl-2-butyl (C 5 ), tert-pentyl (C 5 ) and n-hexyl (C 6 ).
- C 1-6 alkyl also includes heteroalkyl groups in which one or more (e.g., 1, 2, 3, or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, Phosphorus) substitution.
- Alkyl groups may be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
- alkyl abbreviations include: Me(-CH 3 ), Et(-CH 2 CH 3 ), iPr(-CH(CH 3 ) 2 ), nPr(-CH 2 CH 2 CH 3 ), n-Bu(-CH 2 CH 2 CH 2 CH 3 ) or i-Bu(-CH 2 CH(CH 3 ) 2 ).
- C 2-6 alkenyl refers to a straight or branched chain hydrocarbon group having 2 to 6 carbon atoms and at least one carbon-carbon double bond. In some embodiments, C 2-4 alkenyl is preferred. Examples of C 2-6 alkenyl groups include: vinyl (C 2 ), 1-propenyl (C 3 ), 2-propenyl (C 3 ), 1-butenyl (C 4 ), 2-butenyl (C 4 ), butadienyl (C 4 ), pentenyl (C 5 ), pentadienyl (C 5 ), hexenyl (C 6 ), etc.
- C 2-6 alkenyl also includes heteroalkenyl groups in which one or more (e.g., 1, 2, 3, or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, Phosphorus) substitution.
- Alkenyl groups may be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
- C 2-6 alkynyl refers to a straight or branched chain hydrocarbon group having 2 to 6 carbon atoms, at least one carbon-carbon triple bond, and optionally one or more carbon-carbon double bonds. In some embodiments, C 2-4 alkynyl is preferred. Examples of C 2-6 alkynyl groups include, but are not limited to: ethynyl (C 2 ), 1-propynyl (C 3 ), 2-propynyl (C 3 ), 1-butynyl (C 4 ), 2-Butynyl (C 4 ), pentynyl (C 5 ), hexynyl (C 6 ), etc.
- C 2-6 alkynyl also includes heteroalkynyl groups in which one or more (e.g., 1, 2, 3, or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, Phosphorus) substitution.
- An alkynyl group may be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
- C 1-6 alkylene refers to a divalent group formed by removing another hydrogen of C 1-6 alkyl, and may be substituted or unsubstituted. In some embodiments, C 1-4 alkylene, C 2-4 alkylene, and C 1-3 alkylene are preferred.
- the unsubstituted alkylene group includes, but is not limited to: methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), propylene (-CH 2 CH 2 CH 2 -), ethylene Base (-CH 2 CH 2 CH 2 CH 2 -), pentylene (-CH 2 CH 2 CH 2 CH 2 CH 2 -), hexylene (-CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 -) ,etc.
- alkylene groups substituted by one or more alkyl (methyl) include, but are not limited to: substituted methylene (-CH(CH 3 )- , -C(CH 3 ) 2 -), substituted ethylene (-CH(CH 3 )CH 2 -, -CH 2 CH(CH 3 )-, -C(CH 3 ) 2 CH 2 -, -CH 2 C(CH 3 ) 2- ), substituted propylene (-CH(CH 3 )CH 2 CH 2 -, -CH 2 CH(CH 3 )CH 2 -, -CH 2 CH 2 CH(CH 3 ) -, -C(CH 3 ) 2 CH 2 CH 2 -, -CH 2 C(CH 3 ) 2 CH 2 -, -CH 2 CH 2 C(CH 3 ) 2 -), etc.
- C 2-6 alkynylene refers to a divalent group formed by removing the other hydrogen of the C 2-6 alkynyl group, and may be substituted or unsubstituted. In some embodiments, C 2-4 alkynylene is particularly preferred. Exemplary alkynylene groups include, but are not limited to: ethynylene (-C ⁇ C-), substituted or unsubstituted propynylene (-C ⁇ CCH 2 -), and the like.
- C 0-6 alkylene means a chemical bond and the above-mentioned “C 1-6 alkylene”
- C 0-4 alkylene means a chemical bond and the above-mentioned "C 1-4 alkylene”.
- Halo or "halogen” refers to fluorine (F), chlorine (Cl), bromine (Br) and iodine (I).
- C 1-6 haloalkyl refers to the above-mentioned "C 1-6 alkyl” which is substituted by one or more halogen groups.
- C 1-4 haloalkyl is particularly preferred, with C 1-2 haloalkyl being more preferred.
- Exemplary haloalkyl groups include, but are not limited to: -CF 3 , -CH 2 F, -CHF 2 , -CHFCH 2 F, -CH 2 CHF 2 , -CF 2 CF 3 , -CCl 3 , -CH 2 Cl , -CHCl 2 , 2,2,2-trifluoro-1,1-dimethyl-ethyl, etc.
- Haloalkyl groups may be substituted at any available point of attachment, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
- C 3-10 cycloalkyl refers to a non-aromatic cyclic hydrocarbon group having 3 to 10 ring carbon atoms and zero heteroatoms, optionally containing 1, 2 or 3 double or triple bonds. In some embodiments, C 5-10 cycloalkyl, C 3-7 cycloalkyl and C 3-6 cycloalkyl are particularly preferred, with C 5-7 cycloalkyl and C 5-6 cycloalkyl being more preferred base.
- Cycloalkyl also includes ring systems in which the above-described cycloalkyl ring is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the cycloalkyl ring, and in such cases the number of carbons continues as indicated The number of carbons in a cycloalkyl system. Cycloalkyl also includes the above-mentioned cycloalkyl rings, in which the substituents on any non-adjacent carbon atoms are connected to form a bridged ring, which together form a polycyclic alkane sharing two or more carbon atoms.
- Cycloalkyl also includes the above-mentioned cycloalkyl rings, in which substituents on the same carbon atom are connected to form a ring, and together form a polycyclic alkane sharing one carbon atom.
- Exemplary cycloalkyl groups include, but are not limited to: cyclopropyl (C 3 ), cycloalkyl Propenyl (C 3 ), cyclobutyl (C 4 ), cyclobutenyl (C 4 ), cyclopentyl ( C 5 ), cyclopentenyl (C 5 ), cyclohexyl (C 6 ), cyclohexyl Alkenyl (C 6 ), cyclohexadienyl (C 6 ), cycloheptyl (C 7 ), cycloheptenyl (C 7 ), cycloheptadienyl (C 7 ), cycloheptyltrienyl ( C 7 ), etc.
- C 3-10 cycloalkylene refers to a divalent group formed by removing another hydrogen of C 3-10 cycloalkyl, and may be substituted or unsubstituted.
- C 3-6 cycloalkylene and C 3-4 cycloalkylene are particularly preferred, with cyclopropylene being particularly preferred.
- 3-10 membered heterocyclyl refers to a saturated or unsaturated group of 3 to 10 membered non-aromatic ring system having ring carbon atoms and 1 to 5 ring heteroatoms, wherein each heteroatom is independently selected from Nitrogen, oxygen, sulfur, boron, phosphorus and silicon, optionally containing 1, 2 or 3 double or triple bonds.
- the point of attachment may be a carbon or nitrogen atom as long as the valency permits.
- 5-10 membered heterocyclyl is preferred, which is a 5-10 membered non-aromatic ring system having ring carbon atoms and 1 to 5 ring heteroatoms; in some embodiments, 3-7 membered is preferred Heterocyclyl, which is a 3- to 7-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms; preferably 5-7-membered heterocyclyl, which is a 3- to 7-membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms.
- Heterocyclyl also includes ring systems in which the above-described heterocyclyl ring is fused with one or more cycloalkyl groups, wherein the point of attachment is on the heterocyclyl ring, or in which the above-described heterocyclyl ring is fused with one or more aryl groups or Heteroaryl fused ring systems wherein the point of attachment is on the heterocyclyl ring; and in such cases, the number of ring members continues to represent the number of ring members in the heterocyclyl ring system.
- Heterocyclyl also includes the above-mentioned heterocyclyl rings, in which the substituents on any non-adjacent carbon or nitrogen atoms are connected to form a bridged ring, which together form a polycyclic heteroalkane sharing two or more carbon or nitrogen atoms.
- Heterocyclyl also includes the above-mentioned heterocyclyl rings, in which substituents on the same carbon atom are connected to form a ring and together form a polycyclic heteroalkane sharing one carbon atom.
- Exemplary 3-membered heterocyclyl groups containing one heteroatom include, but are not limited to: aziridinyl, oxirinyl, and thiorenyl.
- Exemplary 4-membered heterocyclyl groups containing one heteroatom include, but are not limited to: azetidinyl, oxetanyl, and thietanyl.
- Exemplary 5-membered heterocyclyl groups containing one heteroatom include, but are not limited to: tetrahydrofuryl, dihydrofuryl, tetrahydrothienyl, dihydrothienyl, pyrrolidinyl, dihydropyrrolyl and pyrrolyl-2, 5-diketone.
- Exemplary 5-membered heterocyclyl groups containing two heteroatoms include, but are not limited to: pyrazolidinyl, dioxolyl, oxasulfuranyl, dithiolyl (disulfuranyl) and oxazolidin-2-one.
- Exemplary 5-membered heterocyclyl groups containing three heteroatoms include, but are not limited to: triazolinyl, oxadiazolinyl, and thiadiazolinyl.
- Exemplary 6-membered heterocyclyl groups containing one heteroatom include, but are not limited to: piperidinyl, tetrahydropyranyl, dihydropyridyl, and thianyl.
- Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, but are not limited to: piperazinyl, morpholinyl, dithianyl, and dioxanyl.
- Exemplary 6-membered heterocyclyl groups containing three heteroatoms include, but are not limited to: hexahydrotriazinyl (triazinanyl).
- Exemplary 7-membered heterocyclyl groups containing one heteroatom include, but are not limited to: azepanyl, oxpanyl, and thipanyl.
- Exemplary 5-membered heterocyclyl fused to a C6 aryl ring include, but are not limited to: indolyl, isoindolyl , dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinone, etc.
- Exemplary 6-membered heterocyclyl fused to a C6 aryl ring include, but are not limited to: tetrahydroquinolyl, tetrahydroisoquinolyl, etc.
- Heterocyclyl also includes the above-mentioned heterocyclyl sharing one or two atoms with a cycloalkyl, heterocyclyl, aryl or heteroaryl to form a bridged ring or spiro ring. As long as the valency allows, the shared atoms can be carbon or Nitrogen atom. Heterocyclyl also includes the above-mentioned heterocyclyl and heterocyclyl groups may be optionally substituted by one or more substituents, for example, by 1 to 5 substituents, 1 to 3 substituents or 1 substituent.
- C 6-10 aryl refers to a monocyclic or polycyclic (e.g., bicyclic) 4n+2 aromatic ring system having 6-10 ring carbon atoms and zero heteroatoms (e.g., having a Shared 6 or 10 ⁇ electrons) group.
- an aryl group has six ring carbon atoms ("C 6 aryl”; e.g., phenyl).
- an aryl group has ten ring carbon atoms ("C 10 aryl”; eg, naphthyl, eg, 1-naphthyl and 2-naphthyl).
- Aryl also includes ring systems in which the aryl ring described above is fused to one or more cycloalkyl or heterocyclyl groups, Also the point of attachment is on the aryl ring, in which case the number of carbon atoms continues to represent the number of carbon atoms in the aryl ring system.
- Aryl groups may be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
- 5-14 membered heteroaryl refers to a 5-14 membered monocyclic or bicyclic 4n+2 aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms (e.g., having a 6, 10 or 14 ⁇ electrons), wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur.
- the point of attachment may be a carbon or nitrogen atom as long as the valency permits.
- Heteroaryl bicyclic systems may include one or more heteroatoms in one or both rings.
- Heteroaryl also includes ring systems in which the heteroaryl ring described above is fused to one or more cycloalkyl or heterocyclyl groups, and the point of attachment is on the heteroaryl ring, in which case the carbon atom Number continues to represent the number of carbon atoms in the heteroaryl ring system.
- 5-10 membered heteroaryl groups are preferred, which are 5-10 membered monocyclic or bicyclic 4n+2 aromatic ring systems having ring carbon atoms and 1-4 ring heteroatoms.
- 5-6 membered heteroaryl groups are particularly preferred, which are 5-6 membered monocyclic or bicyclic 4n+2 aromatic ring systems having ring carbon atoms and 1-4 ring heteroatoms.
- Exemplary 5-membered heteroaryl groups containing one heteroatom include, but are not limited to: pyrrolyl, furyl, and thienyl.
- Exemplary 5-membered heteroaryl groups containing two heteroatoms include, but are not limited to: imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl and isothiazolyl.
- Exemplary 5-membered heteroaryl groups containing three heteroatoms include, but are not limited to: triazolyl, oxadiazolyl (eg, 1,2,4-oxadiazolyl), and thiadiazolyl.
- Exemplary 5-membered heteroaryl groups containing four heteroatoms include, but are not limited to: tetrazolyl.
- Exemplary 6-membered heteroaryl groups containing one heteroatom include, but are not limited to: pyridyl or pyridonyl.
- Exemplary 6-membered heteroaryl groups containing two heteroatoms include, but are not limited to: pyridazinyl, pyrimidinyl, and pyrazinyl.
- Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, but are not limited to, triazinyl and tetrazinyl, respectively.
- Exemplary 7-membered heteroaryl groups containing one heteroatom include, but are not limited to: azepantrienyl, oxetapyltrienyl, and thioheptantrienyl.
- Exemplary 5,6-bicyclic heteroaryl groups include, but are not limited to: indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothienyl, isobenzothienyl, benzofuranyl , benzisofuryl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzisothiazolyl, benzothiadiazolyl, Indazinyl and purinyl.
- Exemplary 6,6-bicyclic heteroaryl groups include, but are not limited to: naphthyridinyl, pyridinyl, quinolinyl, isoquinolinyl, quinolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl .
- Heteroaryl groups may be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
- the divalent groups formed by removing another hydrogen from the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups defined above are collectively referred to as "subunits".
- Ring-forming groups such as cycloalkyl, heterocyclyl, aryl and heteroaryl are collectively referred to as "cyclic groups”.
- Alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, etc. are defined herein as optionally substituted groups.
- Each R aa is independently selected from alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two R aa groups are combined to form heterocyclyl or Heteroaryl rings, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl group is independently replaced by 0, 1, 2, 3, 4 or 5 R dd groups group replacement;
- Each R cc is independently selected from hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or two R cc groups are combined to form a heterocycle or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is independently replaced by 0, 1, 2, 3, 4 or 5 R dd group substitution;
- Each R ee is independently selected from alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl Alkyl, heterocyclyl, aryl and heteroaryl are independently substituted by 0, 1, 2, 3, 4 or 5 R gg groups;
- Each R ff is independently selected from hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two R ff groups combine to form a heterocyclyl or a heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is independently replaced by 0, 1, 2, 3, 4 or 5 R gg group substitution;
- cancer includes, but is not limited to, the following cancers: Heart: sarcomas (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyomas, fibromas, lipomas and teratomas; Lung: bronchial carcinoma (squamous cell carcinoma) cystic cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, enchondromatous hamartoma, mesothelioma; gastrointestinal tract: esophagus (squamous cell carcinoma) cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (duct
- cancer includes, but is not limited to, the following cancers: malignant peripheral nerve sheath tumors, mesothelioma, glioblastoma multiforme, pancreatic cancer, cholangiocarcinoma, prostate cancer, breast cancer, brain cancer , skin cancer, cervical cancer, bladder cancer, astrocytoma, colorectal cancer, endometrial cancer, esophageal cancer, gastric cancer, thymoma, head and neck cancer, hepatocellular carcinoma, laryngeal cancer, lung squamous cell carcinoma, lung adenocarcinoma, mouth Cavalous, ovarian, renal and thyroid cancers and sarcomas.
- cancer includes, but is not limited to, the following cancers: hepatocellular carcinoma, breast cancer, skin cancer, bladder cancer, liver cancer, pancreatic cancer, or head and neck cancer.
- treatment refers to reversing, alleviating, inhibiting the progression of, or preventing the disorder or condition to which the term applies, or one or more symptoms of such disorder or condition.
- noun “treat” refers to the action of the verb treat, as just defined.
- the term "pharmaceutically acceptable salts” means those carboxylate salts and amino acid addition salts of the compounds of the present invention which are suitable for contact with patient tissue within the scope of reliable medical judgment and will not produce undue toxicity, Irritation effects, allergic reactions, etc., commensurate with a reasonable benefit/risk ratio, are effective for their intended use, including (where possible) zwitterionic forms of the compounds of the invention.
- Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali metal and alkaline earth metal hydroxides or organic amines.
- metals used as cations are sodium, potassium, magnesium, calcium, etc.
- suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine and procaine.
- Base addition salts of acidic compounds may be prepared in conventional manner by contacting the free acid form with a sufficient amount of the desired base to form the salt.
- the free acid can be regenerated by contacting the salt form with the acid and isolating the free acid in the usual manner.
- the free acid forms differ somewhat from their respective salt forms in certain physical properties, such as solubility in polar solvents, but for the purposes of this invention the salts are nevertheless equivalent to their respective free acids.
- the salts may be sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphates prepared from inorganic acids Salt, chloride, bromide, iodide, acids such as hydrochloric acid, nitric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, etc.
- Representative salts include: hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate Acid, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthoate, Methanesulfonate, glucoheptonate, lactobionate, lauryl sulfonate and isethionate, etc.
- Salts may also be prepared from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, and the like.
- organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, and the like.
- Representative salts include acetate, propionate, octanoate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, malonate Lenate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, naphthoate, benzenesulfonate, toluenesulfonate, phenylbenzoate Acid, citrate, lactate, maleate, tartrate, methanesulfonate, etc.
- Pharmaceutically acceptable salts may include alkali and alkaline earth metal based cations such as sodium, lithium, potassium, calcium, magnesium, etc., as well as non-toxic ammonium, quaternary ammonium and amine cations including, but not limited to, ammonium, tetramethyl Ammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, etc. Also covered are salts of amino acids, such as arginates, gluconates, galacturonates, etc. (see, for example, Berge S.M. et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977; 66:1- 19, incorporated by reference).
- Subjects for administration include, but are not limited to: humans (i.e., males or females of any age group, e.g., pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young Adults, middle-aged adults or older adults) and/or non-human animals, e.g., mammals, e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep , goats, rodents, cats and/or dogs.
- the subject is human.
- the subject is a non-human animal.
- the terms "person,” “patient,” and “subject” are used interchangeably herein.
- treatment includes an action in a subject suffering from a specific disease, disorder or condition that reduces the severity of the disease, disorder or condition, or delays or slows down the disease, disorder or the development of a condition ("therapeutic treatment”), Also included are effects that occur before a subject begins to suffer from a specific disease, disorder or condition ("preventive treatment").
- an "effective amount" of a compound is an amount sufficient to elicit a target biological response.
- the effective amount of a compound of the present invention may vary depending on factors such as, for example, the biological target, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the condition of the subject. Age health conditions and symptoms.
- the effective amount includes a therapeutically effective amount and a preventive effective amount.
- a "therapeutically effective amount" of a compound as used herein is an amount sufficient to provide a therapeutic benefit in treating a disease, disorder, or condition, or to cause one or more symptoms associated with the disease, disorder, or condition The amount to delay or minimize.
- a therapeutically effective amount of a compound is that amount of therapeutic agent that, when used alone or in combination with other therapies, provides a therapeutic benefit in the treatment of a disease, disorder, or condition.
- the term "therapeutically effective amount” may include an amount that improves overall treatment, reduces or avoids symptoms or causes of a disease or disorder, or enhances the therapeutic effect of other therapeutic agents.
- a prophylactically effective amount of a compound as used herein is an amount sufficient to prevent a disease, disorder or condition, or to prevent one or more symptoms associated with a disease, disorder or condition, or to prevent a disease , the amount of recurrence of a disorder or condition.
- a prophylactically effective amount of a compound is that amount of therapeutic agent that, when used alone or in combination with other agents, provides a prophylactic benefit in preventing a disease, disorder, or condition.
- the term “prophylactically effective amount” may include an amount that improves overall prophylaxis, or an amount that enhances the prophylactic effect of other prophylactic agents.
- Combination and related terms refer to the simultaneous or sequential administration of a compound of the invention and another therapeutic agent.
- the compounds of the present invention may be administered simultaneously or sequentially with other therapeutic agents in separate unit dosage forms, or with other therapeutic agents in a single unit dosage form.
- Figures 1 to 4 show the results of the in vivo pharmacodynamic study of the LU99CDX model.
- the "compounds of the present invention” refer to the following compounds of formula (I), formula (II), and their pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, and prodrugs , polymorphs, hydrates or solvates.
- the present invention relates to a compound of formula (X), or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvent thereof Compound:
- Ring A is C 6-10 aryl or 5-10 membered heteroaryl
- L 1 is NH or CHR x ;
- L 2 is CR x R y ;
- L 3 is -C(O)-, -S(O)- or -S(O) 2 -;
- R x and R y are independently H, D, C 1-6 alkyl or C 1-6 haloalkyl
- L 1 is CHR x and L 2 is CR x R y , the two R x groups can be combined to form a chemical bond or a C 1-4 alkylene group;
- n 0, 1, 2, 3 or 4;
- R 4 is selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl
- X 1 is a C atom or N atom, which is optionally substituted by R 2b ;
- X 2 is a C atom or N atom, which is optionally substituted by R 2c ;
- X 3 is a C atom or N atom, which is optionally substituted by R 2d ;
- R 2a is selected from H, D, CN, OR a , NR b R c , C(O)OR a or C(O)NR b R c ;
- R 2b is selected from H, D, halogen, C(O)OR a , C(O)NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl or 3- 10-membered heterocyclyl;
- R 2c is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R 2d is selected from H, D, halogen, CN, NO 2 , OR a , NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 5-10 cycloalkyl, 5-10 membered hetero Ring group, C 6-10 aryl group or 5-10 membered heteroaryl group;
- R 3 is selected from -C 1-6 alkylene -OR a , -C 1-6 alkylene -NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl , C 2-6 alkynyl, -LC 3-10 cycloalkyl, -L-3-10 membered heterocyclyl, -LC 6-10 aryl or -L-5-10 membered heteroaryl, which is optional Replaced by 1, 2 or 3 R 3s1 and 1 R 3s2 ;
- L is a chemical bond, C 1-6 alkylene, C 2-6 alkenylene or C 2-6 alkynylene, which is optionally substituted by 1, 2 or 3 R;
- R 3s1 is selected from H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 3-10 yuan Heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl;
- R 3s2 is selected from H, D, -L-OR a , -L-NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 5-10 membered heterocycle base, C 6-10 aryl or 5-10 membered heteroaryl, which is optionally substituted by 1, 2 or 3 R 3s ;
- R 3s1 , R 3s2 and the carbon atoms to which they are connected together form a C 3-10 cycloalkyl group
- R and R 3s are independently selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 3-10 membered heterocyclyl, C 6-10 Aryl or 5-10 membered heteroaryl; or R b , R c and the atoms they are connected together form a 5-10 membered heterocyclic group;
- the present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, isotopic variants, tautomers thereof Body, stereoisomer, prodrug, polymorph, hydrate or solvate:
- Ring A is C 6-10 aryl or 5-10 membered heteroaryl
- L 1 is NH or CHR x ;
- L 2 is CR x R y ;
- L 3 is -C(O)-, -S(O)- or -S(O) 2 -;
- R x and R y are independently H, D, C 1-6 alkyl or C 1-6 haloalkyl
- L 1 is CHR x and L 2 is CR x R y , the two R x groups can be combined to form a chemical bond or a C 1-4 alkylene group;
- R 1 is selected from H, D, halogen, CN, NO 2 , -L-OR a , -L-SR a , -L-NR b R c , SF 5 , C(O)R a , C(O)OR a , C(O)NR b R c , OC(O)R a , NR b C(O)R c , S(O)R a , S(O) 2 R a , S(O)OR a , S (O) 2 OR a , S(O)NR b R c , S(O) 2 NR b R c , P(O)(R a ) 2 , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, -LC 3-7 cycloalkyl, -L-3-7-membered heterocyclyl, -LC 6-10 aryl or
- n 0, 1, 2, 3 or 4;
- X 1 is a C atom or N atom, which is optionally substituted by R 2b ;
- X 2 is a C atom or N atom, which is optionally substituted by R 2c ;
- X 3 is a C atom or N atom, which is optionally substituted by R 2d ;
- R 2a is selected from H, D, CN, OR a , NR b R c , C(O)OR a or C(O)NR b R c ;
- R 2b is selected from H, D, halogen, C(O)OR a , C(O)NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl or 3- 10-membered heterocyclyl;
- R 2c is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R 2d is selected from H, D, halogen, CN, NO 2 , OR a , NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 5-10 cycloalkyl, 5-10 membered hetero Ring group, C 6-10 aryl group or 5-10 membered heteroaryl group;
- R 3 is selected from -C 1-6 alkylene -OR a , -C 1-6 alkylene -NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl , C 2-6 alkynyl, -LC 3-10 cycloalkyl, -L-3-10 membered heterocyclyl, -LC 6-10 aryl or -L-5-10 membered heteroaryl, which is optional Replaced by 1, 2 or 3 R 3s1 and 1 R 3s2 ;
- L is a chemical bond, C 1-6 alkylene, C 2-6 alkenylene or C 2-6 alkynylene, which is optionally substituted by 1, 2 or 3 R;
- R 3s1 is selected from H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 3-10 yuan Heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl;
- R 3s2 is selected from H, D, -L-OR a , -L-NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 5-10 membered heterocycle base, C 6-10 aryl or 5-10 membered heteroaryl, which is optionally substituted by 1, 2 or 3 R 3s ;
- R and R 3s are independently selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl; or R b , R c and the atoms to which they are connected together form a 5-10 membered heterocyclyl group ;
- Ring A is C 6-10 aryl, preferably phenyl; in another embodiment, Ring A is 5-10 membered heteroaryl, preferably 5-10 membered heteroaryl, such as phenyl , pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl, especially pyridyl or pyridazinyl.
- L 1 is NH; in another embodiment, L 1 is CHR x ; in another embodiment, L 1 is NH and L 2 is CR x R y , -L 1 -L 2 - preferably -L 1 -L 2 - preferably In another embodiment, L 1 is CHR x and L 2 is CR x Ry , -L 1 -L 2 - is preferably In another embodiment, L 3 is -C(O)-; in another embodiment, L 3 is -S(O)-; in another embodiment, L 3 is -S(O) 2 -.
- R 1 is selected from H, D, halogen, CN, NO 2 , -L-OR a , -L-SR a , -L-NR b R c , SF 5 , C 1- 6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, -LC 3-7 cycloalkyl, -L-3-7 membered heterocyclyl, -LC 6-10 Aryl or -L-5-10 membered heteroaryl; in another more specific embodiment, R 1 is selected from H, D, halogen, CN, NO 2 , -L-OR a , -L-SR a , -L-NR b R c , SF 5 , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, -LC 3-7 cycloalkyl, - L-3-7 membere
- X 1 is a C atom; in another embodiment, X 1 is an N atom; in another embodiment, X 1 is CR 2b ; in another embodiment, X 1 is NR 2b ; In one embodiment, X 2 is a C atom; in another embodiment, X 2 is an N atom; in another embodiment, X 2 is CR 2c ; in another embodiment, X 2 is NR 2c ; In one embodiment, X 3 is a C atom; in another embodiment, X 3 is an N atom; in another embodiment, X 3 is CR 2d ; in another embodiment, X 3 is NR 2d .
- X 1 , X 2 and their substituents together form a C 5-10 cycloalkyl group; in another more specific embodiment, X 1 , X 2 and their substituents together form Forming a 5-10 membered heterocyclyl group; in another more specific embodiment, X 1 , X 2 and their substituents together form a C 6-10 aryl group; in another more specific embodiment, X 1 , X 2 and their substituents together form a 5-10 membered heteroaryl; in another more specific embodiment, X 1 , 7-membered heterocyclyl, phenyl or 5-6 membered heteroaryl; in another more specific embodiment, X 1 , X 2 and their substituents together form Preferably form Preferably form Preferably form Preferably form Preferably form Preferably form Preferably form Preferably form Preferably form Preferably form Preferably form Preferably form Preferably form Preferably form Preferably form Preferably form Preferably form Preferably
- R 2a is H; in another embodiment, R 2a is D; in another embodiment, R 2a is CN; in another embodiment, R 2a is OR a ; in another In one embodiment, R 2a is NR b R c ; in another embodiment, R 2a is C(O)OR a ; in another embodiment, R 2a is C(O)NR b R c .
- R 2a is selected from H, D, CN, OR a or NR b R c ; in another more specific embodiment, R 2a is selected from OR a or NR b R c ; in another more specific embodiment, R 2a is selected from OMe or NH 2 , preferably NH 2 .
- R 2b is H; in another embodiment, R 2b is D; in another embodiment, R 2b is halogen; in another embodiment, R 2b is C(O)OR a ; In another embodiment, R 2b is C(O)NR b R c ; In another embodiment, R 2b is C 1-6 alkyl; In another embodiment, R 2b is C 1 -6 haloalkyl; in another embodiment, R 2b is C 3-10 cycloalkyl; in another embodiment, R 2b is 3-10 membered heterocyclyl.
- R 2b is selected from H, D, halogen, C(O)OR a , C(O)NR b R c , C 1-6 alkyl, C 1-6 halo Alkyl, C 3-10 cycloalkyl or 3-10 membered heterocyclyl; in another more specific embodiment, R 2b is selected from H, D, halogen, C(O)NR b R c , C 1 -6 alkyl, C 1-6 haloalkyl or 4-6 membered heterocyclyl; in another more specific embodiment, R 2b is selected from H, D, halogen, C(O)NR b R c , C 1-6 alkyl or C 1-6 haloalkyl; in another more specific embodiment, R 2b is selected from H, D, halogen, C(O)NR b R c or C 1-6 alkyl; in In another more specific embodiment, R 2b is selected from H, F, Cl, Br, Me, CH 2 CH 3 ,
- R 2c is H; in another embodiment, R 2c is D; in another embodiment, R 2c is halogen; in another embodiment, R 2c is C 1-6 alkane group; in another embodiment, R 2c is C 1-6 haloalkyl.
- R 2c is selected from H, halogen or Me; preferably selected from H or Me.
- R 2d is H; in another embodiment, R 2d is D; in another embodiment, R 2d is halogen; in another embodiment, R 2d is CN; in another In an embodiment, R 2d is NO 2 ; in another embodiment, R 2d is OR a ; in another embodiment, R 2d is NR b R c ; in another embodiment, R 2d is C 1 -6 alkyl; in another embodiment, R 2d is C 1-6 haloalkyl; in another embodiment, R 2d is C 5-10 cycloalkyl; in another embodiment, R 2d is 5-10 membered heterocyclyl; in another embodiment, R 2d is C 6-10 aryl; in another embodiment, R 2d is 5-10 membered heteroaryl.
- R 2d is selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl; in another more specific embodiment, R 2d is selected from H or D.
- R 3 is -C 1-6 alkylene-OR a ; in another embodiment, R 3 is -C 1-6 alkylene -NR b R c ; in another embodiment In another embodiment, R 3 is C 1-6 alkyl; in another embodiment, R 3 is C 1-6 haloalkyl; in another embodiment, R 3 is C 2-6 alkenyl; in another embodiment In another embodiment, R 3 is C 2-6 alkynyl; in another embodiment, R 3 is -LC 3-10 cycloalkyl; in another embodiment, R 3 is -L-3-10 membered hetero Cyclic group; in another embodiment, R 3 is -LC 6-10 aryl; in another embodiment, R 3 is -L-5-10 membered heteroaryl; in another embodiment, R 3 is optionally replaced by 1, 2 or 3 R 3s1 and 1 R 3s2 .
- R 3 is selected from C 1-6 alkyl, C 1-6 haloalkyl, -LC 3-10 cycloalkyl, -L-3-10 membered heterocyclyl, -LC 6 -10 aryl or -L-5-10 membered heteroaryl; in another more specific embodiment, R 3 is selected from C 1-6 alkyl, C 1-6 haloalkyl, C 5-6 cycloalkyl base, 5-6 membered heterocyclyl, phenyl or 5-6 membered heteroaryl; in another more specific embodiment, R 3 is selected from Me, Et, iPr, cyclopropyl, cyclobutyl,
- L is a chemical bond; in another embodiment, L is C 1-6 alkylene; in another embodiment, L is C 2-6 alkenylene; in another embodiment , L is C 2-6 alkynylene; in another embodiment, L is optionally substituted by 1, 2 or 3 R.
- R 3s1 is H; in another embodiment, R 3s1 is D; in another embodiment, R 3s1 is halogen; in another embodiment, R 3s1 is C 1-6 alkane group; in another embodiment, R 3s1 is C 1-6 haloalkyl; in another embodiment, R 3s1 is C 2-6 alkenyl; in another embodiment, R 3s1 is C 2-6 Alkynyl; in another embodiment, R 3s1 is C 3-10 cycloalkyl; in another embodiment, R 3s1 is 3-10 membered heterocyclyl; in another embodiment, R 3s1 is C 6-10 aryl; in another embodiment, R 3s1 is 5-10 membered heteroaryl.
- R 3s1 is selected from H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3- 10 cycloalkyl, 3-10 membered heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl; in another more specific embodiment, R 3s1 is selected from H, D, halogen, C 1 -6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3-6 membered heterocyclyl; in another more specific embodiment, R 3s1 is selected from H, D, C 1-6 Alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3-6 membered heterocyclyl; in another more specific embodiment, R 3s1 is selected from H, D, C 1-6 alkyl , C 1-6 haloalkyl or C 3-6 cycloalkyl; in another more specific embodiment, R 3s1 is
- R 3s2 is H; in another embodiment, R 3s2 is D; in another embodiment, R 3s2 is -L-OR a ; in another embodiment, R 3s2 is - L-NR b R c ; in another embodiment, R 3s2 is C 1-6 alkyl; in another embodiment, R 3s2 is C 1-6 haloalkyl; in another embodiment, R 3s2 is C 3-10 cycloalkyl; in another embodiment, R 3s2 is 5-10 membered heterocyclyl; in another embodiment, R 3s2 is C 6-10 aryl; in another embodiment , R 3s2 is a 5-10 membered heteroaryl group; in another embodiment, R 3s2 is optionally substituted by 1, 2 or 3 R 3s .
- R 3s2 is selected from H, D, -L-OR a , -L-NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 ring Alkyl, 5-10 membered heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl; in another more specific embodiment, R 3s2 is selected from H, D, -L-OR a , -L-NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 5-7 cycloalkyl, 5-7 membered heterocyclyl, C 6-10 aryl or 5-10 membered hetero Aryl; in another more specific embodiment, R 3s2 is selected from H, D, -L-OR a , C 1-6 alkyl, C 1-6 haloalkyl, C 5-7 cycloalkyl, benzene group or 5-10 membered heteroaryl; in another more specific embodiment
- R is H; in another embodiment, R is D; in another embodiment, R is halogen; in another embodiment, R is C 1-6 alkyl; in another In one embodiment, R is C 1-6 haloalkyl.
- R 3s is H; in another embodiment, R 3s is D; in another embodiment, R 3s is halogen; in another embodiment, R 3s is C 1-6 alkane group; in another embodiment, R 3s is C 1-6 haloalkyl.
- Ra , Rb , and Rc are independently H; in another embodiment, Ra , Rb, and Rc are independently D; in another embodiment, Ra , R b and R c are independently C 1-6 alkyl; in another embodiment, R a , R b and R c are independently C 1-6 haloalkyl; in another embodiment, R a , R b and R c are independently C 3-10 cycloalkyl; in another embodiment, R a , R b and R c are independently 3-10 membered heterocyclyl; in another embodiment, R a , R b and R c are independently C 6-10 aryl; in another embodiment, R a , R b and R c are independently 5-10 membered heteroaryl; in another embodiment, R b , R c and the atoms to which they are connected together form a 5-10 membered heterocyclic group, preferably a 5-6 membered heterocyclic group.
- any technical solution or any combination thereof in any of the above specific embodiments may be combined with any technical solution or any combination thereof in other specific embodiments.
- any technical solution of ring A or any combination thereof can be combined with L 1 , L 2 , L 3 , R x , Ry , R 1 , m, X 1 , X 2 , X 3 , R 2a , R 2b , R 2c , R 2d , R 3 , L, R, R 1s , R 2s , R 3s , R 3s1 , R 3s2 , R a , R b and R c , etc. or any combination thereof.
- the present invention is intended to include the combination of all these technical solutions. Due to space limitations, it does not List them one by one again.
- the invention provides compounds of formula (X), or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates thereof substance or solvate:
- Ring A is C 6-10 aryl or 5-10 membered heteroaryl
- L 1 is NH or CHR x ;
- L 2 is CR x R y ;
- L 3 is -C(O)-, -S(O)- or -S(O) 2 -;
- R x and R y are independently H, D, C 1-6 alkyl or C 1-6 haloalkyl
- L 1 is CHR x and L 2 is CR x R y , the two R x groups can be combined to form a chemical bond or a C 1-4 alkylene group;
- n 0, 1, 2, 3 or 4;
- R 4 is selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl
- X 1 is a C atom or N atom, which is optionally substituted by R 2b ;
- X 2 is a C atom or N atom, which is optionally substituted by R 2c ;
- X 3 is a C atom or N atom, which is optionally substituted by R 2d ;
- R 2a is selected from H, D, CN, OR a , NR b R c , C(O)OR a or C(O)NR b R c ;
- R 2b is selected from H, D, halogen, C(O)OR a , C(O)NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl or 3- 10-membered heterocyclyl;
- R 2c is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R 2d is selected from H, D, halogen, CN, NO 2 , OR a , NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 5-10 cycloalkyl, 5-10 membered hetero Ring group, C 6-10 aryl group or 5-10 membered heteroaryl group;
- R 3 is selected from -C 1-6 alkylene -OR a , -C 1-6 alkylene -NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl , C 2-6 alkynyl, -LC 3-10 cycloalkyl, -L-3-10 membered heterocyclyl, -LC 6-10 aryl or -L-5-10 membered heteroaryl, which is optional Replaced by 1, 2 or 3 R 3s1 and 1 R 3s2 ;
- L is a chemical bond, C 1-6 alkylene, C 2-6 alkenylene or C 2-6 alkynylene, which is optionally substituted by 1, 2 or 3 R;
- R 3s1 is selected from H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 3-10 yuan Heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl;
- R 3s2 is selected from H, D, -L-OR a , -L-NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 5-10 membered heterocycle base, C 6-10 aryl or 5-10 membered heteroaryl, which is optionally substituted by 1, 2 or 3 R 3s ;
- R and R 3s are independently selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 3-10 membered heterocyclyl, C 6-10 Aryl or 5-10 membered heteroaryl; or R b , R c and the atoms they are connected together form a 5-10 membered heterocyclic group;
- the invention provides compounds of formula (I), or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates thereof substance or solvate:
- Ring A is C 6-10 aryl or 5-10 membered heteroaryl
- L 1 is NH or CHR x ;
- L 2 is CR x R y ;
- L 3 is -C(O)-, -S(O)- or -S(O) 2 -;
- R x and R y are independently H, D, C 1-6 alkyl or C 1-6 haloalkyl
- L 1 is CHR x and L 2 is CR x R y , the two R x groups can be combined to form a chemical bond or a C 1-4 alkylene group;
- R 1 is selected from H, D, halogen, CN, NO 2 , -L-OR a , -L-SR a , -L-NR b R c , SF 5 , C(O)R a , C(O)OR a , C(O)NR b R c , OC(O)R a , NR b C(O)R c , S(O)R a , S(O) 2 R a , S(O)OR a , S (O) 2 OR a , S(O)NR b R c , S(O) 2 NR b R c , P(O)(R a ) 2 , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, -LC 3-7 cycloalkyl, -L-3-7-membered heterocyclyl, -LC 6-10 aryl or
- n 0, 1, 2, 3 or 4;
- X 1 is a C atom or N atom, which is optionally substituted by R 2b ;
- X 2 is a C atom or N atom, which is optionally substituted by R 2c ;
- X 3 is a C atom or N atom, which is optionally substituted by R 2d ;
- R 2a is selected from H, D, CN, OR a , NR b R c , C(O)OR a or C(O)NR b R c ;
- R 2b is selected from H, D, halogen, C(O)OR a , C(O)NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl or 3- 10-membered heterocyclyl;
- R 2c is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- X 1 , X 2 and their substituents together form C 5-10 cycloalkyl, 5-10 membered heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl group, which is optionally substituted by 1, 2 or 3 R 2s ;
- R 2d is selected from H, D, halogen, CN, NO 2 , OR a , NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 5-10 cycloalkyl, 5-10 membered hetero Ring group, C 6-10 aryl group or 5-10 membered heteroaryl group;
- R 3 is selected from -C 1-6 alkylene -OR a , -C 1-6 alkylene -NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl , C 2-6 alkynyl, -LC 3-10 cycloalkyl, -L-3-10 membered heterocyclyl, -LC 6-10 aryl or -L-5-10 membered heteroaryl, which is optional Replaced by 1, 2 or 3 R 3s1 and 1 R 3s2 ;
- L is a chemical bond, C 1-6 alkylene, C 2-6 alkenylene or C 2-6 alkynylene, which is optionally substituted by 1, 2 or 3 R;
- R 3s1 is selected from H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 3-10 yuan Heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl;
- R 3s2 is selected from H, D, -L-OR a , -L-NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 5-10 membered heterocycle base, C 6-10 aryl or 5-10 membered heteroaryl, which is optionally substituted by 1, 2 or 3 R 3s ;
- R and R 3s are independently selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl; or R b , R c and the atoms to which they are connected together form a 5-10 membered heterocyclyl group ;
- the invention provides the above-described compounds, or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvents thereof compound, wherein ring A is phenyl or 5-6 membered heteroaryl; preferably phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl.
- the invention provides the above-described compounds, or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvents thereof compound, wherein L 1 is NH, L 2 is CR x R y ; -L 1 -L 2 - is preferably -L 1 -L 2 - preferably
- the invention provides the above-described compounds, or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvents thereof compound, wherein L 1 is CHR x and L 2 is CR x R y ; -L 1 -L 2 - is preferably
- the invention provides the above-described compounds, or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvents thereof Compounds, wherein L 3 is -C(O)-.
- the invention provides the above-described compounds, or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvents thereof Compounds, wherein R 1 is selected from H, D, halogen, CN, NO 2 , -L-OR a , -L-SR a , -L-NR b R c , SF 5 , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, -LC 3-7 cycloalkyl, -L-3-7 membered heterocyclyl, -LC 6-10 aryl or - L-5-10 membered heteroaryl; preferably selected from H, D, halogen, CN, NO 2 , -L-OR a , -L-SR a , -L-NR b R c , SF 5 , C 1- 6 alky
- the invention provides the above-described compounds, or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvents thereof compound, among which, Selected from Preferably
- the invention provides the above-described compounds, or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvents thereof Compound, wherein R 2a is selected from H, D, CN, OR a or NR b R c ; preferably selected from OR a or NR b R c ; preferably selected from OMe or NH 2 ; preferably NH 2 .
- the invention provides the above-described compounds, or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvents thereof Compounds, wherein R 2b is selected from H, D, halogen, C(O)OR a , C(O)NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 ring Alkyl or 3-10 membered heterocyclyl; preferably selected from H, D, halogen, C(O)NR b R c , C 1-6 alkyl, C 1-6 haloalkyl or 4-6 membered heterocyclyl ;Preferably selected from H, D, halogen, C(O)NR b R c , C 1-6 alkyl or C 1-6 haloalkyl; preferably selected from H, D, halogen, C(O)NR b R c Or C 1-6 alkyl
- the present invention provides the above-mentioned compound of formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, Hydrate or solvate, wherein R 2c is selected from H or Me.
- the invention provides the above-described compounds, or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvents thereof Compounds , wherein X 1 , C 5-7 cycloalkyl, 5-7 membered heterocyclyl, phenyl or 5-6 membered heteroaryl; preferably formed Preferably form Preferably form Preferably form Preferably form Preferably form
- the present invention provides the above-mentioned compounds, or pharmaceutically acceptable salts, isotopic variants, tautomers thereof Isomers, stereoisomers, prodrugs, polymorphs, hydrates or solvates, wherein R 2d is selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl; preferably selected from H or D.
- the invention provides the above-described compounds, or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvents thereof Compound, wherein R 3 is selected from C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, -LC 3-10 cycloalkyl, -L-3 -10-membered heterocyclyl, -LC 6-10 aryl or -L-5-10-membered heteroaryl; preferably selected from C 1-6 alkyl, C 1-6 haloalkyl, -LC 3-10 cycloalkyl base, -L-3-10-membered heterocyclyl, -LC 6-10 aryl or -L-5-10-membered heteroaryl; preferably selected from C 1-6 alkyl, C 1-6 haloalkyl, C 5-6 cycloalkyl, 5-6 membered heteroaryl;
- the invention provides the above-described compounds, or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvents thereof Compounds, wherein R 3s1 is selected from H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl , 3-10 membered heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl; preferably selected from H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 3- 6 -cycloalkyl or 3-6-membered heterocyclyl; preferably selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3-6-membered heterocyclyl; Preferably selected from H, D, C halogen, C 1-6
- the invention provides the above-described compounds, or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvents thereof compound, wherein R 3s2 is selected from H, D, -L-OR a , -L-NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 5 -10-membered heterocyclyl, C 6-10 aryl or 5-10-membered heteroaryl; preferably selected from H, D, -L-OR a , -L-NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 5-7 cycloalkyl, 5-7 membered heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl; preferably selected from H, D, -L-OR a , C 1-6 alkyl, C 1-6 haloalky
- the invention provides the above-described compounds, or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvents thereof compound, which has the following structural formula:
- the invention provides the above-described compounds, or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvents thereof compound, which is a compound of formula (II), wherein,
- L 1 is NH or CHR x ;
- L 2 is CR x R y ;
- R x and R y are independently H, D, C 1-6 alkyl or C 1-6 haloalkyl
- L 1 is CHR x and L 2 is CR x R y , the two R x groups can be combined to form a chemical bond or a C 1-4 alkylene group;
- Z 1 is CH or N
- R 1 is H, D, halogen, CN, OR a , SR a , NR b R c , SF 5 , C 1-6 alkyl, C 1-6 haloalkyl, C 5-7 cycloalkyl or 5-7 One-membered heterocyclyl, optionally substituted by 1, 2 or 3 R 1s ;
- X 1 is a C atom or N atom, which is optionally substituted by R 2b ;
- X 2 is a C atom or N atom, which is optionally substituted by R 2c ;
- X 3 is a C atom or N atom, which is optionally substituted by R 2d ;
- R 2a is selected from H, D, OR a or NR b R c ;
- R 2b is selected from H, D, halogen, C(O)OR a , C(O)NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3- 6-membered heterocyclyl;
- R 2c is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R 2d is selected from H, D, halogen, CN, NO 2 , OR a , NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 5-10 cycloalkyl, 5-10 membered hetero Ring group, C 6-10 aryl group or 5-10 membered heteroaryl group;
- R 1s is selected from H, D, halogen, C(O)OR a , C(O)NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 5-7 cycloalkyl or 5- 7-membered heterocyclyl;
- R 3s1 is selected from H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3-6 membered heterocyclyl;
- R 3s2 is selected from H, D, -L-OR a , -L-NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 5-7 cycloalkyl, 5-7 membered heterocycle base, C 6-10 aryl or 5-10 membered heteroaryl, which is optionally substituted by 1, 2 or 3 R 3s ;
- L is a chemical bond or C 1-6 alkylene group, which is optionally substituted by 1, 2 or 3 R;
- R and R 3s are independently selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl; or R b , R c and the atoms to which they are connected together form a 5-10 membered heterocyclyl group ;
- the present invention provides the compound of formula (II) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, Hydrate or solvate, wherein,
- L 1 is NH or CHR x ;
- L 2 is CR x R y ;
- R x and R y are independently H, D, C 1-6 alkyl or C 1-6 haloalkyl
- Z 1 is CH or N
- R 1 is selected from H, D, halogen, CN, OR a , NR b R c , C 1-6 alkyl, C 1-6 haloalkyl or 5-6 membered heterocyclyl, wherein the heterocyclyl is optional Land is replaced by 1, 2 or 3 R 1s ;
- X 1 is a C atom or N atom, which is optionally substituted by R 2b ;
- X 2 is a C atom or N atom, which is optionally substituted by R 2c ;
- X 3 is a C atom or N atom, which is optionally substituted by R 2d ;
- R 2a is NH 2 ;
- R 2b is selected from H, D, halogen, C(O)OR a , C(O)NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3- 6-membered heterocyclyl;
- R 2c is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R 2d is selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl
- R 1s is selected from H, D, halogen, C(O)OR a , C(O)NR b R c , C 1-6 alkyl or C 1-6 haloalkyl;
- R 3s1 is selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3-6 membered heterocyclyl;
- R 3s2 is selected from H, D, -L-OR a , -L-NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 5-7 cycloalkyl, 5-7 membered heterocycle base, C 6-10 aryl or 5-10 membered heteroaryl, which is optionally substituted by 1, 2 or 3 R 3s ;
- L is a chemical bond or C 1-3 alkylene group, which is optionally substituted by 1, 2 or 3 R;
- R and R 3s are independently selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl.
- the present invention provides the compound of formula (II) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, Hydrate or solvate, wherein,
- L 1 is NH or CHR x ;
- L 2 is CR x R y ;
- R x and R y are independently H, D, C 1-3 alkyl or C 1-3 haloalkyl;
- Z 1 is CH or N
- R 1 is selected from H, D, CN, OR a , C 1-6 alkyl, C 1-6 haloalkyl or 5-6 membered heterocyclyl, which is optionally substituted by 1, 2 or 3 R 1s ;
- X 1 is a C atom or N atom, which is optionally substituted by R 2b ;
- X 2 is a C atom or N atom, which is optionally substituted by R 2c ;
- X 3 is a C atom or N atom, which is optionally substituted by R 2d ;
- R 2a is NH 2 ;
- R 2b is selected from H, D, halogen, C(O)NR b R c , C 1-6 alkyl, C 1-6 haloalkyl or 4-6 membered heterocyclyl;
- R 2c is selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl
- R 2d is selected from H or D
- R 1s is selected from H, D, halogen, C(O)OR a , C 1-6 alkyl or C 1-6 haloalkyl, preferably halogen or C(O)OCH 3 ;
- R 3s1 is selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl or C 3-6 cycloalkyl;
- R 3s2 is selected from H, D, -L-OR a , C 1-6 alkyl, C 1-6 haloalkyl, C 5-7 cycloalkyl, phenyl or 5-10 membered heteroaryl, which is optional is substituted by 1, 2 or 3 R 3s ; preferably, R 3s2 is selected from H, D, Me, CF 3 , CH 2 OCH 3 , cyclopropyl,
- L is a chemical bond or C 1-3 alkylene group, preferably methylene, which is optionally substituted by 1, 2 or 3 R;
- R and R 3s are independently selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl.
- the present invention provides the compound of formula (II) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, Hydrate or solvate, wherein,
- L 1 is NH
- R 1 is selected from H, D, halogen, CN, NO 2 , -L-OR a , -L-SR a , -L-NR b R c , SF 5 , C(O)R a , C(O)OR a , C(O)NR b R c , OC(O)R a , NR b C(O)R c , S(O)R a , S(O) 2 R a , S(O)OR a , S (O) 2 OR a , S(O)NR b R c , S(O) 2 NR b R c , P(O)(R a ) 2 , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, -LC 3-7 cycloalkyl, -L-3-7-membered heterocyclyl, -LC 6-10 aryl or
- n 0, 1, 2, 3 or 4;
- X 1 is a C atom, which is replaced by R 2b ;
- X 2 is a C atom or N atom, which is optionally substituted by R 2c ;
- X 3 is a C atom, which is replaced by R 2d ;
- R 2a is selected from H, D, CN, OR a , NR b R c , C(O)OR a or C(O)NR b R c ;
- R 2b is selected from H, D, halogen, C(O)OR a , C(O)NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl or 3- 10-membered heterocyclyl;
- R 2c is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R 2d is selected from H, D, halogen, CN, NO 2 , OR a , NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 5-10 cycloalkyl, 5-10 membered hetero Ring group, C 6-10 aryl group or 5-10 membered heteroaryl group;
- Z 1 is CH
- L is a chemical bond, C 1-6 alkylene, C 2-6 alkenylene or C 2-6 alkynylene, which is optionally substituted by 1, 2 or 3 R;
- R 3s1 is selected from H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 3-10 yuan Heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl;
- R 3s2 is selected from -L-OR a , -L-NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 5-10 membered heterocyclyl, C 6 -10 aryl or 5-10 membered heteroaryl, which is optionally substituted by 1, 2 or 3 R 3s ;
- R and R 3s are independently selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl; or R b , R c and the atoms to which they are connected together form a 5-10 membered heterocyclyl group ;
- each of the above defined groups is optionally deuterated, up to complete deuteration.
- the present invention provides the compound of formula (II) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, Hydrate or solvate, wherein,
- L 1 is NH
- R 1 is selected from H, D, halogen, CN, NO 2 , -L-OR a , -L-SR a , -L-NR b R c , SF 5 , C(O)R a , C(O)OR a , C(O)NR b R c , OC(O)R a , NR b C(O)R c , S(O)R a , S(O) 2 R a , S(O)OR a , S (O) 2 OR a , S(O)NR b R c , S(O) 2 NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2- 6 alkynyl, -LC 3-7 cycloalkyl, -L-3-7 membered heterocyclyl, -LC 6-10 aryl or -L-5-10 membered heteroaryl, which is
- n 0, 1, 2, 3 or 4;
- X 1 is a C atom, which is replaced by R 2b ;
- X 2 is a C atom or N atom, which is optionally substituted by R 2c ;
- X 3 is a C atom, which is replaced by R 2d ;
- R 2a is selected from H, D, CN, OR a or NR b R c ;
- R 2b is selected from H, D, halogen, C(O)OR a , C(O)NR b R c , C 1-6 alkyl or C 1-6 haloalkyl;
- R 2c is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R 2d is selected from H, D, halogen, CN, NO 2 , OR a , NR b R c , C 1-6 alkyl or C 1-6 haloalkyl;
- Z 1 is CH
- L is a chemical bond, C 1-6 alkylene group, C 2-6 alkenylene group or C 2-6 alkynylene group;
- R 3s1 is selected from H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl;
- R 3s2 is selected from -L-OR a , -L-NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 5-10 membered heterocyclyl, C 6 -10 aryl or 5-10 membered heteroaryl, which is optionally substituted by 1, 2 or 3 R 3s ;
- R 3s is independently selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl; or R b , R c and the atoms to which they are connected together form a 5-10 membered heterocyclyl group ;
- each of the above defined groups is optionally deuterated, up to complete deuteration.
- the present invention provides the compound of formula (II) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, Hydrate or solvate, wherein,
- L 1 is NH
- R 1 is selected from H, D, halogen, CN, NO 2 , -L-OR a , -L-SR a , -L-NR b R c , SF 5 , C(O)R a , C(O)OR a , C(O)NR b R c , S(O)R a , S(O) 2 R a , S(O)OR a , S(O) 2 OR a , S(O)NR b R c , S(O) 2 NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl , C 2-6 alkynyl, -LC 3-7 cycloalkyl, -L- 3-7 membered heterocyclyl, -LC 6-10 aryl or -L-5-10 membered heteroaryl, which is optionally substituted by 1, 2 or 3 R 1s ;
- n 0, 1, 2, 3 or 4;
- X 1 is a C atom, which is replaced by R 2b ;
- X 2 is a C atom or N atom, which is optionally substituted by R 2c ;
- X 3 is a C atom, which is replaced by R 2d ;
- R 2a is selected from H, D, CN, OR a or NR b R c ;
- R 2b is selected from H, D, halogen, C(O)OR a , C(O)NR b R c , C 1-6 alkyl or C 1-6 haloalkyl;
- R 2c is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R 2d is selected from H, D, halogen, CN, NO 2 , C 1-6 alkyl or C 1-6 haloalkyl;
- Z 1 is CH
- L is a chemical bond or C 1-6 alkylene group
- R 1s and R 2s are independently selected from H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl;
- R 3s1 is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R 3s2 is selected from -L-OR a , -L-NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 5-10 membered heterocyclyl, C 6 -10 aryl or 5-10 membered heteroaryl, which is optionally substituted by 1, 2 or 3 R 3s ;
- R 3s is independently selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl; or R b , R c and the atoms to which they are connected together form a 5-10 membered heterocyclyl group ;
- each of the above defined groups is optionally deuterated, up to complete deuteration.
- the present invention provides the compound of formula (II) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, Hydrate or solvate, wherein,
- L 1 is NH
- R 1 is selected from H, D, -L-OR a , -L-SR a , -L-NR b R c , SF 5 , C(O)R a , C(O)OR a , C(O)NR b R c , OC(O)R a , NR b C(O)R c , S(O)R a , S(O) 2 R a , S(O)OR a , S(O) 2 OR a , S(O)NR b R c , S(O) 2 NR b R c , P(O)(R a ) 2 , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, -LC 3-7 cycloalkyl or -L-5-10 membered heteroaryl, which is optionally substituted by 1, 2 or 3 R 1s ;
- n 0, 1, 2, 3 or 4;
- X 1 is a C atom, which is replaced by R 2b ;
- X 2 is a C atom, which is replaced by R 2c ;
- X 3 is a C atom, which is replaced by R 2d ;
- R 2a is selected from H, D, CN, OR a , NR b R c , C(O)OR a or C(O)NR b R c ;
- R 2b is selected from C(O)OR a , C(O)NR b R c , C 1-6 alkyl, C 1-6 haloalkyl;
- R 2c is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R 2d is selected from H, D, halogen, CN, NO 2 , OR a , NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 5-10 cycloalkyl, 5-10 membered hetero Ring group, C 6-10 aryl group or 5-10 membered heteroaryl group;
- Z 1 is CH
- L is a chemical bond, C 1-6 alkylene, C 2-6 alkenylene or C 2-6 alkynylene, which is optionally substituted by 1, 2 or 3 R;
- R 1s and R 2s are independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 3 -10-membered heterocyclyl, C 6-10 aryl or 5-10-membered heteroaryl;
- R 3s1 is selected from H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 3-10 yuan Heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl;
- R 3s2 is selected from -L-OR a , -L-NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 5-10 membered heterocyclyl, C 6 -10 aryl or 5-10 membered heteroaryl, which is optionally substituted by 1, 2 or 3 R 3s ;
- R and R 3s are independently selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl; or R b , R c and the atoms to which they are connected together form a 5-10 membered heterocyclyl group ;
- each of the above defined groups is optionally deuterated, up to complete deuteration.
- the present invention provides the compound of formula (II) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, Hydrate or solvate, wherein,
- L 1 is NH
- R 1 is selected from H, D, -L-OR a , -L-SR a , -L-NR b R c , C(O)R a , C(O)OR a , C(O)NR b R c ,S(O)R a ,S(O) 2 R a ,S(O)OR a ,S(O) 2 OR a ,S(O)NR b R c ,S(O) 2 NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, -LC 3-7 cycloalkyl or -L-5-10 membered heteroaryl, any of which Choose to be replaced by 1, 2 or 3 R 1s ;
- n 0, 1, 2, 3 or 4;
- X 1 is a C atom, which is replaced by R 2b ;
- X 2 is a C atom, which is replaced by R 2c ;
- X 3 is a C atom, which is replaced by R 2d ;
- R 2a is selected from H, D, CN, OR a or NR b R c ;
- R 2b is selected from C(O)OR a , C(O)NR b R c , C 1-6 alkyl, C 1-6 haloalkyl;
- R 2c is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R 2d is selected from H, D, halogen or CN;
- Z 1 is CH
- L is a chemical bond, C 1-6 alkylene group, C 2-6 alkenylene group or C 2-6 alkynylene group;
- R 1s and R 2s are independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl;
- R 3s1 is selected from H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl;
- R 3s2 is selected from -L-OR a , -L-NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 5-10 membered heterocyclyl, C 6 -10 aryl or 5-10 membered heteroaryl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl; or R b , R c and the atoms to which they are connected together form a 5-10 membered heterocyclyl group ;
- each of the above defined groups is optionally deuterated, up to complete deuteration.
- the present invention provides the compound of formula (II) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, Hydrate or solvate, wherein,
- L 1 is NH
- R 1 is selected from H, D, OR a , SR a , NR b R c , C(O)R a , S(O)R a , S(O) 2 R a , C 1-6 alkyl, C 1 -6 haloalkyl, C 3-7 Cycloalkyl or 5-10 membered heteroaryl, which is optionally substituted by 1, 2 or 3 R 1s ;
- n 0, 1, 2, 3 or 4;
- X 1 is a C atom, which is replaced by R 2b ;
- X 2 is a C atom, which is replaced by R 2c ;
- X 3 is a C atom, which is replaced by R 2d ;
- R 2a is selected from OR a or NR b R c ;
- R 2b is selected from C(O)OR a , C(O)NR b R c , C 1-6 alkyl, C 1-6 haloalkyl;
- R 2c is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R 2d is selected from H, D, halogen or CN;
- Z 1 is CH
- L is a chemical bond or C 1-6 alkylene group
- R 1s and R 2s are independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl;
- R 3s1 is selected from H, D, halogen, C 1-4 alkyl or C 1-4 haloalkyl;
- R 3s2 is selected from -L-OR a , -L-NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 5-10 membered heterocyclyl, C 6 -10 aryl or 5-10 membered heteroaryl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl; or R b , R c and the atoms to which they are connected together form a 5-10 membered heterocyclyl group ;
- each of the above defined groups is optionally deuterated, up to complete deuteration.
- the present invention provides the compound of formula (II) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, Hydrate or solvate, wherein,
- L 1 is NH
- R 1 is selected from H, D, OR a , SR a , NR b R c , C(O)R a , S(O)R a , S(O) 2 R a , C 1-6 alkyl, C 1 -6 haloalkyl, C 3-7 cycloalkyl or 5-10 membered heteroaryl, which is optionally substituted by 1, 2 or 3 R 1s ;
- n 0, 1, 2, 3 or 4;
- X 1 is a C atom, which is replaced by R 2b ;
- X 2 is a C atom, which is replaced by R 2c ;
- X 3 is a C atom, which is replaced by R 2d ;
- R 2a is selected from OR a or NR b R c ;
- R 2b is selected from C(O)OR a , C(O)NR b R c or C 1-6 alkyl;
- R 2c is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R 2d is selected from H, D, halogen or CN;
- Z 1 is CH
- L is a chemical bond or C 1-6 alkylene group
- R 1s and R 2s are independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl;
- R 3s1 is selected from Me
- R 3s2 is selected from Et
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl; or R b , R c and the atoms to which they are connected together form a 5-10 membered heterocyclyl group ;
- each of the above defined groups is optionally deuterated, up to complete deuteration.
- the present invention provides the compound of formula (II) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, Hydrate or solvate, wherein,
- L 1 is NH
- R 1 is selected from H, D, OR a , SR a , NR b R c , C(O)R a , S(O)R a , S(O) 2 R a , C 1-6 alkyl, C 1 -6 haloalkyl, C 3-7 cycloalkyl or 5-6 membered heteroaryl, which is optionally substituted by 1, 2 or 3 R 1s ;
- n 0, 1, 2, 3 or 4;
- X 3 is a C atom, which is replaced by R 2d ;
- R 2a is selected from OR a or NR b R c ;
- X 1 , X 2 and their substituents together form a 5-6 membered heteroaryl group, which is optionally substituted by 1, 2 or 3 R 2s ;
- R 2d is selected from H, D, halogen or CN;
- Z 1 is CH
- R 1s and R 2s are independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl;
- R 3s1 is selected from H or D
- R 3s2 is selected from C 3-6 cycloalkyl, 5-6 membered heterocyclyl, phenyl or 5-6 membered heteroaryl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl; or R b , R c and the atoms to which they are connected together form a 5-10 membered heterocyclyl group ;
- each of the above defined groups is optionally deuterated, up to complete deuteration.
- the present invention provides the compound of formula (II) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, Hydrate or solvate, wherein,
- L 1 is NH
- R 1 is selected from H, D, OR a , SR a , NR b R c , C(O)R a , S(O)R a , S(O) 2 R a , C 1-6 alkyl, C 1 -6 haloalkyl, C 3-7 cycloalkyl or 5-6 membered heteroaryl, which is optionally substituted by 1, 2 or 3 R 1s ;
- n 0, 1, 2, 3 or 4;
- X 3 is a C atom, which is replaced by R 2d ;
- R 2a is selected from OR a or NR b R c ;
- X 1 , X 2 and their substituents together form a 5-6 membered heteroaryl group, which is optionally substituted by 1, 2 or 3 R 2s ;
- R 2d is selected from H, D, halogen or CN;
- Z 1 is CH
- L is a chemical bond or C 1-6 alkylene group
- R 1s and R 2s are independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl;
- R 3s1 is selected from C 1-4 alkyl or C 1-4 haloalkyl
- R 3s2 is selected from -L-OR a , -L-NR b R c , C 1-6 alkyl or C 1-6 haloalkyl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl; or R b , R c and the atoms to which they are connected together form a 5-10 membered heterocyclyl group ;
- each of the above defined groups is optionally deuterated, up to complete deuteration.
- the present invention provides the compound of formula (III) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, Hydrate or solvate, wherein,
- L 1 is NH or CHR x ;
- L 2 is CR x R y ;
- R x and R y are independently H, D, C 1-6 alkyl or C 1-6 haloalkyl
- L 1 is CHR x and L 2 is CR x R y , the two R x groups can be combined to form a chemical bond or a C 1-4 alkylene group;
- Z 1 is CH or N
- R 1 is selected from H, D, halogen, CN, OR a , SR a , NR b R c , SF 5 , C 1-6 alkyl, C 1-6 haloalkyl, C 5-7 cycloalkyl or 5- 7-membered heterocyclyl, optionally substituted by 1, 2 or 3 R 1s ;
- X 1 is a C atom or N atom, which is optionally substituted by R 2b ;
- X 2 is a C atom or N atom, which is optionally substituted by R 2c ;
- X 3 is a C atom or N atom, which is optionally substituted by R 2d ;
- R 2b is selected from H, D, halogen, C(O)OR a , C(O)NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3- 6-membered heterocyclyl;
- R 2c is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R 2d is selected from H or D
- R 1s is selected from H, D, halogen, C(O)OR a , C(O)NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 5-7 cycloalkyl or 5- 7-membered heterocyclyl;
- R 3s1 is selected from H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3-6 membered heterocyclyl;
- R 3s is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl; or R b , R c and the atoms to which they are connected together form a 5-10 membered heterocyclyl group ;
- each of the above-mentioned bases in L 1 , L 2 , R x , R y , Z 1 , R 1 , R 2b , R 2c , R 1s , R 2s , R 3s1 , R 3s , R a , R b and R c Group definitions are optionally deuterated until fully deuterated.
- the present invention provides the compound of formula (III) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, Hydrate or solvate, wherein,
- L 1 is NH or CHR x ;
- L 2 is CR x R y ;
- R x and R y are independently H, D, C 1-6 alkyl or C 1-6 haloalkyl
- Z 1 is CH or N
- R 1 is selected from H, D, halogen, CN, OR a , NR b R c , C 1-6 alkyl, C 1-6 haloalkyl or 5-6 membered heterocyclyl, wherein the heterocyclyl is optional Land is replaced by 1, 2 or 3 R 1s ;
- X 1 is a C atom or N atom, which is optionally substituted by R 2b ;
- X 2 is a C atom or N atom, which is optionally substituted by R 2c ;
- X 3 is a C atom or N atom, which is optionally substituted by R 2d ;
- R 2b is selected from H, D, halogen, C(O)OR a , C(O)NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3- 6-membered heterocyclyl;
- R 2c is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R 2d is selected from H or D
- R 1s is selected from H, D, halogen, C(O)OR a , C(O)NR b R c , C 1-6 alkyl or C 1-6 haloalkyl;
- R 3s1 is selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3-6 membered heterocyclyl;
- R 3s is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl.
- the present invention provides the compound of formula (III) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, Hydrate or solvate, wherein,
- L 1 is NH or CHR x ;
- L 2 is CR x R y ;
- R x and R y are independently H, D, C 1-3 alkyl or C 1-3 haloalkyl;
- Z 1 is CH or N
- R 1 is selected from H, D, CN, OR a , C 1-6 alkyl, C 1-6 haloalkyl or 5-6 membered heterocyclyl, which is optionally substituted by 1, 2 or 3 R 1s ;
- X 1 is a C atom or N atom, which is optionally substituted by R 2b ;
- X 2 is a C atom or N atom, which is optionally substituted by R 2c ;
- X 3 is a C atom or N atom, which is optionally substituted by R 2d ;
- R 2b is selected from H, D, halogen, C(O)NR b R c , C 1-6 alkyl, C 1-6 haloalkyl or 4-6 membered heterocyclyl;
- R 2c is selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl
- R 2d is selected from H or D
- R 1s is selected from H, D, halogen, C(O)OR a , C 1-6 alkyl or C 1-6 haloalkyl, preferably halogen or C(O)OCH 3 ;
- R 3s1 is selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl or C 3-6 cycloalkyl;
- R 3s is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl.
- the present invention provides the compound of formula (III) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, Hydrate or solvate, wherein,
- L 1 -L 2 is:
- Z 1 is CH or N
- R 1 is CF 3 , CN, OCF 3 , OCH 2 CH 3 , Preferably CF 3 ;
- X 1 is a C atom or N atom, which is optionally substituted by R 2b ;
- X 2 is a C atom or N atom, which is optionally substituted by R 2c ;
- X 3 is a C atom or N atom, which is optionally substituted by R 2d ;
- R 2b is H, F, Cl, Br, Me, CH 2 CH 3 , C(O)NH 2 or
- R 2c is H or Me
- R 2d is H
- R 3s1 is H, Me or cyclopropyl
- R 3s is H
- the invention provides the above formula (IV), (IV-1), (IV-1a), (IV-1b), (IV-2), (IV-2a) or (IV -2b) Compounds, or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvates thereof, wherein,
- R 1 is selected from H, D, halogen, CN, NO 2 , -L-OR a , -L-SR a , -L-NR b R c , SF 5 , C(O)R a , C(O)OR a , C(O)NR b R c , OC(O)R a , NR b C(O)R c , S(O)R a , S(O) 2 R a , S(O)OR a , S (O) 2 OR a , S(O)NR b R c , S(O) 2 NR b R c , P(O)(R a ) 2 , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, -LC 3-7 cycloalkyl, -L-3-7-membered heterocyclyl, -LC 6-10 aryl or
- n 0, 1 or 2;
- R 4 is selected from H or D
- X 1 is a C atom, which is replaced by R 2b ;
- X 2 is a C atom or N atom, which is optionally substituted by R 2c ;
- X 3 is a C atom, which is replaced by R 2d ;
- R 2a is selected from H, D, CN, OR a , NR b R c , C(O)OR a or C(O)NR b R c ;
- R 2b is selected from H, D, halogen, C(O)OR a , C(O)NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl or 3- 10-membered heterocyclyl;
- R 2c is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R 2d is selected from H, D, halogen, CN, NO 2 , OR a , NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 5-10 cycloalkyl, 5-10 membered hetero Ring group, C 6-10 aryl group or 5-10 membered heteroaryl group;
- Z 1 is CH
- Z 2 is CR 1 or N
- Z 3 is CR 1 or N
- L is a chemical bond, C 1-6 alkylene, C 2-6 alkenylene or C 2-6 alkynylene, which is optionally substituted by 1, 2 or 3 R;
- R 3s1 is selected from H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 3-10 yuan Heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl;
- R 3s2 is selected from H, D, -L-OR a , -L-NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 5-10 membered heterocycle base, C 6-10 aryl or 5-10 membered heteroaryl, which is optionally substituted by 1, 2 or 3 R 3s ;
- R and R 3s are independently selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 3-10 membered heterocyclyl, C 6-10 Aryl or 5-10 membered heteroaryl; or R b , R c and the atoms they are connected together form a 5-10 membered heterocyclic group;
- each of the above defined groups is optionally deuterated, up to complete deuteration.
- the invention provides the above formula (IV), (IV-1), (IV-1a), (IV-1b), (IV-2), (IV-2a) or (IV -2b) Compounds, or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvates thereof, wherein,
- R 1 is selected from H, D, halogen, CN, NO 2 , OR a , SR a , NR b R c , SF 5 , C(O)R a , C(O)OR a , C(O)NR b R c , OC(O)R a , NR b C(O)R c , S(O)R a , S(O) 2 R a , S(O)OR a , S(O) 2 OR a , S( O)NR b R c , S(O) 2 NR b R c , P(O)(R a ) 2 , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2 -6 alkynyl, C 3-7 cycloalkyl, 3-7 membered heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl, which is optionally substituted by 1,
- n 0, 1 or 2;
- R 4 is selected from H or D
- X 1 is a C atom, which is replaced by R 2b ;
- X 2 is a C atom or N atom, which is optionally substituted by R 2c ;
- X 3 is a C atom, which is replaced by R 2d ;
- R 2a is selected from H, D, CN, OR a or NR b R c ;
- R 2b is selected from H, D, halogen, C(O)OR a , C(O)NR b R c , C 1-6 alkyl or C 1-6 haloalkyl;
- R 2c is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R 2d is selected from H, D, halogen, CN, NO 2 , OR a , NR b R c , C 1-6 alkyl or C 1-6 haloalkyl;
- Z 1 is CH
- Z 3 is CR 1 or N
- L is a chemical bond, C 1-6 alkylene, C 2-6 alkenylene or C 2-6 alkynylene, which is optionally substituted by 1, 2 or 3 R;
- R 3s1 is selected from H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 3-10 yuan Heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl;
- R 3s2 is selected from H, D, -L-OR a , -L-NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 5-10 membered heterocycle base, C 6-10 aryl or 5-10 membered heteroaryl, which is optionally substituted by 1, 2 or 3 R 3s ;
- R and R 3s are independently selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 3-10 membered heterocyclyl, C 6-10 Aryl or 5-10 membered heteroaryl; or R b , R c and the atoms they are connected together form a 5-10 membered heterocyclic group;
- each of the above defined groups is optionally deuterated, up to complete deuteration.
- the invention provides the above formula (IV), (IV-1), (IV-1a), (IV-1b), (IV-2), (IV-2a) or (IV -2b) Compounds, or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvates thereof, wherein,
- R 1 is selected from H, D, halogen, CN, NO 2 , OR a , SR a , NR b R c , SF 5 , C(O)R a , S(O)R a , S(O) 2 R a , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 4-6 cycloalkyl, 5-6 membered heterocyclyl, phenyl or 5- 6-membered heteroaryl, optionally substituted by 1, 2 or 3 R 1s ;
- n 0, 1 or 2;
- R 4 is selected from H or D
- X 1 is a C atom, which is replaced by R 2b ;
- X 2 is a C atom or N atom, which is optionally substituted by R 2c ;
- X 3 is a C atom, which is replaced by R 2d ;
- R 2a is selected from OR a or NR b R c ;
- R 2b is selected from H, D, halogen, C(O)OR a , C(O)NR b R c , C 1-6 alkyl or C 1-6 haloalkyl;
- R 2c is selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R 2d is selected from H, D, halogen, CN, NO 2 , C 1-6 alkyl or C 1-6 haloalkyl;
- Z 1 is CH
- Z 3 is CR 1 or N
- L is a chemical bond or C 1-6 alkylene group
- R 1s and R 2s are independently selected from H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl;
- R 3s1 is selected from H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl;
- R 3s2 is selected from H, D, -L-OR a , -L-NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 5-6 membered heterocycle base, phenyl or 5-6 membered heteroaryl, which is optionally substituted by 1, 2 or 3 R 3s ;
- R 3s is independently selected from H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl;
- R a , R b and R c are independently selected from H, D, C 1-6 alkyl or C 1-6 haloalkyl; or R b , R c and the atoms to which they are connected together form a 5-10 membered heterocyclyl group ;
- each of the above defined groups is optionally deuterated, up to complete deuteration.
- the present invention provides compounds of the above formula (X), or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, Hydrate or solvate, wherein the compound is selected from the following:
- the present invention provides compounds of the above formula (X), or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, Hydrate or solvate, wherein the compound is selected from the following:
- the present invention provides compounds of the above formula (X), or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, Hydrate or solvate, wherein the compound is selected from the following:
- the present invention provides compounds of the above formula (X), or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, Hydrate or solvate, wherein the compound is selected from the following:
- the compounds of the present invention may contain one or more asymmetric centers and thus may exist in multiple stereoisomeric forms, for example, enantiomeric and/or diastereomeric forms.
- the compounds of the present invention may be individual enantiomers, diastereomers, or geometric isomers (e.g., cis and trans isomers), or may be in the form of mixtures of stereoisomers, Includes racemic mixtures and mixtures enriched in one or more stereoisomers.
- the isomers may be separated from the mixture by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or the preferred isomers may be separated by Prepared by asymmetric synthesis.
- HPLC high pressure liquid chromatography
- Tautomers are functional group isomers produced by the rapid movement of an atom in a molecule between two positions.
- a tautomer is a special functional group isomer.
- a pair of tautomers can interact with each other. conversion, but usually one of the more stable isomers is its main form of existence. The most important examples are the enol and keto tautomers.
- solvate refers to a form of a compound or a salt thereof that is combined with a solvent, usually formed by a solvolysis reaction. This physical association may include hydrogen bonding.
- solvents include water, methanol, ethanol, acetic acid, DMSO, THF, ether, etc.
- Suitable solvates include pharmaceutically acceptable solvates and further include stoichiometric and non-stoichiometric solvates. In some cases, the solvate will be capable of isolating, for example, when one or more solvent molecules are incorporated into the crystal lattice of the crystalline solid.
- “Solvate” includes both solution solvates and isolable solvates. Representative solvates include hydrates, ethanolates, and methoxides.
- hydrate refers to a compound combined with water. Typically, the ratio of the number of water molecules contained in a hydrate of a compound to the number of molecules of the compound in the hydrate is determined.
- a hydrate of a compound may be represented, for example, by the general formula R.xH2O , where R is the compound and x is a number greater than zero.
- a given compound may form more than one hydrate type, including, for example, monohydrate (x is 1), lower hydrate (x is a number greater than 0 and less than 1), for example, hemihydrate (R ⁇ 0.5 H 2 O)) and polyhydrates (x is a number greater than 1, for example, Dihydrate (R ⁇ 2 H 2 O) and hexahydrate (R ⁇ 6 H 2 O)).
- monohydrate x is 1
- lower hydrate x is a number greater than 0 and less than 1
- hemihydrate R ⁇ 0.5 H 2 O
- polyhydrates x is a number greater than 1, for example, Dihydrate (R ⁇ 2 H 2 O) and hexahydrate (R ⁇ 6 H 2 O)
- the compounds of the invention may be in amorphous or crystalline forms (polymorphs). Furthermore, the compounds of the present invention may exist in one or more crystalline forms. Accordingly, the present invention includes within its scope all amorphous or crystalline forms of the compounds of the invention.
- polymorph refers to a crystalline form of a compound (or a salt, hydrate or solvate thereof) in a specific crystal packing arrangement. All polymorphs have the same elemental composition. Different crystalline forms often have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optoelectronic properties, stability and solubility. Recrystallization solvent, crystallization rate, storage temperature, and other factors can lead to the dominance of one crystalline form. Various polymorphs of the compounds can be prepared by crystallization under different conditions.
- the present invention also includes isotopically labeled compounds (isotopic variants) which are identical to those described in formula (I), except that one or more atoms are surrounded by atoms having an atomic mass or mass number different from that common in nature. replaced.
- isotopes that may be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, such as 2 H, 3 H, 13 C, 11 C, 14 C, 15 N, 18 respectively. O, 17 O, 31 P, 32 P, 35 S, 18 F and 36 Cl.
- the isotope-labeled compounds of formula (A) of the present invention and their prodrugs can generally be prepared by replacing non-isotopes with readily available isotope-labeled reagents when performing the following processes and/or the processes disclosed in the Examples and Preparation Examples. Labeled reagents.
- prodrugs are also included within the context of the present invention.
- the term "prodrug” as used herein refers to a compound that is converted in the body to its active form having a medical effect, for example, by hydrolysis in the blood.
- Pharmaceutically acceptable prodrugs are described in T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems, Vol. 14 of A.C.S. Symposium Series, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, and D. Fleisher, S. Ramon and H. Barbra "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", Advanced Drug Delivery Reviews (1996) 19 (2) 115-130, each introduced This article serves as a reference.
- a prodrug is any covalently bonded compound of the invention that releases the parent compound in the body when administered to a patient.
- Prodrugs are typically prepared by modifying functional groups in a manner such that the modification can be cleaved by conventional manipulations or in vivo to yield the parent compound.
- Prodrugs include, for example, compounds of the invention in which a hydroxyl, amino or thiol group is bonded to any group that can be cleaved to form a hydroxyl, amino or thiol group when administered to a patient.
- representative examples of prodrugs include, but are not limited to, acetate/amide, formate/amide and benzoate/amide derivatives of the hydroxyl, thiol and amino functionality of the compound of formula (A).
- esters such as methyl ester, ethyl ester, etc. can be used.
- the ester itself may be reactive and/or hydrolyzable under human body conditions.
- Suitable pharmaceutically acceptable in vivo hydrolyzable ester groups include those that readily break down in the human body to release the parent acid or salt thereof.
- the present invention also provides pharmaceutical preparations, comprising a therapeutically effective amount of a compound of formula (A) or a therapeutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent or excipient thereof. All these forms belong to the invention.
- the invention provides pharmaceutical compositions comprising a compound of the invention (also referred to as an "active ingredient") and a pharmaceutically acceptable excipient.
- the pharmaceutical compositions comprise an effective amount of a compound of the invention.
- the pharmaceutical compositions comprise a therapeutically effective amount of a compound of the invention.
- the pharmaceutical composition comprises a prophylactically effective amount of the compound of the invention.
- compositions of the present invention refer to non-toxic carriers, adjuvants or vehicles that do not destroy the pharmacological activity of the compounds with which they are formulated.
- Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of the present invention include, but are not limited to, ion exchangers, aluminum oxide, aluminum stearate, lecithin, serum proteins (such as human serum albumin) protein), buffer substances (such as phosphate), glycine, sorbic acid, potassium sorbate, partial glyceride mixture of saturated vegetable fatty acids, water, salt or electrolyte (such as protamine sulfate), disodium hydrogen phosphate, potassium hydrogen phosphate , sodium chloride, zinc salt, silica gel, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylate, wax, polyethylene-polyoxypropylene- Block polymers, polyethylene glycols, and
- Suitable formulations for administering the compounds of the invention will be apparent to those of ordinary skill in the art and include, for example, tablets, pills, capsules, suppositories, lozenges, lozenges, solutions (especially injections (subcutaneous, intravenous solution for intramuscular administration) and infusion (injection)), elixir, syrup, cachet, emulsion, inhalation or dispersible powder.
- the content of one or more pharmaceutically active compounds should range from 0.1 to 90% by weight, preferably from 0.5 to 50% by weight of the composition as a whole, ie an amount sufficient to achieve the dosage ranges specified below. If necessary, the specified dose may be administered several times per day.
- kits eg, pharmaceutical packaging.
- Kits provided may include a compound of the invention, other therapeutic agents, and first and second containers (e.g., vials, ampoules, bottles, syringes, and/or dispersible packaging or other) containing the compounds of the invention, other therapeutic agents. suitable container).
- provided kits may also optionally include a third container containing pharmaceutical excipients for diluting or suspending the compounds of the invention and/or other therapeutic agents.
- the compound of the invention and the other therapeutic agent provided in the first container and the second container are combined to form a unit dosage form.
- parenteral administration as used herein includes subcutaneous administration, intradermal administration, intravenous administration, intramuscular administration, intraarticular administration, intraarterial administration, intrasynovial administration, intrasternal administration , intracerebrospinal membrane drug administration, intralesional drug administration, and intracranial injection or infusion techniques.
- an effective amount of a compound provided herein is administered.
- the amount of compound actually administered can be determined by the physician depending on the circumstances, including the condition being treated, the route of administration chosen, the compound actually administered, the age, weight and response of the individual patient, the severity of the patient's symptoms, etc. .
- a compound provided herein is administered to a subject at risk of developing the condition, typically on the advice of and under the supervision of a physician, at dosage levels as described above.
- Subjects at risk of developing a particular condition generally include subjects with a family history of the condition or those who have been determined by genetic testing or screening to be particularly susceptible to developing the condition.
- compositions provided herein can also be administered over a long period of time ("chronic administration").
- Long-term administration refers to the administration of a compound or pharmaceutical composition thereof over a long period of time, for example, 3 months, 6 months, 1 year, 2 years, 3 years, 5 years, etc., or administration may be continued indefinitely, For example, the rest of the subject's life.
- chronic administration is intended to provide a constant level of the compound in the blood over an extended period of time, eg, within a therapeutic window.
- a pharmaceutical composition may be administered as a bolus injection, eg, in order to increase the concentration of the compound in the blood to an effective level.
- the bolus dose depends on the target systemic levels of the active ingredient through the body, e.g., an intramuscular or subcutaneous bolus dose provides a slow release of the active ingredient, whereas a bolus dose delivered directly into the vein (e.g., via an IV drip) ) can be delivered more quickly, allowing the concentration of active ingredients in the blood to quickly increase to effective levels.
- the pharmaceutical composition may be administered as a continuous infusion, e.g., by IV infusion, thereby Provides a steady-state concentration of the active ingredient in the subject's body. Additionally, in other embodiments, a bolus dose of the pharmaceutical composition may be administered first, followed by a continuous infusion.
- Oral compositions may take the form of bulk liquid solutions or suspensions, or bulk powders. More typically, however, the compositions are provided in unit dosage form to facilitate precise dosing.
- dosage unit form refers to physically discrete units suitable as unitary dosages for human patients and other mammals, each unit containing a predetermined quantity of active material suitable to produce the desired therapeutic effect in association with a suitable pharmaceutical excipient.
- Typical unit dosage forms include prefilled, premeasured ampoules or syringes for liquid compositions, or pills, tablets, capsules, and the like in the case of solid compositions.
- the compound will generally be a minor component (from about 0.1 to about 50% by weight, or preferably from about 1 to about 40% by weight), with the remainder being various components useful in forming the desired administration form. carriers or excipients and processing aids.
- a typical regimen is one to five oral doses per day, especially two to four oral doses, typically three oral doses.
- each dose provides from about 0.01 to about 20 mg/kg of a compound of the invention, with preferred doses each providing from about 0.1 to about 10 mg/kg, especially from about 1 to about 5 mg/kg.
- a transdermal dose is generally selected in an amount of about 0.01 to about 20% by weight, preferably about 0.1 to about 20% by weight, preferably about 0.1 to about 10% by weight, and more preferably from about 0.5 to about 15% by weight.
- Injectable dose levels range from about 0.1 mg/kg/hour to at least 10 mg/kg/hour from about 1 to about 120 hours, especially from 24 to 96 hours. To achieve adequate steady state levels, a preload bolus of about 0.1 mg/kg to about 10 mg/kg or more may also be given. For human patients weighing 40 to 80 kg, the maximum total dose should not exceed approximately 2 g/day.
- Liquid forms suitable for oral administration may include suitable aqueous or non-aqueous carriers as well as buffering agents, suspending and dispersing agents, coloring agents, flavoring agents, and the like.
- Solid forms may include, for example, any of the following components, or compounds of similar nature: binders, for example, microcrystalline cellulose, tragacanth, or gelatin; excipients, for example, starch or lactose, disintegrants, For example, alginic acid, Primogel or corn starch; lubricant, for example, magnesium stearate; glidant, for example, colloidal silicon dioxide; sweetener, for example, sucrose or saccharin; or flavoring agent, for example, mint, water Methyl glycolate or orange flavoring.
- binders for example, microcrystalline cellulose, tragacanth, or gelatin
- excipients for example, starch or lactose, disintegrants, For example, alginic acid, Primogel or corn starch
- Injectable compositions are typically based on injectable sterile saline or phosphate buffered saline, or other injectable excipients known in the art. As stated previously, in such compositions the active compound is typically a minor component, often about 0.05 to 10% by weight, with the remainder being injectable excipients and the like.
- Transdermal compositions are typically formulated as topical ointments or creams containing the active ingredients.
- the active ingredients When formulated as an ointment, the active ingredients are typically combined with a paraffin or water-miscible ointment base.
- the active ingredient may be formulated as a cream with, for example, an oil-in-water cream base.
- Such transdermal formulations are well known in the art and often include other ingredients for promoting stable skin penetration of the active ingredient or formulation. All such known transdermal formulations and components are included within the scope provided by this invention.
- transdermal administration may be achieved using reservoir or porous membrane types, or a variety of solid matrix patches.
- compositions for oral administration, injection or topical administration are merely representative.
- Other materials and processing techniques are described in Part 8 of Remington's Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pennsylvania, which article is incorporated by reference.
- the compounds of the present invention may also be administered in sustained release form or from a sustained release drug delivery system.
- sustained release materials can be found in Remington's Pharmaceutical Sciences.
- the invention also relates to pharmaceutically acceptable formulations of the compounds of the invention.
- the formulation includes water.
- the formulation contains a cyclodextrin derivative.
- the most common cyclodextrins are composed of 6, 7, and 8 ⁇ -1,4-linked cyclodextrins.
- ⁇ -, ⁇ - and ⁇ -cyclodextrins composed of glucose units, which optionally include one or more substituents on the attached sugar moiety, including but not limited to: methylated, hydroxyalkylated , acylated and sulfoalkyl ether substitution.
- the cyclodextrin is a sulfoalkyl ether beta-cyclodextrin, for example, sulfobutyl ether beta-cyclodextrin, also known as Captisol. See, for example, US 5,376,645.
- the formulation includes hexapropyl-beta-cyclodextrin (eg, in water, 10-50%).
- MTA-synergistic PRMT5 inhibitors can provide therapeutic benefits to a large number of tumor patients.
- the compounds of the present invention exert therapeutic effects by negatively regulating the activity of MTA-bound PRMT5 in tumor cells, especially against MTAP-deficient cells or various MTAP-related tumor cells.
- MTA synergistic PRMT5 inhibitors of the invention can treat a variety of cancers, including but not limited to tumor types, such as malignant peripheral nerve sheath tumors, mesothelioma, glioblastoma multiforme, Pancreatic cancer, bile duct cancer, prostate cancer, breast cancer, brain cancer, skin cancer, cervical cancer, bladder cancer, astrocytoma, colorectal cancer, endometrial cancer, esophageal cancer, stomach cancer, thymoma, head and neck cancer, liver Cell carcinoma, laryngeal cancer, lung squamous cell carcinoma, lung adenocarcinoma, oral cancer, ovarian cancer, renal cancer and thyroid cancer, and sarcoma.
- tumor types such as malignant peripheral nerve sheath tumors, mesothelioma, glioblastoma multiforme, Pancreatic cancer, bile duct cancer, prostate cancer, breast cancer, brain cancer, skin cancer, cervical cancer, bladder cancer,
- these compounds are useful in the treatment of: Heart: sarcomas (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma, etc.), myxoma, rhabdomyomas, fibromas, lipomas and teratomas; Lung: bronchial carcinoma ( Squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma, etc.), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; gastrointestinal tract: esophagus (Squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma, etc.), stomach (tumor, lymphoma, leiomyosarcoma, etc.), pancreas (ductal adenodeno
- the MTA synergistic PRMT5 inhibitor of the present invention can be combined with other drugs to treat cancer, and contains at least one target drug/cell activity regulator, including CDK4/6 inhibitors, MAT2A inhibitors, MAPK1/MAPK3 inhibitors, Type I PRMT inhibitor, EGFR inhibitor, SHP2 inhibitor, pan-KRAS inhibitor, KRASG12C inhibitor, RAF inhibitor, MEK inhibitor, ERK inhibitor, Bcl-2 inhibitor, SOS1 inhibitor, PARP inhibitor, MALT1 inhibitor Agent, MALT2 inhibitor, BTK inhibitor, PI3K inhibitor, AKT inhibitor, FGFR inhibitor, DNA methyltransferase (DNMT) inhibitor, EZH1/2 inhibitor, EZH2 inhibitor, Menin-MLL inhibitor, IDH1 Inhibitors, IDH2 inhibitors, IDH1/2 inhibitors, chemotherapy drugs, radiotherapy, STING agonists or immune checkpoint inhibitors/modulators, etc.
- target drug/cell activity regulator including CDK4/6 inhibitors, MAT2A inhibitors, MAPK1/MAPK3 inhibitor
- LC-MS: M+H + 396.2.
- Triethylamine (1080mg) was added to a solution of (R)-1-(pyrimidin-2-yl)ethylamine hydrochloride (2g) in 1,2-dichloroethane (100mL), and stirred at room temperature for 1 hour.
- dichloromethane (50 mL) wash with saturated aqueous sodium bicarbonate solution (50 mL), water (50 mL) and saturated brine (50 mL).
- Trifluoroacetic acid (0.5 mL) was added to a solution of 2-5 (22 mg) in dichloromethane (1.5 mL) under ice bath. Stir at room temperature for 1 hour, concentrate under reduced pressure, and the residue is purified by high performance liquid chromatography (column: Xbridge-C18 150 x 19mm, 5um; mobile phase: ACN--H 2 O (0.05% NH 3 ); B%: 5% -10%, 20 min) to obtain white solid 2 (3.6 mg, yield 23.2%).
- LC-MS: M+H + 488.0.
- Trifluoroacetic acid (2 mL) was added to a solution of 3-2 (21.0 mg) in dichloromethane (2 mL) under ice bath. Stir at room temperature for 1 hour, concentrate under reduced pressure, and the residue is subjected to high performance liquid chromatography (column: Xbridge-C18 150 ⁇ 19mm, 5um; mobile phase: ACN--H 2 O (0.1% FA); B%: 5%-10 %, 20 min) to obtain the formate salt of 3 as a white solid (2.3 mg, yield 16.9%).
- n-propylphosphonic anhydride (260.0mg) and N,N-diisopropylethylamine (84.1mg) were added to the N,N of 25-5 (100.0mg) and 8-1 (77.0mg).
- saturated ammonium chloride solution (10mL) to the reaction solution
- extract with ethyl acetate (10mL ⁇ 3) wash the organic phase with saturated sodium chloride solution (5mL), dry over anhydrous sodium sulfate, and filter.
- the filtrate was concentrated under reduced pressure.
- Methyl acrylate (1.1g), N,N-diisopropylethylamine (2.2g), palladium acetate (0.2g), tris(o-methylphenyl)phosphorus (0.5g) were added to compound 6-1 (2.0 g) of N,N-dimethylformamide (40 mL), stirred at 100°C for 16 hours. Cool to room temperature, slowly pour the reaction solution into ice water (200 mL), extract with ethyl acetate (100 mL ⁇ 3), wash the organic phase with saturated sodium chloride solution (100 mL), dry over anhydrous sodium sulfate, filter, and reduce the filtrate to Pressure concentration.
- Methyl acrylate (0.7g), N,N-diisopropylethylamine (1.3g), and palladium acetate (0.1g) were added to the N,N-dimethylmethane of compound 7-1 (2.0g).
- Amide (20 mL) solution was stirred at 100°C for 16 hours under nitrogen protection. Cool to room temperature, slowly add the reaction solution to ice water (100 mL), extract with ethyl acetate (50 mL ⁇ 3), wash the organic phase with saturated sodium chloride solution (100 mL), dry over anhydrous sodium sulfate, filter, and reduce the filtrate to Pressure concentration.
- Trifluoroacetic acid (2 mL) was added to 7-5 (20.0 mg) in dichloromethane (6 mL), and the reaction was carried out at room temperature for 1 hour. Concentrate under reduced pressure. The residue was purified by high performance liquid chromatography (column: Gemini 5u C18 150 x 21.2mm; mobile phase: [water (TFA)-ACN]; B%: 2%-10%, 8min) to obtain white solid 7 trifluoroethyl acid salt (8.0 mg, yield 57.4%). LC-MS m/z(ESI):457.0[M+H] + .
- the reaction solution was cooled to room temperature, saturated potassium fluoride solution (100 mL) and ethyl acetate (100 mL) were added to the reaction solution, filtered, the organic phase was dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was treated with methanol.
- tert-Butyldiphenylsilyl chloride (3.9 g) was added to a solution of 10-2 (2.0 g) and imidazole (1.2 g) in dichloromethane (20 mL). Stir at 25°C for 16 hours under nitrogen protection.
- N-Bromosuccinimide (2.4 g) was added to a solution of 10-3 (5.0 g) and azobisisobutyronitrile (0.1 g) in carbon tetrachloride (50 mL). Stir at 90°C for 2 hours under nitrogen protection. The reaction solution was cooled to room temperature, (100 mL) water was added to the reaction solution, extracted with dichloromethane (100 mL ⁇ 3), the organic phases were combined, the organic phases were washed with saturated sodium chloride solution (100 mL), and dried over anhydrous sodium sulfate.
- Tris(dibenzylideneacetone)dipalladium (66.2 mg), 1,1'-binaphthyl-2,2'-bisdiphenylphosphine (67.5 mg) and cesium carbonate (176.5 mg) were added to benzophenone A solution of imine (98.2 mg) and 10-9 (150.0 mg) in dioxane (5 mL). Stir at 100°C for 8 hours under nitrogen protection. The reaction solution was cooled to room temperature, (30 mL) water was added to the reaction solution, extracted with ethyl acetate (20 mL ⁇ 3), the organic phases were combined, the organic phases were washed with saturated sodium chloride solution (20 mL), and dried over anhydrous sodium sulfate.
- N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (22.9mg) was added to 10-13 (33.1mg), 10-11 (20.0mg) and methylimidazole (8.9mg) of N,N-dimethylformamide (1 mL). Stir at 25°C for 1 hour under nitrogen protection.
- Cyclopentylamine 486.3 mg was added to a solution of 5-trifluoromethylpyridine-2-carbaldehyde (500.0 mg) and acetic acid (343.0 mg) in 1,2-chloroethane (10 mL), and stirred at room temperature for 1 hour.
- Sodium triacetoxyborohydride 1210.0 mg was added and stirred at room temperature for 1 hour.
- 1-n-Propylphosphoric anhydride (483.0 mg, 50% ethyl acetate solution) was added to N,N-diisopropylethylamine (130.7 mg), 11-1 (148.3 mg) and 1-4 (200.0 mg) in dichloromethane (8 mL). Stir at room temperature for 2 hours. Add ice water (20 mL), extract with dichloromethane (20 mL ⁇ 3), wash the organic phase with saturated sodium chloride solution (15 mL), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure.
- Trifluoroacetic acid (2 mL) was added to a solution of compound 13-2 (40.0 mg) in dichloromethane (4 mL) under ice bath, and the mixture was raised to room temperature and stirred for 2 hours.
- the reaction solution was concentrated under reduced pressure, water (10 mL) was added, and the pH was adjusted to weak alkalinity with saturated sodium carbonate solution and methylene chloride. (20mL ⁇ 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure.
- Trifluoroacetic acid (2 mL) was added to a solution of compound 17-2 (40.0 mg) in dichloromethane (4 mL) under an ice bath, and the mixture was raised to room temperature and stirred for 2 hours.
- Add water (10 mL) adjust the pH to slightly alkaline with saturated sodium carbonate solution, and extract with dichloromethane (20 mL ⁇ 3). Take, dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. The residue was analyzed by high performance liquid chromatography (column: Gemini 5u C18 150 x 21.2mm
- Triethylamine (239.0 mg) was added to a solution of 5-(trifluoromethyl)-2-pyridinemethanamine hydrochloride (334.0 mg) in 1,2-dichloroethane (5 mL), and stirred at room temperature for 3 hours. . 4-acetylthiazole (200.0 mg) was added and stirred at room temperature for 2 hours. Sodium triacetoxyborohydride (667.0 mg) was added, and the mixture was stirred at room temperature for 30 minutes.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
提供了一类式(X)所示的PRMT5抑制剂,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物。还提供了所述化合物的制备方法、包含所述化合物的药物组合物,以及所述化合物在预防和治疗癌症中的作用。
Description
本发明要求提交于2022年7月28日的中国申请CN202210898107.7、提交于2022年12月2日的中国申请CN202211541013.0、提交于2023年4月28日的中国申请CN202310484698.8、以及提交于2023年7月20日的中国申请CN202310897087.6的优先权,将它们以其整体引入本文作为参考。
本发明涉及一类新的PRMT5抑制剂,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物。本发明还涉及所述化合物的制备方法、包含所述化合物的药物组合物,以及所述化合物在预防和治疗PRMT5介导的疾病如癌症中的作用。
蛋白质精氨酸甲基转移酶5(Protein arginine methyltransferase 5,PRMT5)属于二型PRMT,是一类S-腺苷甲硫氨酸(SAM)依赖性甲基转移酶,主要负责将SAM的甲基对称性地转移到组蛋白或其他蛋白质的精氨酸残基末端的胍基氮原子上。在体内,PRMT5与MEP50(methylosome protein 50)形成复合物,才能识别底物并进行定位,同时复合物形态也是PRMT5催化组蛋白2A和组蛋白4甲基转移活性所必需的。PRMT5是一种通用的转录抑制因子,可以调控基因转录和蛋白修饰的过程。同时,PRMT5在肿瘤细胞的增殖、分化、凋亡中发挥着重要功能,是极具潜力的肿瘤治疗靶点。然而,PRMT5也是正常细胞所必需的基因,PRMT5敲除和siRNA敲降研究表明,在正常组织中抑制PRMT5的活性可能引起血小板减少、不孕、骨骼肌损失、心肌肥厚等诸多毒副作用。
2016年,多个独立研究团队报道MTAP(甲硫腺苷磷酸化酶)缺失型肿瘤细胞增加对PRMT5活性的依赖。MTAP的缺失会上调细胞内MTA(甲硫腺苷)的水平,而MTA同时也是天然的PRMT5抑制剂。因此,MTAP缺失型肿瘤细胞会增加对PRMT5活性的依赖,这为靶向MTAP null肿瘤细胞,即靶向PRMT5/MTA复合物,同时不影响MTAP WT细胞提供了可能。
在研PRMT5抑制剂的作用机理包括SAM竞争性抑制剂、底物竞争性抑制剂、SAM和底物双重竞争性抑制剂及MTA协同的抑制剂。非MTA协同的PRMT5抑制剂无差别的抑制PRMT5的活性,已发现剂量限制性的血小板减少、贫血、中性粒细胞减少等毒副作用。其中,MTA协同的抑制剂靶向PRMT5/MTA复合物,有望在抑制MTAP缺失型肿瘤细胞的同时消除对MTAP WT细胞的影响,可以改善治疗窗口。
因此,开发靶向PRMT5/MTA复合物的PRMT5抑制剂将具有重要的临床应用价值,本领域对于该抑制剂存在需求。
发明内容
本发明以PRMT5/MTA复合物作为靶点,研发了一类新的小分子抑制剂,可用于治疗各种癌症。
本发明化合物靶向PRMT5/MTA复合物,是MTA协同的PRMT5抑制剂,具有优异的PRMT5/MTA抑制活性,并对PRMT5/SAM复合物具有明显的选择性。同时,本发明化合物具有良好的ADMET(吸收-分布-代谢-排泄-毒性)性质。
在一个方面,本发明提供了式(X)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物:
其中,
环A为C6-10芳基或5-10元杂芳基;
L1为NH或CHRx;
L2为CRxRy;
L3为-C(O)-、-S(O)-或-S(O)2-;
其中Rx和Ry独立地为H、D、C1-6烷基或C1-6卤代烷基;
或者CRxRy一起形成C=O、C=S或C3-6亚环烷基;
或者当L1为CHRx、L2为CRxRy时,两个Rx基团可以结合形成化学键或C1-4亚烷基;
R1选自H、D、卤素、CN、NO2、-L-ORa、-L-SRa、-L-NRbRc、SF5、C(O)Ra、C(O)ORa、C(O)NRbRc、OC(O)Ra、NRbC(O)Rc、S(O)Ra、S(O)2Ra、S(O)(=NRa)Ra、S(O)ORa、S(O)2ORa、S(O)NRbRc、S(O)2NRbRc、P(O)(Ra)2、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7环烷基、-L-3-7元杂环基、-L-C6-10芳基或-L-5-10元杂芳基,其任选被1、2或3个R1s取代;
m=0、1、2、3或4;
R4选自H、D、C1-6烷基或C1-6卤代烷基;
或者一个R1与R4连接形成-(CH2)q1-X-(CH2)q2-;其中X为O、S、NH或CH2,q1=0、1或2,q2=1、2或3;
X1为C原子或N原子,其任选地被R2b取代;
X2为C原子或N原子,其任选地被R2c取代;
X3为C原子或N原子,其任选地被R2d取代;
R2a选自H、D、CN、ORa、NRbRc、C(O)ORa或C(O)NRbRc;
R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基或3-10元杂环基;
R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
或者X1、X2以及他们的取代基一起形成C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选被1、2或3个R2s取代;
R2d选自H、D、卤素、CN、NO2、ORa、NRbRc、C1-6烷基、C1-6卤代烷基、C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基;
R3选自-C1-6亚烷基-ORa、-C1-6亚烷基-NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-10环烷基、-L-3-10元杂环基、-L-C6-10芳基或-L-5-10元杂芳基,其任选被1、2或3个R3s1和1个R3s2取代;
L为化学键、C1-6亚烷基、C2-6亚烯基或C2-6亚炔基,其任选被1、2或3个R取代;
R1s和R2s独立地选自H、D、卤素、=O、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;
R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;
R3s2选自H、D、-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10
芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;
R和R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
Ra、Rb和Rc独立地选自H、D、C1-6烷基、C1-6卤代烷基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;
其中上述环A、L1、L2、Rx、Ry、R1、R2a、R2b、R2c、R2d、R3、R4、L、R、R1s、R2s、R3s、R3s1、R3s2、Ra、Rb和Rc中的各个基团定义任选地被氘代,直至完全氘代;
条件是当L2为CRxRy、L3为-S(O)-或-S(O)2-时,Ry与R2d结合形成亚乙烯基。
在另一个方面,本发明提供了式(I)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物:
其中,
环A为C6-10芳基或5-10元杂芳基;
L1为NH或CHRx;
L2为CRxRy;
L3为-C(O)-、-S(O)-或-S(O)2-;
其中Rx和Ry独立地为H、D、C1-6烷基或C1-6卤代烷基;
或者CRxRy一起形成C=O、C=S或C3-6亚环烷基;
或者当L1为CHRx、L2为CRxRy时,两个Rx基团可以结合形成化学键或C1-4亚烷基;
R1选自H、D、卤素、CN、NO2、-L-ORa、-L-SRa、-L-NRbRc、SF5、C(O)Ra、C(O)ORa、C(O)NRbRc、OC(O)Ra、NRbC(O)Rc、S(O)Ra、S(O)2Ra、S(O)ORa、S(O)2ORa、S(O)NRbRc、S(O)2NRbRc、P(O)(Ra)2、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7环烷基、-L-3-7元杂环基、-L-C6-10芳基或-L-5-10元杂芳基,其任选被1、2或3个R1s取代;
m=0、1、2、3或4;
X1为C原子或N原子,其任选地被R2b取代;
X2为C原子或N原子,其任选地被R2c取代;
X3为C原子或N原子,其任选地被R2d取代;
R2a选自H、D、CN、ORa、NRbRc、C(O)ORa或C(O)NRbRc;
R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基或3-10元杂环基;
R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
或者X1、X2以及他们的取代基一起形成C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选被1、2或3个R2s取代;
R2d选自H、D、卤素、CN、NO2、ORa、NRbRc、C1-6烷基、C1-6卤代烷基、C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基;
R3选自-C1-6亚烷基-ORa、-C1-6亚烷基-NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-10环烷基、-L-3-10元杂环基、-L-C6-10芳基或-L-5-10元杂芳基,其任选被1、2或3个R3s1和1个R3s2
取代;
L为化学键、C1-6亚烷基、C2-6亚烯基或C2-6亚炔基,其任选被1、2或3个R取代;
R1s和R2s独立地选自H、D、卤素、=O、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;
R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;
R3s2选自H、D、-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;
R和R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;
其中上述环A、L1、L2、Rx、Ry、R1、R2a、R2b、R2c、R2d、R3、L、R、R1s、R2s、R3s、R3s1、R3s2、Ra、Rb和Rc中的各个基团定义任选地被氘代,直至完全氘代;
条件是当L2为CRxRy、L3为-S(O)-或-S(O)2-时,Ry与R2d结合形成亚乙烯基。
在另一个方面,本发明提供了一种药物组合物,所述药物组合物含有本发明化合物,和任选地药学上可接受的赋形剂,例如载体、佐剂或媒介物。
在另一个方面,本发明提供了含有本发明化合物和药学上可接受的赋形剂的药物组合物,其还含有其它治疗剂,例如选自以下靶点药物/细胞活性调节剂,包括CDK4/6抑制剂,MAT2A抑制剂,MAPK1/MAPK3抑制剂,Type I PRMT抑制剂,EGFR抑制剂,SHP2抑制剂,泛KRAS抑制剂,KRASG12C抑制剂,RAF抑制剂,MEK抑制剂,ERK抑制剂,Bcl-2抑制剂,SOS1抑制剂,PARP抑制剂,MALT1抑制剂,MALT2抑制剂,BTK抑制剂,PI3K抑制剂,AKT抑制剂,FGFR抑制剂,DNA甲基转移酶(DNMT)抑制剂,EZH1/2抑制剂,EZH2抑制剂,Menin-MLL抑制剂,IDH1抑制剂,IDH2抑制剂,IDH1/2抑制剂,化疗药物,放射疗法,STING激动剂或免疫检查点抑制剂/调节剂。
在另一个方面,本发明提供了本发明化合物在制备用于治疗和/或预防PRMT5介导的疾病的药物中的用途。
在另一个方面,本发明提供了在受试者中治疗和/或预防PRMT5介导的疾病的方法,包括向所述受试者给药本发明化合物或本发明药物组合物。
在另一个方面,本发明提供了本发明化合物或本发明药物组合物,其用于治疗和/或预防PRMT5介导的疾病。
在具体实施方案中,本发明用于治疗和/或预防癌症。在另一具体实施方案中,本发明用于治疗和/或预防以下癌症:心脏:肉瘤(血管肉瘤、纤维肉瘤、横纹肌肉瘤、脂肪肉瘤)、粘液瘤、横纹肌瘤、纤维瘤、脂肪瘤和畸胎瘤;肺:支气管癌(鳞状细胞、未分化小细胞、未分化大细胞、腺癌)、肺泡(细支气管)癌、支气管腺瘤、肉瘤、淋巴瘤、软骨瘤错构瘤、间皮瘤;胃肠道:食管(鳞状细胞癌、腺癌、平滑肌肉瘤、淋巴瘤)、胃(癌、淋巴瘤、平滑肌肉瘤)、胰腺(导管腺癌、胰岛素瘤、胰高血糖素瘤、胃泌素瘤、类癌瘤、血管瘤)、小肠(腺癌、淋巴瘤、类癌瘤)、卡波西肉瘤、平滑肌瘤、血管瘤、脂肪瘤、神经纤维瘤、纤维瘤)、大肠(腺癌、管状腺瘤、绒毛状腺瘤、错构瘤、平滑肌瘤);泌尿生殖道:肾脏(腺癌、威尔姆氏瘤(肾母细胞瘤)、淋巴瘤、白血病)、膀胱和尿道(鳞状细胞癌、移行细胞癌、腺癌)、前列腺(腺癌、肉瘤)、睾丸(精原细胞瘤、畸胎瘤、胚胎癌、畸胎癌)、绒毛膜癌、肉瘤、间质细胞癌、纤维瘤、纤维腺瘤、腺瘤样肿瘤、脂肪瘤);肝脏:肝细胞瘤(肝细
胞癌)、胆管癌、肝母细胞瘤、血管肉瘤、肝细胞腺瘤、血管瘤;胆道:胆囊癌、壶腹癌、胆管癌;骨:成骨肉瘤(osteosarcoma)、纤维肉瘤、恶性纤维组织细胞瘤、软骨肉瘤、尤文氏肉瘤、恶性淋巴瘤(网状细胞肉瘤)、多发性骨髓瘤、恶性巨细胞瘤脊索瘤、骨慢性外生骨疣(osteocartilaginous exostoses)、良性软骨瘤、软骨母细胞瘤、纤维软骨瘤、软骨粘液纤维瘤、类骨质骨瘤和巨细胞瘤;神经系统:颅骨(骨瘤、血管瘤、肉芽肿、黄色瘤、变形性骨炎)、脑膜(脑膜瘤、脑膜肉瘤、神经胶质瘤)、脑(星形细胞瘤、髓母细胞瘤、神经胶质瘤、室管膜瘤、生殖细胞瘤(松果体瘤)、多形性胶质母细胞瘤、少突胶质细胞瘤、神经鞘瘤、视网膜母细胞瘤、先天性肿瘤)、脊髓神经纤维瘤、脑膜瘤、神经胶质瘤、肉瘤);妇科:子宫(子宫内膜癌)、宫颈(宫颈癌、瘤前宫颈发育不良等)、卵巢(卵巢癌、浆液性囊腺癌、粘液性囊腺癌、未分类癌)、颗粒鞘细胞瘤、支持间质细胞瘤、无性细胞瘤、恶性畸胎瘤)、外阴(鳞状细胞癌、上皮内癌、腺癌、纤维肉瘤、黑色素瘤)、阴道(透明细胞癌、鳞状细胞癌、葡萄样肉瘤(胚胎性横纹肌肉瘤)、输卵管(癌);血液学:血液(髓性白血病(急性和慢性)、急性淋巴细胞白血病、慢性淋巴细胞性白血病、弥漫性大B细胞淋巴瘤、套细胞淋巴瘤(MCL),滤泡性淋巴瘤、骨髓增生性疾病、多发性骨髓瘤、骨髓增生异常综合征)、霍奇金病、非霍奇金淋巴瘤(恶性淋巴瘤);皮肤:恶性黑色素瘤、基底细胞癌、鳞状细胞癌、卡波西肉瘤、痣发育不良痣、脂肪瘤、血管瘤、皮肤纤维瘤、瘢痕疙瘩、牛皮癣;和肾上腺:成神经细胞瘤。
在另一具体实施方案中,本发明所述PRMT5介导的疾病选自以下癌症:恶性周围神经鞘瘤、间皮瘤、多形性胶质母细胞瘤、胰腺癌、胆管癌、前列腺癌、乳腺癌、脑癌、皮肤癌、宫颈癌、膀胱癌、星形细胞瘤、结肠直肠癌、子宫内膜癌、食道癌、胃癌、胸腺瘤、头颈癌、肝细胞癌、喉癌、肺鳞癌、肺腺癌、口腔癌、卵巢癌、肾癌和甲状腺癌以及肉瘤。
在另一具体实施方案中,本发明所述PRMT5介导的疾病选自MTAP相关癌症,例如肝细胞癌、乳腺癌、皮肤癌、膀胱癌、肝癌、胰腺癌或头颈癌。
定义
化学定义
下面更详细地描述具体官能团和化学术语的定义。
当列出数值范围时,既定包括每个值和在所述范围内的子范围。例如“C1-6烷基”包括C1、C2、C3、C4、C5、C6、C1-6、C1-5、C1-4、C1-3、C1-2、C2-6、C2-5、C2-4、C2-3、C3-6、C3-5、C3-4、C4-6、C4-5和C5-6烷基。
“C1-6烷基”是指具有1至6个碳原子的直链或支链饱和烃基团。在一些实施方案中,C1-4烷基和C1-2烷基是优选的。C1-6烷基的例子包括:甲基(C1)、乙基(C2)、正丙基(C3)、异丙基(C3)、正丁基(C4)、叔丁基(C4)、仲丁基(C4)、异丁基(C4)、正戊基(C5)、3-戊基(C5)、戊基(C5)、新戊基(C5)、3-甲基-2-丁基(C5)、叔戊基(C5)和正己基(C6)。术语“C1-6烷基”还包括杂烷基,其中一或多个(例如,1、2、3或4个)碳原子被杂原子(例如,氧、硫、氮、硼、硅、磷)替代。烷基基团可以被一或多个取代基任选取代,例如,被1至5个取代基、1至3个取代基或1个取代基取代。常规烷基缩写包括:Me(-CH3)、Et(-CH2CH3)、iPr(-CH(CH3)2)、nPr(-CH2CH2CH3)、n-Bu(-CH2CH2CH2CH3)或i-Bu(-CH2CH(CH3)2)。
“C2-6烯基”是指具有2至6个碳原子和至少一个碳碳双键的直链或支链烃基团。在一些实施方案中,C2-4烯基是优选的。C2-6烯基的例子包括:乙烯基(C2)、1-丙烯基(C3)、2-丙烯基(C3)、1-丁烯基(C4)、2-丁烯基(C4)、丁二烯基(C4)、戊烯基(C5)、戊二烯基(C5)、己烯基(C6),等等。术语“C2-6烯基”还包括杂烯基,其中一或多个(例如,1、2、3或4个)碳原子被杂原子(例如,氧、硫、氮、硼、硅、磷)替代。
烯基基团可以被一或多个取代基任选取代,例如,被1至5个取代基、1至3个取代基或1个取代基取代。
“C2-6炔基”是指具有2至6个碳原子、至少一个碳-碳叁键以及任选地一个或多个碳-碳双键的直链或支链烃基团。在一些实施方案中,C2-4炔基是优选的。C2-6炔基的例子包括但不限于:乙炔基(C2)、1-丙炔基(C3)、2-丙炔基(C3)、1-丁炔基(C4)、2-丁炔基(C4),戊炔基(C5)、己炔基(C6),等等。术语“C2-6炔基”还包括杂炔基,其中一或多个(例如,1、2、3或4个)碳原子被杂原子(例如,氧、硫、氮、硼、硅、磷)替代。炔基基团可以被一或多个取代基任选取代,例如,被1至5个取代基、1至3个取代基或1个取代基取代。
“C1-6亚烷基”是指除去C1-6烷基的另一个氢而形成的二价基团,并且可以是取代或未取代的。在一些实施方案中,C1-4亚烷基、C2-4亚烷基和C1-3亚烷基是优选的。未取代的所述亚烷基包括但不限于:亚甲基(-CH2-)、亚乙基(-CH2CH2-)、亚丙基(-CH2CH2CH2-)、亚丁基(-CH2CH2CH2CH2-)、亚戊基(-CH2CH2CH2CH2CH2-)、亚己基(-CH2CH2CH2CH2CH2CH2-),等等。示例性的取代的所述亚烷基,例如,被一个或多个烷基(甲基)取代的所述亚烷基,包括但不限于:取代的亚甲基(-CH(CH3)-、-C(CH3)2-)、取代的亚乙基(-CH(CH3)CH2-、-CH2CH(CH3)-、-C(CH3)2CH2-、-CH2C(CH3)2-)、取代的亚丙基(-CH(CH3)CH2CH2-、-CH2CH(CH3)CH2-、-CH2CH2CH(CH3)-、-C(CH3)2CH2CH2-、-CH2C(CH3)2CH2-、-CH2CH2C(CH3)2-),等等。
“C2-6亚烯基”是指除去C2-6烯基的另一个氢而形成的二价基团,并且可以是取代或未取代的。在一些实施方案中,C2-4亚烯基是特别优选的。示例性的未取代的所述亚烯基包括但不限于:亚乙烯基(-CH=CH-)和亚丙烯基(例如,-CH=CHCH2-、-CH2-CH=CH-)。示例性的取代的所述亚烯基,例如,被一个或多个烷基(甲基)取代的亚烯基,包括但不限于:取代的亚乙基(-C(CH3)=CH-、-CH=C(CH3)-)、取代的亚丙烯基(-C(CH3)=CHCH2-、-CH=C(CH3)CH2-、-CH=CHCH(CH3)-、-CH=CHC(CH3)2-、-CH(CH3)-CH=CH-、-C(CH3)2-CH=CH-、-CH2-C(CH3)=CH-、-CH2-CH=C(CH3)-),等等。
“C2-6亚炔基”是指除去C2-6炔基的另一个氢而形成的二价基团,并且可以是取代或未取代的。在一些实施方案中,C2-4亚炔基是特别优选的。示例性的所述亚炔基包括但不限于:亚乙炔基(-C≡C-)、取代或未取代的亚丙炔基(-C≡CCH2-),等等。
“C0-6亚烷基”是指化学键以及上述“C1-6亚烷基”,“C0-4亚烷基”是指化学键以及上述“C1-4亚烷基”。
“卤代”或“卤素”是指氟(F)、氯(Cl)、溴(Br)和碘(I)。
因此,“C1-6卤代烷基”是指上述“C1-6烷基”,其被一个或多个卤素基团取代。在一些实施方案中,C1-4卤代烷基是特别优选的,更优选C1-2卤代烷基。示例性的所述卤代烷基包括但不限于:-CF3、-CH2F、-CHF2、-CHFCH2F、-CH2CHF2、-CF2CF3、-CCl3、-CH2Cl、-CHCl2、2,2,2-三氟-1,1-二甲基-乙基,等等。卤代烷基基团可以在任何可用的连接点上被取代,例如,1至5个取代基、1至3个取代基或1个取代基。
“C3-10环烷基”是指具有3至10个环碳原子和零个杂原子的非芳香环烃基团,其中任选地含有1、2或3个双键或叁键。在一些实施方案中,C5-10环烷基、C3-7环烷基和C3-6环烷基是特别优选的,更优选C5-7环烷基和C5-6环烷基。环烷基还包括其中上述环烷基环与一个或多个芳基或杂芳基稠合的环体系,其中连接点在环烷基环上,且在这样的情况中,碳的数目继续表示环烷基体系中的碳的数目。环烷基还包括其中上述环烷基环,其中任意不相邻的碳原子上的取代基相连形成桥环,一起形成共用两个或两个以上碳原子的多环烷烃。环烷基还包括其中上述环烷基环,其中同一碳原子上的取代基相连成环,一起形成共用一个碳原子的多环烷烃。示例性的所述环烷基包括但不限于:环丙基(C3)、环
丙烯基(C3)、环丁基(C4)、环丁烯基(C4)、环戊基(C5)、环戊烯基(C5)、环己基(C6)、环己烯基(C6)、环已二烯基(C6)、环庚基(C7)、环庚烯基(C7)、环庚二烯基(C7)、环庚三烯基(C7),等等。环烷基基团可以被一或多个取代基任选取代,例如,被1至5个取代基、1至3个取代基或1个取代基取代。
“C3-10亚环烷基”是指除去C3-10环烷基的另一个氢而形成的二价基团,并且可以是取代或未取代的。在一些实施方案中,C3-6亚环烷基和C3-4亚环烷基是特别优选的,尤其优选亚环丙基。
“3-10元杂环基”是指具有环碳原子和1至5个环杂原子的3至10元非芳香环系的饱和或不饱和基团,其中,每个杂原子独立地选自氮、氧、硫、硼、磷和硅,其中任选地含有1、2或3个双键或叁键。在包含一个或多个氮原子的杂环基中,只要化合价允许,连接点可为碳或氮原子。在一些实施方案中,优选5-10元杂环基,其为具有环碳原子和1至5个环杂原子的5至10元非芳香环系;在一些实施方案中,优选3-7元杂环基,其为具有环碳原子和1至4个环杂原子的3至7元非芳香环系;优选5-7元杂环基,其为具有环碳原子和1至3个环杂原子的5至7元非芳香环系;优选3-6元杂环基,其为具有环碳原子和1至3个环杂原子的3至6元非芳香环系;优选4-6元杂环基,其为具有环碳原子和1至3个环杂原子的4至6元非芳香环系;更优选5-6元杂环基,其为具有环碳原子和1至3个环杂原子的5至6元非芳香环系。杂环基还包括其中上述杂环基环与一个或多个环烷基稠合的环体系,其中连接点在杂环基环上,或其中上述杂环基环与一个或多个芳基或杂芳基稠合的环体系,其中连接点在杂环基环上;且在这样的情况下,环成员的数目继续表示在杂环基环体系中环成员的数目。杂环基还包括其中上述杂环基环,其中任意不相邻的碳或氮原子上的取代基相连形成桥环,一起形成共用两个或两个以上碳或氮原子的多环杂烷烃。杂环基还包括其中上述杂环基环,其中同一碳原子上的取代基相连成环,一起形成共用一个碳原子的多环杂烷烃。示例性的包含一个杂原子的3元杂环基包括但不限于:氮杂环丙烷基、氧杂环丙烷基、硫杂环丙烷基(thiorenyl)。示例性的含有一个杂原子的4元杂环基包括但不限于:氮杂环丁烷基、氧杂环丁烷基和硫杂环丁烷基。示例性的含有一个杂原子的5元杂环基包括但不限于:四氢呋喃基、二氢呋喃基、四氢噻吩基、二氢噻吩基、吡咯烷基、二氢吡咯基和吡咯基-2,5-二酮。示例性的包含两个杂原子的5元杂环基包括但不限于:吡唑烷基、二氧杂环戊烷基、氧硫杂环戊烷基(oxasulfuranyl)、二硫杂环戊烷基(disulfuranyl)和噁唑烷-2-酮。示例性的包含三个杂原子的5元杂环基包括但不限于:三唑啉基、噁二唑啉基和噻二唑啉基。示例性的包含一个杂原子的6元杂环基包括但不限于:哌啶基、四氢吡喃基、二氢吡啶基和硫杂环己烷基(thianyl)。示例性的包含两个杂原子的6元杂环基包括但不限于:哌嗪基、吗啉基、二硫杂环己烷基、二噁烷基。示例性的包含三个杂原子的6元杂环基包括但不限于:六氢三嗪基(triazinanyl)。示例性的含有一个杂原子的7元杂环基包括但不限于:氮杂环庚烷基、氧杂环庚烷基和硫杂环庚烷基。示例性的与C6芳基环稠合的5元杂环基(在本文中也称作5,6-双环杂环基)包括但不限于:二氢吲哚基、异二氢吲哚基、二氢苯并呋喃基、二氢苯并噻吩基、苯并噁唑啉酮基,等等。示例性的与C6芳基环稠合的6元杂环基(本文还指的是6,6-双环杂环基)包括但不限于:四氢喹啉基、四氢异喹啉基,等等。杂环基还包括上述杂环基与一个环烷基、杂环基、芳基或杂芳基共享一个或两个原子,形成桥环或螺环,只要化合价允许,共享的原子可为碳或氮原子。杂环基还包括上述杂环基与杂环基基团可以被一或多个取代基任选取代,例如,被1至5个取代基、1至3个取代基或1个取代基取代。
“C6-10芳基”是指具有6-10个环碳原子和零个杂原子的单环或多环的(例如,双环)4n+2芳族环体系(例如,具有以环状排列共享的6或10个π电子)的基团。在一些实施方案中,芳基具有六个环碳原子(“C6芳基”;例如,苯基)。在一些实施方案中,芳基具有十个环碳原子(“C10芳基”;例如,萘基,例如,1-萘基和2-萘基)。芳基还包括其中上述芳基环与一个或多个环烷基或杂环基稠合的环系统,
而且连接点在所述芳基环上,在这种情况下,碳原子的数目继续表示所述芳基环系统中的碳原子数目。芳基基团可以被一或多个取代基任选取代,例如,被1至5个取代基、1至3个取代基或1个取代基取代。
“5-14元杂芳基”是指具有环碳原子和1-4个环杂原子的5-14元单环或双环的4n+2芳族环体系(例如,具有以环状排列共享的6、10或14个π电子)的基团,其中每个杂原子独立地选自氮、氧和硫。在含有一个或多个氮原子的杂芳基中,只要化合价允许,连接点可以是碳或氮原子。杂芳基双环系统在一个或两个环中可以包括一个或多个杂原子。杂芳基还包括其中上述杂芳基环与一个或多个环烷基或杂环基稠合的环系统,而且连接点在所述杂芳基环上,在这种情况下,碳原子的数目继续表示所述杂芳基环系统中的碳原子数目。在一些实施方案中,5-10元杂芳基是优选的,其为具有环碳原子和1-4个环杂原子的5-10元单环或双环的4n+2芳族环体系。在另一些实施方案中,5-6元杂芳基是特别优选的,其为具有环碳原子和1-4个环杂原子的5-6元单环或双环的4n+2芳族环体系。示例性的含有一个杂原子的5元杂芳基包括但不限于:吡咯基、呋喃基和噻吩基。示例性的含有两个杂原子的5元杂芳基包括但不限于:咪唑基、吡唑基、噁唑基、异噁唑基、噻唑基和异噻唑基。示例性的含有三个杂原子的5元杂芳基包括但不限于:三唑基、噁二唑基(例如,1,2,4-噁二唑基)和噻二唑基。示例性的含有四个杂原子的5元杂芳基包括但不限于:四唑基。示例性的含有一个杂原子的6元杂芳基包括但不限于:吡啶基或吡啶酮基。示例性的含有两个杂原子的6元杂芳基包括但不限于:哒嗪基、嘧啶基和吡嗪基。示例性的含有三个或四个杂原子的6元杂芳基分别包括但不限于:三嗪基和四嗪基。示例性的含有一个杂原子的7元杂芳基包括但不限于:氮杂环庚三烯基、氧杂环庚三烯基和硫杂环庚三烯基。示例性的5,6-双环杂芳基包括但不限于:吲哚基、异吲哚基、吲唑基、苯并三唑基、苯并噻吩基、异苯并噻吩基、苯并呋喃基、苯并异呋喃基、苯并咪唑基、苯并噁唑基、苯并异噁唑基、苯并噁二唑基、苯并噻唑基、苯并异噻唑基、苯并噻二唑基、茚嗪基和嘌呤基。示例性的6,6-双环杂芳基包括但不限于:萘啶基、喋啶基、喹啉基、异喹啉基、噌琳基、喹喔啉基、酞嗪基和喹唑啉基。杂芳基基团可以被一或多个取代基任选取代,例如,被1至5个取代基、1至3个取代基或1个取代基取代。
上文定义的烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基等基团除去另一个氢而形成的二价基团统称为“亚基”。环烷基、杂环基、芳基和杂芳基等成环的基团统称为“环基”。
本文定义的烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基等为任选取代的基团。
示例性的碳原子上的取代基包括但不局限于:卤素、-CN、-NO2、-N3、-SO2H、-SO3H、-OH、-ORaa、-ON(Rbb)2、-N(Rbb)2、-N(Rbb)3
+X-、-N(ORcc)Rbb、-SH、-SRaa、-SSRcc、-C(=O)Raa、-CO2H、-CHO、-C(ORcc)2、-CO2Raa、-OC(=O)Raa、-OCO2Raa、-C(=O)N(Rbb)2、-OC(=O)N(Rbb)2、-NRbbC(=O)Raa、-NRbbCO2Raa、-NRbbC(=O)N(Rbb)2、-C(=NRbb)Raa、-C(=NRbb)ORaa、-OC(=NRbb)Raa、-OC(=NRbb)ORaa、-C(=NRbb)N(Rbb)2、-OC(=NRbb)N(Rbb)2、-NRbbC(=NRbb)N(Rbb)2、-C(=O)NRbbSO2Raa、-NRbbSO2Raa、-SO2N(Rbb)2、-SO2Raa、-SO2ORaa、-OSO2Raa、-S(=O)Raa、-OS(=O)Raa、-Si(Raa)3、-OSi(Raa)3、-C(=S)N(Rbb)2、-C(=O)SRaa、-C(=S)SRaa、-SC(=S)SRaa、-SC(=O)SRaa、-OC(=O)SRaa、-SC(=O)ORaa、-SC(=O)Raa、-P(=O)2Raa、-OP(=O)2Raa、-P(=O)(Raa)2、-OP(=O)(Raa)2、-OP(=O)(ORcc)2、-P(=O)2N(Rbb)2、-OP(=O)2N(Rbb)2、-P(=O)(NRbb)2、-OP(=O)(NRbb)2、-NRbbP(=O)(ORcc)2、-NRbbP(=O)(NRbb)2、-P(Rcc)2、-P(Rcc)3、-OP(Rcc)2、-OP(Rcc)3、-B(Raa)2、-B(ORcc)2、-BRaa(ORcc)、烷基、卤代烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基,其中,每个烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基独立地被0、1、2、3、4或5个Rdd基团取代;
或者在碳原子上的两个偕氢被基团=O、=S、=NN(Rbb)2、=NNRbbC(=O)Raa、=NNRbbC(=O)ORaa、
=NNRbbS(=O)2Raa、=NRbb或=NORcc取代;
Raa的每个独立地选自烷基、卤代烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基,或者两个Raa基团结合以形成杂环基或杂芳基环,其中,每个烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基独立地被0、1、2、3、4或5个Rdd基团取代;
Rbb的每个独立地选自:氢、-OH、-ORaa、-N(Rcc)2、-CN、-C(=O)Raa、-C(=O)N(Rcc)2、-CO2Raa、-SO2Raa、-C(=NRcc)ORaa、-C(=NRcc)N(Rcc)2、-SO2N(Rcc)2、-SO2Rcc、-SO2ORcc、-SORaa、-C(=S)N(Rcc)2、-C(=O)SRcc、-C(=S)SRcc、-P(=O)2Raa、-P(=O)(Raa)2、-P(=O)2N(Rcc)2、-P(=O)(NRcc)2、烷基、卤代烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基,或者两个Rbb基团结合以形成杂环基或杂芳基环,其中,每个烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基独立地被0、1、2、3、4或5个Rdd基团取代;
Rcc的每个独立地选自氢、烷基、卤代烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基,或者两个Rcc基团结合以形成杂环基或杂芳基环,其中,每个烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基独立地被0、1、2、3、4或5个Rdd基团取代;
Rdd的每个独立地选自:卤素、-CN、-NO2、-N3、-SO2H、-SO3H、-OH、-ORee、-ON(Rff)2、-N(Rff)2,、-N(Rff)3
+X-、-N(ORee)Rff、-SH、-SRee、-SSRee、-C(=O)Ree、-CO2H、-CO2Ree、-OC(=O)Ree、-OCO2Ree、-C(=O)N(Rff)2、-OC(=O)N(Rff)2、-NRffC(=O)Ree、-NRffCO2Ree、-NRffC(=O)N(Rff)2、-C(=NRff)ORee、-OC(=NRff)Ree、-OC(=NRff)ORee、-C(=NRff)N(Rff)2、-OC(=NRff)N(Rff)2、-NRffC(=NRff)N(Rff)2、-NRffSO2Ree、-SO2N(Rff)2、-SO2Ree、-SO2ORee、-OSO2Ree、-S(=O)Ree、-Si(Ree)3、-OSi(Ree)3、-C(=S)N(Rff)2、-C(=O)SRee、-C(=S)SRee、-SC(=S)SRee、-P(=O)2Ree、-P(=O)(Ree)2、-OP(=O)(Ree)2、-OP(=O)(ORee)2、烷基、卤代烷基、烯基、炔基、环烷基、杂环基、芳基、杂芳基,其中,每个烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基独立地被0、1、2、3、4或5个Rgg基团取代,或者两个偕Rdd取代基可结合以形成=O或=S;
Ree的每个独立地选自烷基、卤代烷基、烯基、炔基、环烷基、芳基、杂环基和杂芳基,其中,每个烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基独立地被0、1、2、3、4或5个Rgg基团取代;
Rff的每个独立地选自氢、烷基、卤代烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基,或者两个Rff基团结合形成杂环基或杂芳基环,其中,每个烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基独立地被0、1、2、3、4或5个Rgg基团取代;
Rgg的每个独立地是:卤素、-CN、-NO2、-N3、-SO2H、-SO3H、-OH、-OC1-6烷基、-ON(C1-6烷基)2、-N(C1-6烷基)2、-N(C1-6烷基)3
+X-、-NH(C1-6烷基)2
+X-、-NH2(C1-6烷基)+X-、-NH3
+X-、-N(OC1-6烷基)(C1-6烷基)、-N(OH)(C1-6烷基)、-NH(OH)、-SH、-SC1-6烷基、-SS(C1-6烷基)、-C(=O)(C1-6烷基)、-CO2H、-CO2(C1-6烷基)、-OC(=O)(C1-6烷基)、-OCO2(C1-6烷基)、-C(=O)NH2、-C(=O)N(C1-6烷基)2、-OC(=O)NH(C1-6烷基)、-NHC(=O)(C1-6烷基)、-N(C1-6烷基)C(=O)(C1-6烷基)、-NHCO2(C1-6烷基)、-NHC(=O)N(C1-6烷基)2、-NHC(=O)NH(C1-6烷基)、-NHC(=O)NH2、-C(=NH)O(C1-6烷基)、-OC(=NH)(C1-6烷基)、-OC(=NH)OC1-6烷基、-C(=NH)N(C1-6烷基)2、-C(=NH)NH(C1-6烷基)、-C(=NH)NH2、-OC(=NH)N(C1-6烷基)2、-OC(NH)NH(C1-6烷基)、-OC(NH)NH2、-NHC(NH)N(C1-6烷基)2、-NHC(=NH)NH2、-NHSO2(C1-6烷基)、-SO2N(C1-6烷基)2、-SO2NH(C1-6烷基)、-SO2NH2、-SO2C1-6烷基、-SO2OC1-6烷基、-OSO2C1-6烷基、-SOC1-6烷基、-Si(C1-6烷基)3、-OSi(C1-6烷基)3、-C(=S)N(C1-6烷基)2、C(=S)NH(C1-6烷基)、C(=S)NH2、-C(=O)S(C1-6烷基)、-C(=S)SC1-6烷基、-SC(=S)SC1-6烷基、-P(=O)2(C1-6
烷基)、-P(=O)(C1-6烷基)2、-OP(=O)(C1-6烷基)2、-OP(=O)(OC1-6烷基)2、C1-6烷基、C1-6卤代烷基、C2-C6烯基、C2-C6炔基、C3-C7环烷基、C6-C10芳基、C3-C7杂环基、C5-C10杂芳基;或者两个偕Rgg取代基可结合形成=O或=S;其中,X-为反离子。
示例性的氮原子上取代基包括但不局限于:氢、-OH、-ORaa、-N(Rcc)2、-CN、-C(=O)Raa、-C(=O)N(Rcc)2、-CO2Raa、-SO2Raa、-C(=NRbb)Raa、-C(=NRcc)ORaa、-C(=NRcc)N(Rcc)2、-SO2N(Rcc)2、-SO2Rcc、-SO2ORcc、-SORaa、-C(=S)N(Rcc)2、-C(=O)SRcc、-C(=S)SRcc、-P(=O)2Raa、-P(=O)(Raa)2、-P(=O)2N(Rcc)2、-P(=O)(NRcc)2、烷基、卤代烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基,或者连接至氮原子的两个Rcc基团结合形成杂环基或杂芳基环,其中,每个烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基独立地被0、1、2、3、4或5个Rdd基团取代,且其中Raa、Rbb、Rcc和Rdd如上所述。
其它定义
术语“癌症”包括但不限于下列癌症:心脏:肉瘤(血管肉瘤、纤维肉瘤、横纹肌肉瘤、脂肪肉瘤)、粘液瘤、横纹肌瘤、纤维瘤、脂肪瘤和畸胎瘤;肺:支气管癌(鳞状细胞、未分化小细胞、未分化大细胞、腺癌)、肺泡(细支气管)癌、支气管腺瘤、肉瘤、淋巴瘤、软骨瘤错构瘤、间皮瘤;胃肠道:食管(鳞状细胞癌、腺癌、平滑肌肉瘤、淋巴瘤)、胃(癌、淋巴瘤、平滑肌肉瘤)、胰腺(导管腺癌、胰岛素瘤、胰高血糖素瘤、胃泌素瘤、类癌瘤、血管瘤)、小肠(腺癌、淋巴瘤、类癌瘤)、卡波西肉瘤、平滑肌瘤、血管瘤、脂肪瘤、神经纤维瘤、纤维瘤)、大肠(腺癌、管状腺瘤、绒毛状腺瘤、错构瘤、平滑肌瘤);泌尿生殖道:肾脏(腺癌、威尔姆氏瘤(肾母细胞瘤)、淋巴瘤、白血病)、膀胱和尿道(鳞状细胞癌、移行细胞癌、腺癌)、前列腺(腺癌、肉瘤)、睾丸(精原细胞瘤、畸胎瘤、胚胎癌、畸胎癌)、绒毛膜癌、肉瘤、间质细胞癌、纤维瘤、纤维腺瘤、腺瘤样肿瘤、脂肪瘤);肝脏:肝细胞瘤(肝细胞癌)、胆管癌、肝母细胞瘤、血管肉瘤、肝细胞腺瘤、血管瘤;胆道:胆囊癌、壶腹癌、胆管癌;骨:成骨肉瘤(osteosarcoma)、纤维肉瘤、恶性纤维组织细胞瘤、软骨肉瘤、尤文氏肉瘤、恶性淋巴瘤(网状细胞肉瘤)、多发性骨髓瘤、恶性巨细胞瘤脊索瘤、骨慢性外生骨疣(osteocartilaginous exostoses)、良性软骨瘤、软骨母细胞瘤、纤维软骨瘤、软骨粘液纤维瘤、类骨质骨瘤和巨细胞瘤;神经系统:颅骨(骨瘤、血管瘤、肉芽肿、黄色瘤、变形性骨炎)、脑膜(脑膜瘤、脑膜肉瘤、神经胶质瘤)、脑(星形细胞瘤、髓母细胞瘤、神经胶质瘤、室管膜瘤、生殖细胞瘤(松果体瘤)、多形性胶质母细胞瘤、少突胶质细胞瘤、神经鞘瘤、视网膜母细胞瘤、先天性肿瘤)、脊髓神经纤维瘤、脑膜瘤、神经胶质瘤、肉瘤);妇科:子宫(子宫内膜癌)、宫颈(宫颈癌、瘤前宫颈发育不良等)、卵巢(卵巢癌、浆液性囊腺癌、粘液性囊腺癌、未分类癌)、颗粒鞘细胞瘤、支持间质细胞瘤、无性细胞瘤、恶性畸胎瘤)、外阴(鳞状细胞癌、上皮内癌、腺癌、纤维肉瘤、黑色素瘤)、阴道(透明细胞癌、鳞状细胞癌、葡萄样肉瘤(胚胎性横纹肌肉瘤)、输卵管(癌);血液学:血液(髓性白血病(急性和慢性)、急性淋巴细胞白血病、慢性淋巴细胞性白血病、弥漫性大B细胞淋巴瘤、套细胞淋巴瘤(MCL),滤泡性淋巴瘤、骨髓增生性疾病、多发性骨髓瘤、骨髓增生异常综合征)、霍奇金病、非霍奇金淋巴瘤(恶性淋巴瘤);皮肤:恶性黑色素瘤、基底细胞癌、鳞状细胞癌、卡波西肉瘤、痣发育不良痣、脂肪瘤、血管瘤、皮肤纤维瘤、瘢痕疙瘩、牛皮癣;和肾上腺:成神经细胞瘤。
在一个实施方案中,术语“癌症”包括但不限于下列癌症:恶性周围神经鞘瘤、间皮瘤、多形性胶质母细胞瘤、胰腺癌、胆管癌、前列腺癌、乳腺癌、脑癌、皮肤癌、宫颈癌、膀胱癌、星形细胞瘤、结肠直肠癌、子宫内膜癌、食道癌、胃癌、胸腺瘤、头颈癌、肝细胞癌、喉癌、肺鳞癌、肺腺癌、口
腔癌、卵巢癌、肾癌和甲状腺癌以及肉瘤。
在个一个实施方案中,术语“癌症”包括但不限于下列癌症:肝细胞癌、乳腺癌、皮肤癌、膀胱癌、肝癌、胰腺癌或头颈癌。
本文所用的术语“治疗”涉及逆转、减轻、抑制该术语适用的障碍或病症的进展或者预防之,或者这类障碍或病症的一种或多种症状。本文所用的名词“治疗”涉及动词治疗的动作,后者是如刚才所定义的。
本文所用的术语“药学上可接受的盐”表示本发明化合物的那些羧酸盐、氨基酸加成盐,它们在可靠的医学判断范围内适用于与患者组织接触,不会产生不恰当的毒性、刺激作用、变态反应等,与合理的益处/风险比相称,就它们的预期应用而言是有效的,包括(可能的话)本发明化合物的两性离子形式。
药学上可接受的碱加成盐是与金属或胺生成的,例如碱金属与碱土金属氢氧化物或有机胺。用作阳离子的金属的实例有钠、钾、镁、钙等。适合的胺的实例有N,N'-二苄基乙二胺、氯普鲁卡因、胆碱、二乙醇胺、乙二胺、N-甲基葡糖胺和普鲁卡因。
酸性化合物的碱加成盐可以这样制备,按照常规方式使游离酸形式与足量所需的碱接触,生成盐。按照常规方式使盐形式与酸接触,再分离游离酸,可以使游离酸再生。游离酸形式在某些物理性质上多少不同于它们各自的盐形式,例如在极性溶剂中的溶解度,但是出于本发明的目的,盐还是等价于它们各自的游离酸。
盐可以是从无机酸制备的硫酸盐、焦硫酸盐、硫酸氢盐、亚硫酸盐、亚硫酸氢盐、硝酸盐、磷酸盐、磷酸一氢盐、磷酸二氢盐、偏磷酸盐、焦磷酸盐、氯化物、溴化物、碘化物,酸例如盐酸、硝酸、硫酸、氢溴酸、氢碘酸、磷酸等。代表性盐包括:氢溴酸盐、盐酸盐、硫酸盐、硫酸氢盐、硝酸盐、乙酸盐、草酸盐、戊酸盐、油酸盐、棕榈酸盐、硬脂酸盐、月桂酸盐、硼酸盐、苯甲酸盐、乳酸盐、磷酸盐、甲苯磺酸盐、柠檬酸盐、马来酸盐、富马酸盐、琥珀酸盐、酒石酸盐、萘甲酸盐、甲磺酸盐、葡庚糖酸盐、乳糖酸盐、月桂基磺酸盐和羟乙磺酸盐等。盐也可以是从有机酸制备的,例如脂肪族一元与二元羧酸、苯基取代的烷酸、羟基烷酸、烷二酸、芳香族酸、脂肪族与芳香族磺酸等。代表性盐包括乙酸盐、丙酸盐、辛酸盐、异丁酸盐、草酸盐、丙二酸盐、琥珀酸盐、辛二酸盐、癸二酸盐、富马酸盐、马来酸盐、扁桃酸盐、苯甲酸盐、氯苯甲酸盆、甲基苯甲酸盐、二硝基苯甲酸盐、萘甲酸盐、苯磺酸盐、甲苯磺酸盐、苯乙酸盐、柠檬酸盐、乳酸盐、马来酸盐、酒石酸盐、甲磺酸盐等。药学上可接受的盐可以包括基于碱金属与碱土金属的阳离子,例如钠、锂、钾、钙、镁等,以及无毒的铵、季铵和胺阳离子,包括但不限于铵、四甲基铵、四乙基铵、甲胺、二甲胺、三甲胺、三乙胺、乙胺等。还涵盖氨基酸的盐,例如精氨酸盐、葡糖酸盐、半乳糖醛酸盐等(例如参见Berge S.M.et al.,"Pharmaceutical Salts,”J.Pharm.Sci.,1977;66:1-19,引入此作为参考)。
给药的“受试者”包括但不限于:人(即,任何年龄组的男性或女性,例如,儿科受试者(例如,婴儿、儿童、青少年)或成人受试者(例如,年轻的成人、中年的成人或年长的成人))和/或非人的动物,例如,哺乳动物,例如,灵长类(例如,食蟹猴、恒河猴)、牛、猪、马、绵羊、山羊、啮齿动物、猫和/或狗。在一些实施方案中,受试者是人。在一些实施方案中,受试者是非人动物。本文可互换使用术语“人”、“患者”和“受试者”。
“疾病”、“障碍”和“病症”在本文中可互换地使用。
除非另作说明,否则,本文使用的术语“治疗”包括受试者患有具体疾病、障碍或病症时所发生的作用,它降低疾病、障碍或病症的严重程度,或延迟或减缓疾病、障碍或病症的发展(“治疗性治疗”),
还包括在受试者开始患有具体疾病、障碍或病症之前发生的作用(“预防性治疗”)。
通常,化合物的“有效量”是指足以引起目标生物反应的数量。正如本领域普通技术人员所理解的那样,本发明化合物的有效量可以根据下列因素而改变:例如,生物学目标、化合物的药代动力学、所治疗的疾病、给药模式以及受试者的年龄健康情况和症状。有效量包括治疗有效量和预防有效量。
除非另作说明,否则,本文使用的化合物的“治疗有效量”是在治疗疾病、障碍或病症的过程中足以提供治疗益处的量,或使与疾病、障碍或病症有关的一或多种症状延迟或最小化的量。化合物的治疗有效量是指单独使用或与其它疗法联用时,治疗剂的量,它在治疗疾病、障碍或病症的过程中提供治疗益处。术语“治疗有效量”可以包括改善总体治疗、降低或避免疾病或病症的症状或病因、或增强其它治疗剂的治疗效果的量。
除非另作说明,否则,本文使用的化合物的“预防有效量”是足以预防疾病、障碍或病症的量,或足以预防与疾病、障碍或病症有关的一或多种症状的量,或防止疾病、障碍或病症复发的量。化合物的预防有效量是指单独使用或与其它药剂联用时,治疗剂的量,它在预防疾病、障碍或病症的过程中提供预防益处。术语“预防有效量”可以包括改善总体预防的量,或增强其它预防药剂的预防效果的量。
“组合”以及相关术语是指同时或依次给药本发明化合物和其它治疗剂。例如,本发明化合物可以与其它治疗剂以分开的单位剂型同时或依次给药,或与其它治疗剂一起在单一单位剂型中同时给药。
图1至图4示出了LU99CDX模型体内药效学研究的结果。
本文中,“本发明化合物”指的是以下的式(I)、式(II)等化合物、其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物。
本文中,化合物使用标准的命名法命名。具有非对称中心的化合物,应该明白(除非另有说明)所有的光学异构体及其混合物均包含在内。此外,除非另有规定,本发明所包括的所有异构体化合物与碳碳双键可能以Z和E的形式出现。在不同的互变异构形式存在的化合物,一个所述化合物并不局限于任何特定的互变异构体,而是旨在涵盖所有的互变异构形式。
在一个实施方案中,本发明涉及式(X)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物:
其中,
环A为C6-10芳基或5-10元杂芳基;
L1为NH或CHRx;
L2为CRxRy;
L3为-C(O)-、-S(O)-或-S(O)2-;
其中Rx和Ry独立地为H、D、C1-6烷基或C1-6卤代烷基;
或者CRxRy一起形成C=O、C=S或C3-6亚环烷基;
或者当L1为CHRx、L2为CRxRy时,两个Rx基团可以结合形成化学键或C1-4亚烷基;
R1选自H、D、卤素、CN、NO2、-L-ORa、-L-SRa、-L-NRbRc、SF5、C(O)Ra、C(O)ORa、C(O)NRbRc、OC(O)Ra、NRbC(O)Rc、S(O)Ra、S(O)2Ra、S(O)(=NRa)Ra、S(O)ORa、S(O)2ORa、S(O)NRbRc、S(O)2NRbRc、P(O)(Ra)2、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7环烷基、-L-3-7元杂环基、-L-C6-10芳基或-L-5-10元杂芳基,其任选被1、2或3个R1s取代;
m=0、1、2、3或4;
R4选自H、D、C1-6烷基或C1-6卤代烷基;
或者一个R1与R4连接形成-(CRssRss)q1-X-(CRssRss)q2-(优选-(CH2)q1-X-(CH2)q2-);其中X为O、S、NH或CH2,q1=0、1或2,q2=1、2或3,Rss独立地选自H、D、C1-6烷基或C1-6卤代烷基,或者两个Rss以及他们连接的碳原子一起形成C3-10环烷基;
X1为C原子或N原子,其任选地被R2b取代;
X2为C原子或N原子,其任选地被R2c取代;
X3为C原子或N原子,其任选地被R2d取代;
R2a选自H、D、CN、ORa、NRbRc、C(O)ORa或C(O)NRbRc;
R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基或3-10元杂环基;
R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
或者X1、X2以及他们的取代基一起形成C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选被1、2或3个R2s取代;
R2d选自H、D、卤素、CN、NO2、ORa、NRbRc、C1-6烷基、C1-6卤代烷基、C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基;
R3选自-C1-6亚烷基-ORa、-C1-6亚烷基-NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-10环烷基、-L-3-10元杂环基、-L-C6-10芳基或-L-5-10元杂芳基,其任选被1、2或3个R3s1和1个R3s2取代;
L为化学键、C1-6亚烷基、C2-6亚烯基或C2-6亚炔基,其任选被1、2或3个R取代;
R1s和R2s独立地选自H、D、卤素、CN、=O、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;或者两个R1s以及他们连接的原子一起形成C3-10环烷基或3-10元杂环基;
R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;
R3s2选自H、D、-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;
或者,R3s1、R3s2以及他们连接的碳原子一起形成C3-10环烷基;
R和R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
Ra、Rb和Rc独立地选自H、D、C1-6烷基、C1-6卤代烷基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;
其中上述环A、L1、L2、Rx、Ry、R1、R2a、R2b、R2c、R2d、R3、R4、L、R、R1s、R2s、R3s、R3s1、R3s2、Ra、Rb和Rc中的各个基团定义任选地被氘代,直至完全氘代;
条件是当L2为CRxRy、L3为-S(O)-或-S(O)2-时,Ry与R2d结合形成亚乙烯基。
在另一个实施方案中,本发明涉及式(I)化合物,或其药学上可接受的盐、同位素变体、互变异构
体、立体异构体、前药、多晶型、水合物或溶剂合物:
其中,
环A为C6-10芳基或5-10元杂芳基;
L1为NH或CHRx;
L2为CRxRy;
L3为-C(O)-、-S(O)-或-S(O)2-;
其中Rx和Ry独立地为H、D、C1-6烷基或C1-6卤代烷基;
或者CRxRy一起形成C=O、C=S或C3-6亚环烷基;
或者当L1为CHRx、L2为CRxRy时,两个Rx基团可以结合形成化学键或C1-4亚烷基;
R1选自H、D、卤素、CN、NO2、-L-ORa、-L-SRa、-L-NRbRc、SF5、C(O)Ra、C(O)ORa、C(O)NRbRc、OC(O)Ra、NRbC(O)Rc、S(O)Ra、S(O)2Ra、S(O)ORa、S(O)2ORa、S(O)NRbRc、S(O)2NRbRc、P(O)(Ra)2、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7环烷基、-L-3-7元杂环基、-L-C6-10芳基或-L-5-10元杂芳基,其任选被1、2或3个R1s取代;
m=0、1、2、3或4;
X1为C原子或N原子,其任选地被R2b取代;
X2为C原子或N原子,其任选地被R2c取代;
X3为C原子或N原子,其任选地被R2d取代;
R2a选自H、D、CN、ORa、NRbRc、C(O)ORa或C(O)NRbRc;
R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基或3-10元杂环基;
R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
或者X1、X2以及他们的取代基一起形成C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选被1、2或3个R2s取代;
R2d选自H、D、卤素、CN、NO2、ORa、NRbRc、C1-6烷基、C1-6卤代烷基、C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基;
R3选自-C1-6亚烷基-ORa、-C1-6亚烷基-NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-10环烷基、-L-3-10元杂环基、-L-C6-10芳基或-L-5-10元杂芳基,其任选被1、2或3个R3s1和1个R3s2取代;
L为化学键、C1-6亚烷基、C2-6亚烯基或C2-6亚炔基,其任选被1、2或3个R取代;
R1s和R2s独立地选自H、D、卤素、=O、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;
R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;
R3s2选自H、D、-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;
R和R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;
其中上述环A、L1、L2、Rx、Ry、R1、R2a、R2b、R2c、R2d、R3、L、R、R1s、R2s、R3s、R3s1、R3s2、Ra、Rb和Rc中的各个基团定义任选地被氘代,直至完全氘代;
条件是当L2为CRxRy、L3为-S(O)-或-S(O)2-时,Ry与R2d结合形成亚乙烯基。
环A
在一个实施方式中,环A为C6-10芳基,优选苯基;在另一个实施方式中,环A为5-10元杂芳基,优选5-10元杂芳基,例如苯基、吡啶基、哒嗪基、嘧啶基或吡嗪基,尤其是吡啶基或哒嗪基。
L1、L2和L3
在一个实施方式中,L1为NH;在另一个实施方式中,L1为CHRx;在另一个实施方式中,L1为NH且L2为CRxRy,-L1-L2-优选为-L1-L2-优选为在另一个实施方式中,L1为CHRx且L2为CRxRy,-L1-L2-优选为在另一个实施方式中,L3为-C(O)-;在另一个实施方式中,L3为-S(O)-;在另一个实施方式中,L3为-S(O)2-。
Rx和Ry
在一个实施方式中,Rx和Ry为H;在另一个实施方式中,Rx和Ry为D;在另一个实施方式中,Rx和Ry为C1-6烷基;在另一个实施方式中,Rx和Ry为C1-6卤代烷基,优选CF3;在另一个实施方式中,CRxRy一起形成C=O;在另一个实施方式中,CRxRy一起形成C=S;在另一个实施方式中,CRxRy一起形成C3-6亚环烷基,优选亚环丙基;在另一个实施方式中,L1为CHRx且L2为CRxRy,并且两个Rx基团结合形成化学键;在另一个实施方式中,L1为CHRx且L2为CRxRy,并且两个Rx基团结合形成C1-4亚烷基,优选亚环丙基。
R1
在一个实施方式中,R1为H;在另一个实施方式中,R1为D;在另一个实施方式中,R1为卤素;在另一个实施方式中,R1为CN;在另一个实施方式中,R1为NO2;在另一个实施方式中,R1为-L-ORa;在另一个实施方式中,R1为-L-SRa;在另一个实施方式中,R1为-L-NRbRc;在另一个实施方式中,R1为SF5;在另一个实施方式中,R1为C(O)Ra;在另一个实施方式中,R1为C(O)ORa;在另一个实施方式中,R1为C(O)NRbRc;在另一个实施方式中,R1为OC(O)Ra;在另一个实施方式中,R1为NRbC(O)Rc;在另一个实施方式中,R1为S(O)Ra;在另一个实施方式中,R1为S(O)2Ra;在另一个实施方式中,R1为S(O)(=NRa)Ra;在另一个实施方式中,R1为S(O)ORa;在另一个实施方式中,R1为S(O)2ORa;在另一个实施方式中,R1为S(O)NRbRc;在另一个实施方式中,R1为S(O)2NRbRc;在另一个实施方式中,R1为P(O)(Ra)2;在另一个实施方式中,R1为C1-6烷基;在另一个实施方式中,R1为C1-6卤代烷基;在另一个实施方式中,R1为C2-6烯基;在另一个实施方式中,R1为C2-6炔基;在另一个实施方式中,R1为-L-C3-7环烷基;在另一个实施方式中,R1为-L-3-7元杂环基;在另一个实施方式中,R1为-L-C6-10芳基;在另一个实施方式中,R1为-L-5-10元杂芳基;在另一个实施方式中,R1
任选被1、2或3个R1s取代。
在一个更具体的实施方式中,R1选自H、D、卤素、CN、NO2、-L-ORa、-L-SRa、-L-NRbRc、SF5、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7环烷基、-L-3-7元杂环基、-L-C6-10芳基或-L-5-10元杂芳基;在另一个更具体的实施方式中,R1选自H、D、卤素、CN、NO2、-L-ORa、-L-SRa、-L-NRbRc、SF5、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7环烷基、-L-3-7元杂环基、-L-C6-10芳基或-L-5-10元杂芳基;在另一个更具体的实施方式中,R1选自H、D、卤素、CN、ORa、SRa、NRbRc、SF5、C1-6烷基、C1-6卤代烷基、C3-7环烷基或3-7元杂环基;在另一个更具体的实施方式中,R1选自H、D、卤素、CN、ORa、SRa、NRbRc、SF5、C1-6烷基、C1-6卤代烷基、C5-7环烷基或5-7元杂环基;在另一个更具体的实施方式中,R1选自H、D、卤素、CN、ORa、NRbRc、C1-6烷基、C1-6卤代烷基、C3-6环烷基或4-6元杂环基;在另一个更具体的实施方式中,R1选自H、D、卤素、CN、ORa、NRbRc、C1-6烷基、C1-6卤代烷基或5-6元杂环基;在另一个更具体的实施方式中,R1选自H、D、CN、ORa、C1-6烷基、C1-6卤代烷基、C3-6环烷基或5-6元杂环基;在另一个更具体的实施方式中,R1选自H、D、CN、ORa、C1-6烷基、C1-6卤代烷基或5-6元杂环基;在另一个更具体的实施方式中,R1选自CF3、CN、OCF3、OCH2CH3、在另一个更具体的实施方式中,R1选自CF3、CN、OCF3、OCH2CH3、在另一个更具体的实施方式中,R1选自CF3。
m
在一个实施方式中,m=0;在另一个实施方式中,m=1;在另一个实施方式中,m=2;在另一个实施方式中,m=3;在另一个实施方式中,m=4。
R4
在一个实施方式中,R4为H;在另一个实施方式中,R4为D;在另一个实施方式中,R4为C1-6烷基;在另一个实施方式中,R4为C1-6卤代烷基;在另一个实施方式中,R1与R4连接形成-(CRssRss)q1-X-(CRssRss)q2-,其中X为O、S、NH或CH2,q1=0、1或2,q2=1、2或3,Rss独立地选自H、D、C1-6烷基或C1-6卤代烷基,或者两个Rss以及他们连接的碳原子一起形成C3-10环烷基,例如C3-6环烷基;在另一个实施方式中,R1与R4连接形成-(CH2)q1-X-(CH2)q2-,其中X为O、S、NH或CH2,q1=0、1或2,q2=1、2或3;在另一个实施方式中,R1与R4连接形成-(CH2)q1-X-(CH2)q2-,其中X为O、S、NH或CH2,q1=0或1,q2=1或2;在另一个实施方式中,R1与R4连接形成-(CH2)q1-X-(CH2)q2-,其中X为O、S或NH2,q1=0或1,q2=1或2。
X1、X2和X3
在一个实施方式中,X1为C原子;在另一个实施方式中,X1为N原子;在另一个实施方式中,X1为CR2b;在另一个实施方式中,X1为NR2b;在一个实施方式中,X2为C原子;在另一个实施方式中,X2为N原子;在另一个实施方式中,X2为CR2c;在另一个实施方式中,X2为NR2c;在一个实施方式中,X3为C原子;在另一个实施方式中,X3为N原子;在另一个实施方式中,X3为CR2d;在另一个实施方式中,X3为NR2d。
在一个更具体的实施方式中,选自
在另一个更具体的实施方式中,为在另一个更具体的实施方式中,为在另一个更具体的实施方式中,为在另一个更具体的实施方式中,为在另一个更具体的实施方式中,为在另一个更具体的实施方式中,为
在一个更具体的实施方式中,X1、X2以及他们的取代基一起形成C5-10环烷基;在另一个更具体的实施方式中,X1、X2以及他们的取代基一起形成5-10元杂环基;在另一个更具体的实施方式中,X1、X2以及他们的取代基一起形成C6-10芳基;在另一个更具体的实施方式中,X1、X2以及他们的取代基一起形成5-10元杂芳基;在另一个更具体的实施方式中,X1、X2以及他们的取代基一起形成C5-7环烷基、5-7元杂环基、苯基或5-6元杂芳基;在另一个更具体的实施方式中,X1、X2以及他们的取代基一起形成
优选形成优选形成优选形成
R2a
在一个实施方式中,R2a为H;在另一个实施方式中,R2a为D;在另一个实施方式中,R2a为CN;在另一个实施方式中,R2a为ORa;在另一个实施方式中,R2a为NRbRc;在另一个实施方式中,R2a为C(O)ORa;在另一个实施方式中,R2a为C(O)NRbRc。
在一个更具体的实施方式中,R2a选自H、D、CN、ORa或NRbRc;在另一个更具体的实施方式中,R2a选自ORa或NRbRc;在另一个更具体的实施方式中,R2a选自OMe或NH2,优选为NH2。
R2b
在一个实施方式中,R2b为H;在另一个实施方式中,R2b为D;在另一个实施方式中,R2b为卤素;在另一个实施方式中,R2b为C(O)ORa;在另一个实施方式中,R2b为C(O)NRbRc;在另一个实施方式中,R2b为C1-6烷基;在另一个实施方式中,R2b为C1-6卤代烷基;在另一个实施方式中,R2b为C3-10环烷基;在另一个实施方式中,R2b为3-10元杂环基。
在一个更具体的实施方式中,R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代
烷基、C3-10环烷基或3-10元杂环基;在另一个更具体的实施方式中,R2b选自H、D、卤素、C(O)NRbRc、C1-6烷基、C1-6卤代烷基或4-6元杂环基;在另一个更具体的实施方式中,R2b选自H、D、卤素、C(O)NRbRc、C1-6烷基或C1-6卤代烷基;在另一个更具体的实施方式中,R2b选自H、D、卤素、C(O)NRbRc或C1-6烷基;在另一个更具体的实施方式中,R2b选自H、F、Cl、Br、Me、CH2CH3、C(O)NH2或在另一个更具体的实施方式中,R2b选自H、F、Cl、Br、Me、CH2CH3或C(O)NH2,优选选自Me或C(O)NH2。
R2c
在一个实施方式中,R2c为H;在另一个实施方式中,R2c为D;在另一个实施方式中,R2c为卤素;在另一个实施方式中,R2c为C1-6烷基;在另一个实施方式中,R2c为C1-6卤代烷基。
在一个更具体的实施方式中,R2c选自H、卤素或Me;优选选自H或Me。
R2d
在一个实施方式中,R2d为H;在另一个实施方式中,R2d为D;在另一个实施方式中,R2d为卤素;在另一个实施方式中,R2d为CN;在另一个实施方式中,R2d为NO2;在另一个实施方式中,R2d为ORa;在另一个实施方式中,R2d为NRbRc;在另一个实施方式中,R2d为C1-6烷基;在另一个实施方式中,R2d为C1-6卤代烷基;在另一个实施方式中,R2d为C5-10环烷基;在另一个实施方式中,R2d为5-10元杂环基;在另一个实施方式中,R2d为C6-10芳基;在另一个实施方式中,R2d为5-10元杂芳基。
在一个更具体的实施方式中,R2d选自H、D、C1-6烷基或C1-6卤代烷基;在另一个更具体的实施方式中,R2d选自H或D。
R3
在一个实施方式中,R3为-C1-6亚烷基-ORa;在另一个实施方式中,R3为-C1-6亚烷基-NRbRc;在另一个实施方式中,R3为C1-6烷基;在另一个实施方式中,R3为C1-6卤代烷基;在另一个实施方式中,R3为C2-6烯基;在另一个实施方式中,R3为C2-6炔基;在另一个实施方式中,R3为-L-C3-10环烷基;在另一个实施方式中,R3为-L-3-10元杂环基;在另一个实施方式中,R3为-L-C6-10芳基;在另一个实施方式中,R3为-L-5-10元杂芳基;在另一个实施方式中,R3任选被1、2或3个R3s1和1个R3s2取代。
在一个更具体的实施方式中,R3选自C1-6烷基、C1-6卤代烷基、-L-C3-10环烷基、-L-3-10元杂环基、-L-C6-10芳基或-L-5-10元杂芳基;在另一个更具体的实施方式中,R3选自C1-6烷基、C1-6卤代烷基、C5-6环烷基、5-6元杂环基、苯基或5-6元杂芳基;在另一个更具体的实施方式中,R3选自Me、Et、iPr、环丙基、环丁基、
L
在一个实施方式中,L为化学键;在另一个实施方式中,L为C1-6亚烷基;在另一个实施方式中,L为C2-6亚烯基;在另一个实施方式中,L为C2-6亚炔基;在另一个实施方式中,L任选被1、2或3个R取代。
R1s
在一个实施方式中,R1s为H;在另一个实施方式中,R1s为D;在另一个实施方式中,R1s为卤素;在另一个实施方式中,R1s为CN;在另一个实施方式中,R1s为=O;在另一个实施方式中,R1s为C(O)ORa;在另一个实施方式中,R1s为C(O)NRbRc;在另一个实施方式中,R1s为C1-6烷基;在另一个实施方式中,R1s为C1-6卤代烷基;在另一个实施方式中,R1s为C2-6烯基;在另一个实施方式中,R1s为C2-6炔基;在另一个实施方式中,R1s为C3-10环烷基;在另一个实施方式中,R1s为3-10元杂环基;在另一个实施方式中,R1s为C6-10芳基;在另一个实施方式中,R1s为5-10元杂芳基;在另一个实施方式中,两个R1s以及他们连接的原子一起形成C3-10环烷基;在另一个实施方式中,两个R1s以及他们连接的原子一起形成3-10元杂环基。
在一个实施方式中,R2s为H;在另一个实施方式中,R2s为D;在另一个实施方式中,R2s为卤素;在另一个实施方式中,R2s为=O;在另一个实施方式中,R2s为C(O)ORa;在另一个实施方式中,R2s为C(O)NRbRc;在另一个实施方式中,R2s为C1-6烷基;在另一个实施方式中,R2s为C1-6卤代烷基;在另一个实施方式中,R2s为C2-6烯基;在另一个实施方式中,R2s为C2-6炔基;在另一个实施方式中,R2s为C3-10环烷基;在另一个实施方式中,R2s为3-10元杂环基;在另一个实施方式中,R2s为C6-10芳基;在另一个实施方式中,R2s为5-10元杂芳基。
在一个更具体的实施方式中,R1s选自H、D、卤素、=O、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;在另一个更具体的实施方式中,R1s选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C5-7环烷基或5-7元杂环基;在另一个更具体的实施方式中,R1s选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基或C1-6卤代烷基;在另一个更具体的实施方式中,R1s选自H、D、卤素、C(O)ORa、C1-6烷基或C1-6卤代烷基;在另一个更具体的实施方式中,R1s选自卤素或C(O)OCH3。
在一个更具体的实施方式中,R2s选自H、D、卤素、=O、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;在另一个更具体的实施方式中,R2s选自H、D、卤素、=O、C1-6烷基或C1-6卤代烷基;在另一个更具体的实施方式中,R2s选自H、D、=O、C1-6烷基或C1-6卤代烷基;在另一个更具体的实施方式中,R2s选自H、D、=O或Me。
R3s1
在一个实施方式中,R3s1为H;在另一个实施方式中,R3s1为D;在另一个实施方式中,R3s1为卤素;在另一个实施方式中,R3s1为C1-6烷基;在另一个实施方式中,R3s1为C1-6卤代烷基;在另一个实施方式中,R3s1为C2-6烯基;在另一个实施方式中,R3s1为C2-6炔基;在另一个实施方式中,R3s1为C3-10环烷基;在另一个实施方式中,R3s1为3-10元杂环基;在另一个实施方式中,R3s1为C6-10芳基;在另一个实施方式中,R3s1为5-10元杂芳基。
在一个更具体的实施方式中,R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;在另一个更具体的实施方式中,R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基;在另一个更具体的实施方式中,R3s1选自H、D、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基;在另一个更具体的实施方式中,R3s1选自H、D、C1-6烷基、C1-6卤代烷基或C3-6环烷基;在另一个更具体的实施方式中,
R3s1选自H、Me或环丙基;优选选自H或Me。
R3s2
在一个实施方式中,R3s2为H;在另一个实施方式中,R3s2为D;在另一个实施方式中,R3s2为-L-ORa;在另一个实施方式中,R3s2为-L-NRbRc;在另一个实施方式中,R3s2为C1-6烷基;在另一个实施方式中,R3s2为C1-6卤代烷基;在另一个实施方式中,R3s2为C3-10环烷基;在另一个实施方式中,R3s2为5-10元杂环基;在另一个实施方式中,R3s2为C6-10芳基;在另一个实施方式中,R3s2为5-10元杂芳基;在另一个实施方式中,R3s2任选地被1、2或3个R3s取代。
在一个更具体的实施方式中,R3s2选自H、D、-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基;在另一个更具体的实施方式中,R3s2选自H、D、-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C5-7环烷基、5-7元杂环基、C6-10芳基或5-10元杂芳基;在另一个更具体的实施方式中,R3s2选自H、D、-L-ORa、C1-6烷基、C1-6卤代烷基、C5-7环烷基、苯基或5-10元杂芳基;在另一个更具体的实施方式中,R3s2选自H、D、Me、CF3、CH2OCH3、环丙基、优选选自C5-7环烷基、5-7元杂环基、C6-10芳基或5-10元杂芳基;优选为C5-7环烷基,例如环丙基;优选为Et。
在另一个更具体的实施方式中,R3s1、R3s2以及他们连接的碳原子一起形成C3-10环烷基,例如C3-6环烷基。
R
在一个实施方式中,R为H;在另一个实施方式中,R为D;在另一个实施方式中,R为卤素;在另一个实施方式中,R为C1-6烷基;在另一个实施方式中,R为C1-6卤代烷基。
R3s
在一个实施方式中,R3s为H;在另一个实施方式中,R3s为D;在另一个实施方式中,R3s为卤素;在另一个实施方式中,R3s为C1-6烷基;在另一个实施方式中,R3s为C1-6卤代烷基。
Ra、Rb和Rc
在一个实施方式中,Ra、Rb和Rc独立地为H;在另一个实施方式中,Ra、Rb和Rc独立地为D;在另一个实施方式中,Ra、Rb和Rc独立地为C1-6烷基;在另一个实施方式中,Ra、Rb和Rc独立地为C1-6卤代烷基;在另一个实施方式中,Ra、Rb和Rc独立地为C3-10环烷基;在另一个实施方式中,Ra、Rb和Rc独立地为3-10元杂环基;在另一个实施方式中,Ra、Rb和Rc独立地为C6-10芳基;在另一个实施方式中,Ra、Rb和Rc独立地为5-10元杂芳基;在另一个实施方式中,Rb、Rc以及他们连接的原子一起形成5-10元杂环基,优选5-6元杂环基。
以上任一具体实施方案中的任一技术方案或其任意组合,可以与其它具体实施方案中的任一技术方案或其任意组合进行组合。例如,环A的任一技术方案或其任意组合,可以与L1、L2、L3、Rx、Ry、R1、m、X1、X2、X3、R2a、R2b、R2c、R2d、R3、L、R、R1s、R2s、R3s、R3s1、R3s2、Ra、Rb和Rc等的任一技术方案或其任意组合进行组合。本发明旨在包括所有这些技术方案的组合,限于篇幅,不
再一一列出。
在更具体的实施方案中,本发明提供了式(X)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物:
其中,
环A为C6-10芳基或5-10元杂芳基;
L1为NH或CHRx;
L2为CRxRy;
L3为-C(O)-、-S(O)-或-S(O)2-;
其中Rx和Ry独立地为H、D、C1-6烷基或C1-6卤代烷基;
或者CRxRy一起形成C=O、C=S或C3-6亚环烷基;
或者当L1为CHRx、L2为CRxRy时,两个Rx基团可以结合形成化学键或C1-4亚烷基;
R1选自H、D、卤素、CN、NO2、-L-ORa、-L-SRa、-L-NRbRc、SF5、C(O)Ra、C(O)ORa、C(O)NRbRc、OC(O)Ra、NRbC(O)Rc、S(O)Ra、S(O)2Ra、S(O)(=NRa)Ra、S(O)ORa、S(O)2ORa、S(O)NRbRc、S(O)2NRbRc、P(O)(Ra)2、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7环烷基、-L-3-7元杂环基、-L-C6-10芳基或-L-5-10元杂芳基,其任选被1、2或3个R1s取代;
m=0、1、2、3或4;
R4选自H、D、C1-6烷基或C1-6卤代烷基;
或者一个R1与R4连接形成-(CH2)q1-X-(CH2)q2-;其中X为O、S、NH或CH2,q1=0、1或2,q2=1、2或3;
X1为C原子或N原子,其任选地被R2b取代;
X2为C原子或N原子,其任选地被R2c取代;
X3为C原子或N原子,其任选地被R2d取代;
R2a选自H、D、CN、ORa、NRbRc、C(O)ORa或C(O)NRbRc;
R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基或3-10元杂环基;
R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
或者X1、X2以及他们的取代基一起形成C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选被1、2或3个R2s取代;
R2d选自H、D、卤素、CN、NO2、ORa、NRbRc、C1-6烷基、C1-6卤代烷基、C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基;
R3选自-C1-6亚烷基-ORa、-C1-6亚烷基-NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-10环烷基、-L-3-10元杂环基、-L-C6-10芳基或-L-5-10元杂芳基,其任选被1、2或3个R3s1和1个R3s2取代;
L为化学键、C1-6亚烷基、C2-6亚烯基或C2-6亚炔基,其任选被1、2或3个R取代;
R1s和R2s独立地选自H、D、卤素、=O、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C2-6
烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;
R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;
R3s2选自H、D、-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;
R和R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
Ra、Rb和Rc独立地选自H、D、C1-6烷基、C1-6卤代烷基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;
其中上述环A、L1、L2、Rx、Ry、R1、R2a、R2b、R2c、R2d、R3、R4、L、R、R1s、R2s、R3s、R3s1、R3s2、Ra、Rb和Rc中的各个基团定义任选地被氘代,直至完全氘代;
条件是当L2为CRxRy、L3为-S(O)-或-S(O)2-时,Ry与R2d结合形成亚乙烯基。
在更具体的实施方案中,本发明提供了式(I)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物:
其中,
环A为C6-10芳基或5-10元杂芳基;
L1为NH或CHRx;
L2为CRxRy;
L3为-C(O)-、-S(O)-或-S(O)2-;
其中Rx和Ry独立地为H、D、C1-6烷基或C1-6卤代烷基;
或者CRxRy一起形成C=O、C=S或C3-6亚环烷基;
或者当L1为CHRx、L2为CRxRy时,两个Rx基团可以结合形成化学键或C1-4亚烷基;
R1选自H、D、卤素、CN、NO2、-L-ORa、-L-SRa、-L-NRbRc、SF5、C(O)Ra、C(O)ORa、C(O)NRbRc、OC(O)Ra、NRbC(O)Rc、S(O)Ra、S(O)2Ra、S(O)ORa、S(O)2ORa、S(O)NRbRc、S(O)2NRbRc、P(O)(Ra)2、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7环烷基、-L-3-7元杂环基、-L-C6-10芳基或-L-5-10元杂芳基,其任选被1、2或3个R1s取代;
m=0、1、2、3或4;
X1为C原子或N原子,其任选地被R2b取代;
X2为C原子或N原子,其任选地被R2c取代;
X3为C原子或N原子,其任选地被R2d取代;
R2a选自H、D、CN、ORa、NRbRc、C(O)ORa或C(O)NRbRc;
R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基或3-10元杂环基;
R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
或者X1、X2以及他们的取代基一起形成C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳
基,其任选被1、2或3个R2s取代;
R2d选自H、D、卤素、CN、NO2、ORa、NRbRc、C1-6烷基、C1-6卤代烷基、C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基;
R3选自-C1-6亚烷基-ORa、-C1-6亚烷基-NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-10环烷基、-L-3-10元杂环基、-L-C6-10芳基或-L-5-10元杂芳基,其任选被1、2或3个R3s1和1个R3s2取代;
L为化学键、C1-6亚烷基、C2-6亚烯基或C2-6亚炔基,其任选被1、2或3个R取代;
R1s和R2s独立地选自H、D、卤素、=O、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;
R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;
R3s2选自H、D、-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;
R和R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;
其中上述环A、L1、L2、Rx、Ry、R1、R2a、R2b、R2c、R2d、R3、L、R、R1s、R2s、R3s、R3s1、R3s2、Ra、Rb和Rc中的各个基团定义任选地被氘代,直至完全氘代;
条件是当L2为CRxRy、L3为-S(O)-或-S(O)2-时,Ry与R2d结合形成亚乙烯基。
在更具体的实施方案中,本发明提供了上述化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,环A为苯基或5-6元杂芳基;优选为苯基、吡啶基、哒嗪基、嘧啶基或吡嗪基。
在更具体的实施方案中,本发明提供了上述化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,L1为NH,L2为CRxRy;-L1-L2-优选为-L1-L2-优选为
在更具体的实施方案中,本发明提供了上述化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,L1为CHRx,L2为CRxRy;-L1-L2-优选为
在更具体的实施方案中,本发明提供了上述化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,L3为-C(O)-。
在更具体的实施方案中,本发明提供了上述化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,R1选自H、D、卤素、CN、NO2、-L-ORa、-L-SRa、-L-NRbRc、SF5、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7环烷基、-L-3-7元杂环基、-L-C6-10芳基或-L-5-10元杂芳基;优选选自H、D、卤素、CN、NO2、-L-ORa、-L-SRa、-L-NRbRc、SF5、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7环烷基、-L-3-7元杂环基、-L-C6-10芳基或-L-5-10元杂芳基;优选选自H、D、卤素、CN、ORa、SRa、NRbRc、SF5、C1-6烷基、C1-6卤代烷基、C3-7环烷基或3-7元杂环基;优选选自H、D、卤素、CN、ORa、SRa、NRbRc、SF5、C1-6烷基、C1-6
卤代烷基、C5-7环烷基或5-7元杂环基;优选选自H、D、卤素、CN、ORa、NRbRc、C1-6烷基、C1-6卤代烷基、C3-6环烷基或4-6元杂环基;优选选自H、D、卤素、CN、ORa、NRbRc、C1-6烷基、C1-6卤代烷基或5-6元杂环基;优选选自H、D、CN、ORa、C1-6烷基、C1-6卤代烷基、C3-6环烷基或5-6元杂环基;优选选自H、D、CN、ORa、C1-6烷基、C1-6卤代烷基或5-6元杂环基;优选选自CF3、CN、OCF3、OCH2CH3、优选选自CF3、CN、OCF3、OCH2CH3、优选为CF3。
在更具体的实施方案中,本发明提供了上述化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,R1与R4连接形成-(CH2)q1-X-(CH2)q2-;其中X为O、S、NH或CH2,q1=0或1,q2=1或2;优选地,R1与R4连接形成-(CH2)q1-X-(CH2)q2-;其中X为O、S或NH,q1=0或1,q2=1或2。
在更具体的实施方案中,本发明提供了上述化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,选自
优选为
在更具体的实施方案中,本发明提供了上述化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,R2a选自H、D、CN、ORa或NRbRc;优选选自ORa或NRbRc;优选选自OMe或NH2;优选为NH2。
在更具体的实施方案中,本发明提供了上述化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基或3-10元杂环基;优选选自H、D、卤素、C(O)NRbRc、C1-6烷基、C1-6卤代烷基或4-6元杂环基;优选选自H、D、卤素、C(O)NRbRc、C1-6烷基或C1-6卤代烷基;优选选自H、D、卤素、C(O)NRbRc或C1-6烷基;优选选自H、F、Cl、Br、Me、CH2CH3、C(O)NH2或优选选自H、F、Cl、Br、Me、CH2CH3或C(O)NH2;优选选自Me或C(O)NH2。
在更具体的实施方案中,本发明提供了上述式(I)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,R2c选自H或Me。
在更具体的实施方案中,本发明提供了上述化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,X1、X2以及他们的取代基一起形成C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基;优选为C5-7环烷基、5-7元杂环基、苯基或5-6元杂芳基;优选形成
优选形成
优选形成优选形成
在更具体的实施方案中,本发明提供了上述化合物,或其药学上可接受的盐、同位素变体、互变
异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,R2d选自H、D、C1-6烷基或C1-6卤代烷基;优选选自H或D。
在更具体的实施方案中,本发明提供了上述化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,R3选自C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-10环烷基、-L-3-10元杂环基、-L-C6-10芳基或-L-5-10元杂芳基;优选选自C1-6烷基、C1-6卤代烷基、-L-C3-10环烷基、-L-3-10元杂环基、-L-C6-10芳基或-L-5-10元杂芳基;优选选自C1-6烷基、C1-6卤代烷基、C5-6环烷基、5-6元杂环基、苯基或5-6元杂芳基;优选选自Me、Et、iPr、环丙基、环丁基、
在更具体的实施方案中,本发明提供了上述化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,R1s选自H、D、卤素、=O、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;优选选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C5-7环烷基或5-7元杂环基;优选选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基或C1-6卤代烷基;优选选自H、D、卤素、C(O)ORa、C1-6烷基或C1-6卤代烷基,优选选自卤素或C(O)OCH3。
在更具体的实施方案中,本发明提供了上述化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,R2s选自H、D、卤素、=O、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;优选选自H、D、卤素、=O、C1-6烷基或C1-6卤代烷基;优选选自H、D、=O、C1-6烷基或C1-6卤代烷基;优选选自H、D、=O或Me。
在更具体的实施方案中,本发明提供了上述化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;优选选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基;优选选自H、D、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基;优选选自H、D、C1-6烷基、C1-6卤代烷基或C3-6环烷基;优选选自H、Me或环丙基;优选选自H或Me。
在更具体的实施方案中,本发明提供了上述化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,R3s2选自H、D、-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基;优选选自H、D、-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C5-7环烷基、5-7元杂环基、C6-10芳基或5-10元杂芳基;优选选自H、D、-L-ORa、C1-6烷基、C1-6卤代烷基、C5-7环烷基、苯基或5-10元杂芳基;优选选自H、D、Me、CF3、CH2OCH3、环丙基、优选选自C5-7环烷基、5-7元杂环基、C6-10芳基或5-10元杂芳基;优选为C5-7环烷基,例如环丙基;优选为Et。
在更具体的实施方案中,本发明提供了上述化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其具有以下结构式:
其中各基团如上文定义。
在更具体的实施方案中,本发明提供了上述化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其为式(II)化合物,其中,
L1为NH或CHRx;
L2为CRxRy;
其中Rx和Ry独立地为H、D、C1-6烷基或C1-6卤代烷基;
或者CRxRy一起形成C=O、C=S或C3-6亚环烷基;
或者当L1为CHRx、L2为CRxRy时,两个Rx基团可以结合形成化学键或C1-4亚烷基;
Z1为CH或N;
R1为H、D、卤素、CN、ORa、SRa、NRbRc、SF5、C1-6烷基、C1-6卤代烷基、C5-7环烷基或5-7元杂环基,其任选地被1、2或3个R1s取代;
m=0、1、2或3,优选m=0;
X1为C原子或N原子,其任选地被R2b取代;
X2为C原子或N原子,其任选地被R2c取代;
X3为C原子或N原子,其任选地被R2d取代;
R2a选自H、D、ORa或NRbRc;
R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基;
R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
或者X1、X2以及他们的取代基一起形成C5-7环烷基、5-7元杂环基、苯基或5-6元杂芳基,其任选被1、2或3个R2s取代;
R2d选自H、D、卤素、CN、NO2、ORa、NRbRc、C1-6烷基、C1-6卤代烷基、C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基;
R1s选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C5-7环烷基或5-7元杂环基;
R2s选自H、D、卤素、=O、C1-6烷基或C1-6卤代烷基;
R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基;
R3s2选自H、D、-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C5-7环烷基、5-7元杂环基、C6-10芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;
L为化学键或C1-6亚烷基,其任选被1、2或3个R取代;
R和R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;
其中上述L1、L2、Rx、Ry、Z1、R1、R2a、R2b、R2c、R2d、R1s、R2s、R3s1、R3s2、L、R、R3s、Ra、Rb和Rc中的各个基团定义任选地被氘代,直至完全氘代。
在更具体的实施方案中,本发明提供了上述式(II)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,
L1为NH或CHRx;
L2为CRxRy;
其中Rx和Ry独立地为H、D、C1-6烷基或C1-6卤代烷基;
或者CRxRy一起形成C=O、C=S或C3-4亚环烷基;
或者当L1为CHRx、L2为CRxRy时,两个Rx基团可以结合形成化学键或C1-3亚烷基;
Z1为CH或N;
R1选自H、D、卤素、CN、ORa、NRbRc、C1-6烷基、C1-6卤代烷基或5-6元杂环基,其中所述杂环基任选地被1、2或3个R1s取代;
m=0、1、2或3,优选m=0;
X1为C原子或N原子,其任选地被R2b取代;
X2为C原子或N原子,其任选地被R2c取代;
X3为C原子或N原子,其任选地被R2d取代;
R2a为NH2;
R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基;
R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
或者X1、X2以及他们的取代基一起形成C5-7环烷基、5-7元杂环基、苯基或5-6元杂芳基,其任选被1、2或3个R2s取代;
R2d选自H、D、C1-6烷基或C1-6卤代烷基;
R1s选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基或C1-6卤代烷基;
R2s选自H、D、=O、C1-6烷基或C1-6卤代烷基;
R3s1选自H、D、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基;
R3s2选自H、D、-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C5-7环烷基、5-7元杂环基、C6-10芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;
L为化学键或C1-3亚烷基,其任选被1、2或3个R取代;
R和R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基。
在更具体的实施方案中,本发明提供了上述式(II)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,
L1为NH或CHRx;
L2为CRxRy;
其中Rx和Ry独立地为H、D、C1-3烷基或C1-3卤代烷基;
或者CRxRy一起形成C=O或亚环丙基;
或者当L1为CHRx、L2为CRxRy时,两个Rx基团可以结合形成化学键或C1-2亚烷基;
Z1为CH或N;
R1选自H、D、CN、ORa、C1-6烷基、C1-6卤代烷基或5-6元杂环基,其任选地被1、2或3个R1s取代;
m=0、1、2或3,优选m=0;
X1为C原子或N原子,其任选地被R2b取代;
X2为C原子或N原子,其任选地被R2c取代;
X3为C原子或N原子,其任选地被R2d取代;
R2a为NH2;
R2b选自H、D、卤素、C(O)NRbRc、C1-6烷基、C1-6卤代烷基或4-6元杂环基;
R2c选自H、D、C1-6烷基或C1-6卤代烷基;
或者X1、X2以及他们的取代基一起形成C5-7环烷基、5-7元杂环基、苯基或5-6元杂芳基,其任选被1、2或3个R2s取代;优选
R2d选自H或D;
R1s选自H、D、卤素、C(O)ORa、C1-6烷基或C1-6卤代烷基,优选卤素或C(O)OCH3;
R2s选自H、D、=O或Me;
R3s1选自H、D、C1-6烷基、C1-6卤代烷基或C3-6环烷基;
R3s2选自H、D、-L-ORa、C1-6烷基、C1-6卤代烷基、C5-7环烷基、苯基或5-10元杂芳基,其任选地被1、2或3个R3s取代;优选地,R3s2选自H、D、Me、CF3、CH2OCH3、环丙基、
L为化学键或C1-3亚烷基,优选亚甲基,其任选被1、2或3个R取代;
R和R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基。
在更具体的实施方案中,本发明提供了上述式(II)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,
L1为NH;
L2为CRxRy;其中CRxRy一起形成C=O或C=S;
R1选自H、D、卤素、CN、NO2、-L-ORa、-L-SRa、-L-NRbRc、SF5、C(O)Ra、C(O)ORa、C(O)NRbRc、OC(O)Ra、NRbC(O)Rc、S(O)Ra、S(O)2Ra、S(O)ORa、S(O)2ORa、S(O)NRbRc、S(O)2NRbRc、P(O)(Ra)2、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7环烷基、-L-3-7元杂环基、-L-C6-10芳基或-L-5-10元杂芳基,其任选被1、2或3个R1s取代;
m=0、1、2、3或4;
X1为C原子,其被R2b取代;
X2为C原子或N原子,其任选地被R2c取代;
X3为C原子,其被R2d取代;
R2a选自H、D、CN、ORa、NRbRc、C(O)ORa或C(O)NRbRc;
R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基或3-10元杂环基;
R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
或者X1、X2以及他们的取代基一起形成C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选被1、2或3个R2s取代;
R2d选自H、D、卤素、CN、NO2、ORa、NRbRc、C1-6烷基、C1-6卤代烷基、C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基;
Z1为CH;
L为化学键、C1-6亚烷基、C2-6亚烯基或C2-6亚炔基,其任选被1、2或3个R取代;
R1s和R2s独立地选自H、D、卤素、=O、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;
R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;
R3s2选自-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;
R和R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;
其中上述各个基团定义任选地被氘代,直至完全氘代。
在更具体的实施方案中,本发明提供了上述式(II)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,
L1为NH;
L2为CRxRy;其中CRxRy一起形成C=O或C=S;
R1选自H、D、卤素、CN、NO2、-L-ORa、-L-SRa、-L-NRbRc、SF5、C(O)Ra、C(O)ORa、C(O)NRbRc、OC(O)Ra、NRbC(O)Rc、S(O)Ra、S(O)2Ra、S(O)ORa、S(O)2ORa、S(O)NRbRc、S(O)2NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7环烷基、-L-3-7元杂环基、-L-C6-10芳基或-L-5-10元杂芳基,其任选被1、2或3个R1s取代;
m=0、1、2、3或4;
X1为C原子,其被R2b取代;
X2为C原子或N原子,其任选地被R2c取代;
X3为C原子,其被R2d取代;
R2a选自H、D、CN、ORa或NRbRc;
R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基或C1-6卤代烷基;
R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
或者X1、X2以及他们的取代基一起形成C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选被1、2或3个R2s取代;
R2d选自H、D、卤素、CN、NO2、ORa、NRbRc、C1-6烷基或C1-6卤代烷基;
Z1为CH;
L为化学键、C1-6亚烷基、C2-6亚烯基或C2-6亚炔基;
R1s和R2s独立地选自H、D、卤素、=O、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基或C2-6炔基;
R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基或C2-6炔基;
R3s2选自-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;
R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;
其中上述各个基团定义任选地被氘代,直至完全氘代。
在更具体的实施方案中,本发明提供了上述式(II)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,
L1为NH;
L2为CRxRy;其中CRxRy一起形成C=O或C=S;
R1选自H、D、卤素、CN、NO2、-L-ORa、-L-SRa、-L-NRbRc、SF5、C(O)Ra、C(O)ORa、C(O)NRbRc、S(O)Ra、S(O)2Ra、S(O)ORa、S(O)2ORa、S(O)NRbRc、S(O)2NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7环烷基、-L-3-7元杂环基、-L-C6-10芳基或-L-5-10元杂芳基,其任选被1、2或3个R1s取代;
m=0、1、2、3或4;
X1为C原子,其被R2b取代;
X2为C原子或N原子,其任选地被R2c取代;
X3为C原子,其被R2d取代;
R2a选自H、D、CN、ORa或NRbRc;
R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基或C1-6卤代烷基;
R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
或者X1、X2以及他们的取代基一起形成C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选被1、2或3个R2s取代;
R2d选自H、D、卤素、CN、NO2、C1-6烷基或C1-6卤代烷基;
Z1为CH;
L为化学键或C1-6亚烷基;
R1s和R2s独立地选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基或C2-6炔基;
R3s1选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
R3s2选自-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;
R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;
其中上述各个基团定义任选地被氘代,直至完全氘代。
在更具体的实施方案中,本发明提供了上述式(II)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,
L1为NH;
L2为CRxRy;其中CRxRy一起形成C=O或C=S;
R1选自H、D、-L-ORa、-L-SRa、-L-NRbRc、SF5、C(O)Ra、C(O)ORa、C(O)NRbRc、OC(O)Ra、NRbC(O)Rc、S(O)Ra、S(O)2Ra、S(O)ORa、S(O)2ORa、S(O)NRbRc、S(O)2NRbRc、P(O)(Ra)2、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7环烷基或-L-5-10元杂芳基,其任选被1、2或3个R1s取代;
m=0、1、2、3或4;
X1为C原子,其被R2b取代;
X2为C原子,其被R2c取代;
X3为C原子,其被R2d取代;
R2a选自H、D、CN、ORa、NRbRc、C(O)ORa或C(O)NRbRc;
R2b选自C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基;
R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
或者X1、X2以及他们的取代基一起形成5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选被1、2或3个R2s取代;
R2d选自H、D、卤素、CN、NO2、ORa、NRbRc、C1-6烷基、C1-6卤代烷基、C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基;
Z1为CH;
L为化学键、C1-6亚烷基、C2-6亚烯基或C2-6亚炔基,其任选被1、2或3个R取代;
R1s和R2s独立地选自H、D、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;
R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;
R3s2选自-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;
R和R3s独立地选自H、D、C1-6烷基或C1-6卤代烷基;
Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;
其中上述各个基团定义任选地被氘代,直至完全氘代。
在更具体的实施方案中,本发明提供了上述式(II)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,
L1为NH;
L2为CRxRy;其中CRxRy一起形成C=O或C=S;
R1选自H、D、-L-ORa、-L-SRa、-L-NRbRc、C(O)Ra、C(O)ORa、C(O)NRbRc、S(O)Ra、S(O)2Ra、S(O)ORa、S(O)2ORa、S(O)NRbRc、S(O)2NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7环烷基或-L-5-10元杂芳基,其任选被1、2或3个R1s取代;
m=0、1、2、3或4;
X1为C原子,其被R2b取代;
X2为C原子,其被R2c取代;
X3为C原子,其被R2d取代;
R2a选自H、D、CN、ORa或NRbRc;
R2b选自C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基;
R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
或者X1、X2以及他们的取代基一起形成5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选被1、2或3个R2s取代;
R2d选自H、D、卤素或CN;
Z1为CH;
L为化学键、C1-6亚烷基、C2-6亚烯基或C2-6亚炔基;
R1s和R2s独立地选自H、D、C1-6烷基、C1-6卤代烷基、C2-6烯基或C2-6炔基;
R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基或C2-6炔基;
R3s2选自-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基;
Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;
其中上述各个基团定义任选地被氘代,直至完全氘代。
在更具体的实施方案中,本发明提供了上述式(II)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,
L1为NH;
L2为CRxRy;其中CRxRy一起形成C=O或C=S;
R1选自H、D、ORa、SRa、NRbRc、C(O)Ra、S(O)Ra、S(O)2Ra、C1-6烷基、C1-6卤代烷基、C3-7
环烷基或5-10元杂芳基,其任选被1、2或3个R1s取代;
m=0、1、2、3或4;
X1为C原子,其被R2b取代;
X2为C原子,其被R2c取代;
X3为C原子,其被R2d取代;
R2a选自ORa或NRbRc;
R2b选自C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基;
R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
或者X1、X2以及他们的取代基一起形成5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选被1、2或3个R2s取代;
R2d选自H、D、卤素或CN;
Z1为CH;
L为化学键或C1-6亚烷基;
R1s和R2s独立地选自H、D、C1-6烷基、C1-6卤代烷基、C2-6烯基或C2-6炔基;
R3s1选自H、D、卤素、C1-4烷基或C1-4卤代烷基;
R3s2选自-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基;
Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;
其中上述各个基团定义任选地被氘代,直至完全氘代。
在更具体的实施方案中,本发明提供了上述式(II)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,
L1为NH;
L2为CRxRy;其中CRxRy一起形成C=O或C=S;
R1选自H、D、ORa、SRa、NRbRc、C(O)Ra、S(O)Ra、S(O)2Ra、C1-6烷基、C1-6卤代烷基、C3-7环烷基或5-10元杂芳基,其任选被1、2或3个R1s取代;
m=0、1、2、3或4;
X1为C原子,其被R2b取代;
X2为C原子,其被R2c取代;
X3为C原子,其被R2d取代;
R2a选自ORa或NRbRc;
R2b选自C(O)ORa、C(O)NRbRc或C1-6烷基;
R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
或者X1、X2以及他们的取代基一起形成5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选被1、2或3个R2s取代;
R2d选自H、D、卤素或CN;
Z1为CH;
L为化学键或C1-6亚烷基;
R1s和R2s独立地选自H、D、C1-6烷基、C1-6卤代烷基、C2-6烯基或C2-6炔基;
R3s1选自Me;
R3s2选自Et;
Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;
其中上述各个基团定义任选地被氘代,直至完全氘代。
在更具体的实施方案中,本发明提供了上述式(II)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,
L1为NH;
L2为CRxRy;其中CRxRy一起形成C=O或C=S;
R1选自H、D、ORa、SRa、NRbRc、C(O)Ra、S(O)Ra、S(O)2Ra、C1-6烷基、C1-6卤代烷基、C3-7环烷基或5-6元杂芳基,其任选被1、2或3个R1s取代;
m=0、1、2、3或4;
X3为C原子,其被R2d取代;
R2a选自ORa或NRbRc;
X1、X2以及他们的取代基一起形成5-6元杂芳基,其任选被1、2或3个R2s取代;
R2d选自H、D、卤素或CN;
Z1为CH;
R1s和R2s独立地选自H、D、C1-6烷基、C1-6卤代烷基、C2-6烯基或C2-6炔基;
R3s1选自H或D;
R3s2选自C3-6环烷基、5-6元杂环基、苯基或5-6元杂芳基;
Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;
其中上述各个基团定义任选地被氘代,直至完全氘代。
在更具体的实施方案中,本发明提供了上述式(II)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,
L1为NH;
L2为CRxRy;其中CRxRy一起形成C=O或C=S;
R1选自H、D、ORa、SRa、NRbRc、C(O)Ra、S(O)Ra、S(O)2Ra、C1-6烷基、C1-6卤代烷基、C3-7环烷基或5-6元杂芳基,其任选被1、2或3个R1s取代;
m=0、1、2、3或4;
X3为C原子,其被R2d取代;
R2a选自ORa或NRbRc;
X1、X2以及他们的取代基一起形成5-6元杂芳基,其任选被1、2或3个R2s取代;
R2d选自H、D、卤素或CN;
Z1为CH;
L为化学键或C1-6亚烷基;
R1s和R2s独立地选自H、D、C1-6烷基、C1-6卤代烷基、C2-6烯基或C2-6炔基;
R3s1选自C1-4烷基或C1-4卤代烷基;
R3s2选自-L-ORa、-L-NRbRc、C1-6烷基或C1-6卤代烷基;
Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;
其中上述各个基团定义任选地被氘代,直至完全氘代。
在更具体的实施方案中,本发明提供了上述式(III)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,
L1为NH或CHRx;
L2为CRxRy;
其中Rx和Ry独立地为H、D、C1-6烷基或C1-6卤代烷基;
或者CRxRy一起形成C=O、C=S或C3-6亚环烷基;
或者当L1为CHRx、L2为CRxRy时,两个Rx基团可以结合形成化学键或C1-4亚烷基;
Z1为CH或N;
R1选自H、D、卤素、CN、ORa、SRa、NRbRc、SF5、C1-6烷基、C1-6卤代烷基、C5-7环烷基或5-7元杂环基,其任选地被1、2或3个R1s取代;
m=0、1、2或3,优选m=0;
X1为C原子或N原子,其任选地被R2b取代;
X2为C原子或N原子,其任选地被R2c取代;
X3为C原子或N原子,其任选地被R2d取代;
R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基;
R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
或者X1、X2以及他们的取代基一起形成C5-7环烷基、5-7元杂环基、苯基或5-6元杂芳基,其任选被1、2或3个R2s取代;
R2d选自H或D;
R1s选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C5-7环烷基或5-7元杂环基;
R2s选自H、D、卤素、=O、C1-6烷基或C1-6卤代烷基;
R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基;
R3s选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
p=0、1、2或3,优选p=0;
Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;
其中上述L1、L2、Rx、Ry、Z1、R1、R2b、R2c、R1s、R2s、R3s1、R3s、Ra、Rb和Rc中的各个基团定义任选地被氘代,直至完全氘代。
在更具体的实施方案中,本发明提供了上述式(III)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,
L1为NH或CHRx;
L2为CRxRy;
其中Rx和Ry独立地为H、D、C1-6烷基或C1-6卤代烷基;
或者CRxRy一起形成C=O、C=S或C3-4亚环烷基;
或者当L1为CHRx、L2为CRxRy时,两个Rx基团可以结合形成化学键或C1-3亚烷基;
Z1为CH或N;
R1选自H、D、卤素、CN、ORa、NRbRc、C1-6烷基、C1-6卤代烷基或5-6元杂环基,其中所述杂环基任选地被1、2或3个R1s取代;
m=0、1、2或3,优选m=0;
X1为C原子或N原子,其任选地被R2b取代;
X2为C原子或N原子,其任选地被R2c取代;
X3为C原子或N原子,其任选地被R2d取代;
R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基;
R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
或者X1、X2以及他们的取代基一起形成C5-7环烷基、5-7元杂环基、苯基或5-6元杂芳基,其任选被1、2或3个R2s取代;
R2d选自H或D;
R1s选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基或C1-6卤代烷基;
R2s选自H、D、=O、C1-6烷基或C1-6卤代烷基;
R3s1选自H、D、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基;
R3s选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
p=0、1、2或3,优选p=0;
Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基。
在更具体的实施方案中,本发明提供了上述式(III)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,
L1为NH或CHRx;
L2为CRxRy;
其中Rx和Ry独立地为H、D、C1-3烷基或C1-3卤代烷基;
或者CRxRy一起形成C=O或亚环丙基;
或者当L1为CHRx、L2为CRxRy时,两个Rx基团可以结合形成化学键或C1-2亚烷基;
Z1为CH或N;
R1选自H、D、CN、ORa、C1-6烷基、C1-6卤代烷基或5-6元杂环基,其任选地被1、2或3个R1s取代;
m=0、1、2或3,优选m=0;
X1为C原子或N原子,其任选地被R2b取代;
X2为C原子或N原子,其任选地被R2c取代;
X3为C原子或N原子,其任选地被R2d取代;
R2b选自H、D、卤素、C(O)NRbRc、C1-6烷基、C1-6卤代烷基或4-6元杂环基;
R2c选自H、D、C1-6烷基或C1-6卤代烷基;
或者X1、X2以及他们的取代基一起形成C5-7环烷基、5-7元杂环基、苯基或5-6元杂芳基,其任选被1、2或3个R2s取代;
R2d选自H或D;
R1s选自H、D、卤素、C(O)ORa、C1-6烷基或C1-6卤代烷基,优选卤素或C(O)OCH3;
R2s选自H、D、=O或Me;
R3s1选自H、D、C1-6烷基、C1-6卤代烷基或C3-6环烷基;
R3s选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
p=0、1、2或3,优选p=0;
Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基。
在更具体的实施方案中,本发明提供了上述式(III)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,
L1-L2为:
Z1为CH或N;
R1为CF3、CN、OCF3、OCH2CH3、优选为CF3;
m=0;
X1为C原子或N原子,其任选地被R2b取代;
X2为C原子或N原子,其任选地被R2c取代;
X3为C原子或N原子,其任选地被R2d取代;
R2b为H、F、Cl、Br、Me、CH2CH3、C(O)NH2或
R2c为H或Me;
或者X1、X2以及他们的取代基一起形成:
R2d为H;
R3s1为H、Me或环丙基;
R3s为H;
p=0。
在更具体的实施方案中,本发明提供了上述式(IV)、(IV-1)、(IV-1a)、(IV-1b)、(IV-2)、(IV-2a)或(IV-2b)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,
R1选自H、D、卤素、CN、NO2、-L-ORa、-L-SRa、-L-NRbRc、SF5、C(O)Ra、C(O)ORa、C(O)NRbRc、OC(O)Ra、NRbC(O)Rc、S(O)Ra、S(O)2Ra、S(O)ORa、S(O)2ORa、S(O)NRbRc、S(O)2NRbRc、P(O)(Ra)2、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7环烷基、-L-3-7元杂环基、-L-C6-10芳基或-L-5-10元杂芳基,其任选被1、2或3个R1s取代;
m=0、1或2;
R4选自H或D;
X1为C原子,其被R2b取代;
X2为C原子或N原子,其任选地被R2c取代;
X3为C原子,其被R2d取代;
R2a选自H、D、CN、ORa、NRbRc、C(O)ORa或C(O)NRbRc;
R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基或3-10元杂环基;
R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
或者X1、X2以及他们的取代基一起形成C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选被1、2或3个R2s取代;
R2d选自H、D、卤素、CN、NO2、ORa、NRbRc、C1-6烷基、C1-6卤代烷基、C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基;
Z1为CH;
Z2为CR1或N;
Z3为CR1或N;
当Z2为CR1时,该R1与R4连接形成-(CH2)q1-X-(CH2)q2-;其中X为O、S、NH或CH2,q1=0、1或2,q2=1、2或3;
L为化学键、C1-6亚烷基、C2-6亚烯基或C2-6亚炔基,其任选被1、2或3个R取代;
R1s和R2s独立地选自H、D、卤素、CN、=O、ORa、NRbRc、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;或者两个R1s以及他们连接的原子一起形成C3-10环烷基或3-10元杂环基;优选选自H、D、卤素、CN、=O、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;
R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;
R3s2选自H、D、-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;
R和R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
Ra、Rb和Rc独立地选自H、D、C1-6烷基、C1-6卤代烷基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;
其中上述各个基团定义任选地被氘代,直至完全氘代。
在更具体的实施方案中,本发明提供了上述式(IV)、(IV-1)、(IV-1a)、(IV-1b)、(IV-2)、(IV-2a)或(IV-2b)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,
R1选自H、D、卤素、CN、NO2、ORa、SRa、NRbRc、SF5、C(O)Ra、C(O)ORa、C(O)NRbRc、OC(O)Ra、NRbC(O)Rc、S(O)Ra、S(O)2Ra、S(O)ORa、S(O)2ORa、S(O)NRbRc、S(O)2NRbRc、P(O)(Ra)2、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-7环烷基、3-7元杂环基、C6-10芳基或5-10元杂芳基,其任选被1、2或3个R1s取代;
m=0、1或2;
R4选自H或D;
X1为C原子,其被R2b取代;
X2为C原子或N原子,其任选地被R2c取代;
X3为C原子,其被R2d取代;
R2a选自H、D、CN、ORa或NRbRc;
R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基或C1-6卤代烷基;
R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
或者X1、X2以及他们的取代基一起形成C5-6环烷基、5-6元杂环基、苯基或5-6元杂芳基,其任选被1、2或3个R2s取代;
R2d选自H、D、卤素、CN、NO2、ORa、NRbRc、C1-6烷基或C1-6卤代烷基;
Z1为CH;
Z2为CR1,且该R1与R4连接形成-(CH2)q1-X-(CH2)q2-;其中X为O、S、NH或CH2,q1=0或1,q2=1或2;
Z3为CR1或N;
L为化学键、C1-6亚烷基、C2-6亚烯基或C2-6亚炔基,其任选被1、2或3个R取代;
R1s和R2s独立地选自H、D、卤素、=O、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;
R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;
R3s2选自H、D、-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;
R和R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
Ra、Rb和Rc独立地选自H、D、C1-6烷基、C1-6卤代烷基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;
其中上述各个基团定义任选地被氘代,直至完全氘代。
在更具体的实施方案中,本发明提供了上述式(IV)、(IV-1)、(IV-1a)、(IV-1b)、(IV-2)、(IV-2a)或(IV-2b)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,
R1选自H、D、卤素、CN、NO2、ORa、SRa、NRbRc、SF5、C(O)Ra、S(O)Ra、S(O)2Ra、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C4-6环烷基、5-6元杂环基、苯基或5-6元杂芳基,其任选被1、2或3个R1s取代;
m=0、1或2;
R4选自H或D;
X1为C原子,其被R2b取代;
X2为C原子或N原子,其任选地被R2c取代;
X3为C原子,其被R2d取代;
R2a选自ORa或NRbRc;
R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基或C1-6卤代烷基;
R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
或者X1、X2以及他们的取代基一起形成C5-6环烷基、5-6元杂环基、苯基或5-6元杂芳基,其任选被1、2或3个R2s取代;
R2d选自H、D、卤素、CN、NO2、C1-6烷基或C1-6卤代烷基;
Z1为CH;
Z2为CR1,且该R1与R4连接形成-(CH2)q1-X-(CH2)q2-;其中X为O、S或NH,q1=0或1,q2=1或2;
Z3为CR1或N;
L为化学键或C1-6亚烷基;
R1s和R2s独立地选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基或C2-6炔基;
R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基或C2-6炔基;
R3s2选自H、D、-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-6环烷基、5-6元杂环基、苯基或5-6元杂芳基,其任选地被1、2或3个R3s取代;
R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;
Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;
其中上述各个基团定义任选地被氘代,直至完全氘代。
在最具体的实施方案中,本发明提供了上述式(X)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,所述化合物选自以下:
在最具体的实施方案中,本发明提供了上述式(X)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,所述化合物选自以下:
在最具体的实施方案中,本发明提供了上述式(X)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,所述化合物选自以下:
在最具体的实施方案中,本发明提供了上述式(X)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,所述化合物选自以下:
本发明化合物可包括一个或多个不对称中心,且因此可以存在多种立体异构体形式,例如,对映异构体和/或非对映异构体形式。例如,本发明化合物可为单独的对映异构体、非对映异构体或几何异构体(例如顺式和反式异构体),或者可为立体异构体的混合物的形式,包括外消旋体混合物和富含一种或多种立体异构体的混合物。异构体可通过本领域技术人员已知的方法从混合物中分离,所述方法包括:手性高压液相色谱法(HPLC)以及手性盐的形成和结晶;或者优选的异构体可通过不对称合成来制备。
本发明化合物可以互变异构体形式存在。互变异构体为因分子中某一原子在两个位置迅速移动而产生的官能团异构体,互变异构体是一种特殊的官能团异构体,一对互变异构体可以互相转换,但通常以比较稳定的一种异构体为其主要的存在形式。最主要的例子为烯醇式和酮式互变异构体。
本领域技术人员将理解,有机化合物可以与溶剂形成复合物,其在该溶剂中发生反应或从该溶剂中沉淀或结晶出来。这些复合物称为“溶剂合物”。当溶剂是水时,复合物称为“水合物”。本发明涵盖了本发明化合物的所有溶剂合物。
术语“溶剂合物”是指通常由溶剂分解反应形成的与溶剂相结合的化合物或其盐的形式。这个物理缔合可包括氢键键合。常规溶剂包括包括水、甲醇、乙醇、乙酸、DMSO、THF、乙醚等。本文所述的化合物可制备成,例如,结晶形式,且可被溶剂化。合适的溶剂合物包括药学上可接受的溶剂合物且进一步包括化学计量的溶剂合物和非化学计量的溶剂合物。在一些情况下,所述溶剂合物将能够分离,例如,当一或多个溶剂分子掺入结晶固体的晶格中时。“溶剂合物”包括溶液状态的溶剂合物和可分离的溶剂合物。代表性的溶剂合物包括水合物、乙醇合物和甲醇合物。
术语“水合物”是指与水相结合的化合物。通常,包含在化合物的水合物中的水分子数与该水合物中该化合物分子数的比率确定。因此,化合物的水合物可用例如通式R·x H2O代表,其中R是该化合物,和x是大于0的数。给定化合物可形成超过一种水合物类型,包括,例如,单水合物(x为1)、低级水合物(x是大于0且小于1的数,例如,半水合物(R·0.5 H2O))和多水合物(x为大于1的数,例如,
二水合物(R·2 H2O)和六水合物(R·6 H2O))。
本发明化合物可以是无定形或结晶形式(多晶型)。此外,本发明化合物可以以一种或多种结晶形式存在。因此,本发明在其范围内包括本发明化合物的所有无定形或结晶形式。术语“多晶型物”是指特定晶体堆积排列的化合物的结晶形式(或其盐、水合物或溶剂合物)。所有的多晶型物具有相同的元素组成。不同的结晶形式通常具有不同的X射线衍射图、红外光谱、熔点、密度、硬度、晶体形状、光电性质、稳定性和溶解度。重结晶溶剂、结晶速率、贮存温度和其他因素可导致一种结晶形式占优。化合物的各种多晶型物可在不同的条件下通过结晶制备。
本发明还包括同位素标记的化合物(同位素变体),它们等同于式(I)所述的那些,但一个或多个原子被原子质量或质量数不同于自然界常见的原子质量或质量数的原子所代替。可以引入本发明化合物中的同位素的实例包括氢、碳、氮、氧、磷、硫、氟和氯的同位素,分别例如2H、3H、13C、11C、14C、15N、18O、17O、31P、32P、35S、18F和36Cl。含有上述同位素和/或其它原子的其它同位素的本发明化合物、其前体药物和所述化合物或所述前体药物的药学上可接受的盐都属于本发明的范围。某些同位素标记的本发明化合物、例如引入放射性同位素(例如3H和14C)的那些可用于药物和/或底物组织分布测定。氚、即3H和碳-14、即14C同位素是特别优选的,因为它们容易制备和检测。进而,被更重的同位素取代,例如氘、即2H,由于代谢稳定性更高可以提供治疗上的益处,例如延长体内半衰期或减少剂量需求,因而在有些情况下可能是优选的。同位素标记的本发明式(A)化合物及其前体药物一般可以这样制备,在进行下述流程和/或实施例与制备例所公开的工艺时,用容易得到的同位素标记的试剂代替非同位素标记的试剂。
此外,前药也包括在本发明的上下文内。本文所用的术语“前药”是指在体内通过例如在血液中水解转变成其具有医学效应的活性形式的化合物。药学上可接受的前药描述于T.Higuchi和V.Stella,Prodrugs as Novel Delivery Systems,A.C.S.Symposium Series的Vol.14,Edward B.Roche,ed.,Bioreversible Carriers in Drug Design,American Pharmaceutical Association and Pergamon Press,1987,以及D.Fleisher、S.Ramon和H.Barbra“Improved oral drug delivery:solubility limitations overcome by the use of prodrugs”,Advanced Drug Delivery Reviews(1996)19(2)115-130,每篇引入本文作为参考。
前药为任何共价键合的本发明化合物,当将这种前药给予患者时,其在体内释放母体化合物。通常通过修饰官能团来制备前药,修饰是以使得该修饰可以通过常规操作或在体内裂解产生母体化合物的方式进行的。前药包括,例如,其中羟基、氨基或巯基与任意基团键合的本发明化合物,当将其给予患者时,可以裂解形成羟基、氨基或巯基。因此,前药的代表性实例包括(但不限于)式(A)化合物的羟基、巯基和氨基官能团的乙酸酯/酰胺、甲酸酯/酰胺和苯甲酸酯/酰胺衍生物。另外,在羧酸(-COOH)的情况下,可以使用酯,例如甲酯、乙酯等。酯本身可以是有活性的和/或可以在人体体内条件下水解。合适的药学上可接受的体内可水解的酯基包括容易在人体中分解而释放母体酸或其盐的那些基团。
本发明还提供药物制剂,包含治疗有效量的式(A)化合物或其治疗学上可接受的盐和其药学上可接受的载体、稀释剂或赋形剂。所有这些形式都属于本发明。
药物组合物和试剂盒
在另一方面,本发明提供了药物组合物,其包含本发明化合物(还称为“活性组分”)和药学上可接受的赋形剂。在一些实施方案中,所述药物组合物包含有效量的本发明化合物。在一些实施方案中,所述药物组合物包含治疗有效量的本发明化合物。在一些实施方案中,所述药物组合物包含预防有效
量的本发明化合物。
用于本发明的药学上可接受的赋形剂是指不会破坏一起调配的化合物的药理学活性的无毒载剂、佐剂或媒剂。可以用于本发明组合物中的药学上可接受的载剂、佐剂或媒剂包括(但不限于)离子交换剂、氧化铝、硬脂酸铝、卵磷脂、血清蛋白(如人类血清白蛋白)、缓冲物质(如磷酸盐)、甘氨酸、山梨酸、山梨酸钾、饱和植物脂肪酸的偏甘油酯混合物、水、盐或电解质(如硫酸鱼精蛋白)、磷酸氢二钠、磷酸氢钾、氯化钠、锌盐、硅胶、三硅酸镁、聚乙烯吡咯烷酮、基于纤维素的物质、聚乙二醇、羧甲基纤维素钠、聚丙烯酸酯、蜡、聚乙烯-聚氧丙烯-嵌段聚合物、聚乙二醇以及羊毛脂。
用于给予本发明化合物的合适制剂将对于本领域普通技术人员而言是显而易见的,并且包括例如片剂、丸剂、胶囊、栓剂、锭剂、糖锭剂、溶液(特别是注射(皮下、静脉内、肌内)和输注(注射剂)用溶液)、酏剂、糖浆、扁囊剂、乳液、吸入剂或可分散粉剂。一种或多种药物活性化合物的含量的范围应该是作为整体的组合物的0.1至90wt%、优选0.5至50wt%,即,其量足以实现以下指定的剂量范围。如有必要,指定的剂量可每天给药若干次。
本发明还包括试剂盒(例如,药物包装)。所提供的试剂盒可以包括本发明化合物、其它治疗剂,以及含有本发明化合物、其它治疗剂的第一和第二容器(例如,小瓶、安瓿瓶、瓶、注射器和/或可分散包装或其它合适的容器)。在一些实施方案中,提供的试剂盒还可以任选包括第三容器,其含有用于稀释或悬浮本发明化合物和/或其它治疗剂的药用赋形剂。在一些实施方案中,提供在第一容器和第二容器中的本发明化合物和其它治疗剂组合形成一个单位剂型。
给药
本发明提供的药物组合物可以通过许多途径给药,包括但不限于:口服给药、肠胃外给药、吸入给药、局部给药、直肠给药、鼻腔给药、口腔给药、阴道给药、通过植入剂给药或其它给药方式。例如,本文使用的肠胃外给药包括皮下给药、皮内给药、静脉内给药、肌肉内给药、关节内给药、动脉内给药、滑膜腔内给药、胸骨内给药、脑脊髓膜内给药、病灶内给药、和颅内的注射或输液技术。
通常,给予有效量的本文所提供的化合物。按照有关情况,包括所治疗的病症、选择的给药途径、实际给予的化合物、个体患者的年龄、体重和响应、患者症状的严重程度,等等,可以由医生确定实际上给予的化合物的量。
当用于预防本发明所述病症时,给予处于形成所述病症危险之中的受试者本文所提供的化合物,典型地基于医生的建议并在医生监督下给药,剂量水平如上所述。处于形成具体病症的危险之中的受试者,通常包括具有所述病症的家族史的受试者,或通过遗传试验或筛选确定尤其对形成所述病症敏感的那些受试者。
还可以长期给予本文所提供的药物组合物(“长期给药”)。长期给药是指在长时间内给予化合物或其药物组合物,例如,3个月、6个月、1年、2年、3年、5年等等,或者可无限期地持续给药,例如,受试者的余生。在一些实施方案中,长期给药意欲在长时间内在血液中提供所述化合物的恒定水平,例如,在治疗窗内。
可以使用各种给药方法,进一步递送本发明的药物组合物。例如,在一些实施方案中,可以推注给药药物组合物,例如,为了使化合物在血液中的浓度提高至有效水平。推注剂量取决于通过身体的活性组分的目标全身性水平,例如,肌内或皮下的推注剂量使活性组分缓慢释放,而直接递送至静脉的推注(例如,通过IV静脉滴注)能够更加快速地递送,使得活性组分在血液中的浓度快速升高至有效水平。在其它实施方案中,可以以持续输液形式给予药物组合物,例如,通过IV静脉滴注,从而在
受试者身体中提供稳态浓度的活性组分。此外,在其它实施方案中,可以首先给予推注剂量的药物组合物,而后持续输液。
口服组合物可以采用散装液体溶液或混悬剂或散装粉剂形式。然而,更通常,为了便于精确地剂量给药,以单位剂量形式提供所述组合物。术语“单位剂型”是指适合作为人类患者及其它哺乳动物的单元剂量的物理离散单位,每个单位包含预定数量的、适于产生所需要的治疗效果的活性物质与合适药学赋形剂。典型的单位剂量形式包括液体组合物的预装填的、预先测量的安瓿或注射器,或者在固体组合物情况下的丸剂、片剂、胶囊剂等。在这种组合物中,所述化合物通常为较少的组分(约0.1至约50重量%,或优选约1至约40重量%),剩余部分为对于形成所需给药形式有用的各种载体或赋形剂以及加工助剂。
对于口服剂量,代表性的方案是,每天一个至五个口服剂量,尤其是两个至四个口服剂量,典型地是三个口服剂量。使用这些剂量给药模式,每个剂量提供大约0.01至大约20mg/kg的本发明化合物,优选的剂量各自提供大约0.1至大约10mg/kg,尤其是大约1至大约5mg/kg。
为了提供与使用注射剂量类似的血液水平,或比使用注射剂量更低的血液水平,通常选择透皮剂量,数量为大约0.01至大约20%重量,优选大约0.1至大约20%重量,优选大约0.1至大约10%重量,且更优选大约0.5至大约15%重量。
从大约1至大约120小时,尤其是24至96小时,注射剂量水平在大约0.1mg/kg/小时至至少10mg/kg/小时的范围。为了获得足够的稳定状态水平,还可以给予大约0.1mg/kg至大约10mg/kg或更多的预载推注。对于40至80kg的人类患者来说,最大总剂量不能超过大约2g/天。
适于口服给药的液体形式可包括合适的水性或非水载体以及缓冲剂、悬浮剂和分散剂、着色剂、调味剂,等等。固体形式可包括,例如,任何下列组份,或具有类似性质的化合物:粘合剂,例如,微晶纤维素、黄蓍胶或明胶;赋形剂,例如,淀粉或乳糖,崩解剂,例如,褐藻酸、Primogel或玉米淀粉;润滑剂,例如,硬脂酸镁;助流剂,例如,胶体二氧化硅;甜味剂,例如,蔗糖或糖精;或调味剂,例如,薄荷、水杨酸甲酯或橙味调味剂。
可注射的组合物典型地基于可注射用的无菌盐水或磷酸盐缓冲盐水,或本领域中已知的其它可注射的赋形剂。如前所述,在这种组合物中,活性化合物典型地为较少的组分,经常为约0.05至10%重量,剩余部分为可注射的赋形剂等。
典型地将透皮组合物配制为含有活性组分的局部软膏剂或乳膏剂。当配制为软膏剂时,活性组分典型地与石蜡或可与水混溶的软膏基质组合。或者,活性组分可与例如水包油型乳膏基质一起配制为乳膏剂。这种透皮制剂是本领域中公知的,且通常包括用于提升活性组分或制剂的稳定的皮肤渗透的其它组份。所有这种已知的透皮制剂和组份包括在本发明提供的范围内。
本发明化合物还可通过经皮装置给予。因此,经皮给药可使用贮存器(reservoir)或多孔膜类型、或者多种固体基质的贴剂实现。
用于口服给予、注射或局部给予的组合物的上述组份仅仅是代表性的。其它材料以及加工技术等阐述于Remington's Pharmaceutical Sciences,17th edition,1985,Mack Publishing Company,Easton,Pennsylvania的第8部分中,本文以引用的方式引入该文献。
本发明化合物还可以以持续释放形式给予,或从持续释放给药系统中给予。代表性的持续释放材料的描述可在Remington's Pharmaceutical Sciences中找到。
本发明还涉及本发明化合物的药学上可接受的制剂。在一个实施方案中,所述制剂包含水。在另一个实施方案中,所述制剂包含环糊精衍生物。最常见的环糊精为分别由6、7和8个α-1,4-连接的葡
萄糖单元组成的α-、β-和γ-环糊精,其在连接的糖部分上任选包括一个或多个取代基,其包括但不限于:甲基化的、羟基烷基化的、酰化的和磺烷基醚取代。在一些实施方案中,所述环糊精为磺烷基醚β-环糊精,例如,磺丁基醚β-环糊精,也称作Captisol。参见,例如,U.S.5,376,645。在一些实施方案中,所述制剂包括六丙基-β-环糊精(例如,在水中,10-50%)。
适应症
在MTAP缺失的肿瘤,开发MTA协同的PRMT5抑制剂可以为大量的肿瘤病人提供治疗获益。本发明中的化合物通过负调节肿瘤细胞内MTA结合的PRMT5的活性发挥治疗作用,尤其是对MTAP缺陷的细胞,或MTAP相关的各种肿瘤细胞。
在一些实施方案中,本发明所述的MTA协同的PRMT5抑制剂可以治疗多种癌症,包括但不限于肿瘤类型,例如恶性周围神经鞘瘤、间皮瘤、多形性胶质母细胞瘤、胰腺癌、胆管癌、前列腺癌、乳腺癌、脑癌、皮肤癌、宫颈癌、膀胱癌、星形细胞瘤、结肠直肠癌、子宫内膜癌、食道癌、胃癌、胸腺瘤、头颈癌、肝细胞癌、喉癌、肺鳞癌、肺腺癌、口腔癌、卵巢癌、肾癌和甲状腺癌以及肉瘤。
更具体地说,这些化合物可用于治疗:心脏:肉瘤(血管肉瘤、纤维肉瘤、横纹肌肉瘤、脂肪肉瘤等)、粘液瘤、横纹肌瘤、纤维瘤、脂肪瘤和畸胎瘤;肺:支气管癌(鳞状细胞、未分化小细胞、未分化大细胞、腺癌等)、肺泡(细支气管)癌、支气管腺瘤、肉瘤、淋巴瘤、软骨瘤错构瘤、间皮瘤;胃肠道:食管(鳞状细胞癌、腺癌、平滑肌肉瘤、淋巴瘤等)、胃(肿瘤、淋巴瘤、平滑肌肉瘤等)、胰腺(导管腺癌、胰岛素瘤、胰高血糖素瘤、胃泌素瘤、类癌瘤、血管瘤等)、小肠(腺癌、淋巴瘤、类癌瘤等)、卡波西肉瘤、平滑肌瘤、血管瘤、脂肪瘤、神经纤维瘤、纤维瘤等)、大肠(腺癌、管状腺瘤、绒毛状腺瘤、错构瘤、平滑肌瘤等);泌尿生殖道:肾脏(腺癌、肾母细胞瘤等)、膀胱和尿道(鳞状细胞癌,移行细胞癌,腺癌等),前列腺(腺癌,肉瘤等),睾丸(精原细胞瘤,畸胎瘤,胚胎癌,畸胎癌,绒癌、肉瘤、间质细胞癌、纤维瘤、纤维腺瘤、腺瘤样肿瘤、脂肪瘤等);肝脏:肝细胞瘤、胆管癌、肝母细胞瘤、血管肉瘤、肝细胞腺瘤、血管瘤;胆道:胆囊癌、壶腹癌、胆管癌等;骨:成骨肉瘤、纤维肉瘤、恶性纤维组织细胞瘤、软骨肉瘤、尤文肉瘤、恶性淋巴瘤(网状细胞肉瘤等)、多发性骨髓瘤、恶性巨细胞瘤脊索瘤、骨软骨瘤(骨软骨外生骨疣)、良性软骨瘤、软骨母细胞瘤、软骨粘液纤维瘤、骨样骨瘤和骨巨细胞瘤;神经系统:颅骨(骨瘤、血管瘤、肉芽肿、黄色瘤、变形性骨炎等)、脑膜(脑膜瘤、脑膜肉瘤、神经胶质瘤等)、脑(星形细胞瘤、髓母细胞瘤、神经胶质瘤、室管膜瘤、生殖细胞瘤(松果体瘤等)、多形性胶质母细胞瘤、少突胶质细胞瘤、神经鞘瘤、视网膜母细胞瘤、先天性肿瘤等)、脊髓神经纤维瘤、脑膜瘤、神经胶质瘤,肉瘤等);妇科:子宫(子宫内膜癌等)、宫颈(宫颈癌、瘤前宫颈发育不良等)、卵巢(卵巢癌、浆液性囊腺癌、粘液性囊腺癌、未分类癌等)、颗粒鞘细胞瘤、支持间质细胞瘤、无性细胞瘤、恶性畸胎瘤等)、外阴(鳞状细胞癌、上皮内癌、腺癌、纤维肉瘤、黑色素瘤等)、阴道(透明细胞癌、鳞状细胞癌、葡萄状肉瘤(胚胎性横纹肌肉瘤等)、输卵管癌等;血液学:血液(髓性白血病(急性和慢性),急性淋巴细胞白血病、慢性淋巴细胞白血病、弥漫性大B细胞淋巴瘤、套细胞淋巴瘤(MCL),滤泡性淋巴瘤、骨髓增生性疾病、多发性骨髓瘤、骨髓增生异常综合征等)、霍奇金病、非霍奇金淋巴瘤(恶性淋巴瘤)等;皮肤:恶性黑色素瘤、基底细胞癌、鳞状细胞癌、卡波西肉瘤、痣发育不良痣、脂肪瘤、血管瘤、皮肤纤维瘤、瘢痕瘤,牛皮癣等;肾上腺:神经母细胞瘤等。
联合用药
本发明所述的MTA协同的PRMT5抑制剂可以与其他药物联合治疗癌症,至少包含一种靶点药物/细胞活性调节剂,包括CDK4/6抑制剂,MAT2A抑制剂,MAPK1/MAPK3抑制剂,Type I PRMT抑制剂,EGFR抑制剂,SHP2抑制剂,泛KRAS抑制剂,KRASG12C抑制剂,RAF抑制剂,MEK抑制剂,ERK抑制剂,Bcl-2抑制剂,SOS1抑制剂,PARP抑制剂,MALT1抑制剂,MALT2抑制剂,BTK抑制剂,PI3K抑制剂,AKT抑制剂,FGFR抑制剂,DNA甲基转移酶(DNMT)抑制剂,EZH1/2抑制剂,EZH2抑制剂,Menin-MLL抑制剂,IDH1抑制剂,IDH2抑制剂,IDH1/2抑制剂,化疗药物,放射疗法,STING激动剂或免疫检查点抑制剂/调节剂等。
实施例
本文所用的原料或试剂为可购买到的或由本领域通常已知的合成方法制备。
1.实施例1的合成
1.1中间体1-1的合成
将二碳酸二叔丁酯(18g),三乙胺(13g),4-二甲氨基吡啶(0.8g)加入到2-胺基-3-甲基-5-硝基吡啶(5g)的二氯甲烷(50mL)溶液中,室温搅拌3小时。乙酸乙酯(100*3mL)萃取,有机相用饱和氯化钠溶液(100mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经柱层析(二氧化硅,石油醚/乙酸乙酯=5/1)纯化,得白色固体1-1(10g,收率82%)。LC-MS:M+Na+=376.1。
1.2中间体1-2的合成
将10%钯碳(2g)加入到化合物1-1(10g)的甲醇(100mL)溶液中,氢气氛围下室温搅拌2小时。过滤,滤液减压浓缩得淡黄色固体1-2(9.2g)。LC-MS:M+H+=324.2。
1.3中间体1-3的合成
0℃,氮气氛围下,将乙酰氯单乙酯(830mg),三乙胺(620mg)加入到1-2(2g)的二氯甲烷(20mL)溶液中,室温搅拌2小时。加入水(20mL),二氯甲烷(10*3mL)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经柱层析(二氧化硅,石油醚/乙酸乙酯=2/1)纯化,得白色固体1-3(2.5g,收率80%)。LC-MS:M+H+=424.0。
1.4中间体1-4的合成
将氢氧化锂(240mg)加入到1-3(3g)的甲醇(10mL)和水(10mL)溶液中,室温搅拌2小时。减压浓缩,加入水(20mL)稀释,用1N的盐酸溶液调节pH=6,过滤,滤饼干燥得白色固体1-4(1g)。LC-MS:M+H+=396.2。
1.5中间体1-5的合成
将三乙胺(1080mg)加入到(R)-1-(嘧啶-2-基)乙胺盐酸盐(2g)的1,2-二氯乙烷(100mL)溶液中,室温搅拌1小时,加入5-三氟甲基吡啶-2-甲醛(1.8g),室温搅拌2小时,加入三乙酰氧基硼氢化钠(3.2g),室温搅拌1小时。加入二氯甲烷(50mL),依次用饱和碳酸氢钠水溶液(50mL),水(50mL)和饱和食盐水(50mL)洗涤,有机相用无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经柱层析(二氧化硅,二氯甲烷/甲醇=100/0-100/3)纯化,得淡黄色油状物1-5(1.8g,收率64%)。LC-MS:M+H+=283.1。
1.6中间体1-6的合成
0℃,氮气保护下,将三氯氧磷(38mg)滴加到1-4(50mg)和1-5(36mg)的吡啶(2mL)溶液中,0℃搅拌1小时。减压浓缩,残余物加入碳酸氢钠水溶液(10mL)和水(20mL),乙酸乙酯(10*3mL)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经柱层析(二氧化硅,二氯甲烷/甲醇=10/1)纯化,得黄色固体1-6(20mg,收率32%)。LC-MS:M+H+=660.0。
1.7化合物1的合成
将三氟乙酸(2mL)加入到1-6(20mg)的二氯甲烷(6mL)溶液中,室温反应1小时。减压浓缩,残余物经高效液相色谱纯化(柱:Gemini 5u C18 150 x 21.2mm;流动相:[H2O(NH3)-ACN];B%:2%-10%,6min),得白色固体1(5mg,产率20%)。LC-MS:M+H+=460.2。1H NMR(400MHz,DMSO-d6)δppm 10.52-10.35(m,1H),8.82-8.73(m,2H),8.14-7.32(m,6H),5.73-5.60(m,3H),5.20-4.57(m,2H),2.03-1.96(m,3H),1.66-1.52(m,3H).
2.实施例2的合成
2.1中间体2-1的合成
将二碳酸二叔丁酯(565mg)加入到4-二甲胺基吡啶(6.8mg),三乙胺(112.9mg)和7-溴-1,3-二氢呋喃并[3,4-c]吡啶-4-胺(120mg)的二氯甲烷(5mL)溶液中,室温搅拌2小时。有机相用饱和氯化钠溶液(1mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经柱层析(二氧化硅,石油醚/乙酸乙酯=5/1-2/1)纯化,得白色固体2-1(160mg,收率65.6%)。LC-MS:M+Na+=437.1,439.1。
2.2化合物2-2的合成
将碘化亚铜(18.1mg)、碳酸铯(200mg),反-(1R,2R)-N,N’-二甲基1,2-环己烷二胺(110.2mg)加入到三氟乙酰胺(71.7mg)和2-1(100mg)的二氧六环(5mL)溶液中。氮气保护下110℃搅拌16小时,冷却至室温,加水(10mL),乙酸乙酯(10mL*3)萃取,有机相用饱和氯化钠溶液(5mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经柱层析(二氧化硅,二氯甲烷/乙酸乙酯=5/1-1/1)纯化,得白色固体2-2(34mg,收率38.7%)。LC-MS:M+H+=352.0。
2.3化合物2-3的合成
冰浴下,将草酰氯单乙酯(139.8mg)加入三乙胺(121.2mg)和2-2(240mg)的二氯甲烷(5mL)溶液中。室温搅拌1小时,有机相用饱和氯化钠溶液(2mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经柱层析(二氧化硅,石油醚/乙酸乙酯=5/1-2/1)纯化,得白色固体2-3(230mg,收率74.6%)。LC-MS:M+H+=451.9。
2.4化合物2-4的合成
将氢氧化理(38.2mg)加入2-3(230mg)的甲醇(5mL)和水(1mL)溶液中。室温搅拌1小时,用1N稀盐酸调节pH=6,乙酸乙酯(10mL*3)萃取,有机相用饱和氯化钠溶液(5mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,冻干得白色固体2-4(170mg,收率71.9%)。LC-MS:M+H+=424.2。
2.5化合物2-5的合成
冰浴下将三氯氧磷(36.2mg)加入到1-5(40mg)和2-4(50mg)的吡啶(2mL)溶液中,室温搅拌1小时。加入饱和碳酸氢钠水溶液(1mL),乙酸乙酯(5mL*3)萃取,有机相用饱和氯化钠溶液(1mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经柱层析(二氧化硅,石油醚/乙酸乙酯=3/1-1/1)纯化,得棕色固体2-5(22mg,收率30.6%)。LC-MS:M+H+=688.2。
2.6化合物2的合成
冰浴下,将三氟乙酸(0.5mL)加入2-5(22mg)的二氯甲烷(1.5mL)溶液中。室温搅拌1小时,减压浓缩,残余物经高效液相色谱纯化(柱:Xbridge-C18 150 x 19mm,5um;流动相:ACN--H2O(0.05%NH3);B%:5%-10%,20min),得白色固体2(3.6mg,收率23.2%)。LC-MS:M+H+=488.0。1H NMR(400MHz,CD3OD)δppm 8.69-8.62(m,2H),8.59(d,J=4.8Hz,1H),7.91(d,J=8.4Hz,1H),7.79-7.63(m,1H),7.52-7.39(m,1H),7.24-7.15(m,1H),5.78-5.66(m,1H),5.23-5.04(m,1H),4.94-4.92(m,1H),4.86-4.79(m,3H),4.71-4.63(m,1H),1.64-1.49(m,3H).
3.实施例3的合成
3.1中间体3-1的合成
将5-三氟甲基吡啶-2-甲醛(200.0mg)和醋酸(102.0mg)加入到甲胺(70.9mg)的1,2-二氯乙烷溶液(5mL)中,室温搅拌2小时。加入三乙酰氧基硼氢化钠(484.2mg),室温搅拌0.5小时。加入饱和碳酸钠溶液(10mL),淬灭反应,二氯甲烷(15mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得白色固体3-1(150.0mg,收率72.0%)。LC-MS m/z(ESI):191.1[M+H]+。
3.2中间体3-2的合成
将2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(120.2mg),N,N-二异丙基乙胺(40.8mg)加入1-4(62.2mg)和3-1(36.0mg)的N,N-二甲基甲酰胺(5mL)溶液中,室温搅拌5小时。加入水(10mL),二氯甲烷(10mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过
滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黑色油状物3-2(21.0mg,收率22.3%)。LC-MS m/z(ESI):568.0[M+H]+。
3.3化合物3的合成
冰浴下,将三氟乙酸(2mL)加入3-2(21.0mg)的二氯甲烷(2mL)溶液中。室温搅拌1小时,减压浓缩,残余物经高效液相色谱(柱:Xbridge-C18 150×19mm,5um;流动相:ACN--H2O(0.1%FA);B%:5%-10%,20min)纯化得白色固体3的甲酸盐(2.3mg,收率16.9%)。LC-MS m/z(ESI):368.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ8.86(s,1H),8.14-8.01(m,2H),7.62-7.55(m,2H),4.84(s,1H),4.59(s,1H),3.28-3.05(m,3H),2.15-2.11(m,3H).
4.实施例4的合成
4.1中间体4-1的合成
将30-7(30.0mg),1-丙基磷酸酐(45.0mg),N,N-二异丙基乙胺(15.0mg)加入到16-1(35.0mg)的N,N-二甲基甲酰胺(1mL)溶液中。室温搅拌12小时。向反应液中加入水(5mL),用乙酸乙酯(5mL×3)萃取,有机相用饱和氯化钠溶液(1mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=2/1-1/1)纯化得淡黄色固体4-1(30.0mg,收率65.8%)。LC-MS m/z(ESI):662.3[M+H]+。
4.2化合物4的合成
冰浴下,将三氟乙酸(0.5mL)加入到4-1(30.0mg)的二氯甲烷(1mL)溶液中。室温搅拌2小时,饱和碳酸钠溶液调节pH=8,二氯甲烷(5mL×3)萃取,减压浓缩,残余物经高效液相色谱(柱:Xbridge-C18 150 x 19mm,5um;流动相:ACN--H2O(0.05%NH3);B%:5%-10%,20min)纯化得白色固体4(6.40mg,收率30.6%)。LC-MS m/z(ESI):462.1[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.68(s,1H),8.96-8.91(m,1H),8.29-8.20(m,1H),7.92-7.84(m,1H),7.66(d,J=4Hz,1H),7.53(d,J=8Hz,1H),6.24-6.18(m,2H),4.91-4.75(m,2H),4.28-4.23(m,3H),3.57-3.45(m,2H),2.67-2.57(m,1H),1.97-1.84(m,2H),1.83-1.66(m,4H).
5.实施例5的合成
5.1中间体5-1的合成
冰浴下,将正丙基膦酸酐(260.0mg)和N,N-二异丙基乙胺(84.1mg)加入到25-5(100.0mg)和8-1(77.0mg)的N,N-二甲基甲酰胺溶液中(3mL)溶液中。室温搅拌1小时,向反应液中加入饱和氯化铵溶液(10mL),乙酸乙酯(10mL×3)萃取,有机相用饱和氯化钠溶液(5mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经高效液相色谱(柱:Xbridge-C18 150×19mm,5um;流动相:ACN--H2O(0.1%FA);B%:5%-60%,20min)纯化得白色固体5-1(20.8mg,收率10.8%)。LC-MS m/z(ESI):454.0[M+H]+。
5.2化合物5的合成
将化合物5-1(20.8mg)经SFC(柱:CHIRALPAK AD-H 250×20mm,5um;流动相:40%IPA(0.2%NH4OH))纯化得白色固体5-P1(5.8mg,收率36.8%)。LC-MS m/z(ESI):454.1[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 11.04-10.79(m,1H),8.92-8.83(m,1H),8.58-8.49(m,1H),8.40-8.37(m,1H),8.24-8.14(m,1H),7.78-7.69(m,2H),7.59-7.57(m,1H),4.75-4.58(m,2H),3.99-3.92(m,4H),1.67-1.43(m,2H),1.19-1.03(m,3H),0.85-0.78(m,3H);
得白色固体5-P2(4.5mg,收率42.1%)。LC-MS m/z(ESI):454.1[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 11.04-10.80(m,1H),8.93-8.83(m,1H),8.58-8.49(m,1H),8.40-8.15(m,2H),7.79-7.57(m,3H),4.75-4.57(m,2H),4.01-3.92(m,4H),1.68-1.45(m,2H),1.19-1.04(m,3H),0.84-0.78(m,3H).
6.实施例6的合成
6.1中间体6-1的合成
将醋酸酐(5.4g)加入到化合物2-氨基-3-甲基-5-溴吡啶(5.0g)的醋酸(40mL)溶液中,120℃
搅拌4小时。冷却至50℃,减压浓缩,残余物溶解到乙酸乙酯(100mL)中,依次用饱和碳酸氢钠溶液(100mL),饱和氯化钠溶液(100mL)洗涤,有机相用无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=5/1)纯化得白色固体6-1(4.5g,收率73%)。LC-MS m/z(ESI):229.0,231.1[M+H]+。
6.2中间体6-2的合成
将丙烯酸甲酯(1.1g),N,N-二异丙基乙胺(2.2g),醋酸钯(0.2g),三(邻甲基苯基)磷(0.5g)加入到化合物6-1(2.0g)的N,N-二甲基甲酰胺(40mL)溶液中,100℃搅拌16小时。冷却至室温,将反应液缓慢倒入冰水(200mL)中,乙酸乙酯(100mL×3)萃取,有机相用饱和氯化钠溶液(100mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=50/1)纯化得淡黄色固体6-2(1.6g,收率80%)。LC-MS m/z(ESI):235.0[M+H]+。
6.3中间体6-3的合成
在0℃下,将氢氧化钠(70.0mg)加入6-2(0.2g)的甲醇(5mL)和水(5mL)溶液中,70℃搅拌5小时。冷却至室温,减压浓缩,残余物用1M的盐酸调节pH=6,乙酸乙酯(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩得白色固体6-3(100.0mg),粗品直接用于下一步反应。LC-MS m/z(ESI):179.0[M+H]+。
6.4化合物6的合成
将6-3(38.0mg),三吡咯烷基溴化鏻六氟磷酸盐(103.0mg),三乙胺(46.0mg)加入到1-5(50.0mg)的N,N-二甲基乙酰胺(2mL)中,室温搅拌16小时。减压过滤,滤液经高效液相色谱(柱:Gemini5u C18 150 x 21.2mm;流动相:[water(FA)-ACN];B%:2%-10%,10min)纯化得白色固体6的甲酸盐(10mg,产率12%)。LC-MS m/z(ESI):443.2[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 8.89-8.71(m,3H),8.15-8.05(m,1H),8.00-7.73(m,2H),7.54-7.31(m,3H),7.25-6.74(m,1H),6.25-6.22(m,2H),5.59-5.88(m,1H),5.19-4.88(m,1H),4.85-4.42(m,1H),2.06-1.98(m,3H),1.63-1.42(m,3H).
7.实施例7的合成
7.1中间体7-1的合成
将二碳酸二叔丁酯(14.6g),三乙胺(10.8g),4-二甲氨基吡啶(0.7g)加入到2-氨基-3-甲基-5-溴吡啶(5.0g)的二氯甲烷(50mL)溶液中,室温搅拌2小时,加入水(100mL),乙酸乙酯(100mL×3)萃取,有机相用饱和氯化钠溶液(100mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=5/1)纯化得白色固体7-1(9.3g,收率85.5%)。LC-MS m/z(ESI):796.9[2M+H]+。
7.2中间体7-2的合成
将丙烯酸甲酯(0.7g),N,N-二异丙基乙胺(1.3g),醋酸钯(0.1g),加入到化合物7-1(2.0g)的N,N-二甲基甲酰胺(20mL)溶液中,氮气保护下,100℃搅拌16小时。冷却至室温,将反应液缓慢加入到冰水(100mL)中,乙酸乙酯(50mL×3)萃取,有机相用饱和氯化钠溶液(100mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=3/1)纯化得白色固体7-2(1.4g,收率63.6%)。LC-MS m/z(ESI):393.1[M+H]+。
7.3中间体7-3的合成
0℃,氮气氛围下,将氢化钠(1.5g,60%)加入到三甲基碘化亚砜(1.3g)的二甲基亚砜(5mL)溶液中,搅拌1小时。加入化合物7-2(1.4g),缓慢升至室温,搅拌16小时。加入1M的盐酸(20mL)调节pH=6,乙酸乙酯(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=5/1)纯化得白色固体7-3(400.0mg,收率52.1%)。LC-MS m/z(ESI):393.1[M+H]+。
7.4中间体7-4的合成
将氢氧化锂(14.1mg)加到化合物7-3(90.0mg)的甲醇(5mL)和水(5mL)混合溶液中,50℃搅拌2小时。冷却至室温,用1M的盐酸调节pH=6,乙酸乙酯(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩得白色固体7-4(50mg,收率34.4%),粗品直接用于下一步反应。LC-MS m/z(ESI):293.1[M+H]+。
7.5中间体7-5的合成
将7-4(50.0mg),2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(101.0mg),N,N-二异丙基乙胺(46.5mg)加入到1-5(45.0mg)的N,N-二甲基甲酰胺(2mL)中,室温搅拌2小时。加入冰水(20mL),乙酸乙酯(10mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=10/1)纯化得黄色固体7-5(20.0mg,收率32.3%)。LC-MS m/z(ESI):557.2[M+H]+。
7.6化合物7的合成
将三氟乙酸(2mL)加入到7-5(20.0mg)的二氯甲烷(6mL)中,室温反应1小时。减压浓缩。残余物经高效液相色谱(柱:Gemini 5u C18 150 x 21.2mm;流动相:[water(TFA)-ACN];B%:2%-10%,8min)纯化得白色固体7的三氟乙酸盐(8.0mg,产率57.4%)。LC-MS m/z(ESI):457.0[M+H]+。1H NMR(400MHz,MeOD-d4)δppm 8.76(d,J=4.8Hz,1H),8.68(d,J=4.8Hz,2H),8.01-7.91(m,1H),7.66-7.57(m,1H),7.42-7.41(m,1H),7.38-7.26(m,2H),6.05-5.83(m,1H),5.25-4.69(m,2H),2.57-2.28(m,1H),2.26-1.98(m,4H),1.71-1.60(m,4H),1.41-1.16(m,1H).
8.实施例8的合成
8.1中间体8-1的合成
将5-三氟甲基吡啶-2-甲醛(200.0mg)和醋酸(137.0mg)加入到2-氨基丁烷(166.0mg)的1,2-二氯乙烷(5mL)溶液中,室温搅拌2小时。加入三乙酰氧基硼氢化钠(485.0mg),室温搅拌30分
钟。加入水(30mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色油状物8-1(200.0mg,收率75.5%)。LC-MS m/z(ESI):233.1[M+H]+。
8.2中间体8-2的合成
将化合物8-1(90.0mg),1-丙基磷酸酐(50%乙酸乙酯溶液,244.0mg)和N,N-二异丙基乙胺(66.0mg)加入到化合物1-4(50.0mg)的N,N-二甲基甲酰胺(3mL)溶液中,室温搅拌2小时。加入水(30mL),乙酸乙酯(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色固体8-2(50.0mg,收率64.9%)。LC-MS m/z(ESI):610.0[M+H]+。
8.3化合物8的合成
冰浴下,将三氟乙酸(2mL)加入到化合物8-2(50.0mg)的二氯甲烷溶液(4mL)中,升至室温搅拌2小时。反应液加压浓缩,加入水(10mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(20mL×3)萃取,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经高效液相色谱(柱:Gemini 5u C18 150x 21.2mm;流动相:ACN--H2O(0.1%FA);B%:2%-30%,12min)纯化得白色固体8的甲酸盐(6.0mg,收率17.8%)。LC-MS m/z(ESI):410.0[M+H]+。1H NMR(400MHz,MeOD-d4)δppm 8.82(s,1H),8.12-7.96(m,2H),7.67-7.46(m,2H),5.14-4.62(m,2H),4.51-4.13(m,1H),2.17-2.11(m,3H),1.74-1.54(m,2H),1.26-1.19(m,3H),0.93-0.88(m,3H).
9.实施例9的合成
9.1中间体9-1的合成
将5-三氟甲基吡啶-2-甲醛(200.0mg)和醋酸(137.0mg)加入到(R)-1-甲氧基-2-丙胺盐酸盐(166.0mg)的1,2-二氯乙烷溶液(5mL)中,室温搅拌2小时。加入三乙酰氧基硼氢化钠(485.0mg),室温搅拌30分钟。加入水(30mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色油状物9-1(20.0mg,收率7.1%)。LC-MS m/z(ESI):249.1[M+H]+。
9.2中间体9-2的合成
将化合物1-4(50.0mg),2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(50.0mg)和N,N-二异丙基乙胺(20.0mg)加入到化合物9-1(20.0mg)的N,N-二甲基甲酰胺溶液(3mL)中,室温搅拌2小时。加入水(30mL),乙酸乙酯(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色固体9-2(15.0mg,收率30.2%)。LC-MS m/z(ESI):626.3[M+H]+。
9.3化合物9的合成
冰浴下,将三氟乙酸(0.5mL)加入到化合物9-2(15.0mg)的二氯甲烷溶液(2mL)中,升至室
温搅拌2小时。反应液加压浓缩,加入水(10mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(20mL×3)萃取,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经高效液相色谱(柱:Gemini 5u C18 150 x 21.2mm;流动相:ACN--H2O(0.1%FA);B%:2%-40%,12min)纯化得白色固体9的甲酸盐(3.0mg,收率29.4%)。LC-MS m/z(ESI):426.2[M+H]+。1H NMR(400MHz,MeOD-d4)δppm 8.71(s,1H),8.02-7.84(m,2H),7.62-7.51(m,2H),4.95(s,1H),4.69(d,J=8.0Hz,1H),4.53-4.43(m,1H),3.36-3.25(m,2H),3.09(d,J=3.6Hz,3H),2.03(d,J=224.8Hz,3H),1.18-1.07(m,3H).
10.实施例10的合成
10.1中间体10-1的合成
将三丁基(1-乙氧基乙烯)锡(13.2g)加入到3-溴-2-氯-4-甲基吡啶(5.0g),碳酸钾(6.7g)和双三苯基磷二氯化钯(850.0mg)的四氢呋喃和水(50mL,V/V=3:1)混合溶剂中。氮气保护下90℃搅拌16小时。反应液冷却至室温,向反应液中加入饱和氟化钾溶液(100mL)和用乙酸乙酯(100mL),过滤,有机相用无水硫酸钠干燥,过滤,滤液减压浓缩,残余物用甲醇(20mL)溶解,将盐酸(6M,10mL)加入到上述溶液中,氮气保护下室温搅拌16小时。反应液减压浓缩,加入饱碳酸氢钠溶液(100mL),乙酸乙酯萃取(100mL×3),合并有机相,有机相用饱和氯化钠溶液(300mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=10/1-20/1)纯化得黄色液体10-1(2.2g,收率53.7%)。LC-MS m/z(ESI):170.0[M+H]+。
10.2中间体10-2的合成
将硼氢化钠(980.0mg)加入到10-1(2.2g)的甲醇(20mL)溶液中。氮气保护下25℃搅拌1小时。向反应液中加入(50mL)水,用乙酸乙酯(50mL×3)萃取,合并有机相,有机相用饱和氯化钠
溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/乙酸乙酯=10/1-5/1)纯化得无色液体10-2(2.0g,收率80.8%)。LC-MS m/z(ESI):172.1[M+H]+。
10.3中间体10-3的合成
将叔丁基二苯基氯硅烷(3.9g)加入到10-2(2.0g)和咪唑(1.2g)的二氯甲烷(20mL)溶液中。氮气保护下25℃搅拌16小时。向反应液中加入(100mL)水,用二氯甲烷(30mL×3)萃取,合并有机相,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=100/1-5/1)纯化得无色油状物79-3(4.5g,收率93.2%)。LC-MS m/z(ESI):410.0[M+H]+。
10.4中间体10-4的合成
将N-溴代丁二酰亚胺(2.4g)加入到10-3(5.0g)和偶氮二异丁腈(0.1g)的四氯化碳(50mL)溶液中。氮气保护下90℃搅拌2小时。反应液冷却至室温,向反应液中加入(100mL)水,用二氯甲烷(100mL×3)萃取,合并有机相,有机相用饱和氯化钠溶液(100mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=100/1-10/1)纯化得无色油状物10-4(4.5g,收率59.8%)。LC-MS m/z(ESI):488.2[M+H]+。
10.5中间体10-5的合成
将四丁基氟化铵(1M,18.4mL)的四氢呋喃溶液加入到10-4(4.5g)的四氢呋喃(50mL)溶液中。氮气保护下25℃搅拌1小时。向反应液中加入(100mL)水,用乙酸乙酯(10mL×3)萃取,合并有机相,有机相用饱和氯化钠溶液(100mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=100/1-5/1)纯化得无色油状物10-5(600.0mg,收率38.0%)。LC-MS m/z(ESI):170.1[M+H]+。
10.6中间体10-6的合成
将1,1'-联萘-2,2'-双二苯膦(418.5mg),三(二亚苄基丙酮)二钯(193.2mg)和叔丁醇钠(645.9mg)加入到10-5(570.0mg)和2,4-二甲氧基苯甲胺(842.9mg)的甲苯(1mL)溶液中。氮气保护下100℃搅拌16小时。反应液冷却至室温,向反应液中加入(50mL)水,用乙酸乙酯(50mL×3)萃取,合并有机相,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=100/1-5/1)纯化得白色固体10-6(410mg,收率40.6%)。LC-MS m/z(ESI):301.1[M+H]+。
10.7中间体10-7的合成
将10-6(410mg)加入到三氟乙酸(3mL)溶液中。氮气保护下25℃搅拌1小时。向反应液中加入(100mL)饱和碳酸氢钠溶液,用乙酸乙酯(50mL×3)萃取,合并有机相,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=5/1-1/10)纯化得白色固体10-7(150.0mg,收率73.2%)。LC-MS m/z(ESI):151.0[M+H]+。
10.8中间体10-8的合成
将N-溴代丁二酰亚胺(213.3mg)加入到10-7(150.0mg)的乙腈(5mL)溶液中。氮气保护下25℃搅拌2小时。向反应液中加入(20mL)水,用乙酸乙酯(20mL×3)萃取,合并有机相,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=5/1-1/1)纯化得白色固体10-8(130.0mg,收率56.8%)。LC-MS m/z(ESI):229.0[M+H]+。
10.9中间体10-9的合成
将二碳酸二叔丁酯(309.6mg)加入到10-8(130.0mg),4-二甲氨基吡啶(6.9mg)和三乙胺(172.3mg)的二氯甲烷(5mL)溶液中。向反应液中加入(20mL)水,用乙酸乙酯(20mL×3)萃取,合并有机相,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=10/1-5/1)纯化得白色固体10-9(150.0mg,收率61.3%)。LC-MS m/z(ESI):451[M+Na]+。
10.10中间体10-10的合成
将三(二亚苄基丙酮)二钯(66.2mg),1,1'-联萘-2,2'-双二苯膦(67.5mg)和碳酸铯(176.5mg)加入到二苯甲酮亚胺(98.2mg)和10-9(150.0mg)的二氧六环(5mL)溶液中。氮气保护下100℃搅拌8小时。反应液冷却至室温,向反应液中加入(30mL)水,用乙酸乙酯(20mL×3)萃取,合并有机相,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=10/1-1/1)纯化得白色固体10-10(60.0mg,收率32.2%)。LC-MS m/z(ESI):530.1[M+H]+。
10.11中间体10-11的合成
0℃下,将HCl的二氧六环溶液(0.6mL,4M)加入到10-10(60.0mg)的四氢呋喃(5mL)溶液中。氮气保护下0℃搅拌1小时。向反应液中加入饱和碳酸钠溶液(20mL)水,用乙酸乙酯(10mL×3)萃取,合并有机相,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=5/1-1/2)纯化得白色固体10-11(25.0mg,收率60.4%)。LC-MS m/z(ESI):366.2[M+H]+。
10.12中间体10-12的合成
将草酰氯单乙酯(70.6mg)加入到10-11(100.0mg)和三乙胺(87.1mg)的二氯甲烷(3mL)溶液中。氮气保护下25℃搅拌1小时。向反应液中加入(50mL)水,用二氯甲烷(30mL×3)萃取,合并有机相,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=100/1-2/1)纯化得棕色油状物10-12(140mg,收率97.8%)。LC-MS m/z(ESI):333.2[M+H]+。
10.13中间体10-13的合成
将一水合氢氧化锂(94.7mg)加入到10-12(150.0mg)的甲醇和水(6mL,V/V=5:1)混合溶剂中。氮气保护下25℃搅拌1小时。向反应液中加入(10mL)水,滴加1M盐酸至反应液pH=5~6,用乙酸乙酯(50mL×3)萃取,合并有机相,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=100/1-5/1)纯化得棕色固体10-13(80.0mg,收率58.2%)。LC-MS m/z(ESI):305.2[M+H]+。
10.14中间体10-14的合成
将N,N,N',N'-四甲基氯甲脒六氟磷酸盐(22.9mg)加入到10-13(33.1mg),10-11(20.0mg)和甲基咪唑(8.9mg)的N,N-二甲基甲酰胺(1mL)溶液中。氮气保护下25℃搅拌1小时。向反应液中加入(10mL)水,用乙酸乙酯(10mL×3)萃取,合并有机相,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=5/1-1/1)纯化得白色固体10-14(10.0mg,收率28.1%)。LC-MS m/z(ESI):652.2[M+H]+。
10.15化合物10的合成
将HCl的二氧六环溶液(0.2mL,4M)加入到10-14(10mg)的二氯甲烷(1mL)溶液中。氮气保护下25℃搅拌3小时。反应液减压浓缩,残余物经薄层色谱(洗脱剂:二氯甲烷/甲醇=10/1)纯化
得白色固体10(5.4mg,收率78.4%)。LC-MS m/z(ESI):452.2[M+H]+。1H NMR(400MHz,DMSO-d6,80℃)δ10.50-10.25(m,1H),8.87(s,1H),8.15(d,J=8.0Hz,1H),7.89(s,1H),7.70-7.60(m,1H),5.72(s,2H),5.25-5.20(m,1H),5.05-4.93(m,1H),4.85(m,1H),4.72(m,1H),4.62-4.52(m,1H),4.10-3.87(m,1H),1.67-1.48(m,2H),1.39(d,J=6.4Hz,2H),1.34-1.31(m,1H),1.20(d,J=6.5Hz,2H),1.07(d,J=6.8Hz,1H),0.84(t,J=7.4Hz,3H)。
11.实施例11的合成
11.1中间体11-1的合成
将环戊胺(486.3mg)加入到5-三氟甲基吡啶-2-甲醛(500.0mg)和醋酸(343.0mg)的1,2-氯乙烷(10mL)溶液中,室温搅拌1小时后加入三乙酰氧基硼氢化钠(1210.0mg),室温搅拌1小时。加入饱和碳酸氢钠溶液(20mL),二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=10/1-8/1)纯化得黄色油状物11-1(540.0mg,收率69.7%)。LC-MS m/z(ESI):245.1[M+H]+。
11.2中间体11-2的合成
将1-正丙基磷酸酐(483.0mg,50%乙酸乙酯溶液)加入N,N-二异丙基乙胺(130.7mg),11-1(148.3mg)和1-4(200.0mg)的二氯甲烷(8mL)溶液中。室温搅拌2小时。加入冰水(20mL),二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(15mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1-10/1)纯化得白色固体11-2(150.0mg,收率43.0%)。LC-MS m/z(ESI):622.3[M+H]+。
11.3化合物11的合成
冰浴下,将HCl的1,4-二氧六环溶液(4mL,4M)加入11-2(140.0mg)中。室温搅拌2小时,减压浓缩,残余物经高效液相色谱(柱:Xbridge-C18 150×19mm,5um;流动相:ACN--H2O(0.1%FA);B%:10%-40%,20min)纯化得白色固体11的甲酸盐(15.1mg,收率15.8%)。LC-MS m/z(ESI):422.0[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.52-10.30(m,1H),8.93-8.88(m,1H),8.28-8.05(m,2H),7.87-7.30(m,2H),5.67-5.60(m,2H),4.88-4.66(m,2H),4.38-4.34(m,1H),2.06-1.95(m,3H),1.84-1.73(m,2H),1.63-1.49(m,6H).
12.实施例12的合成
12.1中间体12-1的合成
将环丙胺(131.0mg)加入到5-三氟甲基吡啶-2-甲醛(200.0mg)的1,2-氯乙烷(2mL)和醋酸
(1mL)溶液中,氮气保护下,室温搅拌1小时后加入三乙酰氧基硼氢化钠(485.0mg),室温搅拌1小时。向反应液中加入饱和碳酸氢钠溶液(10mL),二氯甲烷(30mL×3)萃取,有机相用饱和氯化钠溶液(5mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩得淡黄色液体粗品12-1(10.0mg)。LC-MS m/z(ESI):217.1[M+H]+。
12.2中间体12-2的合成
将1-4(20.0mg),2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(35.0mg),N,N-二异丙基乙胺(10.0mg)加入到12-1(10.0mg)的N,N-二甲基甲酰胺(1mL)溶液中。氮气保护下,室温搅拌2小时。向反应液中加入水(1mL),用二氯甲烷(10mL×3)萃取,有机相用饱和氯化钠溶液(1mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,得淡黄色液体粗品12-2(15.0mg)。LC-MS m/z(ESI):594.0[M+H]+。
12.3化合物12的合成
冰浴下,将三氟乙酸(0.5mL)加入到12-2(15.0mg)的二氯甲烷(1mL)溶液中。室温搅拌1小时,饱和碳酸钠溶液调节pH=8,二氯甲烷(5mL×3)萃取,减压浓缩,残余物经高效液相色谱(柱:Xbridge-C18 150×19mm,5um;流动相:ACN--H2O(0.1%FA);B%:5%-10%,20min)纯化得黄色固体12的甲酸盐(3.47mg,收率34.9%)。LC-MS m/z(ESI):394.1[M+H]+。1H NMR(400MHz,CD3OD)δppm 8.87(s,1H),8.14-8.13(m,1H),8.10-8.09(m,1H),7.63-7.61(m,2H),4.87(s,2H),3.13-3.03(m,1H),2.18(s,3H),0.91-0.83(m,4H).
13.实施例13的合成
13.1中间体13-1的合成
将5-三氟甲基吡啶-2-甲醛(200.0mg)和醋酸(137.0mg)加入到环丁基胺(162.0mg)的1,2-二氯乙烷(5mL)溶液中,室温搅拌2小时。加入三乙酰氧基硼氢化钠(485.0mg),室温搅拌30分钟。加入水(30mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色油状物13-1(250.0mg,收率95.0%)。LC-MS m/z(ESI):230.9[M+H]+。
13.2中间体13-2的合成
将化合物13-1(100.0mg),2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(216.0mg)和N,N-二异丙基乙胺(98.0mg)加入到化合物1-4(150.0mg)的N,N-二甲基甲酰胺(5mL)溶液中,室温搅拌2小时。加入水(50mL),乙酸乙酯(50mL×3)萃取,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色固体13-2(40.0mg,收率17.4%)。LC-MS m/z(ESI):608.2[M+H]+。
13.3化合物13的合成
在冰浴下,将三氟乙酸(2mL)加入到化合物13-2(40.0mg)的二氯甲烷(4mL)溶液中,升至室温搅拌2小时。反应液减压浓缩,加入水(10mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷
(20mL×3)萃取,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得淡黄色固体13(10.0mg,收率37.3%)。LC-MS m/z(ESI):408.0[M+H]+。1H NMR(400MHz,MeOD-d4)δppm 8.84-8.82(m,1H),8.11-7.95(m,2H),7.64-7.47(m,2H),5.10-4.93(m,2H),4.75-4.65(m,1H),2.27-2.06(m,7H),1.72-1.63(m,2H).
14.实施例14-P1和14-P2的合成
14.1中间体14-1的合成
将5-三氟甲基吡啶-2-甲醛(200.0mg)和醋酸(102.0mg)加入到3-氨基四氢吡喃(229.7mg)的1,2-二氯乙烷溶液(5mL)中,室温搅拌2小时。加入三乙酰氧基硼氢化钠(418.6mg),室温搅拌30分钟。加入水(30mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=30/1)纯化得黄色油状物14-1(210.0mg,收率67.9%)。LC-MS m/z(ESI):261.0[M+H]+。
14.2中间体14-2的合成
将1-丙基磷酸酐(216.0mg)和N,N-二异丙基乙胺(98.0mg)加入到化合物14-1(100.0mg)和1-4(150.0mg)的N,N-二甲基甲酰胺溶液(5mL)中,室温搅拌2小时。加入水(50mL),乙酸乙酯(30mL×3)萃取,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=30/1)纯化得黄色固体14-2(210.0mg,收率85.6%)。LC-MS m/z(ESI):638.1[M+H]+。
14.3化合物14-P1和14-P2的合成
冰浴下,将三氟乙酸(2mL)加入到化合物14-2(210.0mg)的二氯甲烷溶液(6mL)中,升至室温搅拌2小时。反应液减压浓缩,加入水(30mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(20mL×3)萃取,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经高效液相色谱(柱:Gemini 5u C18 150x 21.2mm;流动相:[water(FA)-ACN];B%:2%-10%,16min)得白色固体14-3的甲酸盐(82.0mg,收率67.3%)。通过SFC(柱:CHIRALPAK IC 250mm×20mm,5μm;流动相:ETOH(NH4OH 0.2%);B%:40%EtOH,15min)拆分,得白色固体14-P1(30.0mg)。LC-MS m/z(ESI):438.0[M+H]+。1H NMR(400
MHz,MeOD-d4)δppm 8.83(s,1H),8.13-7.90(m,2H),7.68-7.40(m,2H),5.11-4.83(m,2H),4.43-4.12(m,2H),4.03-3.75(m,2H),3.45-3.41(m,1H),2.16-2.09(m,3H),2.04-1.79(m,2H),1.75-1.65(m,2H);
得白色固体14-P2(37.0mg)。LC-MS m/z(ESI):438.0[M+H]+。1H NMR(400MHz,MeOD-d4)δppm8.83(s,1H),8.11-7.90(m,2H),7.68-7.39(m,2H),5.12-4.81(m,2H),4.43-4.09(m,2H),4.03-3.74(m,2H),3.50-3.39(m,1H),2.18-2.06(m,3H),2.03-1.80(m,2H),1.75-1.65(m,2H).
15.实施例15的合成
15.1中间体15-1的合成
将5-三氟甲基吡啶-2-甲醛(100.0mg),乙酸(65.0mg)加到环丙基甲基胺(41.0mg)的无水二氯乙烷(2mL)溶液中,室温搅拌1小时,加入三乙酰氧基硼氢化钠(363.0mg),室温搅拌3小时。加入饱和碳酸氢钠溶液(30mL),二氯甲烷(10mL×3)萃取,有机相用无水硫酸钠干燥,过滤,减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=1/1)纯化得黄色油状物15-1(20.0mg,收率15.2%)。LC-MS m/z(ESI):231.1[M+H]+。
15.2中间体15-2的合成
将1-4(34.0mg),2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(66.0mg),N,N-二异丙基乙胺(23.0mg)加入到15-1的N,N-二甲基甲酰胺(2mL)中,室温搅拌3小时。加入冰水(20mL),乙酸乙酯萃取(10mL×3),有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩得化合物15-2(20.0mg),粗品直接用于下一步反应。LC-MS m/z(ESI):608.3[M+H]+。
15.3化合物15的合成
将三氟乙酸(1mL)加入到15-2(20.0mg)的二氯甲烷(3mL)溶液中,室温搅拌1小时。减压浓缩,残余物用薄层色谱(洗脱剂:石油醚/乙酸乙酯=1/1)纯化得到白色固体15(4.4mg,产率32.8%)。LC-MS m/z(ESI):408.2[M+H]+。1H NMR(400MHz,MeOD-d4)δppm 8.61(s,1H),8.00-7.92(m,2H),7.54-7.44(m,2H),5.04-4.85(m,2H),3.41-3.28(m,2H),2.09-2.03(m,3H),1.00-0.82(m,1H),0.26-0.21(m,2H),0.13-0.11(m,2H).
16.实施例16的合成
16.1中间体16-1的合成
将环丁基甲胺(300.0mg)加入到5-三氟甲基吡啶-2-甲醛(300.0mg)的1,2-氯乙烷(2mL)和醋酸(1mL)溶液中,氮气保护下,室温搅拌1小时后加入三乙酰氧基硼氢化钠(727.0mg),室温搅拌
1小时。向反应液中加入饱和碳酸氢钠溶液(10mL),二氯甲烷(10mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩得淡黄色油状物16-1(300.0mg,收率71.7%)。LC-MS m/z(ESI):245.0[M+H]+。
16.2中间体16-2的合成
将1-4(453.0mg),1-丙基磷酸酐(782.1mg),N,N-二异丙基乙胺(318.0mg)加入到16-1(280.0mg)的N,N-二甲基甲酰胺(3mL)溶液中。室温搅拌12小时。向反应液中加入水(5mL),用乙酸乙酯(5mL×3)萃取,有机相用饱和氯化钠溶液(5mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=2/1)纯化得白色固体16-2(240.0mg,收率33.7%)。LC-MS m/z(ESI):622.0[M+H]+。
16.3化合物16的合成
冰浴下,将三氟乙酸(1mL)加入到16-2(240.0mg)的二氯甲烷(2mL)溶液中。室温搅拌2小时,饱和碳酸钠溶液调节pH=8,二氯甲烷(5mL×3)萃取,减压浓缩,残余物经高效液相色谱(柱:Xbridge-C18 150 x 19mm,5um;流动相:ACN--H2O(0.1%FA);B%:5%-10%,20min)纯化得白色固体16的甲酸盐(145.6mg,收率89.5%)。LC-MS m/z(ESI):422.0[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.54-10.39(m,1H),8.95-8.90(m,1H),8.25-8.21(m,1H),8.06-7.95(m,1H),7.62-7.42(m,2H),5.86-5.66(m,2H),4.91-4.73(m,2H),3.57-3.34(m,2H),2.61-2.56(m,1H),2.05-1.99(m,3H),1.95-1.63(m,6H).
17.实施例17的合成
17.1中间体17-1的合成
将5-三氟甲基吡啶-2-甲醛(200.0mg)和醋酸(137.0mg)加入到环戊基甲基胺(225.0mg)的1,2-二氯乙烷(5mL)溶液中,室温搅拌2小时。加入三乙酰氧基硼氢化钠(485.0mg),室温搅拌30分钟。加入水(30mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色油状物17-1(200.0mg,收率67.8%)。LC-MS m/z(ESI):259.2[M+H]+。
17.2中间体17-2的合成
将化合物17-1(100.0mg),1-丙基磷酸酐(244.0mg,50%乙酸乙酯溶液)和N,N-二异丙基乙胺(66.0mg)加入到化合物1-4(50.0mg)的N,N-二甲基甲酰胺(3mL)溶液中,室温搅拌2小时。加入水(30mL),乙酸乙酯(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色固体17-2(55.0mg,收率68.4%)。LC-MS m/z(ESI):636.1[M+H]+。
17.3化合物17的合成
在冰浴下,将三氟乙酸(2mL)加入到化合物17-2(40.0mg)的二氯甲烷(4mL)溶液中,升至室温搅拌2小时。加入水(10mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(20mL×3)萃
取,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经高效液相色谱(柱:Gemini 5u C18 150 x 21.2mm
;流动相:ACN--H2O(0.1%FA);B%:2%-40%,12min)纯化得白色固体17的甲酸盐(18.0mg,收率27.5%)。LC-MS m/z(ESI):436.1[M+H]+。1H NMR(400MHz,MeOD-d4)δppm 8.84(s,1H),8.13-8.0(m,2H),7.63-7.52(m,2H),5.08-4.86(m,2H),3.62-3.43(m,2H),2.31-2.29(m,1H),2.16-2.11(m,3H),1.75-1.55(m,6H),1.29-1.25(m,2H).
18.实施例18的合成
18.1中间体18-1的合成
将1-甲基-1H-吡唑-4-胺(270.0mg)加入到5-三氟甲基吡啶-2-甲醛(200.0mg)的二氯甲烷(2mL)和三氟乙酸(1mL)溶液中,氮气保护下,室温搅拌1小时后加入三乙基硅烷(1mL),室温搅拌2小时。加入饱和碳酸氢钠溶液(10mL),二氯甲烷(10mL×3)萃取,有机相用饱和氯化钠溶液(5mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=1/1)纯化得黄色液体18-1(240.0mg,收率82.0%)。LC-MS m/z(ESI):257.2[M+H]+。
18.2中间体18-2的合成
将1-4(53.0mg),2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(120.0mg),N,N-二异丙基乙胺(40.0mg)加入到18-1(40.0mg)的N,N-二甲基甲酰胺(1mL)溶液中,室温搅拌2小时。加入水(5mL),用二氯甲烷(5mL×3)萃取,有机相用饱和氯化钠溶液(1mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩得淡黄色油状物18-2(50.0mg),粗品未经纯化直接用于下一步反应。LC-MS m/z(ESI):634.0[M+H]+。
18.3化合物18的合成
冰浴下,将三氟乙酸(0.5mL)加入到18-2(50.0mg)的二氯甲烷(1mL)溶液中,室温搅拌1小时。减压浓缩,残余物经高效液相色谱(柱:Xbridge-C18 150 x 19mm,5um;流动相:ACN--H2O(0.1%FA);B%:5%-10%,20min)纯化得黄色固体18的甲酸盐(9.4mg,收率27.5%)。LC-MS m/z(ESI):434.0[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.77-10.59(m,1H),8.94-8.90(m,1H),8.26-8.23(m,1H),8.06-8.04(m,1H),7.78(s,1H),7.64-7.57(m,2H),7.41-7.38(m,1H),6.21(s,2H),5.29-5.02(m,2H),3.79-3.71(m,3H),2.05(s,3H).
19.实施例19-P1和19-P2的合成
19.1中间体19-1的合成
将三乙胺(239.0mg)加入到5-(三氟甲基)-2-吡啶甲胺盐酸盐(334.0mg)的1,2-二氯乙烷(5mL)溶液中,室温搅拌3小时。加入4-乙酰基噻唑(200.0mg),室温搅拌2小时。加入三乙酰氧基硼氢化钠(667.0mg),室温搅拌搅拌30分钟。加入水(30mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色油状物19-1(150.0mg,收率33.2%)。LC-MS m/z(ESI):288.0[M+H]+。
19.2中间体19-2的合成
将化合物19-1(130.0mg),2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(258.0mg)和N,N-二异丙基乙胺(117.0mg)加入到化合物1-4(180.0mg)的N,N-二甲基甲酰胺(5mL)溶液中,室温搅拌2小时。加入水(50mL),乙酸乙酯(50mL×3)萃取,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色固体19-2(75.0mg,收率24.9%)。LC-MS m/z(ESI):665.2[M+H]+。
19.3化合物19-P1和19-P2的合成
在冰浴下,将三氟乙酸(2mL)加入到化合物19-2(75mg)的二氯甲烷(4mL)溶液中,升至室温搅拌2小时。反应液加压浓缩,加入水(10mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(20mL×3)萃取,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得淡黄色固体19-3(30.0mg,收率57.3%)。化合物19-3经高效液相色谱(柱:SFC Thar prep 80,CHIRALPAK AD-H 250mm x 20mm,5μm;流动相:40%IPA(NH4OH 0.2%)纯化得白色固体19-P1(12.0mg,收率40%)。LC-MS m/z(ESI):464.9[M+H]+。1H NMR(400MHz,MeOD-d4)δppm 8.88-8.87(m,1H),8.70-8.68(m,1H),8.14-7.89(m,2H),7.68-7.60(m,1H),7.54-7.36(m,2H),6.09-5.81(m,1H),5.01-4.60(m,2H),2.16-2.09(m,3H),1.75-1.61(m,3H);
得白色固体19-P2(11.8mg,收率39.3%)。LC-MS m/z(ESI):465.0[M+H]+。1H NMR(400MHz,MeOD-d4)δppm 8.88-8.87(m,1H),8.70-8.68(m,1H),8.14-7.89(m,2H),7.68-7.60(m,1H),7.55-7.36(m,2H),6.09-5.81(m,1H),5.01-4.60(m,2H),2.16-2.10(m,3H),1.75-1.61(m,3H).
20.实施例20的合成
20.1中间体20-1的合成
将5-三氟甲基吡啶-2-甲醛(200.0mg)加入到4-氨甲基-7-氮杂吲哚(167.0mg)和醋酸(136.0mg)的1,2-二氯乙烷(5mL)溶液中,室温搅拌2小时,加入三乙酰氧基硼氢化钠(481.0mg),搅拌30分钟。加入水(20mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(30mL×3)萃取,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色油状物20-1(250.0mg,收率71.4%)。LC-MS m/z(ESI):307.1[M+H]+。
20.2中间体20-2的合成
将化合物20-1(36.5mg),1-丙基磷酸酐(121.0mg,50%乙酸乙酯溶液)和N,N-二异丙基乙胺(33.0mg)加入到化合物1-4(50.0mg)的N,N-二甲基甲酰胺(2mL)溶液中,室温搅拌16小时。加入水(20mL),乙酸乙酯(20mL×3)萃取,有机相用饱和氯化钠溶液洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=5/1-2/1)纯化得黄色固体20-2(40.0mg,收率46.3%)。LC-MS m/z(ESI):684.0[M+H]+。
20.3化合物20的合成
在冰浴下,将三氟乙酸(2mL)加入到化合物20-2(40.0mg)的二氯甲烷(4mL)溶液中,升至室温搅拌2小时。反应液加压浓缩,加入水(10mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1-10/1)纯化得白色固体20(10.0mg,收率35.3%)。LC-MS m/z(ESI):484.0[M+H]+。1H NMR(400MHz,MeOD-d4)δppm 8.76(s,1H),8.16-8.11(m,1H),8.05-7.93(m,2H),7.58-7.47(m,2H),7.39-7.38(m,1H),7.13-7.03(m,1H),6.58-6.57(m,1H),5.32-5.06(m,2H),5.04-4.8(m,2H),2.12-2.16(m,3H).
21.实施例21的合成
21.1中间体21-1的合成
将二碳酸二叔丁酯(12.5g),4-二甲氨基吡啶(1.4g),三乙胺(4.7g)加入到3-溴-5-硝基吡啶-2-胺(5.0g)的二氯甲烷(50mL)溶液中,室温搅拌12小时。有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=5/1-1/1)纯化得淡黄色固体21-1(8.0g,收率83.3%)。LC-MS m/z(ESI):440.1,442.1[M+Na]+。
21.2中间体21-2的合成
将乙烯三氟硼酸钾(540.0mg),碳酸钾(1.3g),1,1-双(二苯基膦)二荗铁二氯化钯(150.0mg),21-1(1.0g)加入到1,4-二氧六环(12mL)和水(4mL)的混合溶液中,氮气保护下,100℃搅拌12小时。冷却至室温,加入水(30mL),用二氯甲烷(30mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=3/1-1/1)纯化得淡黄色固体21-2(500.0mg,收率57.1%)。LC-MS m/z(ESI):753.0[2M+Na]+。
21.3中间体21-3的合成
氮气保护下将钯碳(500.0mg)加入到21-2(500.0mg)的甲醇(10mL)溶液中。通入氢气,置换三次。在氢气氛围下室温搅拌2小时。抽滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=2/1-1/1)纯化得淡黄色固体21-3(400.0mg,收率86.6%)。LC-MS m/z(ESI):338.1[M+H]+。
21.4中间体21-4的合成
冰浴下将草酰氯单乙酯(410.0mg)加入到21-3(1.0g)和N,N-二异丙基乙胺(390.0mg)的二氯甲烷(14mL)溶液中,室温搅拌3小时。加入水(10mL),用二氯甲烷(15mL×3)萃取,有机相用
饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=5/1-1/1)纯化得淡黄色固体21-4(1.0g,收率76.9%)。LC-MS m/z(ESI):438.1[M+H]+。
21.5中间体21-5的合成
将氢氧化锂(110.0mg)加入到21-4(1.0g)的甲醇(9mL)和水(3mL)溶液中。室温搅拌2小时。加入2M盐酸调pH=6,抽滤,得淡黄色固体21-5(800.0mg,收率85.5%)。LC-MS m/z(ESI):410.0[M+H]+。
21.6中间体21-6的合成
将2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(134.2mg),N,N-二异丙基乙胺(45.6mg)加入21-5(87.2mg)和1-5(50.0mg)的N,N-二甲基甲酰胺(5mL)溶液中,室温搅拌5小时。加入水(10mL),二氯甲烷(10mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色油状物21-6(40.0mg,40.7%)。LC-MS m/z(ESI):674.0[M+H]+。
21.7化合物21的合成
冰浴下,将三氟乙酸(2mL)加入21-6(40.0mg)的二氯甲烷(2mL)溶液中。室温搅拌1小时,减压浓缩,残余物经高效液相色谱(柱:Xbridge-C18 150×19mm,5um;流动相:ACN--H2O(0.1%FA);B%:5%-10%,20min)纯化得白色固体21的甲酸盐(2.0mg,收率7.1%)。LC-MS m/z(ESI):474.2[M+H]+。1H NMR(400MHz,DMSO-d6)δ8.71-8.68(m,3H),8.02-7.95(m,2H),7.65-7.63(m,1H),7.54-7.46(m,1H),7.31-7.28(m,1H),5.88-5.80(m,1H),4.59(s,2H),2.51-2.44(m,2H),1.75-1.61(m,3H),1.26-1.17(m,3H).
22.实施例22的合成
22.1中间体22-1的合成
将二碳酸二叔丁酯(14.3g),三乙胺(10.6g)和4-二甲氨基吡啶(0.6g)加入到5-溴-3-氟-吡啶-2-胺(5.0g)的二氯甲烷溶液(50mL)中,室温搅拌2小时。加入水(30mL),二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=20/1)纯化得白色固体22-1(8.8g,收率95.3%)。LC-MS m/z(ESI):804.9[2M+Na]+。
22.2中间体22-2的合成
将草酸酰胺乙酯(134.1mg),碘化亚铜(15.0mg),碳酸铯(497.0mg)和N,N'-二甲基乙二胺(19.4mg)加入到化合物22-1(300mg)的1,4-二氧六环(5mL)溶液中,氮气保护下,100℃搅拌2小时。冷却至室温,加入水(50mL),乙酸乙酯(50mL×3)萃取,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=30/1)纯化得黄色固体22-2(200.0mg,收率49.4%)。LC-MS m/z(ESI):677.3[2M+Na]+。
22.3中间体22-3的合成
冰浴氮气氛围下,将草酰氯单乙酯(82.9mg)加入到三乙胺(61.4mg)和化合物22-2(200.0mg)的二氯甲烷(5mL)溶液中,室温搅拌2小时。加入水(50mL),二氯甲烷(30mL×3)萃取,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=40/1)纯化得黄色油状物22-3(200.0mg,收率71.4%)。LC-MS m/z(ESI):877.0[2M+Na]+。
22.4中间体22-4的合成
将三甲基氢氧化锡(252.6mg)加入到化合物22-3(200.0mg)的1,2-二氯乙烷(5mL)溶液中,70℃搅拌2小时。冷却至室温,加入水(50mL),二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩得黄色固体粗品22-4(180mg)。LC-MS m/z(ESI):821.0[2M+Na]+。
22.5中间体22-5的合成
将1-5(140.6mg),1-丙基磷酸酐(317.6mg)和N,N-二异丙基乙胺(128.8mg)加入到化合物22-4(180.0mg)的N,N-二甲基甲酰胺(3mL)溶液中,室温搅拌2小时。加入水(30mL),乙酸乙酯(20mL×3)萃取,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=30/1)纯化得黄色油状物22-5(80.0mg,收率23.2%)。LC-MS m/z(ESI):664.0[M+H]+。
22.6中间体22的合成
将三氟乙酸(2mL)加入到化合物22-5(80.0mg)的二氯甲烷(6mL)溶液中,室温搅拌2小时。减压浓缩,加入水(10mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(20mL×3)萃取,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得淡黄色固体22(30.0mg,收率53.7%)。LC-MS m/z(ESI):464.1[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.77-10.69(m,1H),8.86-8.71(m,3H),8.17-8.10(m,1H),8.09-7.92(m,1H),7.75-7.64(m,1H),7.50-7.39(m,1H),7.41-7.34(m,1H),6.12-6.10(m,2H),5.75-5.72(m,1H),5.17-4.56(m,2H),1.67-1.52(m,3H).
23.实施例23的合成
23.1中间体23-1的合成
将2-氨基-3-氯-5-硝基吡啶(1.0g),二碳酸二叔丁酯(3.2g)加入4-二甲氨基吡啶(140.0mg)和三乙胺(2.4g)的二氯甲烷(20mL)溶液中,室温搅拌3小时。加水(20mL),二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:乙酸乙酯/石油醚=5/1)纯化得白色固体23-1(1.5g,收率69.4%)。LC-MS m/z(ESI):396.0[M+Na]+。
23.2中间体23-2的合成
将铁粉(743.2mg),氯化铵(711.2mg)加入到23-1(500.0mg)的乙醇(10mL)和水(10mL)混合溶液中,0℃搅拌16小时。过滤,滤液加水(50mL),乙酸乙酯(30mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=10/1)纯化得白色固体23-2(220.0mg,收率47.8%)。LC-MS m/z(ESI):244.0[M-100+H]+。
23.3中间体23-3的合成
0℃下,将草酰氯单乙酯(48.0mg)加入三乙胺(40.0mg)和23-2(100.0mg)的二氯甲烷(5mL)溶液中,室温搅拌2小时。有机相用饱和氯化钠溶液(3mL)洗涤。无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=2/1-1/1)纯化得白色固体23-3(100.0mg,收率77.4%)。LC-MS m/z(ESI):288.0[M-156+H]+。
23.4中间体23-4的合成
将氢氧化锂(20.0mg)加入到23-3(100.0mg)的甲醇(3mL)和水(1mL)溶液中,室温搅拌2小时。1M盐酸调至酸性,过滤,得白色固体粗品23-4(100.0mg)。粗品未经纯化直接用于下一步反应。LC-MS m/z(ESI):437.9[M+Na]+。
23.5中间体23-5的合成
将1-5(70.0mg),2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(142.0mg),N,N-二异丙基乙胺(65.0mg)加入到23-4(100.0mg)的N,N-二甲基甲酰胺(1mL)溶液中。氮气保护下,室温搅拌12小时。向反应液中加入水(1mL),用乙酸乙酯(100mL×3)萃取,有机相用饱和氯化钠溶液(1mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,得黄色固体粗品23-5(50.0mg)。LC-MS m/z(ESI):680.0[M+H]+。
23.6中间体23的合成
冰浴下,将三氟乙酸(1mL)加入23-5(50.0mg)的二氧甲烷(2mL)溶液中。室温搅拌2小时,
饱和碳酸钠溶液调节pH=8,二氯甲烷(10mL×3)萃取,减压浓缩,残余物经高效液相色谱(柱:Xbridge-C18 150×19mm,5um;流动相:ACN--H2O(0.1%FA);B%:5%-10%,20min)纯化得黄色固体23的甲酸盐(19.0mg,收率53.8%)。LC-MS m/z(ESI):480.1[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.77-10.60(m,1H),8.83-8.74(m,3H),8.20-8.06(m,2H),7.92-7.34(m,3H),6.24-6.18(m,2H),5.77-5.70(m,1H),5.21-4.56(m,2H),1.65-1.47(m,3H).
24.实施例24的合成
24.1中间体24-1的合成
将二碳酸二叔丁酯(12.5g),三乙胺(9.3g)和4-二甲氨基吡啶(0.6g)加入到5-硝基-3-溴吡啶-2-胺(5g)的二氯甲烷溶液(50mL)中,室温搅拌2小时。加入水(30mL),二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得白色固体24-1(9.0g,收率97%)。LC-MS m/z(ESI):859.0[2M+Na]+。
24.2中间体24-2的合成
将铁粉(664.5mg)和氯化铵(636.4mg)加入到化合物24-1(500mg)乙醇(5mL)溶液中,50℃搅拌2小时。加入水(50mL),乙酸乙酯(50mL×3)萃取,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色固体24-2(360.0mg,收率72.4%)。LC-MS m/z(ESI):799.0[2M+Na]+。
24.3中间体24-3的合成
将草酰氯单乙酯(82.9mg)和三乙胺(61.4mg)加入到化合物24-2(200.0mg)的二氯甲烷(5mL)溶液中,室温搅拌2小时。加入水(50mL),二氯甲烷(50mL×3)萃取,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色固体24-3(240mg,收率81.4%)。LC-MS m/z(ESI):998.8[2M+Na]+。
24.4中间体24-4的合成
将三甲基氢氧化锡(276.6mg)加入到化合物24-3(240mg)的1,2-二氯乙烷(5mL)溶液中,室温搅拌2小时。加入水(50mL),二氯甲烷(50mL×3)萃取,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩得黄色固体24-4(100mg,收率76.2%)。LC-MS m/z(ESI):942.8[2M+Na]+。
24.5中间体24-5的合成
将1-5(62.6mg),1-丙基磷酸酐(55.9mg)和N,N-二异丙基乙胺(55.8mg)加入到化合物24-4
(100mg)的N,N-二甲基甲酰胺(3mL)溶液中,室温搅拌2小时。加入水(50mL),乙酸乙酯(30mL×3)萃取,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色油状物24-5(80mg,收率23.2%)。LC-MS m/z(ESI):723.9[M+H]+。
24.6化合物24的合成
将三氟乙酸(2mL)加入到化合物24-5(80.0mg)的二氯甲烷溶液(6mL)中,室温搅拌2小时。反应液减压浓缩,加入水(10mL),用饱和碳酸氢钠溶液调节pH至弱碱性,二氯甲烷(20mL×3)萃取,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得淡黄色固体24(9.0mg,收率22.3%)。LC-MS m/z(ESI):524.0,526.0[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.75-10.25(m,1H),8.86-8.73(m,3H),8.15-8.10(m,2H),7.68-7.35(m,3H),6.17-6.11(m,2H),5.71-5.70(m,1H),5.19-4.56(s,2H),1.59-1.52(m,3H).
25.实施例25的合成
25.1中间体25-1的合成
将2-氯-5-硝基烟酸(3.2g)加入甲醇钠(4.3g)的甲醇(40mL)溶液中,60℃搅拌2小时。减压浓缩,残余物加水(20mL)稀释。1M盐酸调pH=7,过滤,得浅黄色固体25-1(1.8g)。粗品未经纯化直接用于下一步反应。LC-MS m/z(ESI):197.0[M-H]+。
25.2中间体25-2的合成
将25-1(1.8g)加入二氯亚砜(20mL)溶液中,80℃搅拌4小时。减压浓缩。残余物加入四氢呋喃(20mL),冰浴下滴加到氨水(9mL)中,0℃搅拌1小时。升至室温,加入水(50mL)稀释,过滤,得白色固体粗品25-2(1.1g)。粗品未经纯化直接用于下一步反应。LC-MS m/z(ESI):198.1[M+H]+。
25.3中间体25-3的合成
氮气保护下,将钯碳(0.1g)加入到25-2(1.0g)的甲醇(12mL)溶液中。通入氢气置换三次,25℃搅拌2小时。过滤,滤液减压浓缩,得类白色固体粗品25-3(0.8g)。粗品未经纯化直接用于下一步反应。LC-MS m/z(ESI):168.1[M+H]+。
25.4中间体25-4的合成
冰浴下将草酰氯单乙酯(270.0mg)滴加到粗品25-3(300.0mg)和三乙胺(272.0mg)的二氯甲烷(8mL)溶液中。室温搅拌1小时。加入二氯甲烷(30mL),有机相用饱和氯化钠溶液(10mL)洗
涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=5/1-4/1)纯化得白色固体25-4(340.0mg,收率63.8%)。LC-MS m/z(ESI):268.0[M+H]+。
25.5中间体25-5的合成
将氢氧化锂(34.4mg)加入到25-5(320.0mg)的(8mL)甲醇和水(V/V=3:1)混合溶液中。室温搅拌1小时。加入1M盐酸调pH=7,抽滤,得白色固体粗品25-5(200.0mg)。粗品未经纯化直接用于下一步反应。LC-MS m/z(ESI):239.9[M+H]+。
25.6化合物25的合成
将2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(254.4mg)加入N,N-二异丙基乙胺(108.1mg),25-5(80.0mg)和1-5(113.3mg)的N,N-二甲基甲酰胺(4mL)溶液中。室温搅拌2小时。加入水(20mL),乙酸乙酯(10mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经高效液相色谱(柱:Xbridge-C18 150×19mm,5um;流动相:ACN--H2O(0.1%FA);B%:10%-60%,20min)纯化得白色固体25的甲酸盐(27.8mg,收率15.7%)。LC-MS m/z(ESI):504.0[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 11.10-10.82(m,1H),8.87-8.71(m,3H),8.54(dd,J=14.8,2.6Hz,1H),8.48-8.39(m,1H),8.21-8.07(m,1H),7.80-7.45(m,3H),7.45-7.34(m,1H),5.78-5.66(m,1H),5.22-4.91(m,1H),4.90-4.49(m,1H),3.97-3.91(m,3H),1.67-1.52(m,3H).
26.实施例26的合成
26.1中间体26-1的合成
在冰浴下,将草酰氯单乙酯(1.1g)缓慢滴加到化合物1-5(2.0g)和三乙胺(0.9g)的二氯甲烷
溶液(20mL)中,升至室温搅拌16小时。加入水(20mL),二氯甲烷(15mL×3),有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=2/1)纯化得黄色油状物26-1(1.9g,收率70.1%)。LC-MS m/z(ESI):393.1[M+H]+。
26.2中间体26-2的合成
冰浴下,将氢氧化锂(238.0mg)加入到化合物26-1(1.9g)的乙醇和水(100mL,V/V=1:1)混合溶液中,升至室温搅拌2小时。减压浓缩,加入水(10mL),用2M盐酸调节pH至弱酸性,二氯甲烷(15mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩得化合物26-2(1.5g,85.2%)。LC-MS m/z(ESI):355.1[M+H]+。
26.3中间体26-3的合成
将氢化钠(200.0mg)加入到2-氨基-5-硝基-4-甲基吡啶(500.0mg)的四氢呋喃(20mL)溶液中。室温搅拌0.5小时,加入碳酸酐二叔丁酯(900.0mg),室温搅拌2小时。向反应液中加入水(50mL),用乙酸乙酯(30mL×3)萃取,有机相用饱和氯化钠溶液(20mL×2)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=1/1)纯化得黄色固体26-3(800.0mg,收率96.9%)。LC-MS m/z(ESI):198.1[M-56+H]+。
26.4中间体26-4的合成
氮气保护下,将26-3(800.0mg)加入到钯碳(200.0mg)的乙醇(20mL)溶液中。通入氢气置换三次,室温搅拌5小时。过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=1/2)纯化得黄色固体26-4(300.0mg,收率40.8%)。LC-MS m/z(ESI):224.1[M+H]+。
26.5中间体26-5的合成
将26-4(100.0mg),N,N-二异丙基乙胺(173.5mg),2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(300.0mg)加入到26-2(250.0mg)的N,N-二甲基甲酰胺(5mL)溶液中,室温搅拌2小时。加入水(10mL),用乙酸乙酯(5mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=1/2)纯化得黄色固体26-5(35.0mg,收率14.8%)。LC-MS m/z(ESI):560.1[M+H]+。
26.6化合物26的合成
冰浴下,将三氟乙酸(1mL)加入到26-5(35.0mg)的二氯甲烷(3mL)溶液中。室温搅拌1小时,减压浓缩,残余物经高效液相色谱(柱:Xbridge-C18 150 x 19mm,5um;流动相:ACN--H2O(0.1%FA);B%:5%-10%,20min)纯化得白色固体26的甲酸盐(12.0mg,收率41.8%)。LC-MS m/z(ESI):460.0[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.10-9.96(m,1H),8.83-8.74(m,3H),8.14-8.10(m,1H),7.70-7.63(m,1H),7.46-7.35(m,2H),6.32-6.25(m,1H),5.95-5.88(m,3H),5.25-4.97(m,1H),4.92-4.59(m,1H),2.01-1.82(m,3H),1.66-1.52(m,3H).
27.实施例27的合成
27.1中间体27-1的合成
将二碳酸二叔丁酯(2.9g)加入到4-二甲胺基吡啶(0.1g),三乙胺(1.6g)和2-氨基-5-溴-3-甲基吡嗪(1.0g)的二氯甲烷(20mL)溶液中,室温搅拌1小时。有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=8/1-6/1)纯化得白色固体27-1(1.9g,收率83.0%)。LC-MS m/z(ESI):410.0,411.9[M+Na]+。
27.2中间体27-2的合成
将碘化亚铜(0.1g)加入到27-1(1.0g),草氨酸乙酯(0.5g),N,N'-二甲基乙二胺(0.1g)和碳酸铯(2.5g)的1,4-二氧六环溶液(10mL)中。氮气保护下,100℃搅拌3小时。冷却至室温,加入水(20mL),乙酸乙酯(10mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=1/1-2/3)纯化得白色固体27-2(600.0mg,收率65.4%)。LC-MS m/z(ESI):325.0[M+H]+。
27.3中间体27-3的合成
冰浴下将草酰氯单乙酯(269.0mg)滴加到27-2(580.0mg)和三乙胺(271.0mg)的二氯甲烷(8mL)溶液中。室温搅拌1小时。加入二氯甲烷(10mL),有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=4/1-3/1)纯化得白色固体27-3(520.0mg,收率61.7%)。LC-MS m/z(ESI):425.0[M+H]+。
27.4中间体27-4的合成
将氢氧化锂(33.9mg)加入到27-3(500.0mg)的甲醇和水(5mL,V/V=3:1)混合溶液中。室温搅拌1小时。加入水(8mL),1M盐酸调pH=7,抽滤,得白色固体粗品27-4(240.0mg)。粗品未经纯化直接用于下一步反应。LC-MS m/z(ESI):397.0[M+H]+。
27.5中间体27-5的合成
将1-正丙基磷酸酐(722.0mg,50%乙酸乙酯溶液)加入N,N-二异丙基乙胺(244.5mg),27-4(150.0mg)和1-5(128.2mg)的二氯甲烷(4mL)溶液中。室温搅拌2小时。加入冰-水(20mL),乙酸乙酯(15mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1-10/1)纯化得白色固体27-5(80.0mg,收率28.8%)。LC-MS m/z(ESI):661.0[M+H]+。
27.6化合物27的合成
冰浴下,将HCl的二氧六环溶液(2mL,4M)加入27-5(70.0mg)的二氧六环(1mL)中,室温搅拌4小时。减压浓缩,残余物经高效液相色谱(柱:Xbridge-C18 150×19mm,5um;流动相:
ACN--H2O(0.1%FA);B%:10%-50%,20min)纯化得白色固体27的甲酸盐(25.4mg,收率51.6%)。LC-MS m/z(ESI):461.2[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 11.03-10.58(m,1H),8.80-8.71(m,3H),8.41-8.06(m,2H),7.69-7.54(m,1H),7.39-7.33(m,1H),6.15-6.11(m,2H),5.71-5.47(m,1H),5.12-4.65(m,2H),2.28-2.22(m,3H),1.64-1.53(m,3H).
28.实施例28的合成
28.1中间体28-1的合成
将三乙胺(153.0mg)加入到(R)-1-(嘧啶-2-基)乙胺盐酸盐(146.0mg)的1,2-二氯乙烷/甲醇(5mL,V/V=1:1)混合溶液中,室温搅拌2小时。加入醋酸(91.0mg)和5-氰基吡啶-2-甲醛(100.0mg),室温搅拌2小时。加入三乙酰氧基硼氢化钠(321.0mg),室温搅拌2小时。加入水(30mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(30mL×3)萃取,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色油状物28-1(70.0mg,收率38.7%)。LC-MS m/z(ESI):240.0[M+H]+。
28.2中间体28-2的合成
将化合物28-1(45.0mg),1-丙基磷酸酐(121.0mg,50%乙酸乙酯溶液)和N,N-二异丙基乙胺(33.0mg)加入到化合物1-4(50.0mg)的N,N-二甲基甲酰胺(3mL)溶液中,室温搅拌2小时。加入水(30mL),乙酸乙酯(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=50/1)纯化得黄色固体28-2(30.0mg,收率38.2%)。LC-MS m/z(ESI):617.3[M+H]+。
28.3化合物28的合成
在冰浴下,将三氟乙酸(1mL)加入到化合物28-2(30.0mg)的二氯甲烷(4mL)溶液中,升至室温搅拌2小时。反应液减压浓缩,加入水(10mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(20mL×3)萃取,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经高效液相色谱(柱:Gemini 5u C18 150 x 21.2mm;流动相:ACN--H2O(0.1%FA);B%:2%-35%,14min)纯化得白色固体28的甲酸盐(1.9mg,收率9.3%)。LC-MS m/z(ESI):417.2[M+H]+。1H NMR(400MHz,MeOD-d4)δppm 8.75-8.69(m,3H),8.08-8.03(m,2H),7.65-7.61(m,1H),7.51-7.49(m,1H),7.34-7.30(m,1H),5.86-5.81(m,1H),5.33-4.69(m,2H),2.16-2.12(m,3H),1.74-1.59(m,3H).
29.实施例29的合成
29.1中间体29-1的合成
将三乙胺(367.0mg)加入到(R)-1-(嘧啶-2-基)乙胺盐酸盐(558.0mg)的1,2-二氯乙烷(10mL)溶液中,室温搅拌2小时。加入醋酸(323.0mg)和5-溴吡啶-2-甲醛(500.0mg),室温搅拌2小时。加入三乙酰氧基硼氢化钠(1140.0mg),室温搅拌2小时。加入水(100mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(50mL×3)萃取,有机相用饱和氯化钠溶液(100mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色油状物29-1(250.0mg,收率31.7%)。LC-MS m/z(ESI):293.1,295.1[M+H]+。
29.2中间体29-2的合成
将二碳酸二叔丁酯(280.0mg)加入到化合物29-1(250.0mg)和三乙胺(175.0mg)的二氯甲烷(5mL)溶液中,室温搅拌16小时。减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=5/1)纯化得黄色固体29-2(240mg,收率71.6%)。LC-MS m/z(ESI):392.9,394.9[M+H]+。
29.3中间体29-3的合成
将3,3-二氟吡咯烷盐酸盐(168.0mg),甲磺酸(2-二环己基膦基-2',6'-二异丙氧基-1,1'-联苯基)(2-氨基-1,1'-联苯-2-基)钯(II)(98.0mg),2-二环己基磷-2',6'-二异丙氧基-1,1'-联苯(109.0mg)和碳酸铯(760.0mg)加入到化合物29-2(230.0mg)的1,4-二氧六环(10mL)溶液中,90℃搅拌16小时。冷却至室温,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=2/1)纯化得黄色油状物29-3(150.0mg,收率56.2%)。LC-MS m/z(ESI):420.0[M+H]+。
29.4中间体29-4的合成
在冰浴下,将三氟乙酸(2mL)加入到化合物29-3(150.0mg)的二氯甲烷(5mL)溶液中,升至室温搅拌2小时。减压浓缩,加入水(20mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(30mL×3)萃取,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色油状物29-4(90.0mg,收率78.9%)。LC-MS m/z(ESI):320.2[M+H]+。
29.5中间体29-5的合成
将化合物29-4(90.0mg),1-丙基磷酸酐(359.0mg,50%乙酸乙酯溶液)和N,N-二异丙基乙胺(110.0mg)加入到化合物1-4(167.0mg)的N,N-二甲基甲酰胺(5mL)溶液中,室温搅拌16小时。加入水(50mL),乙酸乙酯(30mL×3)萃取,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色固体29-5(90.0mg,收率45.9%)。LC-MS m/z(ESI):697.3[M+H]+。
29.6化合物29的合成
在冰浴下,将三氟乙酸(1mL)加入到化合物29-5(90.0mg)的二氯甲烷(3mL)溶液中,升至室温搅拌2小时。反应液减压浓缩,加入水(10mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(30mL×3)萃取,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经高效液相色谱(柱:Gemini 5u C18 150 x 21.2mm;流动相:ACN--H2O(0.1%FA);B%:2%-30%,15min)纯化得白色固体29的甲酸盐(11.0mg,收率17.2%)。LC-MS m/z(ESI):497.2[M+H]+。1H NMR(400MHz,MeOD-d4)δppm 8.71-8.69(m,2H),8.08-7.96(m,1H),7.82-7.72(m,1H),7.62-7.52(m,1H),7.34-7.21(m,2H),7.00-6.94(m,1H),5.72-5.62(m,1H),4.96-4.49(m,2H),3.71-3.63(m,2H),3.55-3.50(m,2H),2.54-2.49(m,2H),2.14-2.11(m,3H),1.68-1.60(m,3H).
30.实施例30的合成
30.1中间体30-1的合成
0℃氮气氛围下,将氢化钠(2.0g,60%)加到4-溴-7-氯-1H-吡唑并[3,4-C]吡啶(3.0g)的N,N-二甲基甲酰胺(30mL)溶液中,搅拌1小时,将碘甲烷(375.0mg)滴加到反应溶液中,升至室温,搅拌2小时,加入水(50mL),乙酸乙酯(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=2/1)纯化得白色固体30-1(1.9g,收率61.9%)。LC-MS m/z(ESI):245.9,247.8[M+H]+。
30.2中间体30-2的合成
氮气氛围下,将碳酸钠(1.6g),对氨基苯甲醚(1.6g)加到30-1(1.9g)的N-甲基吡咯烷酮溶液(20mL)中,130℃搅拌2小时,加入水(60mL),乙酸乙酯(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=2/1)纯化得白色固体30-2(1.6g,收率60.4%)。LC-MS m/z(ESI):346.9,348.9[M+H]+。
30.3中间体30-3的合成
氮气氛围下,将30-2(1.6g)加入到三氟乙酸(20mL)中,60℃搅拌16小时,加入饱和碳酸氢钠溶液(60mL),乙酸乙酯(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=2/1)纯化得白色固体30-3(800.0mg,收率76.9%)。LC-MS m/z(ESI):227.0,229.1[M+H]+。
30.4中间体30-4的合成
氮气氛围下,将三乙胺(1.5g),4-二甲氨基吡啶(80.0mg),二碳酸二叔丁酯醚(1.9g)加到30-3(800mg)的二氯甲烷溶液(20mL)中,室温搅拌2小时,加入水(60mL),二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=3/1)得白色固体30-4(900.0mg,收率59.6%)。LC-MS m/z(ESI):449.0,451.0[M+Na]+。
30.5中间体30-5的合成
将三氟乙酰胺(250.0mg),碳酸铯(380.0mg),碘化亚铜(30.0mg)和反式N,N'-二甲基-1,2-环己二胺(16.0mg)加入到30-4(50.0mg)的无水二氧六环(8mL)溶液中,氮气氛围下,100℃搅拌16小时。冷却至室温,加入水(50mL),二氯甲烷萃取(20mL×3),有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=20/1)纯化得黄色固体30-5(120.0mg,收率56.3%)。LC-MS m/z(ESI):364.2[M+H]+。
30.6中间体30-6的合成
0℃,氮气氛围下,将草酰氯单乙酯(45.0mg)滴加到三乙胺(35.0mg)和30-5(110.0mg)的无水二氯甲烷(5mL)溶液中,0℃搅拌1小时。升至室温,加入水(20mL),二氯甲烷萃取(10mL×3),有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=50/1)纯化得到黄色固体30-6(110mg,收率72.3%)。LC-MS m/z(ESI):464.0[M+H]+。
30.7中间体30-7的合成
室温下,将三甲基氢氧化锡(78.0mg)加入到30-6(40.0mg)的1,2-二氯乙烷(6mL)溶液中,50℃搅拌2小时。冷却至室温,加入二氯甲烷(20mL)和水(20mL),用1M盐酸调pH=4~5,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩得类白色固体粗品30-7(40.0mg),粗品直接用于下一步反应。LC-MS m/z(ESI):436.2[M+H]+。
30.8中间体30-8的合成
氮气氛围室温下,将1-丙基磷酸酐(102.0mg,50%乙酸乙酯溶液)加入到三乙胺(32.0mg),1-5(27.0mg)和30-7(35.0mg)的N,N-二甲基甲酰胺(2mL)溶液中,室温搅拌16小时。加入乙酸乙酯(30mL)稀释,用饱和氯化钠溶液(20mL×3)洗涤,有机相用无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=100/1-30/1)纯化得类白色固体30-8(30.0mg,收率53.5%)。LC-MS m/z(ESI):700.0[M+H]+。
30.9化合物30的合成
冰浴氮气氛围下,将三氟乙酸(1mL)加入30-8(30.0mg)的二氯甲烷(2mL)溶液中。室温搅拌1小时,减压浓缩。残余物经高效液相色谱(柱:Xbridge-C18 150×19mm,5um;流动相:ACN--H2O(0.05%NH4OH);B%:20%-50%,15min)纯化得白色固体30(4.0mg,收率18.7%)。LC-MS m/z(ESI):500.0[M+H]+。1H NMR(400MHz,MeOD-d4)δppm 8.73-8.69(m,3H),8.05-7.82(m,2H),7.75-7.66(m,1H),7.64-7.55(m,1H),7.33-7.29(m,1H),5.91-5.82(m,1H),5.35-5.12(m,1H),5.05-4.78(m,1H),4.34-4.30(m,3H),1.76-1.63(m,3H).
31.实施例31的合成
31.1中间体31-1的合成
将二碳酸二叔丁酯(1442.1mg)加入到4-二甲胺基吡啶(64.6mg),三乙胺(802.4mg)和4-硝基异喹啉-1-胺(500.0mg)的二氯甲烷(8mL)溶液中,室温搅拌1小时。有机相用饱和氯化钠溶液(5mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=1/1-2/3)纯化得白色固体31-1(830.0mg,收率72.5%)。LC-MS m/z(ESI):412.0[M+Na]+。
31.2中间体31-2的合成
氮气保护下,将钯碳(88.5mg)加入到31-1(810.0mg)的甲醇(10mL)溶液中。氢气置换三次,氢气氛下25℃搅拌4小时。过滤,滤液减压浓缩,得类白色固体粗品31-2(600mg)。LC-MS m/z(ESI):360.0[M+H]+。
31.3中间体31-3的合成
氮气保护下,将二氧化铂(73.3mg)加入到31-2(580.0mg)和乙酸(48.5mg)的甲醇(8mL)溶液中。氢气置换三次,氢气氛下25℃搅拌16小时。过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=12/1-10/1)纯化得类白色固体31-3(500.0mg,收率76.7%)。LC-MS m/z(ESI):364.1[M+H]+。
31.4中间体31-4的合成
冰浴下,将草酰氯单乙酯(83.0mg)加到31-3(200.0mg)和三乙胺(83.5mg)的二氯甲烷(4mL)溶液中,室温搅拌1小时。二氯甲烷(20mL)稀释,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=4/1-3/1)纯化得白色固体31-4(240.0mg,收率84.7%)。LC-MS m/z(ESI):464.0[M+H]+。
31.5中间体31-5的合成
将氢氧化锂(13.6mg)加入到31-4(220.0mg)的甲醇和水(5mL,V/V=4:1)溶液中。室温搅拌1小时。加入1M盐酸调节pH=7,抽滤,得白色固体粗品31-5(150.0mg)。粗品未经纯化直接用于下一步反应。LC-MS m/z(ESI):336.0[M+H]+。
31.6化合物31的合成
将2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(170.1mg)加入N,N-二异丙基乙胺(77.1mg),31-5(100.0mg)和1-5(101.0mg)的N,N-二甲基甲酰胺(2mL)溶液中。室温搅拌1小时。加入冰水(10mL),乙酸乙酯(10mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经高效液相色谱(柱:Xbridge-C18 150×19mm,5um;流动相:ACN--H2O(0.1%FA);B%:10%-40%,20min)纯化得白色固体31的甲酸盐(5.5mg,收率3.0%)。LC-MS m/z(ESI):500.0[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.00-9.89(m,1H),8.85-8.73
(m,3H),8.14-8.11(m,1H),7.65-7.59(m,1H),7.47-7.35(m,2H),5.69-5.64(m,2H),5.26-4.59(m,2H),2.49-2.05(m,4H),1.70-1.45(m,8H).
32.实施例32的合成
32.1中间体32-1的合成
0℃下,将浓硝酸(1.0mL)加入到[2,6]萘啶-1-氨基(1.0g)的浓硫酸(20mL)溶液中,搅拌16小时。反应液缓慢倒入饱和碳酸氢钠溶液中,调节pH=8。过滤,滤饼干燥后得黄色固体32-1(1.0g,收率75.8%)。LC-MS m/z(ESI):191.1[M+H]+。
32.2中间体32-2的合成
0℃下,将氢化钠(336.8mg,60%)加入到32-1(1.0g)的四氢呋喃溶液(500mL)中,搅拌0.5小时,加入二碳酸二叔丁酯(10.2g),室温搅拌1小时。加入饱和氯化铵溶液(10mL),无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=2/1)纯化得黄色固体32-2(1.0g,收率65.5%)。LC-MS m/z(ESI):291.1[M+H]+。
32.3中间体32-3的合成
将还原铁粉(1.9g)加入32-2(1.0g)和氯化铵(900.0mg)的乙醇和水(30mL,V/V=1:9)混合溶液中,50℃搅拌8小时。加入水(20mL),乙酸乙酯(30mL×3)萃取,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色油状物32-3(600.0mg,收率66.9%)。LC-MS m/z(ESI):261.2[M+H]+。
32.4中间体32-4的合成
0℃下,将草酰氯单乙酯(130.0mg)加入三乙胺(230.0mg)和32-3(200.0mg)的二氯甲烷(10mL)溶液中。室温搅拌2小时,有机相用饱和氯化钠溶液(5mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=1/1)纯化得淡黄色固体32-4(120.0mg,收率60.3%)。LC-MS m/z(ESI):233.0[M-56+H]+。
32.5中间体32-5的合成
将氢氧化锂(65.8mg),加入到32-4(120.0mg)的四氢呋喃和水(10mL,V/V=5:1)混合溶液中,40℃搅拌5小时。减压浓缩,残余物经高效液相色谱(柱:Daisogel-C18 30 x 250mm,10um;流动相:ACN--H2O(0.1%FA);B%:5%-60%,80min)纯化得淡黄色固体32-5的甲酸盐(60.0mg,收率54.6%)。
LC-MS m/z(ESI):333.0[M+H]+。
32.6化合物32-6的合成
将32-5(60.0mg),N,N-二异丙基乙胺(69.9mg),2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(137.3mg)加入到1-5(50.9mg)的N,N-二甲基甲酰胺(5mL)溶液中。室温搅拌2小时。加入水(10mL),用乙酸乙酯(5mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=1/1)纯化得淡黄色固体32-6(42.7mg,收率11.9%)。LC-MS m/z(ESI):597.1[M+H]+。
32.7化合物32的合成
冰浴下,将三氟乙酸(1mL)加入到32-6(42.7mg)的二氯甲烷(1mL)溶液中。室温搅拌1小时,减压浓缩,残余物经高效液相色谱(柱:Xbridge-C18 150 x 19mm,5um;流动相:ACN--H2O(0.1%FA);B%:5%-10%,20min)纯化得白色固体32的甲酸盐(1.2mg,收率3.4%)。LC-MS m/z(ESI):497.2[M+H]+。1H NMR(400MHz,CD3OD)δppm 9.23-8.98(m,1H),8.69-8.60(m,3H),8.49-8.31(m,3H),7.97-7.89(m,3H),7.52-7.44(m,1H),7.27-7.20(m,1H),5.83-5.81(m,1H),5.31-5.11(m,1H),4.93-4.89(m,1H),1.67-1.53(m,3H).
33.实施例33的合成
33.1中间体33-1的合成
将5-三氟甲基吡啶-2-甲醛(200.0mg)和醋酸(102.0mg)加入到叔丁基胺(249.7mg)的1,2-二氯乙烷溶液(5mL)中,室温搅拌2小时。加入三乙酰氧基硼氢化钠(721.6mg),室温搅拌30分钟。加入水(30mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=40/1)纯化得黄色油状物33-1(220.0mg,收率72.3%)。LC-MS m/z(ESI):233.1[M+H]+。
33.2中间体33-2的合成
将1-丙基磷酸酐(226.0mg)和N,N-二异丙基乙胺(98.0mg)加入到化合物33-1(100.0mg)和1-4(150.0mg)的N,N-二甲基甲酰胺溶液(5mL)中,室温搅拌5小时。加入水(50mL),乙酸乙酯(50mL×3)萃取,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=30/1)纯化得黄色固体33-2(50.0mg,收率25.6%)。LC-MS m/z(ESI):610.2[M+H]+。
33.3化合物33的合成
冰浴下,将三氟乙酸(1mL)加入到化合物33-2(50.0mg)的二氯甲烷溶液(3mL)中,升至室温搅拌2小时。反应液减压浓缩,加入水(10mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(20mL×3)萃取,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经高效液相色谱(柱:Gemini 5u C18 150x 21.2mm;流动相:[water(FA)-ACN];B%:2%-10%,6min)纯化得白色固体33的甲酸盐(2.0mg,收率10.3%)。LC-MS m/z(ESI):410.1[M+H]+。1H NMR(400MHz,MeOD-d4)δppm 8.85(s,1H),8.25(s,1H),
8.10(d,J=8.0,1H),8.01(s,1H),7.71(d,J=8.0Hz,1H),7.53(s,1H),4.96(s,2H),2.12(s,3H),1.46(s,9H).
34.实施例34的合成
34.1中间体34-1的合成
0℃下,将双三甲基硅基胺基锂的四氢呋喃(77.8mL,1M)加入到2-胺基-4-氯-吡啶(5.0g)的四氢呋喃(50mL)溶液中,搅拌0.5小时,将二碳酸二叔丁酯(10.2g)慢慢加入,混合物室温搅拌2小时。加水(50mL),乙酸乙酯(60mL×3)萃取,有机相用饱和氯化钠(50mL)洗涤。无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=2/1-1/1)纯化得白色固体34-1(6.0g,收率60.7%)。LC-MS m/z(ESI):173.0[M-56+H]+。
34.2中间体34-2的合成
-78℃下,将正丁基锂的四氢呋喃(4.4mL,2.4M)加入到34-1(1.0g)的四氢呋喃溶液(10mL)中,氮气保护下,-78℃搅拌0.5小时后加入N,N-二甲基甲酰胺(1.6g),室温搅拌1小时。向反应液中加入饱和氯化铵溶液(10mL),乙酸乙酯(15mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=1/2)纯化得黄色固体34-2(270.0mg,收率20.5%)。LC-MS m/z(ESI):156.9[M-100+H]+。
34.3中间体34-3的合成
冰浴下,将三氟乙酸(600.0mg)加入34-2(270.0mg)的二氯甲烷(3mL)溶液中。室温搅拌1小时,减压浓缩。用饱和碳酸氢钠溶液调pH至弱碱性,二氯甲烷(10mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩得黄色固体粗品34-3(180.0mg)。粗品直接用于下一步反应。LC-MS m/z(ESI):157.0[M+H]+。
34.4中间体34-4的合成
将N-溴代丁亚酰二胺(187.5mg)加入34-3(150.0mg)的1,2-二氯乙烷(3mL)溶液中。50℃搅拌2小时,冷却至室温,有机相用饱和亚硫酸钠(3mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓
缩得黄色固体34-4(180.0mg)。粗品直接用于下一步反应。LC-MS m/z(ESI):235.0,237.0[M+H]+。
34.5中间体34-5的合成
将水合肼(171.9mg)加入34-4(160.0mg)的二甲基亚砜(2mL)溶液中,120℃搅拌2小时。冷却至室温,加水(5mL),乙酸乙酯(5mL×3)萃取,有机相用饱和氯化钠(5mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩后加入二氯甲烷(2mL),过滤得黄色固体34-5(60.0mg,收率35.2%)。LC-MS m/z(ESI):213.0,215.0[M+H]+。
34.6中间体34-6的合成
氮气保护下,0℃将偶氮二甲酸二异丙酯(142.3mg)加入到34-5(100.0mg),三苯基膦(160.0mg)和甲醇(30.0mg)的四氢呋喃(2mL)溶液中,室温搅拌16小时,加入水(5mL),乙酸乙酯(5mL×3)萃取,有机相用饱和氯化钠溶液(5mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/乙酸乙酯=1/2)纯化得白色固体34-6(70.0mg,收率59.1%)。LC-MS m/z(ESI):226.9,228.9[M+H]+。
34.7中间体34-7的合成
将二碳酸二叔丁酯(148.0mg)加入到34-6(70.0mg),三乙胺(62.3mg)和4-二甲氨基吡啶(3.7mg)的二氯甲烷(2mL)溶液中,室温搅拌3小时。减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=1/1)纯化得白色固体34-7(100.0mg,收率89.2%)。LC-MS m/z(ESI):427.0,429.0[M+H]+。
34.8中间体34-8的合成
将34-7(150.0mg),二苯甲酮亚胺(127.2mg),三(二亚卞基丙酮)二钯(32.1mg),1,1'-联苯-2,2'-双二苯膦(32.7mg),碳酸铯(228.7mg)加入甲苯(10mL)溶液中。氮气保护下,110℃搅拌16小时。过滤,减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=1/3)纯化得黄色固体34-8(100.0mg,收率48.6%)。LC-MS m/z(ESI):528.3[M+H]+。
34.9中间体34-9的合成
0℃下,将盐酸(1mL,2M)溶液加入到34-8(90.0mg)四氢呋喃溶液(2mL)中,0℃搅拌1小时,减压浓缩后冻干得黄色固体34-9(20.0mg)。粗品未经纯化直接用于下一步反应。LC-MS m/z(ESI):264.1[M+H]+。
34.10中间体34-10的合成
在冰浴下,将草酰氯单乙酯(1.1g)缓慢滴加到化合物1-5(2.0g)和三乙胺(0.9g)的二氯甲烷溶液(20mL)中,升至室温搅拌16小时。加入水(20mL),二氯甲烷(15mL×3),有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=2/1)纯化得黄色油状物2(1.9g,收率70.1%)。LC-MS m/z(ESI):393.1[M+H]+。
34.11中间体34-11的合成
冰浴下,将氢氧化锂(238.0mg)加入到化合物34-10(1.9g)的乙醇和水(100mL,V/V=1:1)混合溶剂中,升至室温搅拌2小时。减压浓缩,加入水(10mL),用2M盐酸调节pH至弱酸性,二氯甲烷(15mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩得化合物34-11(1.5g,85.2%)。LC-MS m/z(ESI):355.1[M+H]+。
34.12中间体34-12的合成
将N-甲基咪唑(9.4mg)加入34-11(24.2mg)和34-9(15.0mg),四甲基氯代脲六氟磷酸酯(47.9mg)的乙腈(2mL)溶液中。室温搅拌2小时,加入水(5mL),乙酸乙酯(5mL×3)萃取,有机相
用饱和氯化钠溶液(5mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=1/2)得黄色固体34-12(25.0mg)。粗品直接用于下一步反应。LC-MS m/z(ESI):500.2[M-100+H]+。
34.13化合物34的合成
冰浴下,将HCl的二氧六环溶液(2mL,4M)加入34-12(25.0mg)的二氧六环(1mL)溶液中。室温搅拌1小时,饱和碳酸钠溶液调节pH=8,二氯甲烷(5mL×3)萃取,减压浓缩,残余物经高效液相色谱(柱:Xbridge-C18 150×19mm,5um;流动相:ACN--H2O(0.1%FA);B%:5%-10%,20min)纯化得白色固体34的甲酸盐(3.2mg,收率25.2%)。LC-MS m/z(ESI):500.2[M+H]+。1H NMR(400MHz,CD3OD)δppm 8.66-8.61(m,3H),8.14-8.10(m,1H),7.94-7.91(m,1H),7.57-7.42(m,2H),7.26-7.20(m,2H),5.87-5.76(m,1H),5.41-5.05(m,1H),4.03-3.97(m,3H),1.67-1.50(m,3H).
35.实施例35的合成
35.1中间体35-1的合成
0℃下,将草酰氯(755.0mg)加入到6-乙酰氧基哒嗪-3-羧酸(500.0mg)的二氯甲烷(10mL)和N,N-二甲基甲酰胺(0.1mL)溶液中,室温搅拌2小时,加入甲醇(20mL),减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=3/1)得黄色油状物体35-1(500.0mg,收率92.3%)。LC-MS m/z(ESI):183.0[M+H]+。
35.2中间体35-2的合成
将硼氢化钠(190.0mg)和氯化钙(280.0mg)加入到35-1(480.0mg)的四氢呋喃(5mL)和甲醇(1mL)溶液中,氮气保护下,室温搅拌1小时。向反应液中加入水(5mL),乙酸乙酯(10mL×3)萃取,有机相用饱和氯化钠溶液(5mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=10/1)纯化得无色油状物35-2(400.0mg,收率98.5%)。LC-MS m/z(ESI):155.1[M+H]+。
35.3中间体35-3的合成
0℃下,将戴斯马丁氧化剂(1.1g)加入到35-2(200.0mg)的二氯甲烷(10mL)溶液中。室温搅拌2小时,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=1/1)纯化得无色油状物35-3(190.0mg,收率96.3%)。LC-MS m/z(ESI):153.2[M+H]+。
35.4中间体35-4的合成
将(R)-1-嘧啶-2-氨基乙胺盐酸盐(420.0mg)和三乙胺(265.8mg)加入到35-3(200.0mg)的
1,2-氯乙烷(10mL)溶液中。氮气保护下,室温搅拌1小时后加入三乙酰氧基硼氢化钠(557.0mg),室温搅拌1小时。有机相用饱和氯化钠溶液(5mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩得黄色油状物35-4(140.0mg)。粗品未经纯化直接用于下一步反应。LC-MS m/z(ESI):260.2[M+H]+。
35.5中间体35-5的合成
将1-5(240.0mg),2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(360.0mg),N,N-二异丙基乙胺(120.0mg)加入到35-4(120.0mg)的N,N-二甲基甲酰胺(3mL)溶液中。室温搅拌12小时。向反应液中加入水(5mL),用乙酸乙酯(5mL×3)萃取,有机相用饱和氯化钠溶液(3mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,得白色固体35-5(50.0mg)。粗品未经纯化直接用于下一步反应。LC-MS m/z(ESI):637.3[M+H]+。
35.6化合物35的合成
冰浴下,将三氟乙酸(0.5mL)加入到35-5(50.0mg)的二氯甲烷(1mL)溶液中。室温搅拌2小时,饱和碳酸钠溶液调节pH=8,二氯甲烷(10mL×3)萃取,减压浓缩,残余物经高效液相色谱(柱:Xbridge-C18 150 x 19mm,5um;流动相:ACN--H2O(0.1%FA);B%:5%-10%,20min)纯化得白色固体35的甲酸盐(27.16mg,收率79.2%)。LC-MS m/z(ESI):437.2[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.52-10.44(m,1H),8.76-8.73(m,2H),8.03-7.96(m,1H),7.77-7.52(m,1H),7.47-7.43(m,1H),7.40-7.34(m,1H),7.13-7.10(m,1H),5.68-5.54(m,3H),5.13-4.59(m,2H),4.42-4.38(m,2H),2.03-1.99(m,3H)1.65-1.52(m,3H),1.38-1.32(m,3H).
36.实施例36的合成
36.1中间体36-1的合成
将5-三氟甲基吡啶-2-甲醛(412.0mg)加入到(R)-1-环丙基-1-胺(200.0mg)的1,2-氯乙烷(5mL)和醋酸(0.5mL)溶液中,氮气保护下,室温搅拌1小时后加入三乙酰氧基硼氢化钠(996.0mg),室温搅拌1小时。向反应液中加入饱和碳酸氢钠溶液(10mL),二氯甲烷(15mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩得淡黄色油状物36-1(200.0mg)。粗品未经纯化直接用于下一步反应。LC-MS m/z(ESI):245.2[M+H]+。
36.2中间体36-2的合成
将1-4(422.3mg),1-丙基磷酸酐(522.3mg),N,N-二异丙基乙胺(223.0mg)加入到36-1(200.0mg)的N,N-二甲基甲酰胺(2mL)溶液中。室温搅拌12小时。向反应液中加入水(5mL),用乙酸乙酯(5mL×3)萃取,有机相用饱和氯化钠溶液(5mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=2/1)纯化得白色固体36-2(100.0mg,收率19.6%)。LC-MS m/z(ESI):622.2[M+H]+。
36.3化合物36的合成
冰浴下,将三氟乙酸(1mL)加入到36-2(100.0mg)的二氯甲烷(2mL)溶液中。室温搅拌2小时,饱和碳酸钠溶液调节pH=8,二氯甲烷(10mL×3)萃取,减压浓缩,残余物经高效液相色谱(柱:
Xbridge-C18 150 x 19mm,5um;流动相:ACN--H2O(0.1%FA);B%:5%-10%,20min)纯化得白色固体36的甲酸盐(43.21mg,收率63.7%)。LC-MS m/z(ESI):422.2[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.54-10.32(m,1H),8.92-8.86(m,1H),8.24-8.20(m,1H),8.01-7.89(m,1H),7.78-7.58(m,1H),7.48-7.32(m,1H),5.68-5.60(m,2H),5.02-4.73(m,2H),3.29-3.25(m,1H),2.04-1.97(m,3H),1.29-1.14(m,3H),0.99-0.96(m,1H),0.50-0.48(m,1H),0.31-0.11(m,3H).
37.实施例37的合成
37.1中间体37-1的合成
将异丁胺(200.0mg),醋酸硼氢化钠(320.0mg)加入到5-三氟甲基-吡啶-2-甲醛(230.0mg)的1,2-二氯乙烷(10mL)溶液中。室温搅拌2小时。加入饱和碳酸氢钠溶液(10mL),用二氯甲烷(10mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=1/1)纯化得淡黄色固体37-1(180.0mg,收率28.6%)。LC-MS m/z(ESI):233.0[M+H]+。
37.2中间体37-2的合成
将37-1(100.0mg),N,N-二异丙基乙胺(166.1mg),2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(320.0mg)加入到1-4(170.0mg)的N,N-二甲基甲酰胺(5mL)溶液中。室温搅拌2小时。加入水(10mL),用乙酸乙酯(5mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=1/2)纯化得黄色固体37-2(122.7mg,收率46.7%)。LC-MS m/z(ESI):610.2[M+H]+。
37.3化合物37的合成
冰浴下,将三氟乙酸(2mL)加入到37-2(122.7mg)的二氯甲烷(2mL)溶液中。室温搅拌1小时,减压浓缩,残余物经高效液相色谱(柱:Xbridge-C18 150×19mm,5um;流动相:ACN--H2O(0.1%FA);B%:5%-10%,20min)得白色固体37的甲酸盐(73.0mg,收率74.3%)。LC-MS m/z(ESI):410.1[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.48-10.34(m,1H),8.95-8.91(m,1H),8.26-8.20(m,1H),8.03-7.93(m,1H),7.61-7.55(m,1H),7.49-7.39(m,1H),5.67-5.62(m,2H),4.93-4.75(m,2H),3.39(d,J=8.0Hz,1H),3.21(d,J=8.0Hz,1H),2.04-1.96(m,3H),1.96-1.94(m,1H),0.89-0.82(m,6H).
38.实施例38的合成
38.1中间体38-1的合成
0℃,氮气氛围下,将2-溴-5-羟基吡嗪(10.0g)的N,N-二甲基甲酰胺(30mL)和四氢呋喃(30mL)的混合溶液缓慢滴加到氢化钠(2.7g,60%)的N,N-二甲基甲酰胺(30mL)溶液中,0℃搅拌30分钟,加入4-甲氧基苄氯(10.0g)的四氢呋喃(30mL)溶液,缓慢升至室温搅拌16小时。冷却至0℃,滴加饱和氯化铵溶液(10mL)淬灭,加水(500mL)稀释,乙酸乙酯(100mL×3)萃取,有机相用饱和氯化钠溶液(50mL×3)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=3/1-2/1)纯化得白色固体38-1(11.0g,收率65.5%)。LC-MS m/z(ESI):316.9,318.9[M+Na]+。
38.2中间体38-2的合成
0℃,氮气氛围下,将对甲基苯磺酰甲基异腈(8.9g)和38-1(12.2g)的四氢呋喃(60mL)溶液缓慢滴加到氢化钠(2.3g,60%)的四氢呋喃(60mL)溶液中,0℃搅拌30分钟,升至室温搅拌1小时。冷却至0℃,滴加饱和氯化铵溶液(5mL)淬灭,加水(500mL)稀释,乙酸乙酯(100mL×3)萃取,有机相用饱和氯化钠溶液(100mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=2/3-1/4)纯化得白色固体38-2(10.0g,收率72.4%)。LC-MS m/z(ESI):333.9,335.9[M+H]+。
38.3中间体38-3的合成
0℃,氮气氛围下,将三氟甲磺酸(25mL)加入到38-2(10.0g)的三氟乙酸(100mL)和苯甲醚(45mL)的混合溶液中。升至室温搅拌30分钟,40℃搅拌1小时。减压浓缩,缓慢将残余物倒入碳酸氢钠的冰水混合物中,60℃减压浓缩,残余物用二氯甲烷和甲醇(200mL,V/V=10:1)打浆,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=100/5-100/6)纯化得白色固体38-3(4.5g,收率71.4%)。LC-MS m/z(ESI):213.9,215.9[M+H]+。
38.4中间体38-4的合成
将4-甲氧基苄胺(4.6g),1,8-二氮杂环[5,4,0]十一烯-7(6.8g)和苯并三氮唑-1-基氧基三(二甲基氨基)磷鎓六氟磷酸盐(14.8g)加入到38-3(4.5g)的无水乙腈(80mL)溶液中,80℃搅拌16小时。冷却至室温,减压浓缩,加水(100mL)稀释,乙酸乙酯(50mL×3)萃取,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/
乙酸乙酯=3/1-1/1)纯化得淡黄色固体38-4(6.0g,收率85.7%)。LC-MS m/z(ESI):333.1,335.0[M+H]+。
38.5中间体38-5的合成
将38-4(5.0g)加入到三氟乙酸(50mL)中,80℃搅拌16小时。冷却至室温,减压浓缩,残余物用饱和碳酸氢钠溶液调pH至弱碱性,乙酸乙酯(50mL×3)萃取,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=100/3)纯化得黄色固体38-5(2.3g,收率71.8%)。LC-MS m/z(ESI):213.0,214.9[M+H]+。
38.6中间体38-6的合成
将二碳酸二叔丁酯(5.9g),三乙胺(3.2g),4-二甲氨基吡啶(0.3g)加入到38-5(2.3g)的二氯甲烷(30mL)溶液中,室温搅拌16小时。加入二氯甲烷(100mL),饱和氯化钠溶液(50mL)洗涤,有机相用无水硫酸钠干燥,过滤,反应液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=3/1)纯化得黄色固体38-6(2.5g,收率54.3%)。LC-MS m/z(ESI):412.9,414.9[M+H]+。
38.7中间体38-7的合成
将二苯甲酮亚胺(440.0mg),碳酸铯(790.0mg),1,1'-联萘-2,2'-双二苯膦(150.0mg)和三(二亚苄基丙酮)二钯(110.0mg)加入到38-6(500.0mg)的无水甲苯(20mL)溶液中,氮气保护下,100℃搅拌16小时。冷却至室温,加水(50mL)稀释,乙酸乙酯(30mL×3)萃取,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=4/1-3/1)纯化得黄色固体38-7(500.0mg,收率80.3%)。LC-MS m/z(ESI):514.1[M+H]+。
38.8中间体38-8的合成
将盐酸(5mL,2M)加入到38-7(500.0mg)的甲醇(5mL)溶液中,室温搅拌30分钟。用饱和碳酸氢钠溶液调pH至弱碱性,乙酸乙酯(30mL×3)萃取,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=100/31-100/3)纯化得类白色固体38-8(300.0mg,收率88.3%)。LC-MS m/z(ESI):350.2[M+H]+。
38.9中间体38-9的合成
将草酰氯单甲酯(83.0mg),三乙胺(80.0mg)加入到38-8(200.0mg)的二氯甲烷(5mL)溶液中,室温搅拌3小时。加水(10mL)稀释,乙酸乙酯(20mL×3)萃取,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=1/1)纯化得类白色固体38-9(100.0mg,收率40.2%)。LC-MS m/z(ESI):436.1[M+H]+。
38.10中间体38-10的合成
将氢氧化锂(15.0mg)加入到38-9(90.0mg)的甲醇(3mL)和水(3mL)溶液中,室温搅拌2小时。加入水(30mL),用1M盐酸调节pH=6,乙酸乙酯(20mL×3)萃取,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩得白色固体38-10(50.0mg),粗品直接用于下一步反应。LC-MS m/z(ESI):422.0[M+H]+。
38.11中间体38-11的合成
将丙基磷酸酐(60.7mg,50%乙酸乙酯溶液)加入到N,N-二异丙基乙胺(25.0mg),38-10(25.0mg)和1-5(17.0mg)的N,N-二甲基甲酰胺(2mL)溶液中。室温搅拌16小时。用饱和碳酸氢钠溶液调pH至弱碱性,乙酸乙酯(20mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1-10/1)纯化得白色固体38-11(20.0mg,收率49.2%)。LC-MS m/z(ESI):686.0[M+H]+。
38.12化合物38的合成
冰浴下,将三氟乙酸(0.5mL)加入38-11(20.0mg)的二氯甲烷(2mL)溶液中,室温搅拌1小时。减压浓缩,残余物经高效液相色谱(柱:Xbridge-C18 150×19mm,5um;流动相:ACN--H2O(0.1%FA);B%:10%-30%,15min)纯化得白色固体38的甲酸盐(2.0mg,收率14.2%)。LC-MS m/z(ESI):486.1[M+H]+。1H NMR(400MHz,MeOD-d4)δppm 8.77(s,1H),8.73-8.51(m,3H),8.18-8.13(m,1H),7.95-7.68(m,3H),7.31-7.22(m,1H),5.27-4.97(m,2H),4.65-4.55(m,1H),1.77-1.58(m,3H).
39.实施例39的合成
39.1中间体39-1的合成
冰浴下,将草酰氯单甲酯(60.0mg)加入三乙胺(60.0mg)和36-1(100.0mg)的二氯甲烷(5mL)溶液中,室温搅拌3小时。加水(20mL)稀释,二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=5/1-2/1)纯化得白色固体39-1(120.0mg,收率88.9%)。LC-MS m/z(ESI):331.0[M+H]+。
39.2中间体39-2的合成
将氢氧化锂(30.0mg)加入到39-1(120.0mg)的甲醇(3mL)和水(3mL)混合溶液中,室温搅拌2小时。加水(20mL),用1M盐酸调节pH=6,乙酸乙酯(10mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩得白色固体39-2(80.0mg,收率69.6%),粗品直接用于下一步反应。LC-MS m/z(ESI):317.0[M+H]+。
39.3中间体39-3的合成
将N-甲基咪唑(23.0mg)和N,N,N',N'-四甲基氯甲脒六氟磷酸盐(64.0mg)加入到2-2(40.0mg)和39-2(43.0mg)的乙腈(2mL)溶液中,室温搅拌2小时。加水(20mL)稀释,乙酸乙酯(20mL×3)萃取,有机相用饱和氯化钠溶液(2mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=3/1-1/1)纯化得白色固体39-3(20.0mg,收率22.7%)。LC-MS m/z(ESI):650.3[M+H]+。
39.4化合物39的合成
冰浴下,将三氟乙酸(1mL)加入到39-3(20.0mg)的二氯甲烷(2mL)溶液中,室温搅拌1小时。减压浓缩,残余物经高效液相色谱(柱:Xbridge-C18 150×19mm,5um;流动相:ACN--H2O(0.1%FA);B%:5%-30%,80min)纯化得白色固体39的甲酸盐(1.64mg,收率12.6%)。LC-MS m/z(ESI):450.1[M+H]+。1H NMR(400MHz,MeOD-d4)δppm 8.84(d,J=12.0Hz,1H),8.10(d,J=8.0Hz,1H),7.90-7.65(m,2H),5.22-5.07(m,1H),5.04-4.89(m,4H),4.87-4.78(m,1H),3.89-3.35(m,1H),1.40-1.21(m,3H),1.03-0.95(m,1H),0.67-0.48(m,1H),0.44-0.15(m,3H).
40.实施例40的合成
40.1中间体40-1的合成
冰浴下,将草酰氯单乙酯(126.0mg)加入三乙胺(132.0mg)和15-1(200.0mg)的二氯甲烷(5mL)溶液中,升至室温搅拌2小时。有机相用饱和氯化钠溶液(2mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=5/1-1/1)纯化得淡黄色液体40-1(200.0mg,收率69.7%)。LC-MS m/z(ESI):331.0[M+H]+。
40.2中间体40-2的合成
将氢氧化锂(29.0mg)加入到40-1(200.0mg)的四氢呋喃(3mL)和水(1mL)混合溶液中,室温搅拌2小时。1M盐酸调至酸性,二氯甲烷(5mL×3)萃取,有机相用饱和氯化钠溶液(2mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩得淡黄色固体40-2(160.0mg)。粗品未经纯化直接用于下一步反应。LC-MS m/z(ESI):303.0[M+H]+。
40.3中间体40-3的合成
将2-2(30.0mg),N,N,N',N'-四甲基氯甲脒六氟磷酸盐(50.0mg),N-甲基咪唑(15.0mg)加入到40-2(52.0mg)的N,N-二甲基甲酰胺(1mL)溶液中。室温搅拌12小时。向反应液中加入水(5mL),用乙酸乙酯(5mL×3)萃取,有机相用饱和氯化钠溶液(1mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=2/1-1/1)纯化得淡黄色固体40-3(30.0mg,收率55.3%)。LC-MS m/z(ESI):636.0[M+H]+。
40.4化合物40的合成
冰浴下,将三氟乙酸(0.5mL)加入到40-3(30.0mg)的二氯甲烷(1mL)溶液中。室温搅拌2小时,减压浓缩,残余物经高效液相色谱(柱:Xbridge-C18 150 x 19mm,5um;流动相:ACN--H2O(0.1%FA);B%:5%-10%,20min)纯化得黄色固体40的甲酸盐(18.8mg,收率91.6%)。LC-MS m/z(ESI):436.2[M+H]+。1H NMR(400MHz,DMSO-d6)δppmδ10.56-10.37(m,1H),8.93(d,J=10.0Hz,1H),8.23(d,J=8.0Hz,1H),7.86-7.73(m,1H),7.67-7.56(m,1H),6.09-6.05(m,2H),5.02-4.88(m,2H),4.85(s,2H),4.83-4.65(m,2H),3.40-3.36(m,2H),1.12-0.95(m,1H),0.44-0.34(m,2H),0.24-0.15(m,2H).
41.实施例41的合成
41.1中间体41-1的合成
冰浴下,将草酰氯单乙酯(135.0mg)加入到三乙胺(110.0mg)和16-1(200.0mg)的二氯甲烷(5mL)溶液中,升至室温搅拌2小时。有机相用饱和氯化钠溶液(1mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=5/1-1/1)纯化得淡黄色液体41-1(200.0mg,收率70.9%)。LC-MS m/z(ESI):345.1[M+H]+。
41.2中间体41-2的合成
将氢氧化锂(30.0mg)加入到41-1(200.0mg)的四氢呋喃(3mL)和水(1mL)溶液中,室温搅拌2小时。1M盐酸调至酸性,二氯甲烷(10mL×3)萃取,有机相用饱和氯化钠溶液(5mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩得淡黄色固体41-2(150.0mg)。粗品未经纯化直接用于下一步反应。LC-MS m/z(ESI):317.1[M+H]+。
41.3中间体41-3的合成
将N,N,N,N-四甲基氯甲脒六氟磷酸盐(54.0mg)和N-甲基咪唑(16.0mg)加入到41-2(30.0mg)和2-2(40.0mg)的乙腈(2mL)溶液中。室温搅拌5小时。加水(10mL)稀释,乙酸乙酯(10mL×3mL)萃取,有机相用饱和氯化钠溶液(5mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1-10/1)纯化得黄色固体41-3(24.0mg,收率34.9%)。LC-MS m/z(ESI):650.0[M+H]+。
41.4化合物41的合成
冰浴下,将三氟乙酸(2mL)加入41-3(24.0mg)的二氯甲烷(2mL)溶液中。室温搅拌1小时,减压浓缩。残余物经高效液相色谱(柱:Xbridge-C18 150×19mm,5um;流动相:ACN--H2O(0.1%FA);B%:10%-35%,20min)纯化得白色固体41的甲酸盐(6.3mg,收率38.4%)。LC-MS m/z(ESI):450.1[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.51-10.33(m,1H),8.94-8.92(m,1H),8.24(d,J=8.0Hz,1H),8.14(s,1H),7.84-7.69(m,1H),7.62-7.49(m,1H),6.04-5.96(m,2H),4.91-4.64(m,6H),3.54-3.44(m,2H),2.60-2.55(m,1H),1.92-1.65(m,6H).
42.实施例42的合成
42.1中间体42-1的合成
将3,6-二氢-2H-吡喃-4-硼酸频哪醇酯(2.9g),四(三苯基膦)钯(1.7g)和碳酸铯(7.6g)到6-氯哒嗪-3-甲酸甲酯(2.0g)的1,4-二氧六环(20mL)和水(1mL)混合溶液中,氮气保护下,100℃搅拌2小时。冷却至室温,减压浓缩得棕色固体42-1(3.0g),粗品直接用于下一步反应。LC-MS m/z(ESI):207.1[M+H]+。
42.2中间体42-2的合成
将浓硫酸(6mL)加入到化合物42-1(3.0g)的甲醇(30mL)溶液中,70℃搅拌2小时。冷却至室温,加入饱和碳酸氢钠溶液(100mL),乙酸乙酯(50mL×3)萃取,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=2/1)纯化得黄色固体42-2(600.0mg,两步收率24.2%)。LC-MS m/z(ESI):221.0[M+H]+。
42.3中间体42-3的合成
0℃下,将硼氢化钠(515.3mg)加入到化合物42-2(600mg)的甲醇(10mL)溶液中,室温搅
拌2小时。加入水(30mL),二氯甲烷(30mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色固体42-3(310.0mg,收率59.2%)。LC-MS m/z(ESI):193.1[M+H]+。
42.4中间体42-4的合成
将戴斯-马丁氧化剂(1.0g)加入到化合物42-3(310.0mg)的二氯甲烷(5mL)溶液中,室温搅拌2小时。加入水(50mL),二氯甲烷(30mL×3)萃取,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩得黄色固体42-4(150.0mg,收率49.2%)。LC-MS m/z(ESI):209.1[M+H]+。
42.5中间体42-5的合成
将三乙胺(221.0mg)加入到1-2-嘧啶乙胺盐酸盐(349.0mg)的1,2-二氯乙烷(5mL)溶液中,室温搅拌0.5小时。加入42-4(150.0mg)和醋酸(102.0mg),室温搅拌1小时。加入三乙酰氧基硼氢化钠(721.6mg),室温搅拌30分钟。加入水(30mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色油状物42-5(90.0mg,收率58.0%)。LC-MS m/z(ESI):298.1[M+H]+。
42.6中间体42-6的合成
将化合物42-5(50.0mg),1-丙基磷酸酐(113.0mg)和N,N-二异丙基乙胺(38.0mg)加入到化合物1-4(150.0mg)的N,N-二甲基甲酰胺(3mL)溶液中,室温搅拌2小时。加入水(30mL),乙酸乙酯(20mL×3)萃取,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色固体42-6(50.0mg,收率25.6%)。LC-MS m/z(ESI):675.1[M+H]+。
42.7化合物42的合成
将三氟乙酸(1mL)加入到化合物42-6(50.0mg)的二氯甲烷(4mL)溶液中,室温搅拌1小时。减压浓缩,加入水(10mL),用饱和碳酸氢钠溶液调节pH至弱碱性,二氯甲烷(10mL×3)萃取,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经高效液相色谱(柱:Gemini 5u C18 150 x 21.2mm;流动相:[water(FA)-ACN];B%:2%-15%,15min)纯化得白色固体42的甲酸盐(4.0mg,产率12.3%)。LC-MS m/z(ESI):475.0[M+H]+。1H NMR(400MHz,CD3OD-d4)δppm 8.74-8.67(m,2H),8.08-8.06(m,1H),7.81-7.59(m,1H),7.62-7.52(m,2H),7.28-7.25(m,1H),6.95-6.75(m,1H),5.85-5.75(m,1H),5.75-4.95(m,2H),4.46-4.26(m,2H),4.02-3.78(m,2H),2.82-2.58(m,2H),2.25-2.13(m,3H),1.65-1.78(m,3H).
43.实施例43的合成
43.1中间体43-1的合成
将化合物30-7(22.0mg),1-丙基磷酸酐(73.0mg)和N,N-二异丙基乙胺(45.0mg)加入到化合物
15-1(50.0mg)的N,N-二甲基甲酰胺(3mL)溶液中,室温搅拌2小时。加入水(30mL),乙酸乙酯(30mL×3)萃取,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色固体43-1(46.0mg,收率62.2%)。LC-MS m/z(ESI):648.0[M+H]+。
43.2化合物43的合成
将三氟乙酸(1mL)加入到化合物43-1(46.0mg)的二氯甲烷(4mL)溶液中,室温搅拌1小时。减压浓缩,加入水(10mL),用饱和碳酸氢钠溶液调节pH至弱碱性,二氯甲烷(10mL×3)萃取,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经高效液相色谱(柱:Gemini 5u C18 150 x 21.2mm;流动相:[water(NH3)-ACN];B%:10%-40%,15min)纯化得白色固体43(8.0mg,产率25.8%)。LC-MS m/z(ESI):448.0[M+H]+。1H NMR(400MHz,CD3OD-d4)δppm 8.94-8.53(m,1H),8.35-8.25(m,1H),8.24-7.82(m,1H),7.76-7.53(m,2H),5.32-5.07(m,2H),4.49-4.26(m,3H),3.74-3.28(m,2H),1.26-1.03(m,1H),0.52-0.35(m,2H),0.28-0.19(m,2H).
44.实施例44的合成
44.1中间体44-1的合成
氮气氛围室温下,将1-丙基磷酸酐(90.0mg,50%乙酸乙酯溶液)加入到N,N-二异丙基乙胺(27.0mg),30-7(30.0mg)和19-1(20.0mg)的N,N-二甲基甲酰胺(2mL)溶液中,室温搅拌16小时。加入乙酸乙酯(30mL)稀释,用饱和氯化钠溶液(20mL×3)洗涤,有机相用无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=100/1-30/1)纯化得类白色固体44-1(28.0mg,收率58.3%)。LC-MS m/z(ESI):705.0[M+H]+。
44.2化合物44的合成
冰浴氮气氛围下,将三氟乙酸(1mL)加入44-1(28.0mg)的二氯甲烷(4mL)溶液中。室温搅拌1小时,减压浓缩。残余物经高效液相色谱(柱:Xbridge-C18 150×19mm,5um;流动相:ACN--H2O(0.05%NH4OH);B%:10%-40%,13min)纯化得白色固体44(10.0mg,收率50.1%)。LC-MS m/z(ESI):505.1[M+H]+。1H NMR(400MHz,MeOD-d4)δppm 8.95-8.82(m,1H),8.70(d,J=12.0Hz,1H),8.05-7.88(m,2H),7.77-7.67(m,1H),7.62-7.55(m,1H),7.46-7.36(m,1H),6.16-5.75(m,1H),5.04-4.60(m,2H),4.36-4.31(m,3H),1.78-1.60(m,3H).
45.实施例45-P1和45-P2的合成
45.1化合物45-P1和45-P2的合成
将化合物8(70.0mg)经SFC(柱:CHIRALPAK AD-H 250×20mm,5um;流动相:40%IPA(0.2%NH4OH))拆分得白色固体45-P1(25.8mg,收率36.8%)。LC-MS m/z(ESI):410.2[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.50-10.24(m,1H),8.92-8.85(m,1H),8.23-8.15(m,1H),8.04-7.85(m,1H),7.70-7.55(m,1H),7.51-7.27(m,1H),5.68-5.60(m,2H),4.99-4.54(m,2H),4.40-3.93(m,1H),2.05-1.96(m,3H),1.66-1.44(m,2H),1.17-1.03(m,3H),0.84-0.77(m,3H);
得白色固体45-P2(29.5mg,收率42.1%)。LC-MS m/z(ESI):410.2[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.57-10.32(m,1H),8.91-8.85(m,1H),8.23-8.15(m,1H),8.07-7.89(m,1H),7.70-7.55(m,1H),7.55-7.34(m,1H),5.89(s,2H),5.00-4.54(m,2H),4.39-3.93(m,1H),2.06-1.98(m,3H),1.66-1.44(m,2H),1.17-1.03(m,3H),0.84-0.77(m,3H).
46.实施例159的合成
46.1中间体159-1的合成
将浓硫酸(1.0mL)加入到2-氯-6-三氟甲基烟酸(5.0g)的乙醇(50mL)溶液中,80℃搅拌10
小时,加入水(100mL)稀释,乙酸乙酯(200mL×3)萃取,有机相用饱和碳酸氢钠溶液(100mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=5/1)纯化得无色油状物159-1(5.0g,收率88.9%)。LC-MS m/z(ESI):254.0[M+H]+。
46.2中间体159-2的合成
0℃下,依次将氢化钠(1.5g,60%wt)和乙醇酸乙酯(2.2g)加入到159-1(4.5g)的乙二醇二甲醚(50mL)溶液中,室温搅拌10小时,加入水(100mL)稀释,乙酸乙酯(50mL×3)萃取,有机相用饱和氯化钠(50mL)溶液洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色固体159-2(4.0g,收率81.8%)。LC-MS m/z(ESI):276.1[M+H]+。
46.3中间体159-3的合成
将盐酸(10mL,2M)加入到化合物159-2(2.0g)的异丙醇(30mL)溶液中,80℃搅拌16小时。减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得白色固体159-3(0.5g,收率33.7%)。LC-MS m/z(ESI):204.0[M+H]+。
46.4中间体159-4的合成
0℃下,将硼氢化钠(1.0g)缓慢加入到化合物159-3(0.5g)的甲醇(10mL)溶液中,室温搅拌1小时。加入水(50mL),乙酸乙酯(50mL×3)萃取,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得淡黄色固体159-4(0.4g,收率79.2%),LC-MS m/z(ESI):206.1[M+H]+。
46.5中间体159-5的合成
0℃下,将4-硝基苯磺酰胺(0.5g),三苯基膦(0.8g)和偶氮二甲酸二异丙酯(0.5g)加入到化合物159-4(0.4g)的四氢呋喃(10mL)溶液中,室温搅拌5小时,加入水(30mL),乙酸乙酯(30mL×3)萃取,有机相用饱和氯化钠(30mL)溶液洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=30/1)纯化得白色固体159-5(0.2g,收率28.0%),LC-MS m/z(ESI):404.0[M+H]+。
46.6中间体159-6的合成
将碳酸钾(200.0mg)和十二硫醇(200.0mg)加入到化合物159-5(220.0mg)的乙腈溶液(10mL)中,80℃搅拌16小时。冷却至室温,加入(30mL),乙酸乙酯(30mL×3)萃取,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得白色固体159-6(80.0mg,67.2%)。LC-MS m/z(ESI):219.1[M+H]+。
46.7中间体159-7的合成
将中间体30-7(80.0mg),N,N,N',N'-四甲基氯甲脒六氟磷酸盐(100.0mg)和N-甲基咪唑(100.0mg)加入到化合物159-6(50.0mg)的乙腈(5mL)溶液中,室温搅拌4小时。加入水(50mL),乙酸乙酯(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得白色固体159-7(40.0mg,收率27.5%)。LC-MS m/z(ESI):636.2[M+H]+。
46.8化合物159的合成
将HCl的二氧六环溶液(4mL,4M)加入到中间体159-7(40.0mg)的二氯甲烷(2mL)溶液中,室温搅拌5小时。减压浓缩,残余物经高效液相色谱(柱:Gemini 5u C18 150 x 21.2mm;流动相:ACN--H2O(0.05%FA);B%:5%-50%,30min)纯化得白色固体159的甲酸盐(13.5mg,产率69.3%)。
LC-MS m/z(ESI):436.2[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.88-10.80(m,1H),8.15-7.81(m,3H),7.59-7.51(m,1H),6.27(s,2H),6.24-5.95(m,1H),4.94-4.84(m,1H),4.78-4.73(m,1H),4.27(s,3H),2.90-2.63(m,3H).
47.实施例160的合成
47.1中间体160-1的合成
将甲胺的四氢呋喃溶液(22.0mL,2.0M)加入到7-溴异色满-4-酮(2.0g)和醋酸(1.1g)的1,2-二氯乙烷(40mL)溶液中,室温搅拌2小时。加入三乙酰氧基硼氢化钠(3.7g),升温至40℃搅拌16小时。加入水(100mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(100mL×3)萃取,有机相用饱和氯化钠溶液(100mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色液体160-1(1.0g,收率46.9%)。LC-MS m/z(ESI):242.1,244.1[M+H]+。
47.2中间体160-2的合成
将160-1(100.0mg)加入到1-甲基-1,2,3,6-四氢吡啶-4-硼酸频哪醇酯(111.0mg),碳酸钾(115.0mg)和四三苯基膦钯(48.0mg)的1,4-二氧六环(4mL)和水(1mL)混合溶液中,氮气保护下,100℃搅拌3小时。冷却至室温,加入水(30mL),二氯甲烷(30mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1-30/1)纯化得黄色液体160-2(50.0mg,收率47.2%)。LC-MS m/z(ESI):259.2[M+H]+。
47.3中间体160-3的合成
将N,N,N',N'-四甲基氯甲脒六氟磷酸盐(217.0mg)加入到N-甲基咪唑(48.0mg),30-7(84.0mg)和160-2(50.0mg)的乙腈溶液(3mL)中,室温搅拌2小时。加入水(30mL),乙酸乙酯(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=10/1-5/1)纯化得黄色液体160-3(80.0mg,收率61.2%)。
LC-MS m/z(ESI):676.4[M+H]+。
47.4化合物160的合成
冰浴下,将HCl的二氧六环溶液(4mL,4M)加入160-3(80.0mg)的二氧六环溶液(1mL)中,室温搅拌2小时。减压浓缩,残余物用饱和碳酸钠溶液调节pH=8,二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,过滤减压浓缩,残余物经高效液相色谱(柱:Xbridge-C18 150 x 19mm,5um;流动相:ACN--H2O(0.1%FA);B%:5%-10%,20min)纯化得白色固体160的甲酸盐(38.0mg,收率67.5%)。LC-MS m/z(ESI):476.0[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.88-10.64(m,1H),7.99-7.83(m,2H),7.50-7.19(m,3H),6.25(s,2H),6.23-6.17(m,1H),5.56-4.86(m,1H),4.85-4.76(m,1H),4.70-4.57(m,1H),4.32-4.24(m,3H),4.16-3.96(m,2H),3.16-3.05(m,2H),2.81-2.66(m,3H),2.65-2.11(m,2H),2.55-2.51(m,2H),2.40-2.28(m,3H).
48.实施例163(163-P1和163-P2)的合成
48.1中间体163-1的合成
将硼烷的四氢呋喃溶液(10.0mL)滴加入到2-溴-4,5-二氯苯甲酸(1.0g)的四氢呋喃溶液(10mL)中。氮气保护下,50℃搅拌3小时。冷却至室温,缓慢加入水(10mL),用二氯甲烷(25mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1-10/1)纯化得白色固体163-1(800.0mg,收率84.4%)。1H NMR(400MHz,DMSO-d6)δppm 7.94(s,1H),7.66(s,1H),5.68(t,J=5.6Hz,1H),4.47(d,J=5.6Hz,2H).
48.2中间体163-2的合成
冰浴下,将氢化钠(250.0mg)加入到163-1(800.0mg)的四氢呋喃溶液(10mL)中。搅拌0.5
小时,加入3-溴丙烯(760.0mg),室温搅拌过夜。向反应液中加入水(10mL),用乙酸乙酯(20mL×3)萃取,有机相用饱和氯化钠溶液(15mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=20/1-10/1)纯化得无色油状物163-2(500mg,收率54.0%)。1H NMR(400MHz,DMSO-d6)δppm 8.00(s,1H),7.67(s,1H),6.06-5.84(m,1H),5.33(d,J=17.2Hz,1H),5.21(d,J=10.0Hz,2H),4.48(s,2H),4.10(d,J=4.0Hz,2H).
48.3中间体163-3的合成
将碳酸铯(2.2g),三苯基磷(184.0mg)和醋酸钯(84.0mg)加入到163-2(1.0g)的N,N-二甲基甲酰胺溶液(10mL)中,氮气保护下,90℃搅拌12小时。冷却至室温。向反应液中加入水(20mL),用乙酸乙酯(25mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=20/1-10/1)纯化得黄色液体163-3(300.0mg,收率41.2%)。1H NMR(400MHz,DMSO-d6)δppm 8.06(s,1H),7.46(s,1H),5.87(s,1H),5.16(s,1H),4.71(s,2H),4.37(s,2H).
48.4中间体163-4的合成
冰浴下,将臭氧通入到163-3(600.0mg)的二氯甲烷(5mL)和甲醇(5mL)溶液中,搅拌20分钟。向反应液中加入二甲硫醚(1mL),用乙酸乙酯(10mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=20/1-10/1)纯化得白色固体163-4(400.0mg,收率66.1%)。1H NMR(400MHz,DMSO-d6)δppm8.01(s,1H),7.79(s,1H),4.89(s,2H),4.39(s,2H).
48.5中间体163-5的合成
将硼氢化钠(133.0mg)加入到163-4(400.0mg)的甲醇(5mL)溶液中,室温搅拌2小时。向反应液中加入水(10mL),用二氯甲烷(15mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1-10/1)纯化得白色固体163-5(300.0mg,收率74.3%)。1H NMR(400MHz,DMSO-d6)δppm 7.63(s,1H),7.40(s,1H),5.60(s,1H),4.69-4.52(m,3H),3.90-3.86(m,1H),3.61-3.56(m,1H).
48.6中间体163-6的合成
将三苯基磷(468.0mg),N-甲基-4-硝基苯磺酰胺(300.0mg)加入到163-5(300.0mg)的四氢呋喃溶液(5mL)中,冰浴下滴加偶氮二甲酸二异丙酯(420.0mg),升至室温搅拌2小时。加入水(10mL),用乙酸乙酯(15mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=20/1-10/1)纯化得白色固体163-6(300.0mg,收率52.4%)。1H NMR(400MHz,DMSO-d6)δppm 8.45-8.42(m,2H),8.18-8.15(m,2H),7.47(s,1H),6.98(s,1H),5.00(t,J=3.6Hz,1H),4.69(d,J=15.6Hz,1H),4.47(d,J=15.6Hz,1H),3.72-3.61(m,2H),2.61(s,3H).
48.7中间体163-7的合成
将碳酸钾(300.0mg)和正十二硫醇(1.4g)加入到163-6(300.0mg)的乙腈溶液(10mL)中,85℃搅拌12小时。冷却至室温,向反应液中加入水(20mL),用二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(15mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1-10/1)纯化得无色油状物163-7(80.0mg,收率48.0%)。LC-MS m/z(ESI):231.9[M+H]+。
48.8中间体163-8的合成
将1-丙基磷酸酐(440.0mg)加入30-7(152.0mg),N,N-二异丙基乙胺(96.0mg)和163-7(80.0mg)的N,N-二甲基甲酰胺溶液(1mL)中。室温搅拌12小时。向反应液中加入水(5mL),用乙酸乙酯(10mL×3)萃取,有机相用饱和氯化钠溶液(5mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=2/1-1/1)纯化得黄色固体163-8(110.0mg,收率49.0%)。LC-MS m/z(ESI):649.2[M+H]+。
48.9化合物163-P1和163-P2的合成
冰浴下,将HCl的1,4-二氧六环溶液(5mL,4M)加入到163-8(110.0mg)的二氯甲烷溶液(5mL)中。室温搅拌2小时,饱和碳酸钠溶液调节pH=8,二氯甲烷(10mL×3)萃取,减压浓缩,残余物经高效液相色谱(柱:Xbridge-C18 150 x 19mm,5um;流动相:ACN--H2O(0.1%FA);B%:5%-10%,20min)纯化得白色固体(56.1mg,收率73.7%),再通过SFC(柱:CHIRALPAK IC 250mm x 20mm,5um;流动相:ETOH(NH4OH 0.2%);B%:40%EtOH,19min)拆分得到白色固体163-P1(ee值=100%,21.19mg,RT=2.68min,收率38.5%,其为R异构体或S异构体).LC-MS m/z(ESI):448.8[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.87-10.71(m,1H),8.00-7.94(m,2H),7.84-7.77(m,1H),7.54-7.51(m,1H),6.30(s,2H),5.55-4.87(m,2H),4.64-4.55(m,1H),4.28-4.26(m,3H),4.10-4.04(m,2H),2.82-2.70(m,3H);得白色固体163-P2(ee值=99.3%,23.68mg,RT=4.9min,收率43.1%,其为S异构体或R异构体).LC-MS m/z(ESI):448.9[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.85-10.69(m,1H),7.99-7.93(m,2H),7.83-7.77(m,1H),7.54-7.51(m,1H),6.25(s,2H),5.55-4.77(m,2H),4.64-4.55(m,1H),4.27-4.26(m,3H),4.09-4.05(m,2H),2.83-2.70(m,3H).
49.实施例173的合成
49.1中间体173-1的合成
0℃下,将氢化钠(0.9g,60%wt)加到4-溴-7-氯-1H-吡唑并[3,4-c]吡啶(3.5g)的N,N-二甲基甲酰胺溶液(40mL)中,搅拌1小时,滴加氘代碘甲烷(2.6g),升至室温,搅拌2小时,加入水(200mL),乙酸乙酯(50mL×3)萃取,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=5/1)纯化得白色固体173-1(2.1g,收率55.6%)。LC-MS m/z(ESI):248.8,250.8[M+H]+。
49.2中间体173-2的合成
将碳酸钠(1.8g),对4-甲氧基苄胺(1.7g)加到173-1(2.1g)的N-甲基吡咯烷酮溶液(20mL)中,130℃搅拌2小时。冷却至室温,加入水(100mL),乙酸乙酯(30mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=5/1)纯化得白色固体173-2(2.5g,收率70.6%)。LC-MS m/z(ESI):350.0,352.0[M+H]+。
49.3中间体173-3的合成
将173-2(2.5g)加入到三氟乙酸(30mL)溶液中,80℃搅拌16小时。冷却至室温,减压浓缩,加入饱和碳酸氢钠水溶液(60mL),过滤得白色固体173-3(2.2g),粗品直接用于下一步反应。LC-MS m/z(ESI):227.9,229.9[M+H]+。
49.4中间体173-4的合成
将三乙胺(3.9g),4-二甲氨基吡啶(240mg),二碳酸二叔丁酯(5.3g)加到173-3(2.2g)的二氯甲烷(50mL)溶液中,40℃搅拌16小时。冷却至室温,加入水(100mL),二氯甲烷(50mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=5/1)纯化得黄色固体174-4(1.2g,两步收率28.9%)。LC-MS m/z(ESI):429.9,431.9[M+H]+。
49.5中间体173-5的合成
将二苯甲酮亚胺(0.8g),碳酸铯(1.8g),1,1'-联萘-2,2'-双二苯膦(0.4g),三(二亚苄基丙酮)二钯(0.3g)加到173-4(1.2g)的甲苯(20mL)溶液中,100℃搅拌16小时。冷却至室温,减压浓缩,加入水(60mL),乙酸乙酯(30mL×3)萃取,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=3/1)纯化得黄色固体173-5(1.3g,收率73.9%)。LC-MS m/z(ESI):531.0[M+H]+。
49.6中间体173-6的合成
0℃下,将盐酸(5mL,2M)滴加到173-5(1.3g)的甲醇溶液(15mL)中,室温搅拌2小时。加入饱和碳酸氢钠溶液,调pH至弱碱性,二氯甲烷(50mL×3)萃取,有机相用饱和氯化钠溶液(50mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=1/2)纯化得黄色固体173-6(0.7g,收率89.5%)。LC-MS m/z(ESI):367.0[M+H]+。
49.7中间体173-7的合成
将硼氢化钠(56.1mg)加入6-三氟甲基苯并呋喃-3(2H)-酮(200.0mg)的甲醇溶液(3mL)中,室温搅拌2小时。向反应液中加入水(10mL),二氯甲烷(10mL×3)萃取,有机相用饱和氯化钠溶液(5mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=1/2)纯化得白色固体173-7(150.0mg,收率66.8%)。
49.8中间体173-8的合成
冰浴下,将偶氮二羧酸二异丙酯(128.7mg)加入173-7(100.0mg),4-硝基-N-甲基-苯磺酰胺(127.1mg)和三苯基磷(167.0mg)的四氢呋喃溶液(3mL)中。氮气保护下,升至室温搅拌3小时。向反应液中加入水(5mL),二氯甲烷(10mL×3)萃取,有机相用饱和氯化钠溶液(10mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=4/1)纯化得白色固体173-8(60.0mg,收率27.4%)。
49.9中间体173-9的合成
将173-8(280.0mg),碳酸钾(384.7mg)和正十二硫醇(563.4mg)加入到乙腈(2mL)溶液中,80℃搅拌4小时。冷却至室温。加入水(5mL),乙酸乙酯(5mL×3)萃取,有机相用饱和氯化钠(5mL)洗涤。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1-10/1)纯化得黄色固体173-9(100.0mg,收率52.9%)。
49.10中间体173-9-P1的合成
173-9(400.0mg)经手性相色谱(柱:chiralpak AD-H 250 x 20mm,5um;流动相:40%MeOH
(0.2%NH4OH)纯化得黄色油状物173-9-P1(220.0mg,RT=1.85min,收率55.0%)。
49.11中间体173-10的合成
冰浴下,将单草酰氯乙酯(408.6mg)加入到173-9-P1(500.0mg)和三乙胺(349.4mg)的二氯甲烷(5.0mL)溶液中,升至室温搅拌2小时。加入水(5.0mL),分液后有机相用饱和氯化钠溶液(2mL)洗涤。无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经柱层析(二氧化硅,石油醚/乙酸乙酯=3/1)纯化得黄色油状物173-10(500.0mg,收率68.5%)。LC-MS m/z(ESI):340.1[M+H]+。
49.12中间体173-11的合成
将氢氧化锂(49.1mg)加入到173-10(500.0mg)的甲醇(3.0mL)和水(1.0mL)混合溶液中。25℃搅拌1小时,稀盐酸调节pH=6,二氯甲烷(10mL×3)萃取,无水硫酸钠干燥,过滤,滤液减压浓缩得无色油状物粗品173-11(400.0mg)。粗品未经纯化直接用于下一步反应。LC-MS m/z(ESI):288.0[M-H]-。
49.13中间体173-12的合成
将N,N,N,N-四甲基氯甲脒六氟磷酸盐(776.1mg)和N-甲基咪唑(397.4mg)加入到173-11(400.0mg)和173-6(502.6mg)的乙腈(10mL)溶液中,25℃搅拌2小时。加入水(20mL),乙酸乙酯(15mL×3mL)萃取,有机相用饱和氯化钠溶液(5mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1-10/1)纯化得棕色固体173-12(620.0mg,收率63.6%)。LC-MS m/z(ESI):634.9[M+H]+。
49.14化合物173的合成
将173-12(640.0mg)加入HCl的二氧六环溶液(8mL,4M)中。室温搅拌2小时,饱和碳酸钠溶液调节pH=8,二氯甲烷(5mL×3)萃取,减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1-10/1)纯化得灰白色固体173(320.0mg,收率72.3%)。LC-MS m/z(ESI):438.1[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.92-10.59(m,1H),8.01-7.81(m,2H),7.72-7.52(m,1H),7.39-7.33(m,1H),7.30-7.24(m,1H),6.44-6.32(m,2H),6.30-5.79(m,1H),4.85-4.64(m,2H),2.78-2.58(m,3H).
50.实施例211的合成
50.1中间体211-1的合成
将甲胺四氢呋喃溶液(5.0mL,2.0M)加入到4-溴-2-羟基苯甲醛(1.0g)和无水硫酸镁(3.0g)的二氯甲烷(20mL)溶液中,室温搅拌16小时。过滤,滤液减压浓缩得黄色固体211-1(0.6g),粗品直接用于下一步。
50.2中间体211-2的合成
将叔丁醇钾(1.4g)加入到三甲基碘化亚砜(2.7g)的四氢呋喃溶液(20mL)中,室温搅拌30分钟。向反应液中加入化合物211-1(0.6g)的四氢呋喃(5mL)溶液,升温至50℃搅拌3小时。冷却至室温,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1)纯化得黄色油状物211-2(260.0mg,收率29.2%)。
50.3中间体211-3的合成
在冰浴下,将单草酰氯甲酯(168.0mg)加入到化合物211-2(260.0mg)和三乙胺(173.0mg)的二氯甲烷溶液(5mL)中,升至室温搅拌2小时。加入水(30mL),二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=5/1)纯化得黄色油状211-3(240.0mg,收率66.9%)。
50.4中间体211-3-P2的合成
中间体211-3(6.0g)经手性柱(柱:CHIRALPAK AS-H 250mm×20mm,5μm;流动相:40%EtOH(NH4OH 0.2%):60%CO2)拆分得白色固体211-3-P2(2.6g,RT=3.22min,ee值=97.54%,收率43.3%)。
50.5中间体211-4的合成
将[1,1'-双(二苯基膦)二茂铁]二氯化钯(46.0mg)和碳酸钠(135.0mg)加入到化合物211-3-P2
(200.0mg)和1-环丙基吡唑-4-硼酸频醇酯(224.0mg)的1,4-二氧六环和水(5mL,v/v=4:1)混合溶液中,氮气保护下,90℃搅拌2小时。冷却至室温,过滤,滤液用氢氧化钠溶液(30mL,0.5M)稀释,乙醚(30mL×3)洗涤。水相用盐酸溶液(1M)调节pH至弱酸性,二氯甲烷(30mL×3)萃取,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩并冻干得黄色固体211-4(150mg),粗品直接用于下一步。LC-MS m/z(ESI):328.0[M+H]+。
50.6中间体211-5的合成
将N,N,N',N'-四甲基氯甲脒六氟磷酸盐(171.0mg)和N-甲基咪唑(88.0mg)加入到化合物211-4(100.0mg)和化合物30-5(133.0mg)的无水N,N-二甲基甲酰胺溶液(3mL)中,室温搅拌16小时。加入水(30mL),乙酸乙酯(30mL×3)萃取,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=1/2)纯化得黄色固体211-5(140.0mg,收率68.0%)。LC-MS m/z(ESI):673.4[M+H]+。
50.7化合物211的合成
将甲酸(4mL)加入到化合物211-5(130.0mg)的二氯甲烷溶液(1mL)中,室温搅拌16小时。减压浓缩,加入水(30mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(30mL×3)萃取,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=10/1)纯化得白色固211(35.0mg,收率31.5%)。LC-MS m/z(ESI):473.0[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.78-10.62(m,1H),8.26-8.25(m,1H),8.04-7.83(m,3H),7.42-7.28(m,1H),7.24-7.21(m,1H),7.16-7.14(m,1H),6.24(s,2H),6.22-5.70(m,1H),4.75-4.67(m,1H),4.61-4.53(m,1H),4.28(s,3H),3.74-3.70(m,1H),2.72-2.60(m,3H),1.08-1.04(m,2H),1.00-0.95(m,2H).
51.实施例212的合成
51.1中间体212-1的合成
将[1,1'-双(二苯基膦)二茂铁]二氯化钯(46.0mg)和碳酸钠(135.0mg)加入到化合物211-3-P2(200.0mg)和1-环丙基吡唑-5-硼酸频哪醇酯(224.0mg)的1,4-二氧六环和水(v/v=4:1,5mL)混合溶液中,氮气保护,升温至90℃搅拌2小时。冷却至室温,过滤,滤液用氢氧化钠溶液(30mL,0.5M)稀释,乙醚(30mL×3)洗涤。水相用盐酸溶液(1M)调节pH至弱酸性,二氯甲烷(30mL×3)萃取,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩并冻干得黄色固体粗品212-1(130.0mg),粗品直接用于下一步反应。LC-MS m/z(ESI):328.0[M+H]+。
51.2中间体212-2的合成
将N,N,N',N'-四甲基氯甲脒六氟磷酸盐(171.0mg)和N-甲基咪唑(88.0mg)加入到化合物212-1(100.0mg)和化合物30-5(133.0mg)的无水N,N-二甲基甲酰胺溶液(3mL)中,室温搅拌16小时。加入水(30mL),乙酸乙酯(30mL×3)萃取,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠
干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=1/2)纯化得黄色固体212-2(130.0mg,收率63.1%)。LC-MS m/z(ESI):673.3[M+H]+。
51.3化合物212的合成
将甲酸(4mL)加入到化合物212-2(120.0mg)中,室温搅拌16小时。减压浓缩,加入水(30mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(30mL×3)萃取,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=10/1)纯化得白色固212(35.0mg,收率41.5%)。LC-MS m/z(ESI):473.0[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.82-10.64(m,1H),8.05-7.83(m,2H),7.59-7.40(m,2H),7.30-7.25(m,1H),7.21-7.16(m,1H),6.46-6.42(m,1H),6.34-5.80(m,3H),4.82-4.73(m,1H),4.70-4.59(m,1H),4.28(s,3H),3.80-3.70(m,1H),2.77-2.62(m,3H),1.01-0.85(m,4H).
52.实施例213的合成
52.1中间体213-1的合成
将[1,1'-双(二苯基膦)二茂铁]二氯化钯(46.0mg)和碳酸钠(135.0mg)加入到化合物211-3-P2(200.0mg)和4-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-1-(三氟甲基)-1H-吡唑(251.0mg)的1,4-二氧六环和水(v/v=4:1,5mL)混合溶液中,氮气保护,90℃搅拌2小时。冷却至室温,过滤,滤液用氢氧化钠溶液(30mL,0.5M)稀释,乙醚(30mL×3)洗涤。水相用盐酸溶液(1M)调节pH至弱酸性,二氯甲烷(30mL×3)萃取,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩并冻干得黄色固体213-1(150.0mg)粗品,直接用于下一步。LC-MS m/z(ESI):355.9[M+H]+。
52.2中间体213-2的合成
将N,N,N',N'-四甲基氯甲脒六氟磷酸盐(157.0mg)和N-甲基咪唑(81.0mg)加入到化合物213-1(100.0mg)和化合物30-5(122.0mg)的无水N,N-二甲基甲酰胺溶液(3mL)中,室温搅拌16小时。加入水(30mL),乙酸乙酯(30mL×3)萃取,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=1/2)纯化得黄色固体213-2(140.0mg,收率63.1%)。LC-MS m/z(ESI):701.3[M+H]+。
52.3化合物213的合成
将甲酸(4mL)加入到化合物213-2(120.0mg)中,室温搅拌16小时。减压浓缩,加入水(30mL),用饱和碳酸钠溶液调节pH至弱碱性,二氯甲烷(30mL×3)萃取,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=10/1)纯化得白色固体213(42.0mg,收率49.0%)。LC-MS m/z(ESI):500.9[M+H]+。1H NMR(400MHz,DMSO-d6)δppm 10.81-10.62(m,1H),9.02-8.99(m,1H),8.48(s,1H),8.04-7.82(m,2H),7.52-7.33(m,3H),6.27-5.73(m,3H),4.79-4.69(m,1H),4.66-4.56(m,1H),4.28(s,3H),2.74-2.59(m,3H).
53.实施例233的合成
53.1中间体233-1的合成
化合物211-2(2.0g)经手性柱(柱:CHIRALPAK AS-H 250mm×20mm,5μm;流动相:40%MeOH(NH4OH 0.2%):60%CO2)拆分得白色固体233-1(0.8g,RT=3.26min,ee值=99.15%,收率40.0%)。
53.2中间体233-2的合成
将233-1(100.0mg),三甲基硼氧六环(200.0mg)和碳酸铯(515.0mg)加入到1,1'-双二苯基膦二茂铁二氯化钯(38.0mg)的二氧六环(5mL)和水(1mL)混合溶液中。氮气保护下,100℃搅拌16小时。减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=10/1-5/1)纯化得油状液体233-2(60.0mg,收率83.3%)。
53.3中间体233-3的合成
冰浴下,将正丙基膦酸酐(120.0mg)和N,N-二异丙基乙胺(75.0mg)加入到233-2(60.0mg)和30-7(70.0mg)的N,N-二甲基甲酰胺溶液(3mL)中。升至室温搅拌1小时,加入水(10mL),乙酸乙酯(10mL×3)萃取,有机相用饱和氯化钠溶液(5mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1-10/1)纯化得黄色固体233-3(80.0mg,收率37.6%)。LC-MS m/z(ESI):581.3[M+H]+。
53.4化合物233的合成
冰浴下,将溴化锌(130.0mg)加入233-3(80.0mg)的二氯甲烷溶液(3mL)中。升至室温搅拌2小时,过滤,减压浓缩。残余物经高效液相色谱(柱:Xbridge-C18 150×19mm,5um;流动相:ACN--H2O(0.1%NH4OH);B%:5%-10%,20min)纯化得白色固体233(27.3mg,收率51.9%)。LC-MS m/z(ESI):381.0[M+H]+。1H NMR(400MHz,DMSO-d6,80℃)δppm 10.75-10.59(m,1H),8.16-8.09(m,1H),7.98-7.89(m,1H),7.31-7.19(m,1H),6.87-6.71(m,4H),6.18-5.73(m,1H),4.64-4.61(m,1H),4.56-4.49(m,1H),4.32(s,3H),2.72-2.60(m,3H),2.32-2.29(m,3H).
54.实施例235的合成
54.1中间体235-1的合成
冰浴下,将氯甲酸苄酯(418.0mg)加入到160-1(500.0mg)和三乙胺(309.0mg)的二氯甲烷(5mL)溶液中,0℃搅拌2小时。加入水(50mL),二氯甲烷(30mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=5/1-2/1)纯化得黄色液体235-1(600.0g,收率77.1%)。LC-MS m/z(ESI):376.0[M+H]+。
54.2中间体235-1-P1的合成
将235-1(500.0mg)通过SFC(column:CHIRALPAK IC 250mm×4.6mm,5μm;mobile phase:i-PrOH(NH4OH 0.2%);B%:60%CO2,3mL/min)拆分,得到白色化合物235-1-P1(ee=98.29%,200.0mg,收率40.0%,Rt=3.04min)。
54.3中间体235-2的合成
将氢溴酸溶液(5mL,33%wt in HAc)加入到235-1-P1(150.0mg)中,室温搅拌5小时。减压浓缩,残余物用饱和碳酸钠溶液调节pH=8,二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,过滤减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=20/1-10/1)纯化得黄色液体235-2(50.0mg,收率:52.1%)。LC-MS m/z(ESI):242.0,244.0[M+H]+。
54.4中间体235-3的合成
将四三苯基膦钯(20.0mg),碳酸钾(56.0mg)加入到235-2(50.0mg)和2-环丙基-5-吡啶硼酸酯(55.0mg)的1,4-二氧六环和水混合溶液(15mL,v/v=4:1)中,氮气保护下,90℃搅拌2小时。冷却至室温,减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=50/1-20/1)纯化得黄色液体235-3(40.0mg,收率:68.9%)。LC-MS m/z(ESI):281.1[M+H]+。
54.5中间体235-4的合成
将N,N,N',N'-四甲基氯甲脒六氟磷酸盐(78.0mg)加入到N-甲基咪唑(32.0mg),30-7(60.0mg)和235-3(40.0mg)的N,N-二甲基甲酰胺(3mL)溶液中,室温搅拌2小时。加入水(30mL),乙酸乙酯(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=10/1-5/1)纯化得黄色液体235-4(40.0mg,收率40.4%)。LC-MS m/z(ESI):698.1[M+H]+。
54.6化合物235的合成
冰浴下,将无水甲酸(4mL)加入235-4(40.0mg)的二氯甲烷溶液(1mL)中,室温搅拌2小时。减压浓缩,残余物用饱和碳酸钠溶液调节pH=8,二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,过滤减压浓缩,残余物经高效液相色谱(柱:Xbridge-C18150 x 19mm,5um;流动相:ACN--H2O(0.1%FA);B%:5%-10%,20min)纯化得白色固体235的甲酸盐(21.4mg,收率73.7%)。LC-MS m/z(ESI):498.0[M+H]+。1H NMR(400MHz,DMSO-d6,353K)δppm10.69-10.41(m,1H),8.71(s,1H),8.01-7.80(m,3H),7.70-7.29(m,4H),6.01(s,2H),5.66-5.02(m,1H),4.96-4.83(m,1H),4.80-4.65(m,1H),4.31-4.25(m,3H),4.20-4.03(m,2H),2.92-2.70(m,3H),2.19-2.10(m,1H),1.02-0.93(m,4H).
55.实施例236的合成
55.1中间体236-1的合成
将[1,1'-双(二苯基膦)二茂铁]二氯化钯(200.0mg),乙酸钾(720.0mg)和联硼酸频哪醇酯(750.0mg)加入到5-溴-2-环丙基噻唑(500.0mg)的无水1,4-二氧六环溶液(15mL)中,氮气保护下,90℃搅拌16小时。冷却至室温,过滤,滤液减压浓缩得黄色液体236-1(250.0mg),粗品直接用于下一步反应。LC-MS m/z(ESI):170.1[M-81]+。
55.2中间体236-2的合成
将四三苯基膦钯(115.0mg),碳酸钾(206.0mg)加入到236-1(250.0mg)和211-3-P2(300.0mg)的1,4-二氧六环和水混合溶液(15mL,v/v=4:1)中,氮气保护下,80℃搅拌2小时。冷却至室温,减压浓缩,残余物经硅胶柱层析(洗脱剂:石油醚/乙酸乙酯=10/1-5/1)纯化得黄色液体236-2(200.0mg,两步收率:22.7%)。LC-MS m/z(ESI):359.0[M+H]+。
55.3中间体236-3的合成
将氢氧化锂(27.0mg)加入到化合物236-2(200.0mg)的甲醇和水混合溶液(5mL,v/v=1:1)中,室温搅拌2小时。加入水(20mL),乙酸乙酯(20mL×2)洗涤,水相用盐酸(1M)调节pH至
弱酸性,二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(30mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩得黄色固体236-3(120.0mg),粗品直接用于下一步反应。LC-MS m/z(ESI):345.0[M+H]+。
55.4中间体236-4的合成
将N,N,N',N'-四甲基氯甲脒六氟磷酸盐(82.0mg)加入到N-甲基咪唑(36.0mg),30-5(53.0mg)和236-3(50.0mg)的N,N-二甲基甲酰胺(3mL)溶液中,室温搅拌2小时。加入水(30mL),乙酸乙酯(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物经硅胶柱层析(洗脱剂:二氯甲烷/甲醇=10/1-5/1)纯化得黄色液体236-4(50.0mg,收率49.5%)。LC-MS m/z(ESI):690.4[M+H]+。
55.5化合物236的合成
将无水甲酸(4mL)加入236-4(50.0mg)的二氯甲烷(1mL)中,室温搅拌2小时。减压浓缩,残余物用饱和碳酸钠溶液调节pH=8,二氯甲烷(20mL×3)萃取,有机相用饱和氯化钠溶液(20mL)洗涤,无水硫酸钠干燥,过滤,过滤减压浓缩,残余物经高效液相色谱(柱:Xbridge-C18 150 x 19mm,5um;流动相:ACN--H2O(0.1%FA);B%:5%-10%,20min)纯化得白色固体236的甲酸盐(23.3mg,收率65.8%)。LC-MS m/z(ESI):490.1[M+H]+。1H NMR(400MHz,DMSO-d6,80℃)δppm 10.62-10.36(m,1H),8.05-7.78(m,3H),7.52-7.32(m,1H),7.24-7.09(m,2H),6.28-5.80(m,3H),4.81-4.68(m,1H),4.66-4.55(m,1H),4.28(s,3H),2.83-2.60(m,3H),2.44-2.34(m,1H),1.17-1.09(m,2H),1.03-0.96(m,2H).
如下列表化合物,通过实施例4,5,159,160,163-P1,163-P2,173,211,233相同合成策略进行合成:
实验例1:细胞抗增殖实验方法
材料与细胞
HCT116MTAP Deletion细胞来源于Pharmaron(中国);HCT116细胞来源于ATCC;McCoy's 5A培养基购于Invitrogen公司(美国);青霉素-链霉素和胎牛血清购于Gibco公司(美国);384孔板购于PerkinElmer公司(美国);Cell-Titer Glo试剂购于Promega公司(美国)。
化合物储存
化合物溶解:所有化合物使用二甲基亚砜(DMSO)溶解后储存。在室温干燥的条件下短期保存3个月或者-20℃长期保存。
细胞培养及传代
细胞严格按照ATCC要求进行培养。将细胞培养基(McCoy's 5A培养基+10%胎牛血清+1%青霉素+链霉素)转移至15mL离心管中,1000rpm,离心5min。去除上清,用完全培养基重悬细胞,按所需密度接种于培养皿中,置于37℃,95%的潮湿空气,5%二氧化碳的培养箱中培养,视细胞生长情况每2-3天补一次培养液或进行传代。
细胞增殖活性检测
细胞在培养皿中的汇合度达到90%左右时,用PBS清洗细胞两次后,使用胰蛋白酶将细胞处理成单细胞,进行细胞计数,每孔40μl接种于384孔板(50个细胞/孔),置于37℃,5%二氧化碳条件下平衡10-15min。利用Echo550将化合物打入384孔板中,设置阳性对照和阴性对照(0.1%DMSO),每个化合物10个梯度,3倍稀释,双复孔,DMSO含量0.1%。将384孔板置于细胞培养箱中培养10天。
后将40μl细胞增殖检测试剂(CTG)加入到384孔板中并震板混匀,后将384孔板置于37℃,5%二氧化碳的条件下避光孵育30分钟。通过多功能酶标仪Envision进行读数。化合物抑制率百分比的计算公式如下:抑制率百分比=100-(信号值药物处理组-信号值阳性对照组)/(信号值阴性对照组-信号值阳性对照组)×100。根据不同药物浓度及其所对应的抑制率,使用GraphPad 8.0软件进行GI50曲线绘制,分析数据,得出最终IC50值。结果见表1,其中GI50≤0.01μM为AA,0.01μM<GI50≤0.1μM为A,0.1μM<GI50≤1μM为B,1μM<GI50≤10μM为C,10μM<GI50为D。
表1本发明化合物细胞抗增殖活性的测试结果
另外,本发明化合物还具有针对突变型HCT116细胞的选择性,例如化合物33和34对HCT116MTAP
Deletion的GI50为≤0.1μM,但对HCT116的GI50为1-10μM,选择性超过300倍。代表性化合物的选择性数据如表2所示:
表2代表性化合物的选择性数据
实验例2:细胞SDMA In-cell western实验方法
2.1材料与细胞
HCT116MTAP Deletion细胞来源于Horizon;HCT116细胞来源于ATCC;RPMI-1640培养基购于ATCC公司(美国);青霉素-链霉素购于Gibco公司(美国);胎牛血清购于ExCell公司;96孔板购于Corning公司(美国);Symmetric Di-Methyl Arginine Motif[sdme-RG]抗体购于CST(美国);IRDye 800CW Goat anti-Rabbit IgG二抗购于LI-COR(美国),CellTag 700stain购于LI-COR(美国)。
2.2化合物储存
化合物溶解:所有化合物使用二甲基亚砜(DMSO)溶解后储存。-20℃长期保存。
2.3细胞培养及传代
细胞严格按照ATCC要求进行培养。将细胞培养基(RPMI-1640培养基+10%血清+1%青霉素+链霉素)转移至15mL离心管中,1000rpm,离心5min。去除上清,用完全培养基重悬细胞,按所需密度接种于培养皿中,置于37℃,95%的潮湿空气,5%二氧化碳的培养箱中培养,视细胞生长情况每2-3天补一次培养液或进行传代。
2.4SDMA In-cell western实验
细胞在培养皿中的汇合度达到90%左右时,用PBS清洗细胞两次后,用胰酶消化细胞,每孔100μL接种于96孔板(800/孔),在37℃,5%CO2培养箱中培养过夜。将50μL 3x终浓度的化合物加入细胞培养板中,每个化合物10个梯度,3倍稀释,双复孔,DMSO终浓度0.5%,在37℃,5%CO2培养箱中培养96小时。
每孔加入150μL 8%多聚甲醛,常温孵育15分钟。弃上清,PBS洗板,每孔加入200μL新制备
的1x Permeabilization buffer,室温孵育30分钟。弃上清,每孔加入200μL 1x Blocking buffer,室温孵育2小时。弃上清,每孔加入50μL一抗(CST,1x Incubation buffer 1:500稀释),4℃过夜。弃上清,每孔加入250μL 1x Washing buffer,清洗三次。每孔加入50μL二抗(IRDye 800CW Goat anti-Rabbit IgG和CellTag 700染料,Incubation buffer 1:800和1:500稀释),室温孵育1小时。弃上清,1x Washing buffer洗板。使用Licor Odyssey CLX检测信号。化合物抑制率百分比的计算公式如下:抑制率百分比=100-(信号值药物处理组-信号值背景值)/(信号值0.5%DMSO处理组-信号值背景值)×100。根据不同药物浓度及其所对应的抑制率,使用GraphPad 8.0软件进行IC50曲线绘制,分析数据,得出最终IC50值。结果见表3,其中IC50≤0.01μM为AA,0.01μM<IC50≤0.1μM为A,0.1μM<IC50≤1μM为B,1μM<IC50≤10μM为C。
表3细胞SDMA抑制活性
实验例3 LU99 CDX模型体内药效学研究
3.1实验材料:LU99细胞来源于JCRB(日本);RPMI-1640和0.25%胰酶-EDTA购自Gibco(美国);胎牛血清购自东岭(中国);PBS购自Hyclone(美国);青霉素-链霉素购于美仑生物(中国);Matrigel基质胶购于Corning(美国)。
3.2动物信息:BALB/c Nude小鼠,雌性,6-8周龄,体重18-22克,动物购自北京维通利华实验动物技术有限公司,将小鼠饲养在SPF级环境中,每个笼位单独送排风,所有动物都可以自由获取标准认证的商业实验室饮食和自由饮水。
3.3实验方法:
3.3.1细胞培养:人大细胞肺癌细胞LU99体外单层培养,培养条件为RPMI-1640培养基中加10%胎牛血清,37℃5%CO2孵箱培养。一周两次用胰酶-EDTA进行常规消化处理传代。当细胞数量到达要求时,收取细胞,计数。
3.3.2细胞接种:将0.2mL(5×106个)LU99细胞(加基质胶,体积比为1:1)细胞皮下接种于每只小鼠的右后背,肿瘤平均体积达到约150mm3时,依据肿瘤体积和动物体重采用随机分层分组方法开始分组给药。
3.3.3给药:化合物106-P2和112-P1的给药剂量均为30mpk,PO,每天一次给药(QD)×3周。每组6只小鼠。
3.3.4肿瘤测量和实验指标:
每周两次用游标卡尺测量肿瘤直径。肿瘤体积的计算公式为:V=0.5a×b2,a和b分别表示肿瘤的长径和短径。每周两次测量小鼠体重。
化合物的抑瘤疗效用肿瘤生长抑制率TGI(%)来评价。
TGI(%)=[(1-(某处理组给药结束时平均瘤体积-该处理组开始给药时平均瘤体积))/(溶剂对照组
治疗结束时平均瘤体积-溶剂对照组开始治疗时平均瘤体积)]×100%。
实验结果见图1、图2、图3和图4。实验过程中无小鼠发病或死亡。
实验例4灌胃给药后CD1小鼠中脑渗透性考察
4.1实验设计
4.1.1给药信息
4.1.2采集时间:
4.1.3血液样品的采集与处理过程
4.1.4在体实验期评价
4.1.5测试体系
4.2供试品与制剂配制
4.2.1供试品信息
4.2.2制剂配制
4.3样品分析
所有样品经LC-MS/MS分析,标准曲线法测定样品中的待测药物的浓度。
对血浆测定结果,将用WinNonlin(PhoenixTM)或其它类似软件进行药代动力学参数计算。
4.4实验结果
表4本公开化合物的脑渗透性数据
Claims (39)
- 式(X)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物:
其中,环A为C6-10芳基或5-10元杂芳基;L1为NH或CHRx;L2为CRxRy;L3为-C(O)-、-S(O)-或-S(O)2-;其中Rx和Ry独立地为H、D、C1-6烷基或C1-6卤代烷基;或者CRxRy一起形成C=O、C=S或C3-6亚环烷基;或者当L1为CHRx、L2为CRxRy时,两个Rx基团可以结合形成化学键或C1-4亚烷基;R1选自H、D、卤素、CN、NO2、-L-ORa、-L-SRa、-L-NRbRc、SF5、C(O)Ra、C(O)ORa、C(O)NRbRc、OC(O)Ra、NRbC(O)Rc、S(O)Ra、S(O)2Ra、S(O)(=NRa)Ra、S(O)ORa、S(O)2ORa、S(O)NRbRc、S(O)2NRbRc、P(O)(Ra)2、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7环烷基、-L-3-7元杂环基、-L-C6-10芳基或-L-5-10元杂芳基,其任选被1、2或3个R1s取代;m=0、1、2、3或4;R4选自H、D、C1-6烷基或C1-6卤代烷基;或者一个R1与R4连接形成-(CRssRss)q1-X-(CRssRss)q2-(优选-(CH2)q1-X-(CH2)q2-);其中X为O、S、NH或CH2,q1=0、1或2,q2=1、2或3,Rss独立地选自H、D、C1-6烷基或C1-6卤代烷基,或者两个Rss以及他们连接的碳原子一起形成C3-10环烷基;X1为C原子或N原子,其任选地被R2b取代;X2为C原子或N原子,其任选地被R2c取代;X3为C原子或N原子,其任选地被R2d取代;R2a选自H、D、CN、ORa、NRbRc、C(O)ORa或C(O)NRbRc;R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基或3-10元杂环基;R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;或者X1、X2以及他们的取代基一起形成C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选被1、2或3个R2s取代;R2d选自H、D、卤素、CN、NO2、ORa、NRbRc、C1-6烷基、C1-6卤代烷基、C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基;R3选自-C1-6亚烷基-ORa、-C1-6亚烷基-NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-10环烷基、-L-3-10元杂环基、-L-C6-10芳基或-L-5-10元杂芳基,其任选被1、2或3个R3s1和1个R3s2取代;L为化学键、C1-6亚烷基、C2-6亚烯基或C2-6亚炔基,其任选被1、2或3个R取代;R1s和R2s独立地选自H、D、卤素、CN、=O、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;或者两个R1s以及他们连接的原子一起形成C3-10环烷基或3-10元杂环基;R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;R3s2选自H、D、-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;或者,R3s1、R3s2以及他们连接的碳原子一起形成C3-10环烷基;R和R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;Ra、Rb和Rc独立地选自H、D、C1-6烷基、C1-6卤代烷基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;其中上述环A、L1、L2、Rx、Ry、R1、R2a、R2b、R2c、R2d、R3、R4、L、R、R1s、R2s、R3s、R3s1、R3s2、Ra、Rb和Rc中的各个基团定义任选地被氘代,直至完全氘代;条件是当L2为CRxRy、L3为-S(O)-或-S(O)2-时,Ry与R2d结合形成亚乙烯基。 - 权利要求1的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,环A为苯基或5-6元杂芳基;优选为苯基、吡啶基、哒嗪基、嘧啶基或吡嗪基。
- 权利要求1-2中任一项的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,L1为NH,L2为CRxRy;-L1-L2-优选为 -L1-L2-优选为
- 权利要求1-3中任一项的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,L3为-C(O)-。
- 权利要求1-4中任一项的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,R1与R4连接形成-(CH2)q1-X-(CH2)q2-;其中X为O、S、NH或CH2,q1=0或1,q2=1或2;优选地,R1与R4连接形成-(CH2)q1-X-(CH2)q2-;其中X为O、S或NH,q1=0或1,q2=1或2。
- 权利要求1-5中任一项的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,选自 优选为
- 权利要求1-6中任一项的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,R2a选自H、D、CN、ORa或NRbRc;优选选自ORa或NRbRc;优选选自OMe或NH2;优选为NH2。
- 权利要求1-7中任一项的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,X1、X2以及他们的取代基一起形成C5-10环烷基、 5-10元杂环基、C6-10芳基或5-10元杂芳基;优选形成C5-7环烷基、5-7元杂环基、苯基或5-6元杂芳基;优选形成 优选形成优选形成优选形成
- 权利要求1-8中任一项的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,R3选自C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-10环烷基、-L-3-10元杂环基、-L-C6-10芳基或-L-5-10元杂芳基;优选选自C1-6烷基、C1-6卤代烷基、-L-C3-10环烷基、-L-3-10元杂环基、-L-C6-10芳基或-L-5-10元杂芳基;优选选自C1-6烷基、C1-6卤代烷基、C5-6环烷基、5-6元杂环基、苯基或5-6元杂芳基;优选选自Me、Et、iPr、环丙基、环丁基、
- 权利要求1-9中任一项的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其具有以下结构式:
其中各基团如权利要求1-9定义。 - 权利要求10的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其为式(II)化合物,其中,L1为NH或CHRx;L2为CRxRy;其中Rx和Ry独立地为H、D、C1-6烷基或C1-6卤代烷基;或者CRxRy一起形成C=O、C=S或C3-6亚环烷基;或者当L1为CHRx、L2为CRxRy时,两个Rx基团可以结合形成化学键或C1-4亚烷基;Z1为CH或N;R1选自H、D、卤素、CN、ORa、SRa、NRbRc、SF5、C1-6烷基、C1-6卤代烷基、C5-7环烷基或5-7元杂环基,其任选地被1、2或3个R1s取代;m=0、1、2或3,优选m=0;X1为C原子或N原子,其任选地被R2b取代;X2为C原子或N原子,其任选地被R2c取代;X3为C原子或N原子,其任选地被R2d取代;R2a选自H、D、ORa或NRbRc;R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基;R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;或者X1、X2以及他们的取代基一起形成C5-7环烷基、5-7元杂环基、苯基或5-6元杂芳基,其任选被1、2或3个R2s取代;R2d选自H、D、卤素、CN、NO2、ORa、NRbRc、C1-6烷基、C1-6卤代烷基、C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基;R1s选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C5-7环烷基或5-7元杂环基;R2s选自H、D、卤素、=O、C1-6烷基或C1-6卤代烷基;R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基;R3s2选自H、D、-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C5-7环烷基、5-7元杂环基、C6-10芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;L为化学键或C1-6亚烷基,其任选被1、2或3个R取代;R和R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;其中上述L1、L2、Rx、Ry、Z1、R1、R2a、R2b、R2c、R2d、R1s、R2s、R3s1、R3s2、L、R、R3s、Ra、Rb和Rc中的各个基团定义任选地被氘代,直至完全氘代。
- 权利要求11的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,L1为NH或CHRx;L2为CRxRy;其中Rx和Ry独立地为H、D、C1-6烷基或C1-6卤代烷基;或者CRxRy一起形成C=O、C=S或C3-4亚环烷基;或者当L1为CHRx、L2为CRxRy时,两个Rx基团可以结合形成化学键或C1-3亚烷基;Z1为CH或N;R1选自H、D、卤素、CN、ORa、NRbRc、C1-6烷基、C1-6卤代烷基或5-6元杂环基,其中所述杂环基任选地被1、2或3个R1s取代;m=0、1、2或3,优选m=0;X1为C原子或N原子,其任选地被R2b取代;X2为C原子或N原子,其任选地被R2c取代;X3为C原子或N原子,其任选地被R2d取代;R2a为NH2;R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基;R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;或者X1、X2以及他们的取代基一起形成C5-7环烷基、5-7元杂环基、苯基或5-6元杂芳基,其任选被1、2或3个R2s取代;R2d选自H、D、C1-6烷基或C1-6卤代烷基;R1s选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基或C1-6卤代烷基;R2s选自H、D、=O、C1-6烷基或C1-6卤代烷基;R3s1选自H、D、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基;R3s2选自H、D、-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C5-7环烷基、5-7元杂环基、C6-10芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;L为化学键或C1-3亚烷基,其任选被1、2或3个R取代;R和R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基。
- 权利要求11的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,L1为NH或CHRx;L2为CRxRy;其中Rx和Ry独立地为H、D、C1-3烷基或C1-3卤代烷基;或者CRxRy一起形成C=O或亚环丙基;或者当L1为CHRx、L2为CRxRy时,两个Rx基团可以结合形成化学键或C1-2亚烷基;Z1为CH或N;R1选自H、D、CN、ORa、C1-6烷基、C1-6卤代烷基或5-6元杂环基,其任选地被1、2或3个R1s取代;m=0、1、2或3,优选m=0;X1为C原子或N原子,其任选地被R2b取代;X2为C原子或N原子,其任选地被R2c取代;X3为C原子或N原子,其任选地被R2d取代;R2a为NH2;R2b选自H、D、卤素、C(O)NRbRc、C1-6烷基、C1-6卤代烷基或4-6元杂环基;R2c选自H、D、C1-6烷基或C1-6卤代烷基;或者X1、X2以及他们的取代基一起形成C5-7环烷基、5-7元杂环基、苯基或5-6元杂芳基,其任选被1、2或3个R2s取代;优选R2d选自H或D;R1s选自H、D、卤素、C(O)ORa、C1-6烷基或C1-6卤代烷基,优选卤素或C(O)OCH3;R2s选自H、D、=O或Me;R3s1选自H、D、C1-6烷基、C1-6卤代烷基或C3-6环烷基;R3s2选自H、D、-L-ORa、C1-6烷基、C1-6卤代烷基、C5-7环烷基、苯基或5-10元杂芳基,其任选地被1、2或3个R3s取代;优选地,R3s2选自H、D、Me、CF3、CH2OCH3、环丙基、L为化学键或C1-3亚烷基,优选亚甲基,其任选被1、2或3个R取代;R和R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基。
- 权利要求10的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其为式(II)化合物,其中,L1为NH;L2为CRxRy;其中CRxRy一起形成C=O或C=S;R1选自H、D、卤素、CN、NO2、-L-ORa、-L-SRa、-L-NRbRc、SF5、C(O)Ra、C(O)ORa、C(O)NRbRc、OC(O)Ra、NRbC(O)Rc、S(O)Ra、S(O)2Ra、S(O)ORa、S(O)2ORa、S(O)NRbRc、S(O)2NRbRc、P(O)(Ra)2、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7环烷基、-L-3-7元杂环基、-L-C6-10芳基或-L-5-10元杂芳基,其任选被1、2或3个R1s取代;m=0、1、2、3或4;X1为C原子,其被R2b取代;X2为C原子或N原子,其任选地被R2c取代;X3为C原子,其被R2d取代;R2a选自H、D、CN、ORa、NRbRc、C(O)ORa或C(O)NRbRc;R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基或3-10元杂环基;R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;或者X1、X2以及他们的取代基一起形成C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基(优选),其任选被1、2或3个R2s取代;R2d选自H、D、卤素、CN、NO2、ORa、NRbRc、C1-6烷基、C1-6卤代烷基、C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基;Z1为CH;L为化学键、C1-6亚烷基、C2-6亚烯基或C2-6亚炔基,其任选被1、2或3个R取代;R1s和R2s独立地选自H、D、卤素、=O、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;R3s2选自-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;R和R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;Ra、Rb和Rc独立地选自H、D、C1-6烷基、C1-6卤代烷基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基,优选H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;其中上述各个基团定义任选地被氘代,直至完全氘代。
- 权利要求14的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,L1为NH;L2为CRxRy;其中CRxRy一起形成C=O或C=S;R1选自H、D、卤素、CN、NO2、-L-ORa、-L-SRa、-L-NRbRc、SF5、C(O)Ra、C(O)ORa、C(O)NRbRc、OC(O)Ra、NRbC(O)Rc、S(O)Ra、S(O)2Ra、S(O)ORa、S(O)2ORa、S(O)NRbRc、S(O)2NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7环烷基、-L-3-7元杂环基、-L-C6-10芳基或-L-5-10元杂芳基,其任选被1、2或3个R1s取代;m=0、1、2、3或4;X1为C原子,其被R2b取代;X2为C原子或N原子,其任选地被R2c取代;X3为C原子,其被R2d取代;R2a选自H、D、CN、ORa或NRbRc;R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基或C1-6卤代烷基;R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;或者X1、X2以及他们的取代基一起形成C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基(优选),其任选被1、2或3个R2s取代;R2d选自H、D、卤素、CN、NO2、ORa、NRbRc、C1-6烷基或C1-6卤代烷基;Z1为CH;L为化学键、C1-6亚烷基、C2-6亚烯基或C2-6亚炔基;R1s和R2s独立地选自H、D、卤素、=O、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基或C2-6炔基;R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基或C2-6炔基;R3s2选自-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;Ra、Rb和Rc独立地选自H、D、C1-6烷基、C1-6卤代烷基、C3-6环烷基、3-6元杂环基、苯基或5-6元杂芳基,优选H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;其中上述各个基团定义任选地被氘代,直至完全氘代。
- 权利要求14的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,L1为NH;L2为CRxRy;其中CRxRy一起形成C=O或C=S;R1选自H、D、卤素、CN、NO2、-L-ORa、-L-SRa、-L-NRbRc、SF5、C(O)Ra、C(O)ORa、C(O)NRbRc、S(O)Ra、S(O)2Ra、S(O)ORa、S(O)2ORa、S(O)NRbRc、S(O)2NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7环烷基、-L-3-7元杂环基、-L-C6-10芳基或-L-5-10元杂芳基,其任选被1、2或3个R1s取代;m=0、1、2、3或4;X1为C原子,其被R2b取代;X2为C原子或N原子,其任选地被R2c取代;X3为C原子,其被R2d取代;R2a选自H、D、CN、ORa或NRbRc;R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基或C1-6卤代烷基;R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;或者X1、X2以及他们的取代基一起形成C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基(优选),其任选被1、2或3个R2s取代;R2d选自H、D、卤素、CN、NO2、C1-6烷基或C1-6卤代烷基;Z1为CH;L为化学键或C1-6亚烷基;R1s和R2s独立地选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基或C2-6炔基;R3s1选自H、D、卤素、C1-6烷基或C1-6卤代烷基;R3s2选自-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;Ra、Rb和Rc独立地选自H、D、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基,优选H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;其中上述各个基团定义任选地被氘代,直至完全氘代。
- 权利要求14的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,L1为NH;L2为CRxRy;其中CRxRy一起形成C=O或C=S;R1选自H、D、-L-ORa、-L-SRa、-L-NRbRc、SF5、C(O)Ra、C(O)ORa、C(O)NRbRc、OC(O)Ra、NRbC(O)Rc、S(O)Ra、S(O)2Ra、S(O)ORa、S(O)2ORa、S(O)NRbRc、S(O)2NRbRc、P(O)(Ra)2、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7环烷基或-L-5-10元杂芳基,其任选被1、2或3个R1s取代;m=0、1、2、3或4;X1为C原子,其被R2b取代;X2为C原子,其被R2c取代;X3为C原子,其被R2d取代;R2a选自H、D、CN、ORa、NRbRc、C(O)ORa或C(O)NRbRc;R2b选自C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基;R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;或者X1、X2以及他们的取代基一起形成5-10元杂环基、C6-10芳基或5-10元杂芳基(优选),其任选被1、2或3个R2s取代;R2d选自H、D、卤素、CN、NO2、ORa、NRbRc、C1-6烷基、C1-6卤代烷基、C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基;Z1为CH;L为化学键、C1-6亚烷基、C2-6亚烯基或C2-6亚炔基,其任选被1、2或3个R取代;R1s和R2s独立地选自H、D、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;R3s2选自-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;R和R3s独立地选自H、D、C1-6烷基或C1-6卤代烷基;Ra、Rb和Rc独立地选自H、D、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基,优选H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;其中上述各个基团定义任选地被氘代,直至完全氘代。
- 权利要求17的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,L1为NH;L2为CRxRy;其中CRxRy一起形成C=O或C=S;R1选自H、D、-L-ORa、-L-SRa、-L-NRbRc、C(O)Ra、C(O)ORa、C(O)NRbRc、S(O)Ra、S(O)2Ra、S(O)ORa、S(O)2ORa、S(O)NRbRc、S(O)2NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7 环烷基或-L-5-10元杂芳基,其任选被1、2或3个R1s取代;m=0、1、2、3或4;X1为C原子,其被R2b取代;X2为C原子,其被R2c取代;X3为C原子,其被R2d取代;R2a选自H、D、CN、ORa或NRbRc;R2b选自C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基;R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;或者X1、X2以及他们的取代基一起形成5-10元杂环基、C6-10芳基或5-10元杂芳基(优选),其任选被1、2或3个R2s取代;R2d选自H、D、卤素或CN;Z1为CH;L为化学键、C1-6亚烷基、C2-6亚烯基或C2-6亚炔基;R1s和R2s独立地选自H、D、C1-6烷基、C1-6卤代烷基、C2-6烯基或C2-6炔基;R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基或C2-6炔基;R3s2选自-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基;Ra、Rb和Rc独立地选自H、D、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基,优选H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;其中上述各个基团定义任选地被氘代,直至完全氘代。
- 权利要求17的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,L1为NH;L2为CRxRy;其中CRxRy一起形成C=O或C=S;R1选自H、D、ORa、SRa、NRbRc、C(O)Ra、S(O)Ra、S(O)2Ra、C1-6烷基、C1-6卤代烷基、C3-7环烷基或5-10元杂芳基,其任选被1、2或3个R1s取代;m=0、1、2、3或4;X1为C原子,其被R2b取代;X2为C原子,其被R2c取代;X3为C原子,其被R2d取代;R2a选自ORa或NRbRc;R2b选自C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基;R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;或者X1、X2以及他们的取代基一起形成5-10元杂环基、C6-10芳基或5-10元杂芳基(优选),其任选被1、2或3个R2s取代;R2d选自H、D、卤素或CN;Z1为CH;L为化学键或C1-6亚烷基;R1s和R2s独立地选自H、D、C1-6烷基、C1-6卤代烷基、C2-6烯基或C2-6炔基;R3s1选自H、D、卤素、C1-4烷基或C1-4卤代烷基;R3s2选自-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基;Ra、Rb和Rc独立地选自H、D、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基,优选H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;其中上述各个基团定义任选地被氘代,直至完全氘代。
- 权利要求17的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,L1为NH;L2为CRxRy;其中CRxRy一起形成C=O或C=S;R1选自H、D、ORa、SRa、NRbRc、C(O)Ra、S(O)Ra、S(O)2Ra、C1-6烷基、C1-6卤代烷基、C3-7环烷基或5-10元杂芳基,其任选被1、2或3个R1s取代;m=0、1、2、3或4;X1为C原子,其被R2b取代;X2为C原子,其被R2c取代;X3为C原子,其被R2d取代;R2a选自ORa或NRbRc;R2b选自C(O)ORa、C(O)NRbRc或C1-6烷基;R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;或者X1、X2以及他们的取代基一起形成5-10元杂环基、C6-10芳基或5-10元杂芳基(优选),其任选被1、2或3个R2s取代;R2d选自H、D、卤素或CN;Z1为CH;L为化学键或C1-6亚烷基;R1s和R2s独立地选自H、D、C1-6烷基、C1-6卤代烷基、C2-6烯基或C2-6炔基;R3s1选自Me;R3s2选自Et;Ra、Rb和Rc独立地选自H、D、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基,优选H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;其中上述各个基团定义任选地被氘代,直至完全氘代。
- 权利要求17的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,L1为NH;L2为CRxRy;其中CRxRy一起形成C=O或C=S;R1选自H、D、ORa、SRa、NRbRc、C(O)Ra、S(O)Ra、S(O)2Ra、C1-6烷基、C1-6卤代烷基、C3-7环烷基或5-6元杂芳基,其任选被1、2或3个R1s取代;m=0、1、2、3或4;X3为C原子,其被R2d取代;R2a选自ORa或NRbRc;X1、X2以及他们的取代基一起形成5-6元杂芳基(优选),其任选被1、2或3个R2s取代;R2d选自H、D、卤素或CN;Z1为CH;R1s和R2s独立地选自H、D、C1-6烷基、C1-6卤代烷基、C2-6烯基或C2-6炔基;R3s1选自H或D;R3s2选自C3-6环烷基、5-6元杂环基、苯基或5-6元杂芳基;Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;其中上述各个基团定义任选地被氘代,直至完全氘代。
- 权利要求17的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,L1为NH;L2为CRxRy;其中CRxRy一起形成C=O或C=S;R1选自H、D、ORa、SRa、NRbRc、C(O)Ra、S(O)Ra、S(O)2Ra、C1-6烷基、C1-6卤代烷基、C3-7环烷基或5-6元杂芳基,其任选被1、2或3个R1s取代;m=0、1、2、3或4;X3为C原子,其被R2d取代;R2a选自ORa或NRbRc;X1、X2以及他们的取代基一起形成5-6元杂芳基(优选),其任选被1、2或3个R2s取代;R2d选自H、D、卤素或CN;Z1为CH;L为化学键或C1-6亚烷基;R1s和R2s独立地选自H、D、C1-6烷基、C1-6卤代烷基、C2-6烯基或C2-6炔基;R3s1选自C1-4烷基或C1-4卤代烷基;R3s2选自-L-ORa、-L-NRbRc、C1-6烷基或C1-6卤代烷基;Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;其中上述各个基团定义任选地被氘代,直至完全氘代。
- 权利要求10的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其为式(III)化合物,其中,L1为NH或CHRx;L2为CRxRy;其中Rx和Ry独立地为H、D、C1-6烷基或C1-6卤代烷基;或者CRxRy一起形成C=O、C=S或C3-6亚环烷基;或者当L1为CHRx、L2为CRxRy时,两个Rx基团可以结合形成化学键或C1-4亚烷基;Z1为CH或N;R1选自H、D、卤素、CN、ORa、SRa、NRbRc、SF5、C1-6烷基、C1-6卤代烷基、C5-7环烷基或5-7元杂环基,其任选地被1、2或3个R1s取代;m=0、1、2或3,优选m=0;X1为C原子或N原子,其任选地被R2b取代;X2为C原子或N原子,其任选地被R2c取代;X3为C原子或N原子,其任选地被R2d取代;R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基;R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;或者X1、X2以及他们的取代基一起形成C5-7环烷基、5-7元杂环基、苯基或5-6元杂芳基,其任选被1、2或3个R2s取代;R2d选自H或D;R1s选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C5-7环烷基或5-7元杂环基;R2s选自H、D、卤素、=O、C1-6烷基或C1-6卤代烷基;R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基;R3s选自H、D、卤素、C1-6烷基或C1-6卤代烷基;p=0、1、2或3,优选p=0;Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;其中上述L1、L2、Rx、Ry、Z1、R1、R2b、R2c、R1s、R2s、R3s1、R3s、Ra、Rb和Rc中的各个基团定义任选地被氘代,直至完全氘代。
- 权利要求23的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,L1为NH或CHRx;L2为CRxRy;其中Rx和Ry独立地为H、D、C1-6烷基或C1-6卤代烷基;或者CRxRy一起形成C=O、C=S或C3-4亚环烷基;或者当L1为CHRx、L2为CRxRy时,两个Rx基团可以结合形成化学键或C1-3亚烷基;Z1为CH或N;R1选自H、D、卤素、CN、ORa、NRbRc、C1-6烷基、C1-6卤代烷基或5-6元杂环基,其中所述杂环基任选地被1、2或3个R1s取代;m=0、1、2或3,优选m=0;X1为C原子或N原子,其任选地被R2b取代;X2为C原子或N原子,其任选地被R2c取代;X3为C原子或N原子,其任选地被R2d取代;R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂 环基;R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;或者X1、X2以及他们的取代基一起形成C5-7环烷基、5-7元杂环基、苯基或5-6元杂芳基,其任选被1、2或3个R2s取代;R2d选自H或D;R1s选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基或C1-6卤代烷基;R2s选自H、D、=O、C1-6烷基或C1-6卤代烷基;R3s1选自H、D、C1-6烷基、C1-6卤代烷基、C3-6环烷基或3-6元杂环基;R3s选自H、D、卤素、C1-6烷基或C1-6卤代烷基;p=0、1、2或3,优选p=0;Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基。
- 权利要求23的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,L1为NH或CHRx;L2为CRxRy;其中Rx和Ry独立地为H、D、C1-3烷基或C1-3卤代烷基;或者CRxRy一起形成C=O或亚环丙基;或者当L1为CHRx、L2为CRxRy时,两个Rx基团可以结合形成化学键或C1-2亚烷基;Z1为CH或N;R1选自H、D、CN、ORa、C1-6烷基、C1-6卤代烷基或5-6元杂环基,其任选地被1、2或3个R1s取代;m=0、1、2或3,优选m=0;X1为C原子或N原子,其任选地被R2b取代;X2为C原子或N原子,其任选地被R2c取代;X3为C原子或N原子,其任选地被R2d取代;R2b选自H、D、卤素、C(O)NRbRc、C1-6烷基、C1-6卤代烷基或4-6元杂环基;R2c选自H、D、C1-6烷基或C1-6卤代烷基;或者X1、X2以及他们的取代基一起形成C5-7环烷基、5-7元杂环基、苯基或5-6元杂芳基,其任选被1、2或3个R2s取代;R2d选自H或D;R1s选自H、D、卤素、C(O)ORa、C1-6烷基或C1-6卤代烷基,优选卤素或C(O)OCH3;R2s选自H、D、=O或Me;R3s1选自H、D、C1-6烷基、C1-6卤代烷基或C3-6环烷基;R3s选自H、D、卤素、C1-6烷基或C1-6卤代烷基;p=0、1、2或3,优选p=0;Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基。
- 权利要求23的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,L1-L2为:
Z1为CH或N;R1为CF3、CN、OCF3、OCH2CH3、优选为CF3;m=0;X1为C原子或N原子,其任选地被R2b取代;X2为C原子或N原子,其任选地被R2c取代;X3为C原子或N原子,其任选地被R2d取代;R2b为H、F、Cl、Br、Me、CH2CH3、C(O)NH2或R2c为H或Me;或者X1、X2以及他们的取代基一起形成:
R2d为H;R3s1为H、Me或环丙基;R3s为H;p=0。 - 权利要求10的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其为式(IV)、(IV-1)、(IV-1a)、(IV-1b)、(IV-2)、(IV-2a)或(IV-2b)化合物,其中,R1选自H、D、卤素、CN、NO2、-L-ORa、-L-SRa、-L-NRbRc、SF5、C(O)Ra、C(O)ORa、C(O)NRbRc、OC(O)Ra、NRbC(O)Rc、S(O)Ra、S(O)2Ra、S(O)ORa、S(O)2ORa、S(O)NRbRc、S(O)2NRbRc、P(O)(Ra)2、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、-L-C3-7环烷基、-L-3-7元杂环基、-L-C6-10芳基或-L-5-10元杂芳基,其任选被1、2或3个R1s取代;m=0、1或2;R4选自H或D;X1为C原子,其被R2b取代;X2为C原子或N原子,其任选地被R2c取代;X3为C原子,其被R2d取代;R2a选自H、D、CN、ORa、NRbRc、C(O)ORa或C(O)NRbRc;R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基或3-10元杂环基;R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;或者X1、X2以及他们的取代基一起形成C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基(优选),其任选被1、2或3个R2s取代;R2d选自H、D、卤素、CN、NO2、ORa、NRbRc、C1-6烷基、C1-6卤代烷基、C5-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基;Z1为CH;Z2为CR1或N;Z3为CR1或N;当Z2或Z3为CR1时,该任一R1与R4连接形成-(CRssRss)q1-X-(CRssRss)q2-(优选-(CH2)q1-X-(CH2)q2-);其中X为O、S、NH或CH2,q1=0、1或2,q2=1、2或3,Rss独立地选自H、D、C1-6烷基或C1-6卤代烷基,或者两个Rss以及他们连接的碳原子一起形成C3-10环烷基;L为化学键、C1-6亚烷基、C2-6亚烯基或C2-6亚炔基,其任选被1、2或3个R取代;R1s和R2s独立地选自H、D、卤素、CN、=O、ORa、NRbRc、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;或者两个R1s以及他们连接的原子一起形成C3-10环烷基或3-10元杂环基;优选选自H、D、卤素、CN、=O、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;R3s2选自H、D、-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;或者,R3s1、R3s2以及他们连接的碳原子一起形成C3-10环烷基;R和R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;Ra、Rb和Rc独立地选自H、D、C1-6烷基、C1-6卤代烷基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;其中上述各个基团定义任选地被氘代,直至完全氘代。
- 权利要求27的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,R1选自H、D、卤素、CN、NO2、ORa、SRa、NRbRc、SF5、C(O)Ra、C(O)ORa、C(O)NRbRc、OC(O)Ra、NRbC(O)Rc、S(O)Ra、S(O)2Ra、S(O)ORa、S(O)2ORa、S(O)NRbRc、S(O)2NRbRc、P(O)(Ra)2、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-7环烷基、3-7元杂环基、C6-10芳基或5-10元杂芳基,其任选被1、2或3个R1s取代;m=0、1或2;R4选自H或D;X1为C原子,其被R2b取代;X2为C原子或N原子,其任选地被R2c取代;X3为C原子,其被R2d取代;R2a选自H、D、CN、ORa或NRbRc;R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基或C1-6卤代烷基;R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;或者X1、X2以及他们的取代基一起形成C5-6环烷基、5-6元杂环基、苯基或5-6元杂芳基(优选),其任选被1、2或3个R2s取代;R2d选自H、D、卤素、CN、NO2、ORa、NRbRc、C1-6烷基或C1-6卤代烷基;Z1为CH;Z2为CR1,且该R1与R4连接形成-(CRssRss)q1-X-(CRssRss)q2-(优选-(CH2)q1-X-(CH2)q2-);其中X为O、S、NH或CH2,q1=0或1,q2=1或2,Rss独立地选自H、D、C1-6烷基或C1-6卤代烷基,或者两个Rss以及他们连接的碳原子一起形成C3-10环烷基;Z3为CR1或N;L为化学键、C1-6亚烷基、C2-6亚烯基或C2-6亚炔基,其任选被1、2或3个R取代;R1s和R2s独立地选自H、D、卤素、=O、C(O)ORa、C(O)NRbRc、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;或者两个R1s以及他们连接的原子一起形成C3-6环烷基或3-6元杂环基;R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;R3s2选自H、D、-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-10环烷基、5-10元杂环基、C6-10芳基或5-10元杂芳基,其任选地被1、2或3个R3s取代;或者,R3s1、R3s2以及他们连接的碳原子一起形成C3-10环烷基;R和R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;Ra、Rb和Rc独立地选自H、D、C1-6烷基、C1-6卤代烷基、C3-10环烷基、3-10元杂环基、C6-10芳基或5-10元杂芳基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;其中上述各个基团定义任选地被氘代,直至完全氘代。
- 权利要求27的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,R1选自H、D、卤素、CN、NO2、ORa、SRa、NRbRc、SF5、C(O)Ra、S(O)Ra、S(O)2Ra、C1-6烷基、C1-6卤代烷基、C2-6烯基、C2-6炔基、C4-6环烷基、5-6元杂环基、苯基或5-6元杂芳基,其任选被1、2或3个R1s取代;m=0、1或2;R4选自H或D;X1为C原子,其被R2b取代;X2为C原子或N原子,其任选地被R2c取代;X3为C原子,其被R2d取代;R2a选自ORa或NRbRc;R2b选自H、D、卤素、C(O)ORa、C(O)NRbRc、C1-6烷基或C1-6卤代烷基;R2c选自H、D、卤素、C1-6烷基或C1-6卤代烷基;或者X1、X2以及他们的取代基一起形成C5-6环烷基、5-6元杂环基、苯基或5-6元杂芳基(优选),其任选被1、2或3个R2s取代;R2d选自H、D、卤素、CN、NO2、C1-6烷基或C1-6卤代烷基;Z1为CH;Z2为CR1,且该R1与R4连接形成-(CRssRss)q1-X-(CRssRss)q2-(优选-(CH2)q1-X-(CH2)q2-);其中X为O、S或NH,q1=0或1,q2=1或2,Rss独立地选自H、D、C1-6烷基或C1-6卤代烷基,或者两个Rss以及他们连接的碳原子一起形成C3-6环烷基;Z3为CR1或N;L为化学键或C1-6亚烷基;R1s和R2s独立地选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基或C2-6炔基;或者两个R1s以及他们连接的原子一起形成C3-6环烷基或3-6元杂环基;R3s1选自H、D、卤素、C1-6烷基、C1-6卤代烷基、C2-6烯基或C2-6炔基;R3s2选自H、D、-L-ORa、-L-NRbRc、C1-6烷基、C1-6卤代烷基、C3-6环烷基、5-6元杂环基、苯基或5-6元杂芳基,其任选地被1、2或3个R3s取代;或者,R3s1、R3s2以及他们连接的碳原子一起形成C3-6环烷基;R3s独立地选自H、D、卤素、C1-6烷基或C1-6卤代烷基;Ra、Rb和Rc独立地选自H、D、C1-6烷基或C1-6卤代烷基;或者Rb、Rc以及他们连接的原子一起形成5-10元杂环基;其中上述各个基团定义任选地被氘代,直至完全氘代。
- 权利要求1的式(X)化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,其中,所述化合物选自化合物1至化合物245。
- 药物组合物,其包含权利要求1-30中任一项的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,和药学上可接受的载体、佐剂或媒介物,任选地其它治疗剂。
- 权利要求31的药物组合物,其中所述其它治疗剂选自以下靶点药物/细胞活性调节剂,包括CDK4/6抑制剂,MAT2A抑制剂,MAPK1/MAPK3抑制剂,Type I PRMT抑制剂,EGFR抑制剂,SHP2抑制剂,泛KRAS抑制剂,KRASG12C抑制剂,RAF抑制剂,MEK抑制剂,ERK抑制剂,Bcl-2抑制剂,SOS1抑制剂,PARP抑制剂,MALT1抑制剂,MALT2抑制剂,BTK抑制剂,PI3K抑制剂,AKT抑制剂,FGFR抑制剂,DNA甲基转移酶(DNMT)抑制剂,EZH1/2抑制剂,EZH2抑制剂,Menin-MLL抑制剂,IDH1抑制剂,IDH2抑制剂,IDH1/2抑制剂,化疗药物,放射疗法,STING激动剂或免疫检查点抑制剂/调节剂。
- 权利要求1-30中任一项的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物在制备用于治疗或预防PRMT5介导的疾病的药物中的用途。
- 一种在受试者中治疗或预防PRMT5介导的疾病的方法,包括向所述受试者给药权利要求1-30中任一项的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,或权利要求31或32的药物组合物。
- 权利要求1-30中任一项的化合物,或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物,或权利要求31或32的药物组合物,其用于治疗或预防PRMT5介导的疾病。
- 权利要求33的用途或权利要求34的方法或权利要求35的化合物或药物组合物的用途,其中所述疾病为癌症。
- 权利要求33的用途或权利要求34的方法或权利要求35的化合物或药物组合物的用途,其中所述PRMT5介导的疾病选自以下癌症:心脏:肉瘤(血管肉瘤、纤维肉瘤、横纹肌肉瘤、脂肪肉瘤)、粘液瘤、横纹肌瘤、纤维瘤、脂肪瘤和畸胎瘤;肺:支气管癌(鳞状细胞、未分化小细胞、未分化大细胞、腺癌)、肺泡(细支气管)癌、支气管腺瘤、肉瘤、淋巴瘤、软骨瘤错构瘤、间皮瘤;胃肠道: 食管(鳞状细胞癌、腺癌、平滑肌肉瘤、淋巴瘤)、胃(癌、淋巴瘤、平滑肌肉瘤)、胰腺(导管腺癌、胰岛素瘤、胰高血糖素瘤、胃泌素瘤、类癌瘤、血管瘤)、小肠(腺癌、淋巴瘤、类癌瘤)、卡波西肉瘤、平滑肌瘤、血管瘤、脂肪瘤、神经纤维瘤、纤维瘤)、大肠(腺癌、管状腺瘤、绒毛状腺瘤、错构瘤、平滑肌瘤);泌尿生殖道:肾脏(腺癌、威尔姆氏瘤(肾母细胞瘤)、淋巴瘤、白血病)、膀胱和尿道(鳞状细胞癌、移行细胞癌、腺癌)、前列腺(腺癌、肉瘤)、睾丸(精原细胞瘤、畸胎瘤、胚胎癌、畸胎癌)、绒毛膜癌、肉瘤、间质细胞癌、纤维瘤、纤维腺瘤、腺瘤样肿瘤、脂肪瘤);肝脏:肝细胞瘤(肝细胞癌)、胆管癌、肝母细胞瘤、血管肉瘤、肝细胞腺瘤、血管瘤;胆道:胆囊癌、壶腹癌、胆管癌;骨:成骨肉瘤(osteosarcoma)、纤维肉瘤、恶性纤维组织细胞瘤、软骨肉瘤、尤文氏肉瘤、恶性淋巴瘤(网状细胞肉瘤)、多发性骨髓瘤、恶性巨细胞瘤脊索瘤、骨慢性外生骨疣(osteocartilaginous exostoses)、良性软骨瘤、软骨母细胞瘤、纤维软骨瘤、软骨粘液纤维瘤、类骨质骨瘤和巨细胞瘤;神经系统:颅骨(骨瘤、血管瘤、肉芽肿、黄色瘤、变形性骨炎)、脑膜(脑膜瘤、脑膜肉瘤、神经胶质瘤)、脑(星形细胞瘤、髓母细胞瘤、神经胶质瘤、室管膜瘤、生殖细胞瘤(松果体瘤)、多形性胶质母细胞瘤、少突胶质细胞瘤、神经鞘瘤、视网膜母细胞瘤、先天性肿瘤)、脊髓神经纤维瘤、脑膜瘤、神经胶质瘤、肉瘤);妇科:子宫(子宫内膜癌)、宫颈(宫颈癌、瘤前宫颈发育不良等)、卵巢(卵巢癌、浆液性囊腺癌、粘液性囊腺癌、未分类癌)、颗粒鞘细胞瘤、支持间质细胞瘤、无性细胞瘤、恶性畸胎瘤)、外阴(鳞状细胞癌、上皮内癌、腺癌、纤维肉瘤、黑色素瘤)、阴道(透明细胞癌、鳞状细胞癌、葡萄样肉瘤(胚胎性横纹肌肉瘤)、输卵管(癌);血液学:血液(髓性白血病(急性和慢性)、急性淋巴细胞白血病、慢性淋巴细胞性白血病、弥漫性大B细胞淋巴瘤、套细胞淋巴瘤(MCL),滤泡性淋巴瘤、骨髓增生性疾病、多发性骨髓瘤、骨髓增生异常综合征)、霍奇金病、非霍奇金淋巴瘤(恶性淋巴瘤);皮肤:恶性黑色素瘤、基底细胞癌、鳞状细胞癌、卡波西肉瘤、痣发育不良痣、脂肪瘤、血管瘤、皮肤纤维瘤、瘢痕疙瘩、牛皮癣;和肾上腺:成神经细胞瘤。
- 权利要求33的用途或权利要求34的方法或权利要求35的化合物或药物组合物的用途,其中所述PRMT5介导的疾病选自以下癌症:恶性周围神经鞘瘤、间皮瘤、多形性胶质母细胞瘤、胰腺癌、胆管癌、前列腺癌、乳腺癌、脑癌、皮肤癌、宫颈癌、膀胱癌、星形细胞瘤、结肠直肠癌、子宫内膜癌、食道癌、胃癌、胸腺瘤、头颈癌、肝细胞癌、喉癌、肺鳞癌、肺腺癌、口腔癌、卵巢癌、肾癌和甲状腺癌以及肉瘤。
- 权利要求33的用途或权利要求34的方法或权利要求35的化合物或药物组合物的用途,其中所述PRMT5介导的疾病选自MTAP相关癌症,例如肝细胞癌、乳腺癌、皮肤癌、膀胱癌、肝癌、胰腺癌或头颈癌。
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210898107 | 2022-07-28 | ||
CN202210898107.7 | 2022-07-28 | ||
CN202211541013.0 | 2022-12-02 | ||
CN202211541013 | 2022-12-02 | ||
CN202310484698.8 | 2023-04-28 | ||
CN202310484698 | 2023-04-28 | ||
CN202310897087 | 2023-07-20 | ||
CN202310897087.6 | 2023-07-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024022433A1 true WO2024022433A1 (zh) | 2024-02-01 |
Family
ID=89705438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/109524 WO2024022433A1 (zh) | 2022-07-28 | 2023-07-27 | Prmt5抑制剂 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024022433A1 (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021004547A1 (en) * | 2019-07-11 | 2021-01-14 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of hpk1 |
US11077101B1 (en) * | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
WO2022026892A1 (en) * | 2020-07-31 | 2022-02-03 | Tango Therapeutics, Inc. | Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers |
WO2023146987A1 (en) * | 2022-01-26 | 2023-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
-
2023
- 2023-07-27 WO PCT/CN2023/109524 patent/WO2024022433A1/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11077101B1 (en) * | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
WO2021004547A1 (en) * | 2019-07-11 | 2021-01-14 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of hpk1 |
WO2022026892A1 (en) * | 2020-07-31 | 2022-02-03 | Tango Therapeutics, Inc. | Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers |
WO2023146987A1 (en) * | 2022-01-26 | 2023-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
Non-Patent Citations (2)
Title |
---|
BOGOLUBSKY ANDREY V., MOROZ YURII S., MYKHAILIUK PAVEL K., PIPKO SERGEY E., ZHEMERA ANTON V., KONOVETS ANZHELIKA I., STEPANIUK OLE: "2,2,2-Trifluoroethyl Chlorooxoacetate—Universal Reagent for One-Pot Parallel Synthesis of N 1 -Aryl- N 2 -alkyl-Substituted Oxamides", ACS COMBINATIONAL SCIENCE, AMERICAN CHEMICAL SOCIETY, US, vol. 17, no. 10, 12 October 2015 (2015-10-12), US , pages 615 - 622, XP093034800, ISSN: 2156-8952, DOI: 10.1021/acscombsci.5b00091 * |
ZACUTO MICHAEL J.: "Synthesis of Acrylamides via the Doebner–Knoevenagel Condensation", THE JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 84, no. 10, 17 May 2019 (2019-05-17), pages 6465 - 6474, XP093134542, ISSN: 0022-3263, DOI: 10.1021/acs.joc.9b00450 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3558985B1 (en) | Benzooxazole derivatives as immunomodulators | |
TWI765908B (zh) | 苯並咪唑類化合物激酶抑制劑及其製備方法和應用 | |
CN107074859B (zh) | 用于治疗癌症的作为吲哚胺-2,3-双加氧酶(ido)拮抗剂的环己基乙基取代的二氮杂-和三氮杂-三环化合物 | |
CN113784963B (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
JP7092405B2 (ja) | キナーゼ活性を阻害するためのジ(ヘテロ)アリール大環状化合物 | |
CN114656514A (zh) | 一种甾族类衍生物调节剂及其制备方法和应用 | |
EP3884939B1 (en) | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | |
WO2023134266A1 (zh) | 2-哌啶基或2-吡唑基取代的嘧啶化合物作为egfr抑制剂 | |
WO2021098883A1 (zh) | 用作egfr激酶抑制剂的化合物及其应用 | |
EP3715350B1 (en) | Arylphosphine oxides for inhibiting kinase activity | |
WO2020020385A1 (zh) | 含三并环类衍生物抑制剂、其制备方法和应用 | |
WO2024022433A1 (zh) | Prmt5抑制剂 | |
WO2021129841A1 (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
WO2021129584A1 (zh) | Pd-l1拮抗剂化合物 | |
CN113929688B (zh) | 作为atr激酶抑制剂的吡唑并嘧啶化合物 | |
UA121315C2 (uk) | Макроциклічні інгібітори кінази rip2 | |
CN114057823B (zh) | 白桦脂酸衍生物,其制备方法、药物组合物和应用 | |
WO2024037607A1 (zh) | Prmt5抑制剂 | |
CN112638928B (zh) | 一种甾族类衍生物调节剂的盐及其晶型 | |
WO2021057796A1 (zh) | 取代的稠合三环衍生物及其组合物及用途 | |
EP4155304A1 (en) | Compound used as ret kinase inhibitor and application thereof | |
CN115894600A (zh) | 别白桦醇衍生物及其制备方法、药物组合物和应用 | |
EP4180434A1 (en) | Pb2 inhibitor, and preparation method therefor and use thereof | |
WO2024037608A1 (zh) | Prmt5抑制剂 | |
WO2023202626A1 (zh) | 稠和哒嗪酮化合物作为prmt5抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23845640 Country of ref document: EP Kind code of ref document: A1 |